
<html lang="en"     class="pb-page"  data-request-id="4c5d7482-ec12-4cd1-b0d8-d4753974d28a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2021.64.issue-6;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c02050;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes" /></meta><meta name="dc.Creator" content="Kunal  Kumar" /></meta><meta name="dc.Creator" content="Chalada  Suebsuwong" /></meta><meta name="dc.Creator" content="Peng  Wang" /></meta><meta name="dc.Creator" content="Adolfo  Garcia-Ocana" /></meta><meta name="dc.Creator" content="Andrew F.  Stewart" /></meta><meta name="dc.Creator" content="Robert J.  DeVita" /></meta><meta name="dc.Description" content="According to the World Health Organization (WHO), 422 million people are suffering from diabetes worldwide. Current diabetes therapies are focused on optimizing blood glucose control to prevent lon..." /></meta><meta name="Description" content="According to the World Health Organization (WHO), 422 million people are suffering from diabetes worldwide. Current diabetes therapies are focused on optimizing blood glucose control to prevent lon..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 8, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02050" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02050" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02050" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02050" /></link>
        
    
    

<title>DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02050" /></meta><meta property="og:title" content="DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0013.jpeg" /></meta><meta property="og:description" content="According to the World Health Organization (WHO), 422 million people are suffering from diabetes worldwide. Current diabetes therapies are focused on optimizing blood glucose control to prevent long-term diabetes complications. Unfortunately, current therapies have failed to achieve glycemic targets in the majority of people with diabetes. In this context, regeneration of functional insulin-producing human β-cells in people with diabetes through the use of DYRK1A inhibitor drugs has recently received special attention. Several small molecule DYRK1A inhibitors have been identified that induce human β-cell proliferation in vitro and in vivo. Furthermore, DYRK1A inhibitors have also been shown to synergize β-cell proliferation with other classes of drugs, such as TGFβ inhibitors and GLP-1 receptor agonists. In this perspective, we review the status of DYRK1A as a therapeutic target for β-cell proliferation and provide perspectives on technical and scientific challenges for future translational development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02050"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02050">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02050&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02050&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02050&amp;href=/doi/10.1021/acs.jmedchem.0c02050" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2901-2922</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01851" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c02120" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Kunal Kumar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kunal Kumar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Institute and Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kunal++Kumar">Kunal Kumar</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chalada Suebsuwong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chalada Suebsuwong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Institute and Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chalada++Suebsuwong">Chalada Suebsuwong</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peng Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peng Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peng++Wang">Peng Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adolfo Garcia-Ocana</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adolfo Garcia-Ocana</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adolfo++Garcia-Ocana">Adolfo Garcia-Ocana</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew F. Stewart</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew F. Stewart</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diabetes, Obesity, and Metabolism Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+F.++Stewart">Andrew F. Stewart</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Robert J. DeVita</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert J. DeVita</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Institute and Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#97e5f8f5f2e5e3b9f3f2e1fee3f6d7fae4e4fab9f2f3e2"><span class="__cf_email__" data-cfemail="73011c111601075d1716051a0712331e00001e5d161706">[email protected]</span></a>; Phone: 212-659-5542</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+J.++DeVita">Robert J. DeVita</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2671-8497" title="Orcid link">http://orcid.org/0000-0002-2671-8497</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02050&amp;href=/doi/10.1021%2Facs.jmedchem.0c02050" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2901–2922</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 8, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 November 2020</li><li><span class="item_label"><b>Published</b> online</span>8 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 March 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02050" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02050</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2901%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DKunal%2BKumar%252C%2BChalada%2BSuebsuwong%252C%2BPeng%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D6%26contentID%3Dacs.jmedchem.0c02050%26title%3DDYRK1A%2BInhibitors%2Bas%2BPotential%2BTherapeutics%2Bfor%2B%25CE%25B2-Cell%2BRegeneration%2Bfor%2BDiabetes%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2922%26publicationDate%3DMarch%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02050"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1703</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02050" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Kunal&quot;,&quot;last_name&quot;:&quot;Kumar&quot;},{&quot;first_name&quot;:&quot;Chalada&quot;,&quot;last_name&quot;:&quot;Suebsuwong&quot;},{&quot;first_name&quot;:&quot;Peng&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Adolfo&quot;,&quot;last_name&quot;:&quot;Garcia-Ocana&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;F. Stewart&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;J. DeVita&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2901-2922&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02050&quot;},&quot;abstract&quot;:&quot;According to the World Health Organization (WHO), 422 million people are suffering from diabetes worldwide. Current diabetes therapies are focused on optimizing blood glucose control to prevent long-term diabetes complications. Unfortunately, current therapies have failed to achieve glycemic targets in the majority of people with diabetes. In this context, regeneration of functional insulin-producing human β-cells in people with diabetes through the use of DYRK1A inhibitor drugs has recently received special attention. Several small molecule DYRK1A inhibitors have been identified that induce human β-cell proliferation in vitro and in vivo. Furthermore, DYRK1A inhibitors have also been shown to synergize β-cell proliferation with other classes of drugs, such as TGFβ inhibitors and GLP-1 receptor agonists. In this perspective, we review the status of DYRK1A as a therapeutic target for β-cell proliferation and provide perspectives on technical and scientific challenges for future translational development.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02050&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02050" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02050&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02050" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02050&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02050" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02050&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02050&amp;href=/doi/10.1021/acs.jmedchem.0c02050" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02050" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02050" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02050%26sid%3Dliteratum%253Aachs%26pmid%3D33682417%26genre%3Darticle%26aulast%3DKumar%26date%3D2021%26atitle%3DDYRK1A%2BInhibitors%2Bas%2BPotential%2BTherapeutics%2Bfor%2B%25CE%25B2-Cell%2BRegeneration%2Bfor%2BDiabetes%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D6%26spage%3D2901%26epage%3D2922%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=290659" title="DNA replication">DNA replication</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/jmcmar.2021.64.issue-6/20210325/jmcmar.2021.64.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">According to the World Health Organization (WHO), 422 million people are suffering from diabetes worldwide. Current diabetes therapies are focused on optimizing blood glucose control to prevent long-term diabetes complications. Unfortunately, current therapies have failed to achieve glycemic targets in the majority of people with diabetes. In this context, regeneration of functional insulin-producing human β-cells in people with diabetes through the use of DYRK1A inhibitor drugs has recently received special attention. Several small molecule DYRK1A inhibitors have been identified that induce human β-cell proliferation <i>in vitro</i> and <i>in vivo.</i> Furthermore, DYRK1A inhibitors have also been shown to synergize β-cell proliferation with other classes of drugs, such as TGFβ inhibitors and GLP-1 receptor agonists. In this perspective, we review the status of DYRK1A as a therapeutic target for β-cell proliferation and provide perspectives on technical and scientific challenges for future translational development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84214" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84214" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">According to the World Health Organization (WHO), 422 million people are suffering from diabetes worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In the United States (US), there are an estimated 30 million people with diabetes, as reported in the National Diabetes Statistic Report by the Center for Disease Control and Prevention.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Diabetes is a group of diseases defined by high levels of blood glucose and is generally classified into two major subgroups, type 1 diabetes (T1D) and type 2 diabetes (T2D). T1D, previously known as insulin-dependent diabetes or juvenile diabetes, results from autoimmune destruction of insulin-producing pancreatic β-cells, ultimately leading to a deficiency in insulin production.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3−6)</a> People suffering from T1D are dependent on insulin administration for survival.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> A reduction of functional β-cells is a primary cause of T2D diabetes.<a onclick="showRef(event, 'ref4 ref6 ref8'); return false;" href="javascript:void(0);" class="ref ref4 ref6 ref8">(4,6,8)</a> People with T2D do not respond effectively to endogenous insulin, a condition described as “insulin resistance”. In addition to exogenous administration of insulin, many drugs, including metformin, sulfonylureas and meglitinides, thiazolidinediones, glucagon-like peptide-1 (GLP-1) analogues, dipeptidyl peptidase 4 (DPP4) inhibitors, and many others have been developed as treatment options for T2D.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Importantly, loss of β-cell mass resulting in inadequate insulin production is a major factor behind the pathogenesis of both T1D and T2D.<a onclick="showRef(event, 'ref4 ref6 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref4 ref6 ref8 ref9">(4,6,8,9)</a> All of the available therapies for both T1D and T2D are focused on normalizing blood glucose concentrations. Importantly, current approaches fail to address one of the root causes of T1D and T2D: the inadequate mass of functional human β-cells, and consequent inadequate insulin production. This unmet medical need creates a drug discovery opportunity for both T1D and T2D: identifying novel and safe therapeutic strategies to expand and maintain β-cell mass.</div><div class="NLM_p">With this goal in mind, researchers have sought therapeutic approaches that might reduce β-cell death or other loss or that might enhance β-cell differentiation and/or promote β-cell proliferation, as reviewed previously.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13">(10−13)</a> Expansion of β-cell mass has been a major obstacle, reflecting their native, extremely low rate of proliferation (∼2%) in only the early phase of life (from newborn to ∼2 years of age), the latter attributed variably to quiescence, terminal differentiation, or senescence. The resistance to proliferation of adult β-cells remains a major challenge.<a onclick="showRef(event, 'ref6 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref6 ref14 ref15">(6,14,15)</a> Over the last six years, despite this challenge, several small molecules have been identified that significantly enhance human β-cell proliferation both <i>in vitro</i> and <i>in vivo</i>, in a range that may be relevant to therapeutic β-cell expansion (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of DYRK1A inhibitors that induce human β-cell proliferation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Summary of <i>in Vitro</i> and <i>in Vivo</i> Data of β-Cell Proliferative DYRK1A Inhibitors<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">DYRK1A inhibition IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>in vitro</i> human β-cell proliferation</th><th class="colsep0 rowsep0" align="center"><i>in vivo</i> human β-cell proliferation</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b> (harmine)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="left">2-fold increase in Ki67 labeling and BrdU incorporation at 10 μM</td><td class="colsep0 rowsep0" align="left">2–3-fold increase in Ki67 labeling at 10 mg/kg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>3</b> (5-IT)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">13</td><td class="colsep0 rowsep0" rowspan="2" align="left">ND</td><td class="colsep0 rowsep0" align="left">5–6-fold increase in Ki67 labeling at 0.25 mg/kg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4-fold increase in PDXl/BrdU incorporation at 0.25 mg/kg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b> (CC-401)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></td><td class="colsep0 rowsep0" align="char" char=".">ND</td><td class="colsep0 rowsep0" align="left">2–10-fold increase in Ki67 labeling</td><td class="colsep0 rowsep0" align="left">2-fold increase in BrdU incorporation at 25 mg/kg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b> (harmine analogue)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="left">1.5-fold increase in Ki67 labeling at 3 μM</td><td class="colsep0 rowsep0" align="left">2–3-fold increase in Ki67 labeling at 1 mg/kg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b> (GNF7156)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="left">3–6% EdU incorporation at 50 mg/kg, EC<sub>50</sub> 0.76 ± 0.45 nM</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b> (GNF4877)<a onclick="showRef(event, 'ref25 ref23'); return false;" href="javascript:void(0);" class="ref ref25 ref23">(25,23)</a></td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="left">3–6% EdU incorporation at 50 mg/kg, EC<sub>50</sub> 54 ± 0.17 nM</td><td class="colsep0 rowsep0" align="left">3-fold increase in BrdU incorporation at 50 mg/kg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b> (GNF2133)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="left">induced EdU incorporation with EC<sub>50</sub> 210 nM</td><td class="colsep0 rowsep0" align="left">increase in Ki67 labeling and Cyclin D1 levels at 30 mg/kg for 5 days</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b> (1,5-naphthridine)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></td><td class="colsep0 rowsep0" align="char" char=".">223</td><td class="colsep0 rowsep0" align="left">induced β-cell proliferation with EC<sub>50</sub> 27 nM</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">ND: no data available.</p></div></div></div><div class="NLM_p last">A number of biological targets have been studied in the context of human β-cell replication, including <u class="uu">D</u>ual Specificity <u class="uu">T</u>yrosine Phosphorylation-<u class="uu">R</u>egulated <u class="uu">K</u>inase 1 A (DYRK1A),<a onclick="showRef(event, 'ref11 ref12 ref13 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27">(11−13,16−27)</a> Inhibitor-κB kinase ε (IKKε) and Erb3 binding protein-1 (EBP1),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> glycogen synthase kinase 3β (GSK3β),<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23−25)</a> receptor activator of nuclear factor kB (RANK),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> serine protease inhibitor B1 (SERPINB1),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a><i>gamma</i>-aminobutyric acid (GABA) receptor,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> GLP-1 receptor,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> the transforming growth factor (TGFβ) superfamily,<a onclick="showRef(event, 'ref33 ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35 ref36 ref37">(33−37)</a> V-growth factor (VGF) derived peptide,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> cell cycle-dependent kinase CDKN2C/p18 or CDKN1A/p21,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> adenosine signaling pathways,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and L-type calcium channels (LTCC).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Several recent reviews have been published that summarize the results for targets other than DYRK1A.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11−13)</a> Among the putative human β-cell regenerative compounds, DYRK1A inhibitors appear to have the greatest promise: many laboratories have identified small molecule DYRK1A inhibitors that induce human β-cell proliferation both <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref11 ref12 ref13 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27">(11−13,16−27)</a> Therefore, in this perspective, we focus on the recent advances in DYRK1A as key cellular target for β-cell proliferation, summarizing identification of novel β-cell proliferative DYRK1A inhibitors, medicinal chemistry structure–activity relationship studies for their <i>in vitro</i> and <i>in vivo</i> human β-cell proliferation activities, pharmacokinetic (PK)/pharmacodynamic (PD) analyses, and their safety/tolerability. We believe this perspective will be of primary interest to readers involved in medicinal chemistry and translational drug discovery as well as to scientists and clinicians in the diabetes therapeutic area.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Harmine and the Identification of DYRK1A as a Key Biological Target for β-Cell Proliferation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In 2015, Wang et al. reported a small molecule natural product called harmine <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) as a novel inducer of human β-cell proliferation both <i>in vitro</i> and in several <i>in vivo</i> models, most promisingly in NOD-SCID mice transplanted with human islets.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> This was the first report that described a role for DYRK1A in human β-cell proliferation and showed that the DYRK1A-NFAT pathway controls human β-cell proliferation. Wang et al. developed a luciferase-based, phenotypic small-molecule high throughput screening (HTS) strategy to detect molecules that directly or indirectly activate the <i>MYC</i> gene promoter in the human hepatocyte cell line HepG2. 102,300 compounds from the US Food and Drug Administration (FDA) and commercial screening library sources were screened for luciferase activation in HepG2 cells. Those compounds found to activate luciferase (normalized percentage activation (NPA) > 7.5%))<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> were further profiled for their ability to induce c-MYC protein expression as well as BrdU incorporation (a marker for cellular proliferation) in rat pancreatic β-cells. From these assays, compound <b>1</b> was the only compound from this screening library that induced both c-MYC protein expression and BrdU incorporation into rat β-cells. Subsequent follow up studies confirmed BrdU incorporation and <i>K</i>i-67 labeling (markers of cell proliferation) in human β-cells, with the appearance of double nuclei, suggesting recent cell division. Chemical biology pathway analysis of known activities of compound <b>1</b>, which includes DYRK1A kinase inhibition, led to testing of another structural class of DYRK1A inhibitor, <b>2</b> (INDY <u class="uu">IN</u>hibitor of <u class="uu">DY</u>RK1A),<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> which also caused proliferation in both rat and human β-cells, revealing proliferation as a class effect of DYRK1A inhibitors. These results, first from a phenotypic screen and subsequently from orthogonal β-cell assays, genetic silencing of DYRK1A in human β-cells, and chemical biology studies uncovered the potential of DYRK1A kinase as a therapeutic target for identification of novel small molecule inducers of β-cell proliferation for the first time.</div><div class="NLM_p">Three different <i>in vivo</i> animal models were used to assess the ability of <b>1</b> to induce β-cell proliferation, increase β-cell mass, and enhance glycemic control. In the first, the partial pancreatectomy (PPX) model, compound <b>1</b> induced <i>K</i><sub>i</sub>-67 labeling in β-cells in both sham-operated mice and in mice subjected to PPX. The most robust proliferation occurred in the β-cells of PPX mice treated with <b>1</b>. Most importantly, restoration of β-cell mass following PPX was significantly more rapid in mice treated with <b>1</b> than in the vehicle control groups, reaching near-normal values in only 14 days. In the second model, an immunodeficient NOD-SCID mouse model that permits transplantation of human islets into the mouse, BrdU and <i>K</i>i-67 labeling were two- to three-fold higher in human β-cells transplanted into the mice treated with <b>1</b>, without any observed β-cell death, as compared to vehicle-treated euglycemic control mice. In the third model, a marginal mass human islet transplant model in streptozotocin-diabetic NOD-SCID mice, compound <b>1</b> treatment resulted in near-normal glycemic control after transplant, as assessed both by postprandial and fasting glucose values and by intraperitoneal glucose tolerance challenge. Furthermore, gene expression analysis of human islets treated with <b>1</b> showed increased production of important β-cell differentiation markers NKX6.1, PDX1, and MAFA, increases in expression of cell cycle activator genes such as cyclin A, cyclin E, and CDK1, accompanied by decreases in cell cycle inhibitor genes such as p15<sup>INK4</sup>, p16<sup>INK4</sup>, and p57<sup>KIP2</sup>.</div><div class="NLM_p">In addition to DYRK1A inhibition, harmine (<b>1)</b> has many other known biological targets. One of the most well-known targets, monoamine oxidase (MAO), was excluded as a regenerative target because harmaline and harmane (structurally similar to <b>1</b> and inhibitors of monoamine oxidase A (MAO) but not of DYRK1A) did not induce β-cell proliferation.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The activity of two different classes of DYRK1A inhibitors (<b>1</b> and <b>2</b>) allowed the DYRK1A pathway to be the focus for further biological mechanism of action studies for the observed β-cell proliferation. Heit et al. and Goodyer et al. had previously reported in rodent systems that the calcineurin-nuclear factor of activate T-cells (NFAT) signaling pathway regulates growth and function of pancreatic β-cells.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Wang et al. therefore explored the hypothesis that DYRK1A might have a key role in activation of a human β-cell proliferation through NFAT pathways. Several experiments were designed for harmine (<b>1)</b>-treated rat and human β-cells to assess this pathway, including inactivation of calcineurin NFAT signaling, genetic overexpression and silencing of DYRK1A mRNA, as well as NFAT translocation from cytosol to the nucleus. It was found that blocking the NFAT-calcineurin interaction with the NFAT inhibitor VIVIT and inhibition of calcineurin activity with FK-506 resulted in decreased <i>K</i>i-67 labeling in both rat and human β-cells treated with <b>1</b> as compared to vehicle control, suggesting a role for calcineurin-NFAT signaling on <b>1</b> mediated β-cell proliferation. Consequently, nuclear localization of NFAT family members in human β-cells was determined using adenovirally expressed NFAT2 (encoded by NFATC1) fused to green fluorescent protein (GFP). Both <b>1</b> and <b>2</b> treated β-cells showed significant translocation of NFATs from the cytoplasm to the nucleus, as compared to vehicle controls. In a separate experiment, adenovirus-induced overexpression of DYRK1A competitively attenuated compound <b>1</b>-induced β-cell proliferation in human islets as compared to sham adenovirus-treated controls. In addition, genetic silencing of DYRK1A using shRNA led to a three-fold higher degree of proliferation of the human β-cells as compared to scrambled shRNA-treated β-cells. These data further confirmed DYRK1A as a relevant regulator of proliferation in human β-cells. Subsequently, these results have been confirmed in other labs with DYRK1A inhibitors unrelated to the harmine scaffold (described below), further validating DYRK1A as key cellular target for human β-cell proliferation.</div><div class="NLM_p">In addition to DYRK1A, harmine (<b>1</b>) is known to inhibit other members of the CMGC family: cyclin dependent kinases (CDK)), mitogen activated protein kinases (MAPK), GSK, and cell division cycle (CDC-like) kinases, notably DYRKs and CLKs, drawing the inference that these kinases may be relevant targets as well.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Kinase profiling of DYRK1A inhibitors that induce β-cell proliferation (harmine analogues (<b>1</b>, <b>7</b>, <b>8</b>, and <b>9</b>), 5-IT (<b>3</b>), CC-401 (<b>4</b>), thiadiazines (<b>10</b> and <b>12</b>), GNF2133 (<b>14</b>), GNF4487 (<b>16</b>), and 1,5-naphthridines (<b>23</b>, <b>24</b>, and <b>25</b>)) suggest that potential target candidates could be DYRKs (DYRK1A, DYRK1B, DYRK2, DYRK3, and DYRK4), glycogen synthase kinase GSK3α and GSK3β, CDC-like kinases (CLK1, CLK2, and CLK4), and casein kinases (CSNK1A, 1D, and 1E). To have a better understanding of the mechanisms of action of DYRK1A inhibitors, including harmine (<b>1</b>), INDY (<b>2</b>), 5-IT (<b>3</b>), CC-401 (<b>4</b>), leucettine-L41 (<b>5</b>), GNF4877 (<b>16</b>), TG003, and AZ191, for human β cell proliferation, Ackeifi et al. performed studies using RNA-seq profiles, kinome screens, pharmacologic studies, and genetic silencing approaches.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> They developed a library of adenoviruses that can either silence independently or simultaneously all the members of the DYRK family in human islets and then studied their effects on human β-cell proliferation, as measured by insulin <i>K</i>i-67 coimmunolabeling. As expected, silencing of DYRK1A induced proliferation. In contrast, independent silencing of DYRKs 2, 3, and 4 had no effect on proliferation, while silencing DYRK1B alone showed only a minor increase in proliferation as compared to DYRK1A silencing alone. Immunoblots of human islets in which DYRK1A had been silenced showed a marked increase in DYRK1B, not evident at the mRNA level, suggesting a potential compensatory role for DYRK1B on proliferation in the absence of DYRK1A. This was confirmed upon simultaneous silencing of both DYRK1A and DYRK1B, which led to a greater increase in β-cell proliferation as compared to silencing either target alone. This demonstrates that a given DYRK1A inhibitor will be more effective on proliferation if it also inhibits DYRK1B. Notably, similar synergistic effects on proliferation were not observed by adding shRNAs against DYRKs 2, 3, and 4 to DYRK1A and DYRK1B. Collectively, these data indicate that among the DYRK family of kinases, DYRK1A is the major driver of β-cell proliferation along with DYRK1B.</div><div class="NLM_p">With respect to the GSK and CLK families, silencing of GSK3s individually had no effect on β-cell proliferation, and silencing the GSK3s along with DYRK1A and DYRK1B also showed no increase in proliferation when compared to silencing DYRK1A and DYRK1B. Moreover, silencing or overexpression of GSK3β in human islets had little to no additional proliferation effect on human islets treated with harmine (<b>1</b>), 5-IT (<b>3</b>) or GNF4877 (<b>16</b>), further suggesting that GSKs are less likely to be important for human β-cell proliferation. Similarly, silencing CLKs individually, in combinations, or CLKs along with DYRK1A and DYRK1B did not have any additional effect on proliferation, indicating that CLK inhibition is not required for proliferation. Collectively, these data indicate that among the DYRK, CLK, and GSK families of kinases, inhibition of DYRK1A and DYRK1B are the major drivers of β-cell proliferation.</div><div class="NLM_p">It has been reported that DYRK1A-haploinsufficient mice have impaired β-cell development and decreased β-cell proliferation and mass, leading to glucose intolerance, in contrast to the <i>in vitro</i> DYRK1A silencing experiments.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> However, based on the large amount of evidence (described above) indicating that inhibition of DYRK1A leads to a marked increase in adult rodent and human β-cell replication and mass, it is likely that DYRK1A plays a different role in islet development through embryogenesis as compared with homeostasis in the adult organism.</div><div class="NLM_p">In addition to DYRK, CLK, and GSK3 families, other possible targets for human β-cell proliferation could be CSNKs, haspin, and HIPKs.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> CSNK inhibitors do not induce human β-cell proliferation, and the kinome profiles of known DYRK1A inhibitor β-cell proliferation inducers make them unlikely targets, with the possible exception being haspin, based on the following data. Harmine analogue (<b>1</b>, <b>8</b>, <b>9</b>, and <b>10</b>),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> 5-IT (<b>3</b>),<a onclick="showRef(event, 'ref18 ref46'); return false;" href="javascript:void(0);" class="ref ref18 ref46">(18,46)</a> and Leucettine-L41 (<b>5</b>)<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> do not inhibit CSNKs. Similarly, HIPK2 and HIPK3 are not inhibited by leucettine-L41 (<b>5</b>), GNF4877 (<b>16</b>),<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> or 5-IT (<b>3</b>). Interestingly, harmine (<b>1</b>), 5-IT (<b>3</b>), and GNF4877 (<b>16</b>) all inhibit haspin to a lesser extent, and it remains a viable candidate which requires further studies. It is also possible that proteins other than kinases may be involved in DYRK1A inhibitor mediated human β-cell proliferation. For example, 5-IT (<b>1</b>) is a DYRK1A inhibitor, but it is also a potent inhibitor of adenosine kinase,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> illustrating the fact that regenerative DYRK1A inhibitors may have targets beyond protein kinases, exemplified by signaling proteins, cell surface receptors, and other cellular proteins. Their potential relevance to β-cell proliferation, if any, is not yet known and will require additional proteomic and metabolic studies.</div><div class="NLM_p">The current understanding of the mechanism of action of <b>1</b> acting via the calcineurin-NFAT-DYRK1A pathway is shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. Increases in intracellular calcium (Ca<sup>2+</sup>) activate calmodulin (CAM), which in turn activates the calcineurins A and B (CnA and CnB). CnA and CnB dephosphorylate the NFAT family transcription factors, causing their translocation from cytoplasm to the nucleus. Once in nucleus, these transcription factors transactivate promoters of cell cycle-activating genes and repress promoters of cell cycle inhibitory genes, resulting in cell cycle entry and proliferation. The nuclear kinase DYRK1A rephosphorylates NFAT members, forcing their export from the nucleus to the cytoplasm, terminating β-cell proliferation. This inhibitory control of cell cycle entry can be overcome pharmacologically by DYRK1A inhibitors including <b>1</b>, permitting β-cell proliferation.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Mechanism of DYRK1A-NFAT mediated human β-cell proliferation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It is important to point out that other DYRK1A targets may be involved in the control of human β-cell proliferation. For example, Annes et al. have shown that DYRK1A can phosphorylate and thereby destabilize the cell cycle inhibitor p27<sup>KIP1</sup>, which is known to participate in maintaining human β-cell quiescence.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Furthermore, they have shown that LIN52, a member of the quiescence-enforcing DREAM complex, is also phosphorylated by DYRK1A.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Thus, it appears likely that in addition to modulating NFAT signaling, DYRK1A inhibitors will prove to act via multiple confluent pathways to drive human β-cell proliferation.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">DYRK1A Inhibitors As Inducers of Human β-Cell Proliferation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18076" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18076" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Harmine and Related Analogues</h3><div class="NLM_p">As mentioned earlier, Wang et al. identified harmine (<b>1</b>), a known DYRK1A inhibitor, as a promoter of human β-cell proliferation both <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Because DYRK1A is widely expressed and is known to play key roles in other tissues and organs<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and because <b>1</b> suffers from suboptimal selectivity and may have off-target CNS effects,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> safety concerns may limit the therapeutic potential of <b>1</b> itself. These potential suboptimal pharmacological properties of <b>1</b> could be addressed by developing more selective analogues with limited CNS activities as pharmacological lead candidates while retaining human β-cell proliferative effects. In this context, a systematic medicinal chemistry strategy was developed to investigate structure–activity relationships (SAR) of analogues of <b>1</b> for both DYRK1A activity and β-cell proliferation with the intention of identifying a kinase and CNS off-target selective as well as linkable <b>1</b> analogues for targeted therapy (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref21 ref22 ref27'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref27">(21,22,27)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. SAR study of harmine analogues and crystal structure of harmine bound to DYRK1A (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ANR">3ANR</a>) showing key interactions with Lys188 and Leu241.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on harmine-DYRK1A X-ray cocrystal structures, modifications of three positions of <b>1</b>, specifically 1-methyl, 7-methoxy, and 9-<i>N</i> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), were made. Modification of the 1-position of compound <b>1</b> led to 17 compounds, of which 6 displayed potent DYRK1A inhibition, with an IC<sub>50</sub> in the range of 8–100 nM.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Two of these compounds bearing a small polar hydroxymethyl group exhibited robust human β-cell proliferation at doses against 3–30 μM. Kinome scan of 468 kinases indicated that compound <b>7</b> (R = CH<sub>2</sub>OH) exhibited a cleaner kinome profile (<20% activity remaining against 8 kinases) as compared to <b>1</b> (<20% activity remaining against 18 kinases) at a concentration of 10 μM. These data indicated the potential for improvement of compound <b>1</b> scaffold for kinase selectivity, resulting in β-cell proliferation at lower concentration <i>in vitro</i>, with the potential for a cleaner off-target kinase profile.</div><div class="NLM_p">Next, modifications of the 7-position of harmine (<b>1</b>) were carried out by introducing substituents bearing terminal methyl ester, carboxamide, carboxylic acid, and amino/substituted-amino groups with chain lengths varying from 1 to 5 carbon atoms (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Among 33 7-substituted analogues synthesized, 2 compounds were active at less than 100 nM in the biochemical DYRK1A inhibition assay, ∼3–4-fold less than that of <b>1</b>. Of all the analogues, compound <b>8</b> exhibited the most potent DYRK1A inhibition with IC<sub>50</sub> = 89 nM. However, the majority of 7-substituted analogues, regardless of carbon chain lengths or functional groups, did not show any improvement in DYRK1A inhibitory activity. It was inferred from modeling studies that 7-position analogues resulted in disruption of key binding contacts of <b>1</b> to DYRK1A. Specifically, the H-bond to the backbone of Leu241 or the introduction of unproductive electrostatic interactions within the binding pocket of <b>1</b> likely account for decreased DYRK1A activity. In human β-cell proliferation assays, the two most potent 7-O analogues did induce human β-cell proliferation in a dose-dependent manner but required 3-fold higher concentration (30 μM) to induce maximal proliferation, 66% that of harmine (<b>1</b>) at 10 μM. Collectively, these data indicate that modifications of 7-position of harmine are less promising for retaining potent DYRK1A inhibition and β-cell proliferation.</div><div class="NLM_p">Next, focus was moved to 9-<i>N</i>-position modification of harmine (<b>1</b>). Twenty-nine novel analogues bearing terminal methyl, carboxamide, carboxylic acid, and amino/substituted-amino functional groups with varying chain lengths of 1–5 carbon atoms were synthesized (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Modifications at the harmine 9-<i>N</i> position were generally better tolerated as compared to 7- and 1-position analogues. Several 9-<i>N</i>-substituted analogues showed comparable or better DYRK1A inhibitory activity than that of <b>1</b>. Among the 29 compounds synthesized, compound <b>9</b> (<b>2</b>–<b>2c</b>) had the most promising biological profile in this series. <b>9</b> induced comparable degrees of human β-cell proliferation but at doses two- to threefold lower than those of <b>1</b> in both rat and human islets while maintaining or improving β-cell differentiation, like <b>1</b>. This bodes well for both Type 1 and Type 2 diabetes therapy, where β-cell dedifferentiation is known to occur. Further, the selectivity profile for the full 468 kinase panel indicated that compound <b>9</b> had ∼20% improved kinase selectivity over harmine (with activity at only 12 other kinases in addition to DYRK1A). When tested in CNS off-target assays for which <b>1</b> shows activity, compound <b>9</b> was far more selective, showing no binding activity to 8 of the 9 CNS-targets studied (adrenergic and serotoninergic GPCRs, MAOs), with the sole exception being retention of monoamine oxidase A activity. This enhanced <i>in vitro</i> CNS selectivity was recapitulated <i>in vivo</i>: supra-efficacious doses of <b>9</b> at 10 or even 30 mg/kg in 12 week-old male C57BL6N mice did not produce tremor, motor alterations, or other signs of psychoactivity, as observed for harmine at the efficacious dose of 10 mg/kg, further confirming the improved CNS tolerability of <b>9</b><i>in vivo.</i> In addition, compound <b>9</b> also showed low brain penetration in mice, which may have been influenced by the addition of the polar carboxamide pharmacophore, further diminishing possible CNS safety concerns for this harmine analogue.</div><div class="NLM_p last">The three different <i>in vivo</i> animal models previously used to study efficacy of compound <b>1</b> were also used to assess the ability of compound <b>9</b> to enhance mouse and human β-cell proliferation and augment β-cell mass in mice. Compound <b>9</b> (1 mg/kg) showed <i>in vivo</i> efficacy for β-cell proliferation similar to <b>1</b> in three different models of diabetes, but at 10-fold lower dose than <b>1</b> (10 mg/kg). In conclusion, through extensive SAR studies and biological characterization, a promising <i>in vivo</i> lead candidate 9 (<b>2</b>–<b>2c</b>) was identified, which retains the positive attributes of <b>1</b> (potent DYRK1A inhibition, <i>in vitro</i> and <i>in vivo</i> β-cell proliferation), while separating its negative liabilities of poor kinase selectivity and untoward <i>in vitro</i> activities and <i>in vivo</i> CNS effects.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> 5-Iodotubericidin (5-IT)</h3><div class="NLM_p">Annes et al. also developed an HTS platform for the identification of small molecule inducers of β-cell replication by measuring the percentage of PDX-1+ cells (a β-cell-specific transcription factor) that coexpressed <i>K</i>i-67.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Among the 850 compounds screened, they identified 5-iodotubericidin (<b>3</b>) (for structure, see <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) class of adenosine kinase inhibitors (ADK-Is) that promoted replication of only β-cells and not α-cells in both rat and porcine islets.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Subsequently, Dirice et al. evaluated the effect of <b>3</b> on human β-cell proliferation.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> After 6 days of treatment, <b>3</b> increased EdU incorporation in rat β-cells, indicating a 10- to 12-fold increase in β-cell proliferation with maximal effect at 1 μM. Notably, <b>3</b> did not induce proliferation of all cell types except for a few cells that appeared to weakly express glucagon, suggesting a β-cell-specific effect. Additionally, an increase in glucose-stimulated insulin secretion (GSIS) was observed upon treatment with <b>3</b>, emphasizing that the human β-cells are proliferating, alive, and functional for glucose regulation.</div><div class="NLM_p">Because 5-IT (<b>3</b>) is a known adenosine kinase inhibitor, and to understand whether promotion of human β-cell proliferation was dependent on adenosine kinase inhibition, human islets were treated with the structurally unrelated adenosine kinase inhibitor, ABT-702, which was found to have no effect on β-cells EdU incorporation. This suggested that the mechanism of action of <b>3</b> in human β-cells may be independent of adenosine kinase. As was observed for harmine (<b>1</b>), a kinome profile of <b>3</b> against a panel of 253 human kinases at 100 nM revealed that compound <b>3</b> strongly inhibited several CMCG family of kinases alluded to earlier. Similar to <b>3</b>, compound <b>1</b> also caused EdU incorporation in human islets, lending credence to the hypothesis that compound <b>3</b> induced β-cell proliferation is mediated via DYRK1A-NFAT pathway. This was further confirmed when FK506, an inhibitor of calcineurin and NFAT activation, attenuated proliferation of <b>1</b> or <b>3</b> treated human β-cells by blocking the activation of NFAT. Finally, genetic knockdown of DYRK1A resulted in increase in EdU-positive β-cells, providing further evidence on the role of DYRK1A inhibition on β-cell proliferation.</div><div class="NLM_p">Gene expression analysis of compound <b>3</b> treated human β-cells indicated that 10 of the 30 enriched gene sets were involved in cell proliferation. Interestingly, upregulation of the SLC2A2 gene which encodes the glucose transporter, GLUT2, may contribute to the beneficial effects of <b>3</b> on GSIS. Compound <b>3</b> promoted human β-cell proliferation transplanted into NSG mice: immunohistochemical analysis showed a ∼5–6-fold increase in proliferation as assessed by BrdU incorporation and <i>K</i>i-67 labeling and a 4-fold increase in PDX1/BrdU double-positive cells in human β-cell grafts. Interestingly, no α-cell proliferation was observed, suggesting a β-cell specific effect of compound <b>3</b>.</div><div class="NLM_p last">In summary, compound <b>3</b> potently promotes human β-cell proliferation both <i>in vitro</i> and <i>in vivo</i> mediated via inhibition of DYRK1A. Similar to <b>1</b>, challenges will need to be overcome to advance compound <b>3</b> as a clinical candidate. Since the target DYRK1A is ubiquitously expressed, <b>3</b> may require β-cell-specific targeting. Additionally, compound <b>3</b> suffers from poor kinase selectivity,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> making it a less promising candidate for translational drug discovery. These concerns can be overcome by either developing strategies to specifically deliver <b>3</b> to β-cells or through SAR by fine-tuning the kinase selectivity profile, thus reducing its liabilities.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> 1,3,4-Thiadiazines</h3><div class="NLM_p">Because current small molecule DYRK1A inhibitors are ATP-competitive inhibitors (Type I inhibitors) and share the “generic” ATP binding pocket in DYRK1A, synthesizing perfectly or uniquely selective DYRK1A inhibitors is a particularly difficult challenge. To work around this intrinsic constraint of Type 1 inhibitors, we have focused on identifying novel DYRK1A inhibitor scaffolds with the potential for a unique binding mode to DYRK1A, distinct from the canonical ATP-competitive binding mode, such as the DFG-out conformation.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> As a starting point, a computational approach was proposed to model DYRK1A in an as yet not observed inactive conformation, the DFG-out conformation, and then perform a virtual screen to identify new inhibitor scaffolds with possible alternative binding modes.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The DFG model,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> a recently reported computational method to model the inactive conformations of many kinases, was used on DYRK1A. The type-II DFG-out model of DYRK1A was used for virtual screening of lead-like molecules (2,268,809 compounds). Virtual hits were further analyzed for their binding pose and curated for drug-like properties, yielding a set of 67 hits that were purchased commercially. Binding and functional kinase assays identified a novel DYRK1A inhibitor hit <b>10</b> with an IC<sub>50</sub> of 9.41 μM (<i>K</i><sub>d</sub> 7.3 μM) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). With a new, confirmed DYRK1A inhibitor scaffold in hand, hit-to-lead SAR studies were carried out to improve its DYRK1A binding potency and <i>in vitro</i> biological activity. Systematic, single structural modifications were explored at the thiadiazine 2-amino position (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). It was observed that the substitution pattern of the 2-benzylamino group substantially impacts the DYRK1A binding activity of this hit series. The majority of thiadiazine analogues bearing fluoro-, chloro-, cyano-, and trifluoromethyl-benzylamino substituents at the thiadiazine 2-position showed significantly improved DYRK1A binding affinity as compared to unsubstituted benzyl group of hit <b>1</b>. In addition, 4-chloro (<b>11</b>) and 4-fluoro (<b>12</b>) benzylamino thiadiazine were the most potent analogues identified with <i>K</i><sub>d</sub> values of 185 and 71 nM, respectively, a ∼50–100-fold improvement in DYRK1A binding. The effect on human β-cell proliferation of the most active DYRK1A inhibitor from the hit to lead exercise, <b>12</b>, was next investigated. Thiadiazine compound <b>12</b> induced human β-cell proliferation at 5 μM as compared to vehicle-treated cells, while also exhibiting impressive selectivity for DYRK1A over closely related kinases DYRK1B and DYRK2 at 10 μM screening concentration. Further improvements in DYRK1A binding affinity as well pharmacological studies beyond DYRK1A binding of this lead series will be required to advance this novel DYRK1A inhibitor scaffold and determine its binding mode.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. SAR study of 1,3,4-thiadiazines as DYRK1A inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> GNF 7156 and 4877</h3><div class="NLM_p">Building on their earlier work,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> the Laffitte lab carried out a high-throughput screen of 850,000 compounds and identified an aminopyrazine compound <b>13</b>, which induced β-cell proliferation in R7T1 cells (an immortalized mouse β-cell line) but not in rat islets (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> However, replacement of 4-aminopiperidine substituent with 4-carboxylpiperidine (GNF7156, <b>14</b>) improved the β-cell proliferation activity. Moving forward, further medicinal chemistry optimization of compound <b>14</b> was carried out while retaining the carboxylic acid substituent to identify compounds with improved β-cell proliferation. Replacement of 3-pyridyl with other pyridyl isomers or a phenyl ring resulted in partial or complete loss of DYRK1A inhibition potency, indicating the critical role of pyridyl nitrogen interaction with DYKR1A Lys188 as defined by a docking model. Piperidine amine was optimal, while azetidine and pyrrolidine analogues showed significantly decreased <i>in vitro</i> activity. Additionally, 3-(<i>R</i>)-substituted carboxylic acid (on piperidine) was superior to 4-position acid or the 3-(<i>S</i>) enantiomer. Furthermore, replacement of piperidine with piperazine and the 3-position carboxylic acid with methylenecarboxylic acid were detrimental for activity. Based on docking studies that showed unoccupied space around the phenyl ring 6-position, further optimization of the phenyl ring was explored. Introduction of substituents at the phenyl ring 2- and 4-positions reduced DYRK1A activity. This may be explained due to the twisting of the phenyl ring out of planarity by 2-position substituents and potential clash of 4-position substituents with Ty243. However, larger substituents at the 3-position were tolerated. Consequently, introduction of a small fluorine group at the 2-position along with trifluoromethoxy (<b>15</b>) or an iso-propoxy group (GNF4487, <b>16</b>) at the 3-position greatly improved the activity. Docking of <b>16</b> to DYRK1A showed that the 6-position iso-propoxy group fits nicely into the proposed hydrophobic pocket.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Optimization of aminopyrazine <b>13</b> toward discovery of GNF4877 (<b>16</b>)</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several <i>in vitro</i> and <i>in vivo</i> models were used for two optimized lead compounds, <b>16</b> and <b>14</b>, to evaluate their effects on human β-cell proliferation, insulin production, and glycemic control.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Both compounds caused EdU incorporation into 3–6% of β-cells in human islets with EC<sub>50</sub> = 540 ± 0.171 and 760 ± 0.49 nM, respectively. Global transcriptional analyses revealed significant increases in expression of the insulin-1 gene (<i>Ins1</i>) and other genes associated with cell cycle progression and cytokinesis. Furthermore, cells treated with these aminopyrazine compounds did not induce β-cell death, as there was no change in the number of TUNEL-positive β-cells. <b>16</b> showed 20-fold increase in <i>K</i>i-67/insulin positive β-cells <i>in vitro</i> after treatment of human islets for 7 days. Furthermore, immune compromised streptozotocin-diabetic mice transplanted with human islets showed greater BrdU incorporation into β-cells after treatment with <b>16</b> (oral dosage 50 mg/kg) for 9 days as compared to vehicle-treated mice, indicating that the aminopyrazine compounds induce proliferation of functional human β-cells <i>in vivo.</i> Additionally, compound <b>16</b> significantly improved glycemic control in a mouse model of T1D without showing any difference in body weight. Moreover, diabetic mice treated with compound <b>16</b> (oral dosage 50 mg/kg for 12 days) exhibited improved oral glucose tolerance without altering insulin sensitivity. These data indicate that the improved glycemic control was caused by improved β-cell function and not by increased insulin sensitivity, and that compounds <b>14</b> and <b>16</b> induce proliferation of functional human β-cells both <i>in vitro</i> and <i>in vivo</i>.</div><div class="NLM_p last">Because some aminopyrazine compounds were reported to be GSK3β inhibitors<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> and GSK3β had been suggested to be involved in β-cell proliferation,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> it was proposed that the mechanism of action for compound <b>16</b> was most likely mediated by GSK3β inhibition. Both <b>16</b> and <b>14</b> inhibited GSK3β with IC<sub>50</sub> values of 40 and 16 nM, respectively. However, other selective GSK3β inhibitors (1-Akp, Chiron99021) had no effect on human β-cell proliferation,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> making GSK3β alone an unlikely target. This was further confirmed when overexpression of GSK3β only partially lowered the β-cell proliferation upon treatment with the inhibitors. To further understand their mechanism of action, kinome profiling of compounds <b>16</b> and <b>14</b> (Ambit KINOMEscan) revealed that both the compounds are potent inhibitors of DYRK1A (IC<sub>50</sub> 6 and 100 nM, respectively). Because the other kinases inhibited by aminopyrazines are not highly expressed in β-cells, the focus was directed to DYRK1A. A GSK3β selective analogue, GNF6324, that lacked DYRK1A inhibitory potency, did not induce rat or human β-cell proliferation, again indicating that inhibition of DYRK1A is crucial for the proliferation with these compounds. This was further confirmed when overexpression of DYRK1A inhibited β-cell proliferation induced by the aminopyrazines. More importantly, the reduction in β-cell proliferation was more pronounced upon genetic overexpression of DYRK1A as compared to GSK3β, again confirming that DYRK1A was definitely a major contributor for activity of this lead class. Last, the authors emphasized the role of dual inhibition by showing the additive induction of rat β-cells when treated with the combination of selective GSK3β inhibitor Chiron99021 and TG003. However, these results were not confirmed in human islets. Similar results have been reported by Ackeifi et al.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Interestingly, Ackeifi et al. observed that reductions in human β-cell proliferation due to silencing of both DYRK1A and DYRK1B was less marked for islets treated with compound <b>16</b> than for <b>1</b> or <b>3</b>, suggesting that compound <b>16</b> may have additional mitogenic targets as compared to <b>1</b> or <b>3</b>.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Notably, because both DYRK1A and DYRK1B are implicated in human β-cell proliferation (see above) and the kinase profile of compound <b>16</b> indicates that it also potently inhibits DYRK1B at 10 μM, a beneficial role for DYRK1B inhibition by aminopyrazine induced β-cell proliferation is likely.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> In summary, the aminopyrazines <b>16</b> and <b>14</b> induce β-cell proliferation <i>in vitro</i> and <i>in vivo</i>, increase β-cell insulin secretion, and ultimately improve glycemic control in diabetic mice.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> GNF 2133</h3><div class="NLM_p">Long-term inhibition of GSK3β can activate pathways responsible for tumor development and progression.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> In this context, Liu et al. reported the discovery of 6-azaindole derivative GNF2133 (<b>21</b>) as a potent and selective DYRK1A inhibitor that induces β-cell proliferation and avoids any potential side effects caused by inhibition of GSK3β (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> In a previous study seeking to identify compounds preserving β-cell mass and function, Liu et al. identified a potent and selective DYRK1A inhibitor <b>17</b> (IC<sub>50</sub> = 43 nM) based on a 6-azaindole core with low but measurable GSK3β inhibition (IC<sub>50</sub> > 8300 nM).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> SAR studies were carried out at the 1- and 3-positions of the 7-azaindole <b>17</b> to improve DYRK1A potency and selectivity over GSK3β. Groups such as cyclopropyl, ethers, and benzyl reduced DYRK1A inhibition but maintained selectivity over GSK3β (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Introduction of a phenyl group at azaindole nitrogen afforded the most potent compound <b>18</b> with >600-fold improvement on selectivity over GSK3β as compared to DYRK1A. However, compound <b>18</b> suffered from poor human, mouse, and rat microsomal stability.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Optimization and SAR studies of 7-azaindoles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further studies to improve ADME-PK and other drug-like properties were explored next. Docking of <b>18</b> to the DYRK1A model revealed the opportunity for modification of the 2-position of the pyridyl ring to help improve metabolic stability without affecting the DYRK1A potency. Introduction of <i>ortho</i> 2-amino and 2-carboxamide substituents to the pyridyl ring reduced selectivity for GSK3β. However, the carboxamide substituted analogue <b>19</b> was well tolerated, with potent, selective DYRK1A inhibition and improved microsomal stability. Unfortunately, <b>19</b> exhibited potent hERG channel inhibition, a major cardiovascular safety liability. Based on the docking study of <b>19</b> to hERG, sterically bulky substituents such as cyclohexanol (<b>20</b>), piperazine (GNF2133, <b>21</b>) with potential to clash with hERG protein were introduced to reduce activity at the ion channel. Both compounds <b>20</b> and <b>21</b> induced β-cell proliferation in human and rat islets, exhibited improved physicochemical properties and ADMET profile. Unfortunately, <b>20</b> was found to be mutagenic and positive for genotoxicity through oxidative DNA damage. Modification of the core 6-azaindole was also carried out, but no improvement in DYRK1A activity and selectivity was observed.</div><div class="NLM_p">The cocrystal structure of <b>21</b> in complex with DYRK1A revealed that it binds using typical type 1 kinase inhibitor polar contacts with backbone of Leu241 and side chain of Lys188. In addition to the polar contacts, several arene-H interactions were also observed with side chains of Phe238, Val306, and Val173. Kinase profile screen of <b>21</b> against 250 kinases at 0.2 and 2 μM was relatively clean with 90% inhibition of DYRKs, RIPK2, FLT4, and CLK1/2/4. The intravenous and oral <i>in vivo</i> PK profile of <b>21</b> in mouse showed promising ADME-PK properties with moderate plasma clearance (Cl<sub>p</sub> = 23.5 mL/min/kg), high volume of distribution (<i>V</i><sub>dss</sub> = 11 L/kg), longer half-life (6.6 h), and moderate plasma exposure (AUC = 3268 nM-hr), making it a useful chemical probe for <i>in vivo</i> studies.</div><div class="NLM_p">Compound <b>21</b> increased the rat β-cell proliferation marker <i>K</i>i-67 with insulin at oral dosage of 30 mg/kg (administered once a day) for 5 days, confirming its <i>in vivo</i> β-cell proliferation efficacy. Additionally, compound <b>21</b> greatly reduced glucose levels and increased insulin secretion in the RIP-DTA mouse model at an oral dosage of 10 and 30 mg/kg after 35 days of treatment. As discussed earlier, one liability of DYRK1A is its ubiquitous expression. To explore this liability further, compound <b>21</b> was investigated for nontarget cellular proliferation and organ toxicity at 100 mg/kg for 2 weeks. Compound <b>21</b> was observed to induce proliferation in other tissues, including exocrine pancreas (six-fold increase), liver (four-fold increase), heart (four-fold increase), and kidney (fivefold increase) at the doses studied</div><div class="NLM_p last">In summary, despite showing promising <i>in vivo</i> β-cell proliferation activity along with optimal drug-like PK properties, compound <b>21</b> suffers from a small safety window (3–10×, if at all) from nonpancreatic tissue proliferation, a liability that would appear to limit its potential for development as a diabetes therapeutic.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> CC-401</h3><div class="NLM_p">To gain better understanding of molecular pathways that influence β-cell proliferation and to identify novel modulators of β-cell replication, Annes et al. developed a HTS platform which identifies β-cell proliferation by measuring the percentage of PDX-1+ cells (marker of β-cell proliferation) that coexpressed <i>K</i>i-67 in rat β-cells.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Abdolazimi et al. used the platform to screen a library of 2400 bioactive compounds to identify novel modulators of rat β-cell replication activity.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Among these, 62 compounds exhibited a 2-fold induction of β-cell replication at one concentration or 1.4-fold induction at more than one concentration. The 62 hit compounds were found to belong to the class of adenosine kinase inhibitors 5-iodotubercidin and ABT-702, the insulin-secretion modulator glibenclamide, the phosphodiesterase inhibitor dipyridamole, and the GSK3β inhibitor CHIR99021. Previously identified ABT-702, dipyridamole and newly found compound <b>4</b> (CC-401, for structure, see <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), JaK3 inhibitor VI, CNS-1102, BML-266, and tivozanib, which induced the most robust rat β-cell proliferation, were selected for <i>in vitro</i> study of human β-cell replication. Among the six compounds, only <b>4</b> and JaK3 inhibitor VI consistently induced human β-cell proliferation <i>in vitro.</i> Compound <b>4</b> was subsequently selected as the lead for further studies.</div><div class="NLM_p">Because compound <b>4</b> is a JNK inhibitor, it was hypothesized that <b>4</b> induces β-cell replication by inhibiting JNK. However, no other JNK inhibitors induced robust β-cell replication, indicating different mechanism of action. Kinome profiling of <b>4</b> against a panel of 453 human kinases at 10 μM revealed that DYRK1A/B were the most highly inhibited kinases, as had been previously implicated in human β-cell replication, for compounds <b>1</b> (harmine), <b>3</b> (5-IT), and <b>16</b> (GNF4877), making DYRK1A/B the most likely target for β-cell proliferation activity of <b>4</b>. To assess whether compounds <b>1</b> and <b>4</b> have similar mechanisms of action, β-cell replication was measured in response to <b>1</b> and <b>4</b>, both individually and in combination. As expected, the combination of <b>1</b> and <b>4</b> showed no further increase in β-cell replication as compared to each individually, further supporting DYRK1A/B as the likely target for <b>4</b>. In contrast to <b>1</b> and <b>3</b>, which induce β-cell proliferation by NFAT activation resulting from DYRK1A inhibition, compound <b>4</b>-induced proliferation seemed to be independent of NFAT pathway, as FK506, an inhibitor of the calcineurin-NFAT signaling, only partially inhibited proliferation. Additionally, <b>4</b> inhibited DYRK1A-dependent phosphorylation/stabilization of the β-cell-replication inhibitor p27<sup>KIP1</sup>. In addition, transcriptome and gene ontology analysis of rat β-cells treated with <b>4</b> suggested involvement of E2F transcription factors and DREAM complex targets FOXM1 and MYBL2. Thus, compound <b>4</b> may drive β-cell proliferation via multiple pathways, including DYRK1A inhibition, p27 destabilization, and interference with the cell cycle repressive DREAM complex.</div><div class="NLM_p last">To summarize, <b>4</b> is a novel inducer of human β-cell proliferation likely mediated via DYRK1A/B inhibition. One limitation of this study is the lack of <i>in vivo</i> studies with human islets. Second, long-term compound <b>4</b> treatment caused weight loss and led to conflicting reports on effects of <b>4</b> on glucose homeostasis and β-cell replication/expansion. Like <b>1</b> (harmine), <b>3</b> (5-IT), and the GNF compounds (<b>14</b>, <b>16</b>, and <b>21</b>), because <b>4</b> acts via DYRK1A/B inhibition, development of strategies to deliver them specifically to β-cells may be necessary to avoid proliferation in non-β-cell tissues.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> 1,5-Naphthridines</h3><div class="NLM_p">After identifying compound <b>4</b> as a novel promoter of human β-cell replication, the Annes lab performed differential gene expression analysis on rat β-cells treated with <b>4</b>. They reported that the cell-cycle regulator MELK gene was overexpressed by 2.6-fold.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Because MELK plays an important role in activating FOXM1,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> a regulator of β-cell replication,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> it was proposed that inhibition of MELK would attenuate compound <b>4</b> induced human β-cell proliferation. Contrary to expectations, compound <b>22</b> (<b>OTS167</b>),<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> a MELK-inhibitor, induced human β-cell replication in a narrow dose range ∼5–40 nM. Full kinase profile of <b>22</b> against 468 kinases at 100 nM revealed that it was very promiscuous, inhibiting 69 additional kinases with% remaining activity less than 1% (>99% inhibition) at relatively low screening dose of 100 nM. Importantly, this compound also inhibited DYRK1A (0% residual activity at 100 nM), suggesting a probable role for DYRK1A on compound <b>22</b> mediated proliferation. Data from genetic knockdown experiments of MELK expression and/or the study of more selective MELK kinase inhibitors may shed more light on the role, if any, of MELK on β-cell proliferation.</div><div class="NLM_p">Based on the <i>in silico</i> binding mode to DYRK1A ATP-site, three regions of <b>22</b>, the 3-position (methyl ester group), 5-position (dimethylamino group), and 6-position (dichlorophenol group) of the 1,5-napthyridine ring were selected for modifications (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). A library of 51 1,5-naphthyridine analogues was synthesized with modifications in these three regions to identify analogues with reduced toxicity and improved human β-cell proliferation activity. Modification of the 3-position of the 1,5-naphthyridine system did not have a significant effect on DYRK1A inhibition potency. However, two analogues with ethyl ester and nitrile substituents, respectively, at the 3-position considerably reduced the <i>in vitro</i> cell cytotoxicity of these analogues as measured by dual luciferase reporter assay.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Contrary to the 3-position, modification at the dimethylamino group at the 4-position had larger effects on the cell cytotoxicity and DYRK1A inhibition potency. Importantly, introduction of a basic amino group significantly increased the toxicity of the compounds, whereas a 4-aminopiperidine group (<b>23</b>), cyclic secondary amino substituents, piperazine, and amino cyclohexane carboxamide resulted in dramatic increases in DYRK1A inhibition-cytotoxicity index compared to compound <b>22</b>.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Optimization and SAR studies of 1,5-naphthyridine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Modification of the headgroup (dichlorophenol group) that interacts with Lys188 was found to be particularly sensitive to the DYRK1A inhibition potency. As expected, removal of the hydroxyl group greatly reduced the DYRK1A inhibition potency. Replacement of the 6-position chlorophenyl group with a methylphenyl group resulted in the best inhibition-cytotoxicity index score with DYRK1A inhibition potency EC<sub>50</sub> of 10 nM and no cytotoxicity observed at >10 μM. The 2-methyl pyridyl group was not optimal for DYRK1A inhibition, whereas a 2-amino pyridyl addition greatly enhanced the DYRK1A inhibition-cytotoxicity index.</div><div class="NLM_p last">Eighteen additional compounds from the primary screening set were selected to assess β-cell cytotoxicity and human β-cell replication potency. All of the compounds were significantly less cytotoxic as compared to <b>22</b>, as measured in the R7T1 mouse β-cell line. Two compounds, <b>23</b> and <b>24</b>, exhibited β-cell replication potency greater than the hit <b>22</b> (EC<sub>min</sub> = 10 nM) and GNF-4877 (EC<sub>min</sub> < 100 nM) with EC<sub>min</sub> = 3.3 nM. For several compounds, there was discordance between the DYRK1A inhibition potency and β-cell replication activity, indicating that the correlation between DYRK1A inhibition and β-cell replication is not necessarily direct. Most importantly, among all the compounds, analogues <b>23</b>, <b>24</b>, and <b>25</b> had greatly improved replication-toxicity indices (R7T1 CC50/Islet EC<sub>min</sub>) of 117, 143, and 259, respectively. Compound <b>25</b> also exhibited much improved kinase selectivity profile when screened against a panel of 468 kinases at 500 nM concentration. Of the 40 kinases which were strongly inhibited (<2% remaining activity) by <b>22</b> at a concentration of 100 nM, none were inhibited by compound <b>25</b> at 500 nM, confirming the improved kinase selectivity of <b>25</b> over <b>22</b>. Interestingly, <b>25</b> inhibited both DYRK1A and DYRK1B at 100 and 500 nM concentration. To summarize, through structure-based <i>in silico</i> docking, the Annes lab demonstrated that it is possible to separate the cellular cytotoxicity and β-cell replication potency of hit <b>22</b>, leading to highly potent and relatively noncytotoxic analogues with significantly improved replication-toxicity index. Limitations of the study are lack of <i>in vitro</i> and <i>in vivo</i> pharmacokinetic studies and <i>in vivo</i> proliferative efficacy studies in rodent and human β-cell transplant models. As with other DYRK1A inhibitors, additional studies are warranted to determine the necessity for development of targeted β-cell delivery.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">DYRK1A Inhibitors in Combination with TGFβ Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53224" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53224" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Most of the DYRK1A inhibitors that have been described earlier induce human β-cell proliferation in the range of 2–3%. However, a more rapid rate of proliferation likely will be required from therapeutic point of view to fully restore functional β-cell mass in T1D and T2D. With the goal of achieving higher rates of human β-cell proliferation, Wang et al. have investigated combinations of DYRK1A inhibitors with other classes of compounds thought to be mitogenic for β-cells. Genomic and transcriptomic analyses of β-cell mitogenic pathways in large numbers of human insulinomas, benign β-cell tumors, revealed that TGFβ superfamily members and SMAD signaling pathways (SMADs are the downstream signaling molecules that mediate TGFβ action) comprise the single greatest number of mutations.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In addition, several studies have reported that inhibition of TGFβ signaling pathway led to rodent (but not human) β-cell proliferation.<a onclick="showRef(event, 'ref16 ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref16 ref33 ref34 ref35 ref36">(16,33−36)</a></div><div class="NLM_p">As one example, Annes et al. reported that compound <b>4</b> and TGFβ inhibitor combination increased both rat and human β-cell proliferation.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Administration of <b>4</b> (25 mg/kg i.p.) daily for 7 days increased BrdU incorporation by 2-fold in mouse β-cells <i>in vivo</i>, yet did not promote proliferation in α-cells or δ-cells.</div><div class="NLM_p">Along similar lines, Wang et al. explored the effect of combined inhibition of DYRK1A and TGFβ signaling on human β-cell proliferation both <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> As expected, the TGFβ superfamily inhibitors (TGFβ, bone morphogenic protein (BMP) and activin receptor inhibitors) alone did not induce human β-cell proliferation, as assessed using <i>K</i>i-67 labeling and BrdU incorporation of insulin-positive cells. In contrast, these TGFβ superfamily inhibitors in combination with compound <b>1</b> exhibited dramatic increases in β-cell proliferation with rates in the range of 5–8%, 2–4-fold greater than that of <b>1</b> alone. Similar effects were observed in β-cells obtained from organ donors with T2D. Additionally, using flow cytometry, the combination of <b>1</b> and the TGFβ inhibitor, LY364947, increased not only β-cell proliferation <i>markers</i>, but actual <i>numbers</i> of both stem cell-derived and adult human β-cells. This synergistic combination effect was not limited to compound <b>1</b>: other DYRK1A inhibitors including leucettines (<b>5</b> and <b>6</b>) and <b>2</b>, in combination with TGFβ inhibitors, displayed similar synergistic responses on human β-cell proliferation.</div><div class="NLM_p">It is important to note that the proliferation was also observed in alpha, delta, ductal, and non-β-cells in islets. However, no adverse β-cell effects (DNA damage, cell death) were observed. Because TGFβ inhibitors are in current use and are known to have important and multiple adverse effects, they will need to be targeted to the β-cells for clinical usage. Concerned that activation of mitogenic pathways might lead to dedifferentiation of β-cells, gene expression analyses of β-cell differentiation markers were performed using qPCR and RNaseq. These studies revealed that combination of a TGFβ inhibitor and <b>1</b> did not induce dedifferentiation. Remarkably, expression of key β-cell markers was actually enhanced, as was glucose-stimulated insulin secretion.</div><div class="NLM_p">To understand the mechanism behind synergistic pharmacology of <b>1</b> and TGFβ inhibitor combinations on proliferation, expression levels of SMADs in human islets treated with compound <b>1</b> and the TGFβ inhibitor, ALK5, were measured. Interestingly, there was no effect on the abundance of SMAD2/3, whereas a significant reduction of SMADs1/5/9 was observed. Furthermore, genetic silencing of SMAD2, SMAD3 and SMAD4 in human islets treated with <b>1</b> enhanced β-cell proliferation. Similarly, overexpression of the inhibitory SMAD6 and SMAD7 in combination with <b>1</b> also enhanced human β-cell proliferation. These findings collectively suggest that the marked increase in proliferation due to combined treatment of <b>1</b> and TGFβ inhibitors is mediated via the SMAD pathway signaling.</div><div class="NLM_p">Similar to <b>1</b> alone, the combination of TGFβ inhibitors plus <b>1</b> induced expression of cell-cycle activators genes (<i>CDK1</i>, <i>CCNA1</i>, <i>CCNE2</i>, and <i>CDC25A</i>). In contrast, TGFβ inhibitors alone or with compound <b>1</b> reduced expression of cell cycle inhibitor genes (<i>CDKN2B</i>, <i>CDKN1A</i>, and <i>CDKN1C</i>), encoding p15<sup>INK4</sup>, p21<sup>CIP</sup>, and p57<sup>KIP1</sup>, respectively.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Furthermore, genetic silencing of either or both <i>CDKN1A</i> and <i>CDKN1C</i> in the presence of <b>1</b> led to robust increase in human β-cell proliferation, whereas their overexpression significantly reduced the observed proliferation.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> These results confirm that inhibition of CDKN1A and CDKN1C may play particularly important roles in the proliferative synergy observed with the TGFβ inhibitor-harmine (<b>1</b>) combination. Additionally, silencing or overexpression of DYRK1A led to enhancement or inhibition, respectively, of combined compound <b>1</b> and TGFβ inhibitor-induced proliferation. These results further confirm the crucial role of DYRK1A in the synergistic proliferation derived by the combination <b>1</b> and TGFβ inhibitor.</div><div class="NLM_p">Because Trithorax and SMAD signaling have been linked to human β-cell proliferation in human insulinomas,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Wang et al. investigated whether R-SMADS-2, -3, and/or -4 directly interact with regulatory regions of the <i>CDKN1A</i> and/or <i>CDKN1C</i> genes, along with associated Trithorax members MEN1 and KDM6A in human islets. Chromatin immunoprecipitation (ChIP) experiments revealed that the combination of <b>1</b> and TGFβ inhibitor directly or indirectly dissociates or remodels the interaction of MEN1 and KDM6A with <i>CDKN1A</i> and <i>CDKN1C</i> genes in human islets, associated with enhanced β-cell proliferation. Collectively, these findings indicate that mechanisms for synergistic effects on proliferation can be primarily attributed to both the compound <b>1</b> induced activation of cell cycle activators accompanied by dissociation (or remodeling) of the SMAD-Trithorax-dependent inhibition of cell cycle inhibitors <i>CDKN1A</i> and <i>CDKN1C</i> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mechanism of synergistic effect of <b>1</b> and TGFβ inhibitor on human β-cell proliferation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The <i>in vitro</i> effects of the combination of <b>1</b> and TGFβ inhibitor on human β-cell proliferation translated well to three different <i>in vivo</i> mouse models. The combination of <b>1</b> at 10 mg/kg/day and the TGFβ inhibitor GW788388 at 30 mg/kg/day for 7 days doubled the extent of proliferation in comparison to <b>1</b> and GW788388 alone, with <i>K</i>i-67 labeling of 2%. In the PPX mouse model, β-cell mass almost normalized within 7 days in mice that had undergone a 60% PPX followed by treatment with the combination of <b>1</b> and GW788388 (10 and 30 mg/kg/day, respectively), whereas no change in β-cell mass was observed in vehicle-treated PPX mice. Similarly, the combination of <b>1</b> and GW788388 was substantially more effective in driving β-cell proliferation in transplanted human islets in the NOD-SCID mouse than either compound alone.</div><div class="NLM_p">In summary, DYRK1A inhibitor in combination with any TGFβ superfamily inhibitor can synergistically enhance human β-cell proliferation both <i>in vitro</i> (5–8%) and <i>in vivo</i> (∼2%) by inhibition of DYRK1A and subsequent activation of downstream cell cycle activators (Cyclins and CDKs), accompanied by SMAD-Trithorax mediated reductions in cell cycle inhibitors (CDKN1C and CDKN1A).</div><div class="NLM_p last">Notably, the DYRK1A and TGFβ inhibitor combination approach has several drug development challenges that require further discussion. Because SMAD and DYRK1A are ubiquitously expressed, DYRK1A-TGFβ inhibition may lead to off-target effects, as evident from the high level of proliferation in islet alpha and ductal cells induced by the combination <b>1</b> and TGFβ inhibitors.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Thus, as reported with the DYRK1A inhibitors, it will be crucial to deliver these TGFβ inhibitors selectively to the β-cells. An approach one can consider is by conjugation to β-cell specific ligands such as GLP-1<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> or mouse monoclonal antibodies<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> as “proof of concept” carriers to target the β-cells (<i>vide infra</i>). Additionally, it is important to highlight that several reports predict that the long-term inhibition of TGFβ may result in cell dedifferentiation. Nevertheless, despite these challenges, this remarkable combination approach demonstrates the largest known <i>in vitro</i> proliferation rates with the potential for development as therapeutic strategy for expansion of β-cell mass and preservation of their function as a possible cure for T1D and T2D.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">DYRK1A Inhibitors in Combination with GLP-1 Agonists</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25402" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25402" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As discussed above, one of the main challenges for the combination of DYRK1A-TGFβ inhibitors is the lack of β-cell specificity for both DYRK1A and TGFβ receptors, as they are widely expressed in a wide variety of cell types. To identify a safer and more selective combination approach, Ackeifi et al. investigated the effect of harmine (<b>1</b>) in combination with β-cell-specific drugs, exemplified by the meglitinides, sulfonylureas, and glucagon-like peptide-1 receptor (GLP1R) agonists on human β-cell proliferation.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> GLP1R agonists not only exhibit greater β-cell specificity<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> as compared to TGFβ but are also widely used, safe, and efficacious current treatments for diabetes. Sulfonylureas and meglitinides displayed no proliferative effects and no synergy with <b>1</b>. As reported previously, GLP-1 alone had no effect on human β-cell proliferation.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In contrast, as had occurred with the combination of <b>1</b> and TGFβ inhibitor, the GLP1 and <b>1</b> combination displayed remarkable synergistic effects: the combination of <b>1</b> (10 μM) and GLP-1 (5 nM) showed a higher rate of proliferation (5–8%) as assessed by <i>K</i>i-67 immunolabeling <i>in vitro</i> than compound <b>1</b> alone (2.4%). Additionally, treatment of human islets with 10 μM of <b>1</b> with increasing doses of GLP-1 showed dose-dependent enhancement in proliferation, as compared to <b>1</b> or GLP-1 alone. Furthermore, lower, ineffective compound <b>1</b> concentrations of 1 and 3 μM in combination with even trivial dose of GLP-1 (<1 nM) induced robust proliferation similar to that of <b>1</b> at 10 μM, its most effective dose alone. Importantly, multiple β-cell proliferative DYRK1A inhibitors (<b>2</b>, <b>3</b>, <b>5</b>, <b>6</b>, and <b>16</b>) also exhibited similar synergy in combination with GLP-1, indicating that this enhancement in proliferation is a class effect of all β-cell proliferative DYRK1A inhibitors. Concordantly, a variety of commercially available and broadly used GLP1R agonists (exenatide, liraglutide, lixisenatide, and semaglutide) showed similar synergy with <b>1</b>.</div><div class="NLM_p">To further confirm that increase in <i>K</i>i-67 labeling actually translates to increases in β-cell numbers, Ad.RIP-ZsGreen-transduced human islets were treated with the combination of <b>1</b> and GLP-1, and subsequently, β-cells were quantified using FACS. After 4 days of treatment <i>in vitro</i>, the actual numbers of human β-cells in the compound <b>1</b>-GLP-1 combination group were 40% higher than those in the vehicle-treated group, attributed to increases in β-cell proliferation, and possibly enhanced β-cell survival as well. No evidence of DNA damage nor β-cell death was observed using immunocytochemistry in response to the compound <b>1</b> and GLP-1 combination. Furthermore, as compared to <b>1</b> alone, the <b>1</b> and GLP-1 combination only further induced proliferation in β-cells and CK19<sup>+</sup> cells, reflecting the greater specificity of this combination as compared to the <b>1</b> and TGFβ inhibitor combination.</div><div class="NLM_p">Ackeifi et al. next explored the cellular mechanism(s) of action responsible for the synergistic effects on proliferation. First, they looked at the role of DYRK1A inhibition on combination of <b>1</b> and GLP-1 mediated synergy. Human islets in which DYRK1A had been silenced exhibited the same degree of proliferation upon treatment with GLP-1 as that of the compound <b>1</b>-GLP-1 combination. In contrast, overexpression of DYRK1A completely inhibited β-cell proliferation in human islets treated with <b>1</b> and GLP1 alone or in combination. These studies confirm unequivocally the importance of DYRK1A on the synergistic proliferation. Because the GLP1R can signal via adenylyl cyclase (cAMP), several cAMP agonists or mimics were studied in combination with <b>1</b>. Interestingly, forskolin, dibutyryl cAMP, and phosphodiesterase inhibitors did not induce human β-cell proliferation. However, each compound in combination with <b>1</b> synergized to increase proliferation to a level similar to the combination of <b>1</b> and GLP-1. Furthermore, PKA and EPAC agonists in combination with <b>1</b> also exhibited similar rates of proliferation as that of the GLP-1 and <b>1</b> combination, and PKA and EPAC inhibitors blocked the enhanced β-cell proliferation of the GLP-1 and <b>1</b> combination, indicating that the synergistic proliferation requires cAMP/PKA/EPAC signaling. Downstream of PKA and EPAC, it is likely that the synergy involves activation and partnering of CREB/CREBBP family members, as suggested by the ability of naphthol-AS-E phosphate, which disrupts these interactions, to reduce the proliferation induced by the combination of <b>1</b> and GLP-1. Quantitative gene expression analysis of human islets after treatment with combination of <b>1</b> and GLP-1 indicated no change in expression levels of cell cycle activators and inhibitors in comparison to <b>1</b> and GLP-1 alone, with the only exception being cell cycle activator cyclin A showing greater abundance at protein level.</div><div class="NLM_p">Gene expression analyses of human islets following treatment with combination of <b>1</b> and GLP-1 did not reveal reductions in β-cell differentiation markers, but rather enhanced the expression of these markers, with greatest increase observed for GLUT2. Similar effects were observed in islets derived from human donors with T2D. Additionally, the insulin secretion response to glucose was significantly amplified by the compound <b>1</b> and GLP-1 combination.</div><div class="NLM_p">To evaluate the effects of combination of <b>1</b> and exenatide (a stable GLP-1 analogue) <i>in vivo</i>, the immunodeficient streptozotocin-diabetic NSG mouse model was transplanted with a minimal mass of human islets and treated intraperitoneally with either exenatide alone (0.5 μg/kg), <b>1</b> alone (1 mg/kg, 10-fold lower dosage for efficacy alone), or the combination of exenatide and <b>1</b>. The combination of <b>1</b> and exenatide restored normal glucose levels and increased plasma human insulin levels as compared to <b>1</b> or exenatide alone, documenting the beneficial role of compound <b>1</b> and GLP1R agonist combination on enhancing human β-cell function <i>in vivo.</i> Next, the effect of <b>1</b> and exenatide combination on β-cell proliferation of transplanted human islets in nondiabetic NSG mice was studied. As expected, the combination of <b>1</b> (1 mg/kg) and exenatide (0.5 μg/kg) <i>in vivo</i> using this diabetic model induced <i>K</i>i-67 labeling (0.8%) similar to that of <b>1</b> alone at 10-fold higher dosage (10 mg/kg). Both 1 and 10 mg/kg doses of <b>1</b> showed synergistic effect on proliferation in combination with exenatide with <i>K</i>i-67 labeling double that of <b>1</b> (10 mg/kg) alone.</div><div class="NLM_p">To address potential clinical safety concerns associated with GLP1R agonists, particularly pancreatitis and hyperplasia, histopathology of multiple organs was examined. No evidence of hyperplasia or other abnormalities was observed in pancreas, liver, intestine, kidney, or spleen. Longer term efficacy along with higher dose safety/tolerability studies will be required to further define the therapeutic window for these synergistic β-cell proliferative effects.</div><div class="NLM_p last">In summary, DYRK1A inhibitors in combination with a wide variety of GLP1R agonists synergistically enhance β-cell proliferation and function both <i>in vivo</i> and <i>in vitro</i> without causing β-cell dedifferentiation but rather improve β-cell differentiation and function. Because GLP1R agonists are widely used for the treatment of diabetes, they become attractive candidates for combination β-cell proliferative therapy when administered with DYRK1A inhibitors. As discussed above, several potential challenges and limitations remain to be addressed. First, the wide expression of DYRK1A and the lack of β-cell specificity for harmine and other DYRK1A inhibitors remains an important issue. However, in the case of GLP-1-harmine combination, this issue may be overcome partially by taking advantage of GLP1R β-cell specificity and by using an ineffective lower and possibly safer dose of <b>1</b> in combination with known safe or lower doses of GLP1R agonist.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Effect of Leukemia Inhibitory Factor (LIF) Pathway on Synergistic β-Cell Proliferation Induced by DYRK1A and TGFβ Inhibitor</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72626" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72626" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Recently, Rosado-Olivieri et al. developed a YAP overexpression system to induce replication of stem-cell-derived β-cells (SC-β).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Single-cell RNA sequence analysis of the proliferating cells revealed an upregulation of the LIF pathway genes.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Although this pathway has been reported to regulate proliferation and survival of various cell types,<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> its role on β-cell proliferation was unknown before this study. It was observed that activation of the LIF pathway induced replication of human β-cells both <i>in vitro</i> and <i>in vivo</i> as measured by <i>K</i>i-67 labeling and EdU incorporation. Gene expression analysis of LIF-stimulated SC-β-cells showed increased expression of cell cycle regulators similar to those regulated by the combined inhibition of DYRK1A and TGFβ signaling in human β-cells observed earlier.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Consequently, Rosado-Olivieri et al. investigated whether LIF might have any synergistic effect on proliferation induced by inhibition of DYRK1A and TGFβ signaling. Interestingly, activation of LIF pathway in combination with DYRK1A inhibitor harmine (<b>1</b>) and TGFβ inhibitor LY364947 significantly enhanced SC-β cells proliferation, as indicated by EdU incorporation. However, one limitation of this study is that this synergy experiment was carried out on SC-β cells. To further confirm the synergy of the LIF pathway with DYRK1A and TGFβ, further studies could be considered to translate these results to meaningful proliferation in mouse and human β-cells <i>in vitro</i> and <i>in vivo.</i> Additionally, further studies to understand the mechanism of LIF activation in the synergy with DYRK1A and TGFβ inhibition are required.</div></div><div id="sec6_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">β-Cell Targeted Therapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Because DYRK1A is widely expressed and is known to play a key role in other diseases,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and <b>1</b> suffers from poor selectivity both against kinases as well as CNS off-targets, there are safety concerns which may limit the therapeutic potential of <b>1</b> itself. Some might interpret that DYRK1A inhibitors will likely be safe in humans when administered systemically because preliminary preclinical toxicology studies report no adverse tissue effects on tissue histology, and therapeutic efficacy can be achieved in rodents with low doses of analogues of <b>1</b> that have no apparent psychoactive effects.<a onclick="showRef(event, 'ref22 ref62'); return false;" href="javascript:void(0);" class="ref ref22 ref62">(22,62)</a> One might also argue that recreational forms of <b>1</b> contained in ayahuasca have been used for centuries and have no evident link to oncogenesis or other long-term safety issues.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> On the other hand, as mentioned earlier, DYRK1A inhibitors can activate a low level of proliferation in alpha cells and ductal cells in human islets;<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> others might suggest that DYRK1A inhibitors are likely to have off-target effects that will require selective delivery to β-cells by conjugation to a β-cell targeting molecule.</div><div class="NLM_p">The bottom line is that it is currently unknown whether compound <b>1</b> or other DYRK1A inhibitors will prove to be safe in humans: there are no FDA-quality preclinical studies in large animal models, and there are no meaningful human safety data to adjudicate this question. Thus, human safety and toxicity of DYRK1A inhibitors will not be clear until rigorous phase 1 and 2 studies have been performed in humans. While these issues await resolution, it is reasonable to consider potential β-cell targeting strategies. In the sections below, we discuss rationales and approaches to β-cell targeting of β-cell regenerative compounds.</div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Antibody–Drug Conjugates</h3><div class="NLM_p">Antibody–drug conjugates (ADCs) consist of monoclonal antibodies (MAbs) connected with small molecules (warheads) <i>via</i> chemical linkers. The MAbs act as a “magic bullet” for selective targeting of cells through the antigen–antibody interaction on the cell surface.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a> ADCs are one of the fast growing strategies in oncology therapeutics over the past two decades because they selectively deliver cytotoxic drugs directly to cancer cells.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Recently, ADCs have been investigated for other therapeutic targets<a onclick="showRef(event, 'ref69 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref69 ref70 ref71">(69−71)</a> and have also been considered as an option for selective targeting of β-cells for proliferation as a treatment of diabetes.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></div><div class="NLM_p last">Ectonucleoside triphosphate diphosphohydrolase-3 (NTPDase3 or ENTPD3), an enzyme localized to the endocrine islet in human pancreas that modulates local extracellular nucleotide levels, has been identified as cell-surface marker specific to human pancreatic β-cells by Powers and coworkers in 2019.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> NTPDase3 expression is observed in adult pancreatic β-cells and a small percentage of somatostatin-expressing δ-cells, whereas no NTPDase3 expression is observed in adult α-cells, pancreatic polypeptide cells, and acinar cells. Furthermore, NTPDase3 expression could be found in human β-cells from people with both type 1 and 2 diabetes. Because NTPDase3 is highly expressed in pancreatic β-cells, Saunders et al. investigated the use of NTPDAse3 as β-cell specific biomarker. Using a NTPDase3 antibody, they were able to effectively FACS-sort subpopulation of δ-cells and β-cells.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Additionally, transplanted human islets in immunodeficient mice showed that the fluorescent tagged NTPDase3 antibody bound to human β-cells with high specificity, indicating at its viability as <i>in vivo</i> imaging agent for β-cells. These results suggested that NTPDase3 antibody has the potential to be a “magic bullet” for delivery of small molecule inducers of proliferation to β-cells, specifically.</div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Peptide–Drug Conjugates</h3><div class="NLM_p">In 2018, Ämmälä et al. reported targeted delivery of anti-sense oligonucleotides (ASOs) to pancreatic β-cells by conjugation of ASOs with β-cells specific ligand.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> ASO’s have been developed to target genes encoding proteins associated with human diseases that are considered undruggable by small molecules.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> ASOs are approved by the FDA to treat diseases such as cytomegalovirus retinitis,<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> neovascular age-related macular degeneration,<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> homozygous familial hypercholesterolemia,<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> hepatic veno-occlusive disease,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> and hereditary transthyretin amyloidosis.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p">After systemic administration, ASO’s mostly distribute to the liver and kidney<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> with limited systemic exposure to other organs. Therefore, targeting other tissues and cell types remains a major challenge. In this study, Ämmälä et al. used a GLP1R agonist to deliver ASOs to β-cells.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Ribonuclease (RNase) H1-dependent ASO aptamers were connected to an engineered GLP1R peptide ligand (eGLP1) generated by fusion of human GLP1 and exenatide fragments via a disulfide bond (eGLP1–ASO (<b>27</b>), <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A). The eGLP1–ASO conjugate (<b>27</b>) consists of two metabolically labile sites, the disulfide linkage and a trinucleotide phosphodiester at the 5′ end of ASO, both of which are cleaved inside cells to liberate the free ASO. Overnight treatment of GLP1R-HEK293 cells and mouse islets with various concentrations of ASO or <b>27</b> showed that the conjugate <b>27</b> significantly increased productive uptake of ASO as compared to the unconjugated ASO (<i>P</i> < 0.005). <i>In vivo</i> mouse studies also showed no enhanced ASO uptake in tissues that did not express GLP1R. Furthermore, islets isolated from mice 72 h after subcutaneous injection of <b>27</b> showed a dose-dependent reduction of target gene expression.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Structure of eGLP1–ASO (<b>26</b>) with fluorescent tag. (B) Structure of amino pyrazine (<b>13</b>) β-cell proliferation inducer, DTBZ (<b>27</b>), and AP-DTBZ conjugate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">This study demonstrated a novel strategy for targeted delivery of ASO’s to pancreatic β-cells. A conjugation of ASO with GLP1R agonist concept can be modified for small molecule delivery by using GLP1R agonists as β-cells targeting vehicle.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Using similar approach, DiMarchi and colleagues conjugated estrogen derivatives to GLP-1 analogue peptides to effectively target mouse β-cells.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Thus, one can envision a strategy to deliver β-cell proliferative molecules by conjugating them to GLP1R agonists. After the GLP1–small molecule conjugate binds to GLP1R and is internalized in the β-cells, it may be cleaved by cellular enzymes to release GLP1R peptide ligand and the proliferative small molecule.</div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Small Molecule–Drug Conjugates</h3><div class="NLM_p">Hao et al. reported a β-cell-specific delivery strategy using a small molecule vesicular monoamine transporter-2 (VMAT2) ligand (+)-dihydrotetrabenazine (DTBZ, <b>27</b>).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Compound <b>27</b> has been used as a pancreatic β-cell specific imaging agent in rodents and in human cells with partial success. Due to the tissue specificity of <b>27</b>, β-cell proliferation inducer aminopyrazine AP (<b>13</b>) was conjugated to <b>27</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B). The AP-DBTZ conjugate <b>28</b> exhibited higher pancreas AUC exposure in Balb/C mice as compared with liver, kidney, and brain while retaining both proliferative activity in mouse cell line and VMAT2 transporter affinity. However, it is important to note that conjugate <b>28</b> exhibited minimal proliferative activity in rat β-cells, which could be due to reduced DYRK1A inhibition potency of the conjugate. Additionally, total pancreas exposure may not directly indicate β-cell specific delivery. Furthermore, <i>in vitro</i> and <i>in vivo</i> human β-cell studies in the presence of the conjugate <b>28</b> are required to validate this finding. Having said that, these proof-of-principle studies illustrate that a small molecule β-cell regenerative drug could be conjugated to a small molecule β-cell targeting agent, if such a perfect small molecule β-cell targeting agent is identified.</div><div id="sec6_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Zinc Chelating Small Molecule–Drug Conjugates</h4><div class="NLM_p">Pancreatic β-cell insulin secretory granules contain Zn<sup>2+</sup> concentrations of ∼30 mM, >10<sup>7</sup>-fold higher than the cytosolic Zn<sup>2+</sup> concentrations in most other cells (∼400 pM), as well as in plasma and interstitial fluid (∼1 nM).<a onclick="showRef(event, 'ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref82 ref83">(82,83)</a> To leverage a high level of Zn<sup>2+</sup> in β-cells, zinc chelators like DTZ,<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> FluoZin,<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a><i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetrakis(2-pyridylmethyl)etha-1,2-diamine (TPEN),<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> 6-methoxy-8-<i>p</i>-toluenesulfonamido-quinoline (TSQ),<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> and (ZIMIR)<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> have been developed for pancreatic β-cell imaging. To assess the viability of small molecule zinc chelators for β-cell targeting, Horton et al. measured the accumulation of TSQ in zinc rich RT71 β-cells and mouse pancreatic islets using quantitative LC-MS/MS.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Both RT71 β-cells and mouse pancreatic islets demonstrated higher accumulation of TSQ. Because TSQ preferably accumulated in islets, Horton et al. proposed that conjugation of β-cell proliferation inducer <b>16</b> (GNF44877) to zinc chelator 2,2′-dipicoylamine (DPA) may result in specific delivery of the compound to β-cells. Remarkably, GNF4877-EXT-DPA conjugate <b>29</b> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A) bearing <b>16</b> with DPA (zinc chelators) was found to exhibit preferential mouse and human islet accumulation similar to TSQ. More interestingly, this favors accumulation of conjugate <b>29</b> which translated to preferential proliferation of β-cells over non-β-cells. Even though these results are encouraging, it is important to highlight that the magnitude of the superior β-cell accumulation and proliferation effect was relatively small in human islets from a therapeutic point of view. Further medicinal chemistry studies need to be carried out to find better small molecule zinc chelator–drug conjugates.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Structures of GNF4877-EXT-DPA (<b>29</b>) and (B) structures of prodrug ZnPD5 (<b>30</b>) and its Zn(II) mediated ester cleavage products ZP1 (<b>31</b>) and <b>16</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Recently, Lee and coworkers reported a zinc-based prodrug system for β-cell targeted delivery by conjugation of the β-cell proliferation inducer <b>16</b><a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> with a zinc chelating ligand <b>30</b> (ZnPD5) that takes advantage of the high concentration of Zn<sup>2+</sup> in β-cells to release the drug.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The prodrug consists of zinc binding ligand and <b>16</b> connected <i>via</i> ester or carbamate linkers (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B). The high intracellular Zn<sup>2+</sup> concentration is proposed to activate hydrolytic cleavage of the conjugate by chelation of Zn<sup>2+</sup> with <b>30</b> triggering the release of the fluorescent ligand <b>31</b> (ZP1) and <b>16</b>. The β-cells were highly fluorescent compared to other cell types after 1h incubation. Furthermore, <b>30</b> displayed dose-dependent induction of proliferation similar to <b>16</b>. This strategy is appealing for delivery of a small molecule that cannot tolerate modifications without a loss of activity and does not require enzymatic activation. Further studies are required to demonstrate these selective cellular effects <i>in vivo</i> as well as efficacy and β-cell specificity in preclinical animal models of diabetes.</div></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52063" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52063" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The discovery of DYRK1A inhibitors as novel inducers of human β-cell proliferation has brought about a defining shift in the field of diabetes research with special focus for the first time on β-cell regeneration and preservation as a potential “cure” for T1D and T2D. Since the identification of <b>1</b> by Wang et al., many small molecule DYRK1A inhibitors have been reported to induce human β-cell proliferation <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref11 ref12 ref13 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27">(11−13,16−27)</a> Here, we have highlighted recent advances in our understanding of DYRK1A as a key cellular target for β-cell proliferation, summarizing the identification of novel β-cell proliferative DYRK1A inhibitors, and medicinal chemistry structure–activity relationship studies for their <i>in vitro</i> and <i>in vivo</i> human β-cell proliferation activities. In marked contrast to the state of this research field five years ago, there is current unanimity that multiple DYRK1A inhibitors are able to induce excellent rates of human β-cell proliferation both <i>in vitro</i> and <i>in vivo</i> without β-cell dedifferentiation, death, or damage.</div><div class="NLM_p">Though progress on this small molecule approach to β-cell regeneration has been remarkable over the past few years, several challenges remain to reach full potential for clinical development and eventual treatment of diabetes patients. First, it is unknown whether the rate of proliferation observed with these DYRK1A inhibitors is therapeutically sufficient. This is primarily due to the absence of reliable methods to measure β-cell mass in humans. Current methods to measure human β-cell proliferation employ biomarkers exemplified by <i>K</i>i-67, BrdU, and EdU, which suggest S- and/or G2M-phase entry but do not prove cell division with actual formation of daughter cells. Keeping this in mind, it is difficult to assess whether the increase in <i>K</i>i-67 labeling translates to actual increase in functional β-cell numbers <i>in vivo.</i> Thus, to define a therapeutic level of human β-cell replication, long-term studies of transplanted human islets in immunodeficient mice will be crucial. The observation that harmine (<b>1</b>) in combination with GLP-1 agonists or TGFβ inhibitors enhances human β-cell proliferation (5–8%) as compared to DYRK1A inhibitors alone (1–3%) is encouraging, but we will not know whether these effects translate to human with T1D or T2D until these compounds are explored in human clinical studies. Additionally, the potential for synergy of drug combinations also requires safety assessment studies. One could speculate that combination of nontherapeutic doses of DYRK1A inhibitor (no effect alone), with low dose TGFβ inhibitor or better, widely used GLP1R agonist(s), may have potential to provide a wider therapeutic window for β-cell proliferation therapy than DYRK1A inhibition alone.</div><div class="NLM_p">Furthermore, noninvasive monitoring of β-cell mass using imaging remains to be achieved. We expect imaging will be necessary for clinical development of any β-cell regenerative therapy. Unchecked proliferation of β-cell themselves could lead to excess insulin production resulting in hypoglycemia; therefore, biomarker approaches that effectively correlate target engagement with accurate assessments of β-cell mass increase and insulin production will also provide key data sets to compile during preclinical and eventual clinical development.</div><div class="NLM_p">While higher rates of β-cell proliferation are desirable for T1D and T2D, the safety of this approach needs to be fully studied to understand the therapeutic safety window (if any) and potential off-target effects. Specifically, activation of β-cell regenerative pathways has the potential to lead to hyperplasia and/or possible oncogenic effects in non-β-cell cells and organs.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> There are, however, many examples of mitogenic or regenerative drugs that are approved and in widespread clinical use. These include nuclear hormone receptor agonists (estrogen and testosterone),<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> growth hormone,<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> parathyroid hormone,<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> and insulin itself. In the context of β-cells, Ackeifi et al. observed that histology of multiple organs (mouse liver, kidney, pancreas, intestine, heart, and spleen) after treatment with <b>1</b> (10 mg/kg) and combination of <b>1</b> (10 mg/kg) and exenatide (0.5 μg/kg) did not show any evidence of pancreatic ductular hyperplasia or proliferation or other abnormalities in organs outside the pancreas during 1 week of treatment. In contrast, <b>21</b> induced proliferation, as measured by <i>K</i>i-67 labeling, in exocrine pancreas (6-fold increase), liver (4-fold increase), heart (4-fold increase), and kidney (5-fold increase).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> It is difficult to assess whether these preliminary results are compound-specific because data for <b>1</b> are more encouraging and because <b>21</b> has a broad range of kinase targets, even at the low doses studied. Similarly, improved safety and tolerability may also be enhanced by consideration of β-cell regenerative therapy until effective β-cell mass is achieved, followed by “drug holiday” once insulin levels reach normal range. More preclinical and clinical studies are needed to clarify this issue.</div><div class="NLM_p">When considering the future of small molecule β-cell regenerative drug therapies, it is important to benchmark them against other currently approved and experimental approaches to restoring β-cell mass and endogenous insulin production in people with diabetes (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Whole pancreas transplantation for diabetes is approved by some regulatory agencies around the world, and is performed on a several thousand people annually. This is highly effective, but also extremely expensive and not scalable to hundreds of millions of people with diabetes, because of its excessive cost, limited donor organ availability and patient-donor histocompatibility limitations.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> In addition, organ transplantation and the immunosuppressive drug therapy required to diminish organ rejection are associated with induction of lymphoma and other types of cancer. Pancreatic islet transplantation is a promising experimental approach and is less invasive than whole pancreas transplant, but this approach, again, is extremely expensive and is not scalable to hundreds of millions of people with diabetes for reasons of cost and pancreas donor availability. Pancreatic islet transplantation also requires immunosuppressive drug administration to prevent rejection of transplanted islets, and this comes with oncogenic risk and other adverse effects. Experimental approaches to generate unlimited supplies of human β-cells derived from human embryonic stem cells and induced pluripotent cells (iPSCs) are in various stages of development, from basic research to early clinical trials, and hold great promise.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> These also may be developed in a way that avoids autoimmune rejection in T1D as well allograft rejection.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> However, as with whole pancreas and islet transplants, iPSC cell approaches will be extremely expensive, poorly scalable to hundreds of millions of people with diabetes, and carry a small but nonetheless worrisome risk of teratoma.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Development of epigenetic modulating drugs that might cause trans-differentiation of alpha cells to β-cells or redifferentiation of β-cells are also being considered.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> If such drugs are ever developed, and if they prove safe and free of off-target and oncogenic effects, they will be less expensive per patient and far more scalable than transplant and stem cell approaches. Seen from these perspectives, the development of small molecule DYRK1A inhibitors for β-cell regeneration is remarkably attractive: if safe and effective, it will be inexpensive and scalable to all 420 million people in world with diabetes, 30 million of whom are already taking GLP1R agonists.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Potential Therapeutic Approaches To Human β-Cell Regeneration and Replacement</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">approach</th><th class="colsep0 rowsep0" align="center">efficacy<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">scalability<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">cost</th><th class="colsep0 rowsep0" align="center">oncogenic</th><th class="colsep0 rowsep0" align="center">in use</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pancreas or islet transplant</td><td class="colsep0 rowsep0" align="left">4+</td><td class="colsep0 rowsep0" align="left">1+</td><td class="colsep0 rowsep0" align="left">high</td><td class="colsep0 rowsep0" align="left">lymphoma squamous</td><td class="colsep0 rowsep0" align="left">yes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iPSC/hESC β-cells</td><td class="colsep0 rowsep0" align="left">2+</td><td class="colsep0 rowsep0" align="left">2+</td><td class="colsep0 rowsep0" align="left">high</td><td class="colsep0 rowsep0" align="left">teratoma</td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">transdifferentiation from α-cells or redifferentiation: epigenetic approach</td><td class="colsep0 rowsep0" align="left">1+</td><td class="colsep0 rowsep0" align="left">2+</td><td class="colsep0 rowsep0" align="left">medium</td><td class="colsep0 rowsep0" align="left">many cancers possible</td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">small molecule β-cell regeneration</td><td class="colsep0 rowsep0" rowspan="4" align="left">unknown</td><td class="colsep0 rowsep0" rowspan="4" align="left">3+</td><td class="colsep0 rowsep0" rowspan="4" align="left">low</td><td class="colsep0 rowsep0" rowspan="4" align="left">unknown</td><td class="colsep0 rowsep0" align="left">in development<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">harmine,<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GLP-1 agonist,<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TGFβ inhibitor<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The higher the number, the better efficacy and feasibility of scalability (4 being the highest and 1 being the lowest).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Small molecule DYRK1A inhibitors alone or in combination with GLP1 agonists/TGFβ inhibitors as a β-cell regeneration agent are in developmental phase.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Many preclinical studies have been carried out to study the toxicological effect of harmine, a major component of ayahuasca.<a onclick="showRef(event, 'ref49 ref97'); return false;" href="javascript:void(0);" class="ref ref49 ref97">(49,97)</a></p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">FDA approved GLP-1 agonists: exenatide, liraglutide, albiglutide, dulaglutide, semaglutide, lixisenatide.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">TGFβ inhibitors: galunisertib, AVID200 (phase 1 clinical trial, <a href="http://www.clinicaltrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT03834662).</p></div></div></div><div class="NLM_p">The concern of possible off-target effects of DYRK1A inhibition is also relevant because the kinase is ubiquitous and has been implicated in various other diseases, including cancer, Alzheimer’s disease, and Down syndrome. Therefore, accurate safety assessment of on-target-based DYRK1A inhibition cellular effects versus compound-based specific toxicity is required to move small molecule inhibitors forward in preclinical and clinical development. Only one clinical trial using a DYRK1A inhibitor, epigallocatechin-3-gallate (EGCG), has been performed, exploring its use as a therapeutic candidate for improvement of cognitive performance and deceleration of Alzheimer’s disease (<a href="http://www.clinicaltrials.gov" class="extLink">ClinicalTrials.gov</a>, identifier: NCT01394796).</div><div class="NLM_p">In addition, one can observe that known compounds with both DYRK1A inhibition and β-cell proliferation activity (i.e., those shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) have different kinase profiles as well as other off-target activities. Developing a deeper understanding of the minimal kinase activity profile (DYRK1A alone <i>or</i> with other kinases) as well as the potential for additive/synergistic effects on β-cell proliferation by modulating DYRK1A <i>and</i> other biological pathways with a single molecule will require more complex genetic, chemical biology, and pharmacology studies in the future.</div><div class="NLM_p">One strategy to address possible off-target effects of DYRK1A inhibition and the cell specificity issue is to deliver these inhibitors specifically to β-cells by using putative β-cell specific targeting ligands. As discussed above in the section on targeting strategies, some progress has been made to identify and characterize potential novel targeting ligands with some specificity for β-cells.<a onclick="showRef(event, 'ref61 ref60 ref81 ref98'); return false;" href="javascript:void(0);" class="ref ref61 ref60 ref81 ref98">(61,60,81,98)</a> These are initial examples of a potential β-cell specific delivery of a small molecule that may provide a reliable strategy to deliver other DYRK1A inhibitors more selectively to β-cells. However, detailed <i>in vivo</i> studies are required to gain better understanding of the specificity of this approach.</div><div class="NLM_p">One also might reasonably be concerned, with or without β-cell-targeted treatment, that once initiated, β-cell proliferation might become autonomous, as for example occurs in pancreatic neuroendocrine tumors such as insulinoma. On the other hand, one might be reassured here, by the observation, as noted above, that many tissue-expanding drugs (e.g., estrogens, testosterone, growth hormone, parathyroid hormone, insulin) are widely used in effective and safe doses to induce tissue proliferation. This tissue proliferation ceases when the desired tissue-enhancing effect is achieved and the drug is withdrawn. Whether or not this paradigm can be achieved with systemic or β-cell targeted DYRK1A inhibitors remains to be determined in ongoing and future preclinical and clinical studies.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div class="NLM_p">Lastly, it is well-known that the immune system of T1D patients attack and destroy β-cells as a result of both genetic and environmental factors. Therefore, the robustness of newly generated β-cells to destructive autoimmune responses is another challenge that needs to be studied in depth and addressed at therapeutic level. This can best be accomplished if and when DYRK1A inhibitors reach later stage Phase 1B or Phase 2 clinical trials. At a minimum, effective β-cell regeneration will require rates of β-cell regeneration that exceed their rates of destruction. Studies on transplant of iPSC β-cell implants may shed led light on these challenges because these approaches are showing some success, although with high cost and limited ability to scale to more than a few thousand patients per year (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Approaches to modulate the immune response of early stage T1D have shown promise in prolonging β-cell survival, endogenous insulin production, and delaying insulin-dependence.<a onclick="showRef(event, 'ref99 ref100 ref101 ref102 ref103'); return false;" href="javascript:void(0);" class="ref ref99 ref100 ref101 ref102 ref103">(99−103)</a> Drugs that safely modulate autoimmunity could be helpful to people with T1D during the development of β-cell regenerative drugs. Interestingly, because autoimmunity is not a feature of T2D, enhanced β-cell expansion may be more easily achieved, though higher safety window for efficacy will be required for this much larger patient population.</div><div class="NLM_p last">Going forward, there are many technical, regulatory, and scientific challenges to overcome to achieve β-cell regeneration as a therapeutic option. Lack of reliable and fully normal human β-cell lines for study and techniques to measure β-cell mass in humans in a noninvasive manner remain a key barrier to research and development of β-cell regenerative drugs. Safety, toxicity, and No Adverse Effect Levels (NOAEL) in GLP/GMP safety assessment studies of multiple selective DYRK1A inhibitors will be required to understand both compound-based and target-based toxicity. In years to come, path-breaking advances in these aspects of drug development will be crucial in determining the future course and fate of small molecule driven β-cell regenerative medicine as a field. The development of DYRK1A kinase inhibitors for β-cell proliferation, alone or in combination with other drugs, shows unequivocal promise and merits further drug development with the potential reward to end insulin dependence for hundreds of millions of people with both T1D and T2D.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02050" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67034" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67034" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert J. DeVita</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Institute and Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2671-8497" title="Orcid link">http://orcid.org/0000-0002-2671-8497</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#483a272a2d3a3c662c2d3e213c2908253b3b25662d2c3d"><span class="__cf_email__" data-cfemail="04766b666176702a6061726d706544697777692a616071">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kunal Kumar</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Institute and Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chalada Suebsuwong</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Institute and Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peng Wang</span> - <span class="hlFld-Affiliation affiliation">Diabetes,
Obesity, and Metabolism Institute, Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adolfo Garcia-Ocana</span> - <span class="hlFld-Affiliation affiliation">Diabetes,
Obesity, and Metabolism Institute, Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew F. Stewart</span> - <span class="hlFld-Affiliation affiliation">Diabetes,
Obesity, and Metabolism Institute, Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The co-authors and institution have filed patents related to DYRK1A inhibitors as potential therapeutics for diabetes.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83160" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83160" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Kunal Kumar</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=BIO-d7e3331-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last">Dr. Kunal Kumar is a synthetic organic chemist with particular emphasis on medicinal chemistry and drug discovery. He received his Ph.D. degree in organic chemistry from Stony Brook University, United States under the guidance of Dr. Iwao Ojima in 2011. Subsequently, he did postdoctoral work at Stony Brook University and Icahn School of Medicine, United States. Currently, he is working as a Senior Scientist at Icahn School of Medicine, United States. His research interests are focused on identifying novel Type I and Type II DYRK1A inhibitors as therapeutics for diabetes.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Chalada Suebsuwong</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=BIO-d7e3334-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last">Dr. Chalada Suebsuwong obtained her B.Sc. degree in Pharmacy from Chulalongkorn University, Thailand and Ph.D. degree in Organic Chemistry from the University of Houston, Texas under the supervision of Dr. Gregory D. Cuny. In 2017, she moved to New York City for postdoctoral training at the Icahn School of Medicinal at Mount Sinai in the Dr. Robert J. DeVita Research Group. Currently, she is a Medicinal Chemist at VantAI, and her main research focuses on structure-based and computer-aided drug design to identify and optimize new molecular entities for targets of interest.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Peng Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=BIO-d7e3337-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last">Dr. Peng Wang is an Associate Professor at the Diabetes Obesity and Metabolism Institute at the Icahn School of Medicine. His research focuses on pancreatic β-cell proliferation by developing cell-based strategies for small molecule screens aimed at inducing human β-cell expansion and survival. He participated in the high-throughput screen with the Integrated Screening Core and identified the harmalog family of small molecules that can drive human β-cell proliferation. He also has extensive experience with the preparation and use of adeno- and lentiviruses to overexpress and silence genes of interest, exemplified by his work in <i>Nature Medicine</i>, <i>Nature Communications</i>, <i>Cell Metabolism</i>, and <i>Science Translational Medicine</i>. He has generated the majority of the work relating to the DREAM Complex in his role as Co-PI.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Adolfo Garcia-Ocana</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=BIO-d7e3352-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last">Dr. Garcia-Ocaña is Professor of Medicine in the Diabetes, Obesity and Metabolism Institute at the Icahn School of Medicine at Mount Sinai in New York and Director of the Human Islet and Adenovirus Core of the Einstein-Sinai Diabetes Research Center. His research lab has recently reported that sulfated polysaccharides can preserve pancreatic β-cells, induce immune tolerance, and ameliorate diabetes in a rodent model of type 1 diabetes. His research group has also recently demonstrated that treatment with harmine and exendin-4 remarkably expands human β-cell mass <i>in vivo</i> in immunosuppressed mice transplanted with human islets. His research clearly focuses on developing innovative and effective therapies for pancreatic β-cell preservation, immunomodulation, and pancreatic β-cell regeneration for the treatment of diabetes.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Andrew F. Stewart</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=BIO-d7e3358-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last">Dr. Stewart is the Director of the Diabetes, Obesity and Metabolism Institute at the Icahn School of Medicine at Mount Sinai in New York. His group was the first to demonstrate that growth factors can drive β-cell expansion and function <i>in vivo</i> in mammals, comprehensively define cell cycle control in the human β-cell, and employ gene therapy approaches to reverse diabetes. He defined the genomic pathways that led to β-cell expansion and insulin oversecretion in human insulinomas, producing a roadmap for discovery of human β-cell regenerative drugs. In 2015, his group described the first class of small molecule drugs able to induce human β-cells to replicate, the DYRK1A inhibitors. The work has clear translational implications for diabetes.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Robert J. DeVita</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=BIO-d7e3364-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last">Dr. DeVita is Professor in the Pharmacological Sciences Department at the Icahn School of Medicine at Mt. Sinai and Director of Medicinal Chemistry at the Drug Discovery Institute. His team has collaborated with the Stewart Lab since 2014 to discover and develop DYRK1A inhibitors for β-cell proliferation. Previously, Dr. DeVita worked in the pharmaceutical industry at Merck Research Laboratories and in biotech at Agios. He has published with collaborators in CNS, pain, diabetes, CV, obesity, and oncology drug discovery as well as oral, brain, peripheral, and gastrointestinal tract drug targeting and PET imaging agents. Dr. DeVita is active in the ACS Medicinal Chemistry Division as an alternate academic counselor, in MEDI LRPC, and organizing committees for national and international meetings. He also serves on many NIH study sections.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was partially supported by the Human Islet and Adenovirus Core (HIAC) of the Einstein-Sinai Diabetes Research Center and the following grants: NIH P-30 DK 020541, R-01 DK105015, R-01 DK116873, R-01 DK116904, R-01 DK125285, R-01 DK126450, R-01 DK113079, and JDRF Grant JDRF 2-SRA-2017 514-S-B</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ADCs</td><td class="NLM_def"><p class="first last">antibody–drug conjugates</p></td></tr><tr><td class="NLM_term">ASO</td><td class="NLM_def"><p class="first last">anti-sense oligonucleotides</p></td></tr><tr><td class="NLM_term">AP</td><td class="NLM_def"><p class="first last">aminopyrazine</p></td></tr><tr><td class="NLM_term">BMP</td><td class="NLM_def"><p class="first last">bone morphogenic protein</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin dependent kinases</p></td></tr><tr><td class="NLM_term">CDC</td><td class="NLM_def"><p class="first last">cell division cycle</p></td></tr><tr><td class="NLM_term">CAM</td><td class="NLM_def"><p class="first last">calmodulin</p></td></tr><tr><td class="NLM_term">CnA and CnB</td><td class="NLM_def"><p class="first last">calcineurins A and B</p></td></tr><tr><td class="NLM_term">DPP4</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase 4</p></td></tr><tr><td class="NLM_term">DTBZ</td><td class="NLM_def"><p class="first last">(+)-dihydrotetrabenazine</p></td></tr><tr><td class="NLM_term">DYRK1A</td><td class="NLM_def"><p class="first last">dual specificity tyrosine phosphorylation-regulated kinase 1 A</p></td></tr><tr><td class="NLM_term">EBP1</td><td class="NLM_def"><p class="first last">Erb3 binding protein-1</p></td></tr><tr><td class="NLM_term">EGCG</td><td class="NLM_def"><p class="first last">epigallocatechin-3-gallate</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">United States Food and Drug Administration</p></td></tr><tr><td class="NLM_term">GLP-1</td><td class="NLM_def"><p class="first last">glucagon-like peptide-1</p></td></tr><tr><td class="NLM_term">GSK3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase 3β</p></td></tr><tr><td class="NLM_term">GABA</td><td class="NLM_def"><p class="first last"><i>gamma</i>-aminobutyric acid</p></td></tr><tr><td class="NLM_term">GFP</td><td class="NLM_def"><p class="first last">green fluorescent protein</p></td></tr><tr><td class="NLM_term">GSIS</td><td class="NLM_def"><p class="first last">glucose-stimulated insulin secretion</p></td></tr><tr><td class="NLM_term">GLP1R</td><td class="NLM_def"><p class="first last">glycogen like peptide-1 receptor</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high throughput screening</p></td></tr><tr><td class="NLM_term">IKK ε</td><td class="NLM_def"><p class="first last">inhibitor-κB kinase ε</p></td></tr><tr><td class="NLM_term">INDY</td><td class="NLM_def"><p class="first last">inhibitor of DYRK1A</p></td></tr><tr><td class="NLM_term">iPSCs</td><td class="NLM_def"><p class="first last">induced pluripotent cells</p></td></tr><tr><td class="NLM_term">LIF</td><td class="NLM_def"><p class="first last">leukemia inhibitory factor</p></td></tr><tr><td class="NLM_term">LTCC</td><td class="NLM_def"><p class="first last">L-type calcium channels</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">NFAT</td><td class="NLM_def"><p class="first last">nuclear factor of activate T-cells</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen activated protein kinases</p></td></tr><tr><td class="NLM_term">MAbs</td><td class="NLM_def"><p class="first last">monoclonal antibodies</p></td></tr><tr><td class="NLM_term">NPA</td><td class="NLM_def"><p class="first last">normalized percentage activation</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PPX</td><td class="NLM_def"><p class="first last">partial pancreatectomy</p></td></tr><tr><td class="NLM_term">RANK</td><td class="NLM_def"><p class="first last">receptor activator of nuclear factor kB</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SERPINB1</td><td class="NLM_def"><p class="first last">serine protease inhibitor B1</p></td></tr><tr><td class="NLM_term">T1D</td><td class="NLM_def"><p class="first last">type 1 diabetes</p></td></tr><tr><td class="NLM_term">T2D</td><td class="NLM_def"><p class="first last">type 2 diabetes</p></td></tr><tr><td class="NLM_term">TPEN</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetrakis(2-pyridylmethyl)etha-1,2-diamine</p></td></tr><tr><td class="NLM_term">TSQ</td><td class="NLM_def"><p class="first last">6-methoxy-8-<i>p</i>-toluenesulfonamido-quinoline</p></td></tr><tr><td class="NLM_term">TGF</td><td class="NLM_def"><p class="first last">transforming growth factor</p></td></tr><tr><td class="NLM_term">VGF</td><td class="NLM_def"><p class="first last">V-growth factor</p></td></tr><tr><td class="NLM_term">VMAT2</td><td class="NLM_def"><p class="first last">vesicular monoamine transporter-2</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr><tr><td class="NLM_term">ZIMIR</td><td class="NLM_def"><p class="first last">zinc indicator for monitoring induced exocytotic release</p></td></tr><tr><td class="NLM_term">ZnPD5</td><td class="NLM_def"><p class="first last">zinc chelating ligand</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03767" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03767" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 103 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <i>Executive Summary Global
Reports on Diabetes</i>; <span class="NLM_publisher-name">World Health Organization</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Executive+Summary+Global%0AReports+on+Diabetes%3B+World+Health+Organization%2C+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DExecutive%2520Summary%2520Global%250AReports%2520on%2520Diabetes%26pub%3DWorld%2520Health%2520Organization%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span> <i>National Diabetes Satistics
Report</i>; <span class="NLM_publisher-name">Center
for Disease Control and Prevention (CDC)</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+National+Diabetes+Satistics%0AReport%3B+Center%0Afor+Disease+Control+and+Prevention+%28CDC%29%2C+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DNational%2520Diabetes%2520Satistics%250AReport%26pub%3DCenter%250Afor%2520Disease%2520Control%2520and%2520Prevention%2520%2528CDC%2529%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bluestone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbarth, G.</span></span> <span> </span><span class="NLM_article-title">Genetics, pathogenesis and clinical interventions in type 1 diabetes</span>. <i>Nature (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span> (<span class="NLM_issue">7293</span>),  <span class="NLM_fpage">1293</span>– <span class="NLM_lpage">1300</span>, <span class="refDoi"> DOI: 10.1038/nature08933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnature08933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltl2ltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=1293-1300&issue=7293&author=J.+A.+Bluestoneauthor=K.+Heroldauthor=G.+Eisenbarth&title=Genetics%2C+pathogenesis+and+clinical+interventions+in+type+1+diabetes&doi=10.1038%2Fnature08933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Genetics, pathogenesis and clinical interventions in type 1 diabetes</span></div><div class="casAuthors">Bluestone, Jeffrey A.; Herold, Kevan; Eisenbarth, George</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7293</span>),
    <span class="NLM_cas:pages">1293-1300</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Type 1 diabetes is an autoimmune disorder afflicting millions of people worldwide.  Once diagnosed, patients require lifelong insulin treatment and can experience numerous disease-assocd. complications.  The last decade has seen tremendous advances in elucidating the causes and treatment of the disease based on extensive research both in rodent models of spontaneous diabetes and in humans.  Integrating these advances has led to the recognition that the balance between regulatory and effector T cells dets. disease risk, timing of disease activation, and disease tempo.  Here the authors describe current progress, the challenges ahead and the new interventions that are being tested to address the unmet need for preventative or curative therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrinJVAyiy2CbVg90H21EOLACvtfcHk0liszaSQuFZfYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltl2ltr8%253D&md5=c5de4f26364038119187cd1cc364711f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature08933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08933%26sid%3Dliteratum%253Aachs%26aulast%3DBluestone%26aufirst%3DJ.%2BA.%26aulast%3DHerold%26aufirst%3DK.%26aulast%3DEisenbarth%26aufirst%3DG.%26atitle%3DGenetics%252C%2520pathogenesis%2520and%2520clinical%2520interventions%2520in%2520type%25201%2520diabetes%26jtitle%3DNature%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2010%26volume%3D464%26issue%3D7293%26spage%3D1293%26epage%3D1300%26doi%3D10.1038%2Fnature08933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrannini, E.</span></span> <span> </span><span class="NLM_article-title">The stunned β cell: a brief history</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2010.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2010.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=20444416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtleis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=349-352&issue=5&author=E.+Ferrannini&title=The+stunned+%CE%B2+cell%3A+a+brief+history&doi=10.1016%2Fj.cmet.2010.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The stunned β cell: a brief history</span></div><div class="casAuthors">Ferrannini, Ele</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-352</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  β Cell dysfunction is sufficient to cause hyperglycemia; β cell loss is not necessary but, if severe, can be sufficient and may be accompanied by intrinsic β cell dysfunction.  Clin. testing can differentiate β cell capacity from β cell glucose sensitivity but cannot ascribe either to relative changes in β cell mass vs. function.  However, longitudinal and intervention studies indicate that β cell glucose insensitivity (stunning) closely tracks with hyperglycemia and is, at least in part, reversible.  Rescuing stunned β cells is a key therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3OBfJdbqmjbVg90H21EOLACvtfcHk0liszaSQuFZfYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtleis7o%253D&md5=418ba1462e578d7d0ed2e847cbba4a9c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2010.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2010.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DFerrannini%26aufirst%3DE.%26atitle%3DThe%2520stunned%2520%25CE%25B2%2520cell%253A%2520a%2520brief%2520history%26jtitle%3DCell%2520Metab.%26date%3D2010%26volume%3D11%26issue%3D5%26spage%3D349%26epage%3D352%26doi%3D10.1016%2Fj.cmet.2010.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meier, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizza, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, P. C.</span></span> <span> </span><span class="NLM_article-title">Sustained β-cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2221</span>– <span class="NLM_lpage">2228</span>, <span class="refDoi"> DOI: 10.1007/s00125-005-1949-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1007%2Fs00125-005-1949-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=16205882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Skt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2221-2228&issue=11&author=J.+J.+Meierauthor=A.+Bhushanauthor=A.+E.+Butlerauthor=R.+A.+Rizzaauthor=P.+C.+Butler&title=Sustained+%CE%B2-cell+apoptosis+in+patients+with+long-standing+type+1+diabetes%3A+indirect+evidence+for+islet+regeneration%3F&doi=10.1007%2Fs00125-005-1949-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?</span></div><div class="casAuthors">Meier, J. J.; Bhushan, A.; Butler, A. E.; Rizza, R. A.; Butler, P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2221-2228</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Aims/hypothesis: Type 1 diabetes is widely held to result from an irreversible loss of insulin-secreting beta cells.  However, insulin secretion is detectable in some people with long-standing type 1 diabetes, indicating either a small population of surviving beta cells or continued renewal of beta cells subject to ongoing autoimmune destruction.  The aim of the present study was to evaluate these possibilities.  Materials and methods: Pancreatic sections from 42 individuals with type 1 diabetes and 14 non-diabetic individuals were evaluated for the presence of beta cells, beta cell apoptosis and replication, T lymphocytes and macrophages.  The presence and extent of periductal fibrosis was also quantified.  Results: Beta cells were identified in 88% of individuals with type 1 diabetes.  The no. of beta cells was unrelated to duration of disease (range 4-67 years) or age at death (range 14-77 years), but was higher (p<0.05) in individuals with lower mean blood glucose.  Beta cell apoptosis was twice as frequent in type 1 diabetes as in control subjects (p<0.001), but beta cell replication was rare in both groups.  The increased beta cell apoptosis in type 1 diabetes was accompanied by both increased macrophages and T lymphocytes and a marked increase in periductal fibrosis (p<0.001), implying chronic inflammation over many years, consistent with an ongoing supply of beta cells.  Conclusions/interpretation: Most people with long-standing type 1 diabetes have beta cells that continue to be destroyed.  The mechanisms underlying increased beta cell death may involve both ongoing autoimmunity and glucose toxicity.  The presence of beta cells despite ongoing apoptosis implies, by definition, that concomitant new beta cell formation must be occurring, even after long-standing type 1 diabetes.  We conclude that type 1 diabetes may be reversed by targeted inhibition of beta cell destruction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqLVyfuuqQ_LVg90H21EOLACvtfcHk0lifVqCmNzdm0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Skt7vJ&md5=089daf7c1358b2e1c8abc9fa57581408</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs00125-005-1949-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-005-1949-2%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26aulast%3DBhushan%26aufirst%3DA.%26aulast%3DButler%26aufirst%3DA.%2BE.%26aulast%3DRizza%26aufirst%3DR.%2BA.%26aulast%3DButler%26aufirst%3DP.%2BC.%26atitle%3DSustained%2520%25CE%25B2-cell%2520apoptosis%2520in%2520patients%2520with%2520long-standing%2520type%25201%2520diabetes%253A%2520indirect%2520evidence%2520for%2520islet%2520regeneration%253F%26jtitle%3DDiabetologia%26date%3D2005%26volume%3D48%26issue%3D11%26spage%3D2221%26epage%3D2228%26doi%3D10.1007%2Fs00125-005-1949-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiaschi-Taesch, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasavada, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">Diabetes mellitus-advances and challenges in human β-cell proliferation</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2015.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrendo.2015.9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=25687999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=201-212&issue=4&author=P.+Wangauthor=N.+M.+Fiaschi-Taeschauthor=R.+C.+Vasavadaauthor=D.+K.+Scottauthor=A.+Garcia-Ocanaauthor=A.+F.+Stewart&title=Diabetes+mellitus-advances+and+challenges+in+human+%CE%B2-cell+proliferation&doi=10.1038%2Fnrendo.2015.9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetes mellitus-advances and challenges in human β-cell proliferation</span></div><div class="casAuthors">Wang, Peng; Fiaschi-Taesch, Nathalie M.; Vasavada, Rupangi C.; Scott, Donald K.; Garcia-Ocana, Adolfo; Stewart, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">201-212</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The treatment of diabetes mellitus represents one of the greatest medical challenges of our era.  Diabetes results from a deficiency or functional impairment of insulin-producing β cells, alone or in combination with insulin resistance.  It logically follows that the replacement or regeneration of β cells should reverse the progression of diabetes and, indeed, this seems to be the case in humans and rodents.  This concept has prompted attempts in many labs. to create new human β cells using stem-cell strategies to transdifferentiate or reprogram non-β cells into β cells or to discover small mols. or other compds. that can induce proliferation of human β cells.  This latter approach has shown promise, but has also proven particularly challenging to implement.  In this Review, we discuss the physiol. of normal human β-cell replication, the mol. mechanisms that regulate the cell cycle in human β cells, the upstream intracellular signalling pathways that connect them to cell surface receptors on β cells, the epigenetic mechanisms that control human β-cell proliferation and unbiased approaches for discovering novel mols. that can drive human β-cell proliferation.  Finally, we discuss the potential and challenges of implementing strategies that replace or regenerate β cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyZARqiz5cV7Vg90H21EOLACvtfcHk0lifVqCmNzdm0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWktL4%253D&md5=32e771cd720d326dacf886def4ae87ed</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2015.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2015.9%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DFiaschi-Taesch%26aufirst%3DN.%2BM.%26aulast%3DVasavada%26aufirst%3DR.%2BC.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DDiabetes%2520mellitus-advances%2520and%2520challenges%2520in%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2015%26volume%3D11%26issue%3D4%26spage%3D201%26epage%3D212%26doi%3D10.1038%2Fnrendo.2015.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, W. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, L. G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, T. N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, E. S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattamisra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candasamy, M.</span></span> <span> </span><span class="NLM_article-title">Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention</span>. <i>Diabetes Metab Syndr</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1016/j.dsx.2018.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.dsx.2018.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30641727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A280%3ADC%252BB3cjht1OisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=364-372&issue=1&author=S.+Y.+Tanauthor=W.+J.+L.+Meiauthor=Y.+J.+Simauthor=S.+S.+Wongauthor=S.+H.+Tanauthor=L.+G.+P.+Lingauthor=T.+N.+W.+Rongauthor=N.+C.+Annanauthor=E.+S.+A.+Mohamedauthor=S.+K.+Bhattamisraauthor=M.+Candasamy&title=Type+1+and+2+diabetes+mellitus%3A+A+review+on+current+treatment+approach+and+gene+therapy+as+potential+intervention&doi=10.1016%2Fj.dsx.2018.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention</span></div><div class="casAuthors">Tan Sin Yee; Mei Wong Joyce Ling; Sim Yan Jinn; Wong Su Sie; Tan Sean Hong; Ling Lim Grace Pei; Rong Tay Nicole Wuen; Annan Naveenya Chetty; Mohamed Elhassan Safa Abdelgadir; Bhattamisra Subrat Kumar; Candasamy Mayuren</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes & metabolic syndrome</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">364-372</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type 1 and type 2 diabetes mellitus is a serious and lifelong condition commonly characterised by abnormally elevated blood glucose levels due to a failure in insulin production or a decrease in insulin sensitivity and function.  Over the years, prevalence of diabetes has increased globally and it is classified as one of the leading cause of high mortality and morbidity rate.  Furthermore, diabetes confers a huge economic burden due to its management costs as well as its complications are skyrocketing.  The conventional medications in diabetes treatment focusing on insulin secretion and insulin sensitisation cause unwanted side effects to patients and lead to incompliance as well as treatment failure.  Besides insulin and oral hypoglycaemic agents, other treatments such as gene therapy and induced β-cells regeneration have not been widely introduced to manage diabetes.  Therefore, this review aims to deliver an overview of the current conventional medications in diabetes, discovery of newer pharmacological drugs and gene therapy as a potential intervention of diabetes in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9gChR5MMa5N0Q2ypr7jHkfW6udTcc2eYVc1NV6kLuwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjht1OisA%253D%253D&md5=d46edec4547793fc86f34eeb8e7a3262</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.dsx.2018.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dsx.2018.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DS.%2BY.%26aulast%3DMei%26aufirst%3DW.%2BJ.%2BL.%26aulast%3DSim%26aufirst%3DY.%2BJ.%26aulast%3DWong%26aufirst%3DS.%2BS.%26aulast%3DTan%26aufirst%3DS.%2BH.%26aulast%3DLing%26aufirst%3DL.%2BG.%2BP.%26aulast%3DRong%26aufirst%3DT.%2BN.%2BW.%26aulast%3DAnnan%26aufirst%3DN.%2BC.%26aulast%3DMohamed%26aufirst%3DE.%2BS.%2BA.%26aulast%3DBhattamisra%26aufirst%3DS.%2BK.%26aulast%3DCandasamy%26aufirst%3DM.%26atitle%3DType%25201%2520and%25202%2520diabetes%2520mellitus%253A%2520A%2520review%2520on%2520current%2520treatment%2520approach%2520and%2520gene%2520therapy%2520as%2520potential%2520intervention%26jtitle%3DDiabetes%2520Metab%2520Syndr%26date%3D2019%26volume%3D13%26issue%3D1%26spage%3D364%26epage%3D372%26doi%3D10.1016%2Fj.dsx.2018.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner-Weir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritzel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizza, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, P. C.</span></span> <span> </span><span class="NLM_article-title">β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.2337/diabetes.52.1.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdiabetes.52.1.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=12502499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVaisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2003&pages=102-110&issue=1&author=A.+E.+Butlerauthor=J.+Jansonauthor=S.+Bonner-Weirauthor=R.+Ritzelauthor=R.+A.+Rizzaauthor=P.+C.+Butler&title=%CE%B2-cell+deficit+and+increased+%CE%B2-cell+apoptosis+in+humans+with+type+2+diabetes&doi=10.2337%2Fdiabetes.52.1.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes</span></div><div class="casAuthors">Butler, Alexandra E.; Janson, Juliette; Bonner-Weir, Susan; Ritzel, Robert; Rizza, Robert A.; Butler, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-110</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">Type 2 diabetes is characterized by impaired insulin secretion.  Some but not all studies suggest that a decrease in β-cell mass contributes to this.  We examd. pancreatic tissue from 124 autopsies: 91 obese cases (BMI >27 kg/m2; 41 with type 2 diabetes, 15 with impaired fasting glucose [IFG], and 35 nondiabetic subjects) and 33 lean cases (BMI <25 kg/m2; 16 type 2 diabetic and 17 nondiabetic subjects).  We measured relative β-cell vol., frequency of β-cell apoptosis and replication, and new islet formation from exocrine ducts (neogenesis).  Relative β-cell vol. was increased in obese vs. lean nondiabetic cases (P = 0.05) through the mechanism of increased neogenesis (P < 0.05).  Obese humans with IFG and type 2 diabetes had a 40% (P < 0.05) and 63% (P < 0.01) deficit and lean cases of type 2 diabetes had a 41% deficit (P < 0.05) in relative β-cell vol. compared with nondiabetic obese and lean cases, resp.  The frequency of β-cell replication was very low in all cases and no different among groups.  Neogenesis, while increased with obesity, was comparable in obese type 2 diabetic, IFG, or nondiabetic subjects and in lean type 2 diabetic or nondiabetic subjects.  However, the frequency of β-cell apoptosis was increased 10-fold in lean and 3-fold in obese cases of type 2 diabetes compared with their resp. nondiabetic control group (P < 0.05).  We conclude that β-cell mass is decreased in type 2 diabetes and that the mechanism underlying this is increased β-cell apoptosis.  Since the major defect leading to a decrease in β-cell mass in type 2 diabetes is increased apoptosis, while new islet formation and β-cell replication are normal, therapeutic approaches designed to arrest apoptosis could be a significant new development in the management of type 2 diabetes, because this approach might actually reverse the disease to a degree rather than just palliate glycemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVcyE2o6KAcbVg90H21EOLACvtfcHk0ljiRmismW-5rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVaisA%253D%253D&md5=ce00b44af8145b182dd17131a75e14ae</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.52.1.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.52.1.102%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DA.%2BE.%26aulast%3DJanson%26aufirst%3DJ.%26aulast%3DBonner-Weir%26aufirst%3DS.%26aulast%3DRitzel%26aufirst%3DR.%26aulast%3DRizza%26aufirst%3DR.%2BA.%26aulast%3DButler%26aufirst%3DP.%2BC.%26atitle%3D%25CE%25B2-cell%2520deficit%2520and%2520increased%2520%25CE%25B2-cell%2520apoptosis%2520in%2520humans%2520with%2520type%25202%2520diabetes%26jtitle%3DDiabetes%26date%3D2003%26volume%3D52%26issue%3D1%26spage%3D102%26epage%3D110%26doi%3D10.2337%2Fdiabetes.52.1.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell-Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaddis, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserfall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugliese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M. A.</span></span> <span> </span><span class="NLM_article-title">Insulitis and β-cell mass in the natural history of type 1 diabetes</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.2337/db15-0779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb15-0779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26581594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKltLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=719-731&issue=3&author=M.+Campbell-Thompsonauthor=A.+Fuauthor=J.+S.+Kaddisauthor=C.+Wasserfallauthor=D.+A.+Schatzauthor=A.+Puglieseauthor=M.+A.+Atkinson&title=Insulitis+and+%CE%B2-cell+mass+in+the+natural+history+of+type+1+diabetes&doi=10.2337%2Fdb15-0779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Insulitis and β-cell mass in the natural history of type 1 diabetes</span></div><div class="casAuthors">Campbell-Thompson, Martha; Fu, Ann; Kaddis, John S.; Wasserfall, Clive; Schatz, Desmond A.; Pugliese, Alberto; Atkinson, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">719-731</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Descriptions of insulitis in human islets throughout the natural history of type 1 diabetes are limited.  We detd. insulitis frequency (the percent of islets displaying insulitis to total islets), infiltrating leukocyte subtypes, and β-cell and α-cell mass in pancreata recov- ered from organ donors with type 1 diabetes (n = 80), as well as from donors without diabetes, both with islet au- toantibodies (AAb-, n = 18) and without islet autoanti- bodies (AAb-, n = 61).  Insulitis was obsd. in four of four donors (100%) with type 1 diabetes duration of ≤1 yr and two AAb- donors (2 of 18 donors, 11%).  Insulitis frequency showed a significant but limited inverse corre- lation with diabetes duration (r = -0.58, P = 0.01) but not with age at disease onset.  Residual β-cells were obsd. in all type 1 diabetes donors with insulitis, while β-cell area and mass were significantly higher in type 1 diabetes do- nors with insulitis compared with those without insulitis.  Insulitis affected 33% of insulin' islets compared with 2% of insulin islets in donors with type 1 diabetes.  A signifi- cant correlation was obsd. between insulitis frequency and CD45+, CD+, CD4+, CD8+, and CD20+ cell nos. within the insulitis (r = 0.53-0.73, P = 0.004-0.04), but not CD68+ or CD11c+ cells.  The presence of β-cells as well as insulitis several years after diagnosis in children and young adults suggests that the chronicity of islet autoimmunity extends well into the postdiagnosis period.  This informa- tion should aid considerations of therapeutic strategies seeking type 1 diabetes prevention and reversal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFzD4FuUdazrVg90H21EOLACvtfcHk0ljiRmismW-5rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKltLfM&md5=536b4f6374259c00b7b1c80f2c9aeac0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2337%2Fdb15-0779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb15-0779%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell-Thompson%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DA.%26aulast%3DKaddis%26aufirst%3DJ.%2BS.%26aulast%3DWasserfall%26aufirst%3DC.%26aulast%3DSchatz%26aufirst%3DD.%2BA.%26aulast%3DPugliese%26aufirst%3DA.%26aulast%3DAtkinson%26aufirst%3DM.%2BA.%26atitle%3DInsulitis%2520and%2520%25CE%25B2-cell%2520mass%2520in%2520the%2520natural%2520history%2520of%2520type%25201%2520diabetes%26jtitle%3DDiabetes%26date%3D2016%26volume%3D65%26issue%3D3%26spage%3D719%26epage%3D731%26doi%3D10.2337%2Fdb15-0779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.-M.</span></span> <span> </span><span class="NLM_article-title">Cellular signaling pathways regulating β-cell proliferation as a promising therapeutic target in the treatment of diabetes (review)</span>. <i>Exp. Ther. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWmtrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=1-11&issue=4&author=W.-J.+Jiangauthor=Y.-C.+Pengauthor=K.-M.+Yang&title=Cellular+signaling+pathways+regulating+%CE%B2-cell+proliferation+as+a+promising+therapeutic+target+in+the+treatment+of+diabetes+%28review%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelial stem cells attenuate cardiac apoptosis via downregulating cardiac microRNA-146a in a rat model of coronary heart disease</span></div><div class="casAuthors">Fang, Yeqing; Chen, Shaoyuan; Liu, Zhenguo; Ai, Wen; He, Xiaofang; Wang, Lei; Xie, Peiyi; Jiang, Bimei; Fang, Hongcheng</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Therapeutic Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">ETMXA2</span>;
        ISSN:<span class="NLM_cas:issn">1792-1015</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Coronary artery disease (CAD) is one of the main causes of hospitalization worldwide and has high morbidity.  It has previously been demonstrated that stem cells serve an important role in improving myocardial function.  MicroRNA (miRNA)-146a downregulation has been reported to inhibit vascular smooth muscle cell apoptosis in a rat model of coronary heart disease.  The aim of the present study was to investigate the mechanisms underlying the effects of endothelial stem cell (ESC)-derived paracrine factors and cardiac miRNAs in CAD.  Acute myocardial infarction was induced in 20 rats.  Autologous ESCs (n=10; exptl. group) or PBS (n=10; control group) were injected in the border zone.  Reverse transcription-quantitativepolymerase chain reaction, ELISA and immunohistochem. assays were performed to analyze the therapeutic effects of ESCs in rats with coronary heart disease rats.  Serum interleukin (IL)-1, IL-17 and tumor necrosis factor-α were reduced in the exptl. group compared with control rats, as was the no. of circulating proatherogenic cells.  The results demonstrated that ESC transplantation markedly downregulatedmiRNA-146a expression and decreased apoptosis in the myocardium compared with the control group.  Rats in the exptl. group also had higher levels of vascular endothelial growth factor compared with the control group.  In addn., it was demonstrated that miRNA-146 knockdown reduced cardiac apoptosis and increased VEGF expression.  Furthermore, the infarct area in the border zone or rats with CAD was reduced in the exptl. group compared with the control group.  In conclusion, these results suggest that ESC transplantation may improve cardiac function via downregulating miR-146a, which may be have potential as a treatment for CAD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpba9Xas-bqwrVg90H21EOLACvtfcHk0ljiRmismW-5rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWmtrvK&md5=c8d7d920ced4952b1558ec822f70b88b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DW.-J.%26aulast%3DPeng%26aufirst%3DY.-C.%26aulast%3DYang%26aufirst%3DK.-M.%26atitle%3DCellular%2520signaling%2520pathways%2520regulating%2520%25CE%25B2-cell%2520proliferation%2520as%2520a%2520promising%2520therapeutic%2520target%2520in%2520the%2520treatment%2520of%2520diabetes%2520%2528review%2529%26jtitle%3DExp.%2520Ther.%2520Med.%26date%3D2018%26volume%3D16%26issue%3D4%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karakose, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackeifi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">Advances in drug discovery for human β-cell regeneration</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1693</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1007/s00125-018-4639-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1007%2Fs00125-018-4639-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=29770834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFyhs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1693-1699&issue=8&author=E.+Karakoseauthor=C.+Ackeifiauthor=P.+Wangauthor=A.+F.+Stewart&title=Advances+in+drug+discovery+for+human+%CE%B2-cell+regeneration&doi=10.1007%2Fs00125-018-4639-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in drug discovery for human beta cell regeneration</span></div><div class="casAuthors">Karakose, Esra; Ackeifi, Courtney; Wang, Peng; Stewart, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1693-1699</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The nos. of insulin-secreting pancreatic beta cells are reduced in people with type 1 and type 2 diabetes.  Driving beta cell regeneration in the pancreases of people with diabetes would be an attractive approach to reversing diabetes.  While adult human beta cells have long been believed to be terminally differentiated and, therefore, irreversibly quiescent, it has become clear over recent years that this is not true.  More specifically, both candidate and unbiased high-throughput screen approaches have revealed several classes of mols. that are clearly able to induce human beta cell proliferation.  Here, we review recent approaches and accomplishments in human beta cell regenerative drug discovery.  We also list the challenges that this rapidly moving field must confront to translate beta cell regenerative therapy from the lab. to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwrd9iOZ9UrLVg90H21EOLACvtfcHk0lgBgtYIW2w84Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFyhs7w%253D&md5=6e9b8f40e4e07a3cd6b8eba1af284856</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs00125-018-4639-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-018-4639-6%26sid%3Dliteratum%253Aachs%26aulast%3DKarakose%26aufirst%3DE.%26aulast%3DAckeifi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DAdvances%2520in%2520drug%2520discovery%2520for%2520human%2520%25CE%25B2-cell%2520regeneration%26jtitle%3DDiabetologia%26date%3D2018%26volume%3D61%26issue%3D8%26spage%3D1693%26epage%3D1699%26doi%3D10.1007%2Fs00125-018-4639-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirakawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span> <span> </span><span class="NLM_article-title">Novel factors modulating human β-cell proliferation</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">S1</span>),  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1111/dom.12731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1111%2Fdom.12731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=27615134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyltr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=71-77&issue=S1&author=J.+Shirakawaauthor=R.+N.+Kulkarni&title=Novel+factors+modulating+human+%CE%B2-cell+proliferation&doi=10.1111%2Fdom.12731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Novel factors modulating human β-cell proliferation</span></div><div class="casAuthors">Shirakawa, J.; Kulkarni, R. N.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">71-77</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">β-Cell dysfunction in type 1 and type 2 diabetes is accompanied by a progressive loss of β-cells, and an understanding of the cellular mechanism(s) that regulate β-cell mass will enable approaches to enhance hormone secretion.  It is becoming increasingly recognized that enhancement of human β-cell proliferation is one potential approach to restore β-cell mass to prevent and/or cure type 1 and type 2 diabetes.  While several reports describe the factor(s) that enhance β-cell replication in animal models or cell lines, promoting effective human β-cell proliferation continues to be a challenge in the field.  In this review, we discuss recent studies reporting successful human β-cell proliferation including WS6, an IkB kinase and EBP1 inhibitor; harmine and 5-IT, both DYRK1A inhibitors; GNF7156 and GNF4877, GSK-3β and DYRK1A inhibitors; osteoprotegrin and Denosmab, receptor activator of NF-kB (RANK) inhibitors; and SerpinB1, a protease inhibitor.  These studies provide important examples of proteins and pathways that may prove useful for designing therapeutic strategies to counter the different forms of human diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9FUo37-cG7bVg90H21EOLACvtfcHk0lgBgtYIW2w84Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyltr3E&md5=aa02d20a9e03ee38c74ef3af2d0e5f6a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fdom.12731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12731%26sid%3Dliteratum%253Aachs%26aulast%3DShirakawa%26aufirst%3DJ.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26atitle%3DNovel%2520factors%2520modulating%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26issue%3DS1%26spage%3D71%26epage%3D77%26doi%3D10.1111%2Fdom.12731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vetere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the pancreatic β-cell to treat diabetes</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1038/nrd4231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrd4231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=24525781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFSht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=278-289&issue=4&author=A.+Vetereauthor=A.+Choudharyauthor=S.+M.+Burnsauthor=B.+K.+Wagner&title=Targeting+the+pancreatic+%CE%B2-cell+to+treat+diabetes&doi=10.1038%2Fnrd4231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the pancreatic β-cell to treat diabetes</span></div><div class="casAuthors">Vetere, Amedeo; Choudhary, Amit; Burns, Sean M.; Wagner, Bridget K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">278-289</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Diabetes is a leading cause of morbidity and mortality worldwide, and predicted to affect over 500 million people by 2030.  However, this growing burden of disease has not been met with a comparable expansion in therapeutic options.  The appreciation of the pancreatic β-cell as a central player in the pathogenesis of both type 1 and type 2 diabetes has renewed focus on ways to improve glucose homeostasis by preserving, expanding and improving the function of this key cell type.  Here, we provide an overview of the latest developments in this field, with an emphasis on the most promising strategies identified to date for treating diabetes by targeting the β-cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9e3CEl2cNAbVg90H21EOLACvtfcHk0lgBgtYIW2w84Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFSht7Y%253D&md5=703d2104e872c969a1acbad3e92d61fb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd4231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4231%26sid%3Dliteratum%253Aachs%26aulast%3DVetere%26aufirst%3DA.%26aulast%3DChoudhary%26aufirst%3DA.%26aulast%3DBurns%26aufirst%3DS.%2BM.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26atitle%3DTargeting%2520the%2520pancreatic%2520%25CE%25B2-cell%2520to%2520treat%2520diabetes%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D4%26spage%3D278%26epage%3D289%26doi%3D10.1038%2Fnrd4231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregg, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demozay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, C. J.</span></span> <span> </span><span class="NLM_article-title">Formation of a human β-cell population within pancreatic islets is set early in life</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3197</span>– <span class="NLM_lpage">3206</span>, <span class="refDoi"> DOI: 10.1210/jc.2012-1206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1210%2Fjc.2012-1206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=22745242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtlymu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=3197-3206&issue=9&author=B.+E.+Greggauthor=P.+C.+Mooreauthor=D.+Demozayauthor=B.+A.+Hallauthor=M.+Liauthor=A.+Husainauthor=A.+J.+Wrightauthor=M.+A.+Atkinsonauthor=C.+J.+Rhodes&title=Formation+of+a+human+%CE%B2-cell+population+within+pancreatic+islets+is+set+early+in+life&doi=10.1210%2Fjc.2012-1206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Formation of a human β-cell population within pancreatic islets is set early in life</span></div><div class="casAuthors">Gregg, Brigid E.; Moore, Patrick C.; Demozay, Damien; Hall, Ben A.; Li, Mei; Husain, Aliya; Wright, Amy J.; Atkinson, Mark A.; Rhodes, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3197-3206</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Context: Insulin resistance can be compensated by increased functional pancreatic β-cell mass; otherwise, diabetes ensues.  Such compensation depends not only on environmental and genetic factors but also on the baseline β-cell mass from which the expansion originates.  Objective: Little is known about assembly of a baseline β-cell mass in humans.  Here, we examd. formation of β-cell populations relative to other pancreatic islet cell types and assocd. neurons throughout the normal human lifespan.  Design and Methods: Human pancreatic sections derived from normal cadavers aged 24 wk premature to 72 yr were examd. by immunofluorescence.  Insulin, glucagon, and somatostatin were used as markers for β-, α-, and δ-cells, resp.  Cytokeratin-19 marked ductal cells, Ki67 cell proliferation, and Tuj1 (neuronal class III β-tubulin) marked neurons.  Results: Most β-cell neogenesis was obsd. preterm with a burst of β-cell proliferation peaking within the first 2 yr of life.  Thereafter, little indication of β-cell growth was obsd.  Postnatal proliferation of α- and δ-cells was rarely seen, but a wave of ductal cell proliferation was found mostly assocd. with exocrine cell expansion.  The β-cell to α-cell ratio doubled neonatally, reflecting increased growth of β-cells, but during childhood, there was a 7-fold change in the β-cell to δ-cell ratio, reflecting an addnl. loss of δ-cells.  A close assocn. of neurons to pancreatic islets was noted developmentally and retained throughout adulthood.  Negligible neuronal assocn. to exocrine pancreas was obsd.  Conclusion: Human baseline β-cell population and appropriate assocn. with other islet cell types is established before 5 yr of age.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3K2h2ve0i07Vg90H21EOLACvtfcHk0lgBgtYIW2w84Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtlymu7vJ&md5=e71533f2d6e1a26f3a98e82ae5126ca9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1210%2Fjc.2012-1206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2012-1206%26sid%3Dliteratum%253Aachs%26aulast%3DGregg%26aufirst%3DB.%2BE.%26aulast%3DMoore%26aufirst%3DP.%2BC.%26aulast%3DDemozay%26aufirst%3DD.%26aulast%3DHall%26aufirst%3DB.%2BA.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHusain%26aufirst%3DA.%26aulast%3DWright%26aufirst%3DA.%2BJ.%26aulast%3DAtkinson%26aufirst%3DM.%2BA.%26aulast%3DRhodes%26aufirst%3DC.%2BJ.%26atitle%3DFormation%2520of%2520a%2520human%2520%25CE%25B2-cell%2520population%2520within%2520pancreatic%2520islets%2520is%2520set%2520early%2520in%2520life%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2012%26volume%3D97%26issue%3D9%26spage%3D3197%26epage%3D3206%26doi%3D10.1210%2Fjc.2012-1206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meier, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saisho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monchamp, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizza, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, P. C.</span></span> <span> </span><span class="NLM_article-title">β-Cell replication is the primary mechanism subserving the postnatal expansion of β-cell mass in humans</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1584</span>– <span class="NLM_lpage">1594</span>, <span class="refDoi"> DOI: 10.2337/db07-1369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb07-1369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=18334605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsF2isr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2008&pages=1584-1594&issue=6&author=J.+J.+Meierauthor=A.+E.+Butlerauthor=Y.+Saishoauthor=T.+Monchampauthor=R.+Galassoauthor=A.+Bhushanauthor=R.+A.+Rizzaauthor=P.+C.+Butler&title=%CE%B2-Cell+replication+is+the+primary+mechanism+subserving+the+postnatal+expansion+of+%CE%B2-cell+mass+in+humans&doi=10.2337%2Fdb07-1369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">β-Cell replication is the primary mechanism subserving the postnatal expansion of β-cell mass in humans</span></div><div class="casAuthors">Meier, Juris J.; Butler, Alexandra E.; Saisho, Yoshifumi; Monchamp, Travis; Galasso, Ryan; Bhushan, Anil; Rizza, Robert A.; Butler, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1584-1594</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Little is known about the capacity, mechanisms, or timing of growth in β-cell mass in humans.  We sought to establish if the predominant expansion of β-cell mass in humans occurs in early childhood and if, as in rodents, this coincides with relatively abundant β-cell replication.  We also sought to establish if there is a secondary growth in β-cell mass coincident with the accelerated somatic growth in adolescence.  To address these questions, pancreas vol. was detd. from abdominal computer tomogs. in 135 children aged 4 wk to 20 years, and morphometric analyses were performed in human pancreatic tissue obtained at autopsy from 46 children aged 2 wk to 21 years.  We report that (1) β-cell mass expands by several-fold from birth to adulthood, (2) islets grow in size rather than in no. during this transition, (3) the relative rate of β-cell growth is highest in infancy and gradually declines thereafter to adulthood with no secondary accelerated growth phase during adolescence, (4) β-cell mass (and presumably growth) is highly variable between individuals, and (5) a high rate of β-cell replication is coincident with the major postnatal expansion of β-cell mass.  These data imply that regulation of β-cell replication during infancy plays a major role in β-cell mass in adult humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7r0YX6A1w-7Vg90H21EOLACvtfcHk0lh4BS_w7fdqeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsF2isr0%253D&md5=e07d494d4a1c440c8ee18bc2fff4652a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2337%2Fdb07-1369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb07-1369%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26aulast%3DButler%26aufirst%3DA.%2BE.%26aulast%3DSaisho%26aufirst%3DY.%26aulast%3DMonchamp%26aufirst%3DT.%26aulast%3DGalasso%26aufirst%3DR.%26aulast%3DBhushan%26aufirst%3DA.%26aulast%3DRizza%26aufirst%3DR.%2BA.%26aulast%3DButler%26aufirst%3DP.%2BC.%26atitle%3D%25CE%25B2-Cell%2520replication%2520is%2520the%2520primary%2520mechanism%2520subserving%2520the%2520postnatal%2520expansion%2520of%2520%25CE%25B2-cell%2520mass%2520in%2520humans%26jtitle%3DDiabetes%26date%3D2008%26volume%3D57%26issue%3D6%26spage%3D1584%26epage%3D1594%26doi%3D10.2337%2Fdb07-1369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdolazimi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allegretti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCutcheon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalizi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annes, J. P.</span></span> <span> </span><span class="NLM_article-title">CC-401 promotes β-cell replication via pleiotropic consequences of DYRK1A/B inhibition</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>159</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3143</span>– <span class="NLM_lpage">3157</span>, <span class="refDoi"> DOI: 10.1210/en.2018-00083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1210%2Fen.2018-00083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=29514186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCgu7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2018&pages=3143-3157&issue=9&author=Y.+Abdolazimiauthor=Z.+Zhaoauthor=S.+Leeauthor=H.+Xuauthor=P.+Allegrettiauthor=T.+M.+Hortonauthor=B.+Yehauthor=H.+P.+Moellerauthor=R.+J.+Nicholsauthor=D.+McCutcheonauthor=A.+Shaliziauthor=M.+Smithauthor=N.+A.+Armstrongauthor=J.+P.+Annes&title=CC-401+promotes+%CE%B2-cell+replication+via+pleiotropic+consequences+of+DYRK1A%2FB+inhibition&doi=10.1210%2Fen.2018-00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">CC-401 promotes β-cell replication via pleiotropic consequences of DYRK1A/B inhibition</span></div><div class="casAuthors">Abdolazimi, Yassan; Zhao, Zhengshan; Lee, Sooyeon; Xu, Haixia; Allegretti, Paul; Horton, Timothy M.; Yeh, Benjamin; Moeller, Hannah P.; Nichols, Robert J.; McCutcheon, David; Shalizi, Aryaman; Smith, Mark; Armstrong, Neali A.; Annes, Justin P.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3143-3157</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">1945-7170</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Pharmacol. expansion of endogenous β cells is a promising therapeutic strategy for diabetes.  To elucidate the mol. pathways that control β-cell growth we screened ∼2400 bioactive compds. for rat β-cell replication-modulating activity.  Numerous hit compds. impaired or promoted rat β-cell replication, including CC-401, an advanced clin. candidate previously characterized as a c-Jun N-terminal kinase inhibitor.  Surprisingly, CC-401 induced rodent (in vitro and in vivo) and human (in vitro) β-cell replication via dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) 1A and 1B inhibition.  In contrast to rat β cells, which were broadly growth responsive to compd. treatment, human β-cell replication was only consistently induced by DYRK1A/B inhibitors.  This effect was enhanced by simultaneous glycogen synthase kinase-3β (GSK-3β) or activin A receptor type II-like kinase/transforming growth factor-β (ALK5/TGF-β) inhibition.  Prior work emphasized DYRK1A/B inhibition-dependent activation of nuclear factor of activated T cells (NFAT) as the primary mechanism of human β-cell-replication induction.  However, inhibition of NFAT activity had limited effect on CC-401-induced β-cell replication.  Consequently, we investigated addnl. effects of CC-401-dependent DYRK1A/B inhibition.  Indeed, CC-401 inhibited DYRK1A-dependent phosphorylation/stabilization of the β-cell-replication inhibitor p27Kip1.  Addnl., CC-401 increased expression of numerous replication-promoting genes normally suppressed by the dimerization partner, RB-like, E2F and multivulval class B (DREAM) complex, which depends upon DYRK1A/B activity for integrity, including MYBL2 and FOXM1.  In summary, we present a compendium of compds. as a valuable resource for manipulating the signaling pathways that control β-cell replication and leverage a DYRK1A/B inhibitor (CC-401) to expand our understanding of the mol. pathways that control β-cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0bClqAWU1ZLVg90H21EOLACvtfcHk0lh4BS_w7fdqeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCgu7rP&md5=35cb7f0245f44f2d8a66eae8a78b390e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1210%2Fen.2018-00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2018-00083%26sid%3Dliteratum%253Aachs%26aulast%3DAbdolazimi%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DAllegretti%26aufirst%3DP.%26aulast%3DHorton%26aufirst%3DT.%2BM.%26aulast%3DYeh%26aufirst%3DB.%26aulast%3DMoeller%26aufirst%3DH.%2BP.%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26aulast%3DMcCutcheon%26aufirst%3DD.%26aulast%3DShalizi%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DN.%2BA.%26aulast%3DAnnes%26aufirst%3DJ.%2BP.%26atitle%3DCC-401%2520promotes%2520%25CE%25B2-cell%2520replication%2520via%2520pleiotropic%2520consequences%2520of%2520DYRK1A%252FB%2520inhibition%26jtitle%3DEndocrinology%26date%3D2018%26volume%3D159%26issue%3D9%26spage%3D3143%26epage%3D3157%26doi%3D10.1210%2Fen.2018-00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allegretti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdolazimi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annes, J. P.</span></span> <span> </span><span class="NLM_article-title">Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115193</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.bmc.2019.115193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=31757680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1amsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115193&author=P.+A.+Allegrettiauthor=T.+M.+Hortonauthor=Y.+Abdolazimiauthor=H.+P.+Moellerauthor=B.+Yehauthor=M.+Caffetauthor=G.+Michelauthor=M.+Smithauthor=J.+P.+Annes&title=Generation+of+highly+potent+DYRK1A-dependent+inducers+of+human+%CE%B2-Cell+replication+via+Multi-Dimensional+compound+optimization&doi=10.1016%2Fj.bmc.2019.115193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization</span></div><div class="casAuthors">Allegretti, Paul A.; Horton, Timothy M.; Abdolazimi, Yassan; Moeller, Hannah P.; Yeh, Benjamin; Caffet, Matthew; Michel, Guillermina; Smith, Mark; Annes, Justin P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115193</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Small mol. stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes.  Although chem. inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replication, current lead compds. have inadequate cellular potency for in vivo application.  Herein, we report the clin. stage anti-cancer kinase inhibitor OTS167 as a structurally novel, remarkably potent DYRK1A inhibitor and inducer of human β-cell replication.  Unfortunately, OTS167's target promiscuity and cytotoxicity curtails utility.  To tailor kinase selectivity towards DYRK1A and reduce cytotoxicity we designed a library of fifty-one OTS167 derivs. based upon a modeled structure of the DYRK1A-OTS167 complex.  Indeed, deriv. characterization yielded several leads with exceptional DYRK1A inhibition and human β-cell replication promoting potencies but substantially reduced cytotoxicity.  These compds. are the most potent human β-cell replication-promoting compds. yet described and exemplify the potential to purposefully leverage off-target activities of advanced stage compds. for a desired application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1KYUl2Lp-FrVg90H21EOLACvtfcHk0lh4BS_w7fdqeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1amsLvL&md5=e01d93661157162b14a0995c19c5b6f2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115193%26sid%3Dliteratum%253Aachs%26aulast%3DAllegretti%26aufirst%3DP.%2BA.%26aulast%3DHorton%26aufirst%3DT.%2BM.%26aulast%3DAbdolazimi%26aufirst%3DY.%26aulast%3DMoeller%26aufirst%3DH.%2BP.%26aulast%3DYeh%26aufirst%3DB.%26aulast%3DCaffet%26aufirst%3DM.%26aulast%3DMichel%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DAnnes%26aufirst%3DJ.%2BP.%26atitle%3DGeneration%2520of%2520highly%2520potent%2520DYRK1A-dependent%2520inducers%2520of%2520human%2520%25CE%25B2-Cell%2520replication%2520via%2520Multi-Dimensional%2520compound%2520optimization%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115193%26doi%3D10.1016%2Fj.bmc.2019.115193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dirice, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpita, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dancik, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of DYRK1A stimulates human beta-cell proliferation</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1660</span>– <span class="NLM_lpage">1671</span>, <span class="refDoi"> DOI: 10.2337/db15-1127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb15-1127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26953159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWns7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=1660-1671&issue=6&author=E.+Diriceauthor=D.+Walpitaauthor=A.+Vetereauthor=B.+C.+Meierauthor=S.+Kahramanauthor=J.+Huauthor=V.+Dancikauthor=S.+M.+Burnsauthor=T.+J.+Gilbertauthor=D.+E.+Olsonauthor=P.+A.+Clemonsauthor=R.+N.+Kulkarniauthor=B.+K.+Wagner&title=Inhibition+of+DYRK1A+stimulates+human+beta-cell+proliferation&doi=10.2337%2Fdb15-1127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of DYRK1A stimulates human beta-cell proliferation</span></div><div class="casAuthors">Dirice, Ercument; Walpita, Deepika; Vetere, Amedeo; Meier, Bennett C.; Kahraman, Sevim; Hu, Jiang; Dancik, Vlado; Burns, Sean M.; Gilbert, Tamara J.; Olson, David E.; Clemons, Paul A.; Kulkarni, Rohit N.; Wagner, Bridget K.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1660-1671</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Restoring functional β-cell mass is an important therapeutic goal for both type 1 and type 2 diabetes (1).  While proliferation of existing β-cells is the primary means of β-cell replacement in rodents (2), it is unclear whether a similar principle applies to humans, as human β-cells are remarkably resistant to stimulation of division (3,4).  Here, we show that 5-iodotubercidin (5-IT), an annotated adenosine kinase inhibitor previously reported to increase proliferation in rodent and porcine islets (5), strongly and selectively increases human β-cell proliferation in vitro and in vivo.  Remarkably, 5-IT also increased glucose-dependent insulin secretion after prolonged treatment.  Kinome profiling revealed 5-IT to be a potent and selective inhibitor of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) and cell division cycle-like kinase families.  Induction of β-cell proliferation by either 5-IT or harmine, another natural product DYRK1A inhibitor, was suppressed by coincubation with the calcineurin inhibitor FK506, suggesting involvement of DYRK1A and nuclear factor of activated T cells signaling.  Gene expression profiling in whole islets treated with 5-IT revealed induction of proliferation- and cell cycle-related genes, suggesting that true proliferation is induced by 5-IT.  Furthermore, 5-IT promotes β-cell proliferation in human islets grafted under the kidney capsule of NOD-scid IL2Rgnull mice.  These results point to inhibition of DYRK1A as a therapeutic strategy to increase human β-cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqLKPVi2wkdrVg90H21EOLACvtfcHk0lj04YlpkDYgfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWns7vP&md5=c383c8d1f2c1739252ad3cfe4361585c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2337%2Fdb15-1127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb15-1127%26sid%3Dliteratum%253Aachs%26aulast%3DDirice%26aufirst%3DE.%26aulast%3DWalpita%26aufirst%3DD.%26aulast%3DVetere%26aufirst%3DA.%26aulast%3DMeier%26aufirst%3DB.%2BC.%26aulast%3DKahraman%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DDancik%26aufirst%3DV.%26aulast%3DBurns%26aufirst%3DS.%2BM.%26aulast%3DGilbert%26aufirst%3DT.%2BJ.%26aulast%3DOlson%26aufirst%3DD.%2BE.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26atitle%3DInhibition%2520of%2520DYRK1A%2520stimulates%2520human%2520beta-cell%2520proliferation%26jtitle%3DDiabetes%26date%3D2016%26volume%3D65%26issue%3D6%26spage%3D1660%26epage%3D1671%26doi%3D10.2337%2Fdb15-1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jarhad, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashelkar, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, L. S.</span></span> <span> </span><span class="NLM_article-title">Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) inhibitors as potential therapeutics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9791</span>– <span class="NLM_lpage">9810</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00185</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12jsLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9791-9810&issue=22&author=D.+B.+Jarhadauthor=K.+K.+Mashelkarauthor=H.-R.+Kimauthor=M.+Nohauthor=L.+S.+Jeong&title=Dual-Specificity+Tyrosine+Phosphorylation-Regulated+Kinase+1A+%28DYRK1A%29+inhibitors+as+potential+therapeutics&doi=10.1021%2Facs.jmedchem.8b00185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics</span></div><div class="casAuthors">Jarhad, Dnyandev B.; Mashelkar, Karishma K.; Kim, Hong-Rae; Noh, Minsoo; Jeong, Lak Shin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9791-9810</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a member of an evolutionarily conserved family of protein kinases that belongs to the CMGC group of kinases.  DYRK1A, encoded by a gene located in the human chromosome 21q22.2 region, has attracted attention due to its assocn. with both neuropathol. phenotypes and cancer susceptibility in patients with Down syndrome (DS).  Inhibition of DYRK1A attenuates cognitive dysfunctions in animal models for both DS and Alzheimer's disease (AD).  Furthermore, DYRK1A has been studied as a potential cancer therapeutic target because of its role in the regulation of cell cycle progression by affecting both tumor suppressors and oncogenes.  Consequently, selective synthetic inhibitors have been developed to det. the role of DYRK1A in various human diseases.  Our perspective includes a comprehensive review of potent and selective DYRK1A inhibitors and their forthcoming therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYrGtCZLBQ77Vg90H21EOLACvtfcHk0lgLkNsEqYgxVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12jsLvO&md5=6ffb927f58fc34f16f19c5e5b8beebcf</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00185%26sid%3Dliteratum%253Aachs%26aulast%3DJarhad%26aufirst%3DD.%2BB.%26aulast%3DMashelkar%26aufirst%3DK.%2BK.%26aulast%3DKim%26aufirst%3DH.-R.%26aulast%3DNoh%26aufirst%3DM.%26aulast%3DJeong%26aufirst%3DL.%2BS.%26atitle%3DDual-Specificity%2520Tyrosine%2520Phosphorylation-Regulated%2520Kinase%25201A%2520%2528DYRK1A%2529%2520inhibitors%2520as%2520potential%2520therapeutics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D22%26spage%3D9791%26epage%3D9810%26doi%3D10.1021%2Facs.jmedchem.8b00185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man-Un Ung, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1016</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.ejmech.2018.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30170319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1ent7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=1005-1016&author=K.+Kumarauthor=P.+Man-Un+Ungauthor=P.+Wangauthor=H.+Wangauthor=H.+Liauthor=M.+K.+Andrewsauthor=A.+F.+Stewartauthor=A.+Schlessingerauthor=R.+J.+DeVita&title=Novel+selective+thiadiazine+DYRK1A+inhibitor+lead+scaffold+with+human+pancreatic+%CE%B2-cell+proliferation+activity&doi=10.1016%2Fj.ejmech.2018.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity</span></div><div class="casAuthors">Kumar, Kunal; Man-Un Ung, Peter; Wang, Peng; Wang, Hui; Li, Hailing; Andrews, Mary K.; Stewart, Andrew F.; Schlessinger, Avner; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1005-1016</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) is an enzyme that has been implicated as an important drug target in various therapeutic areas, including neurol. disorders (Down syndrome, Alzheimer's disease), oncol., and diabetes (pancreatic β-cell expansion).  Current small mol. DYRK1A inhibitors are ATP-competitive inhibitors that bind to the kinase in an active conformation.  As a result, these inhibitors are promiscuous, resulting in pharmacol. side effects that limit their therapeutic applications.  None are in clin. trials at this time.  In order to identify a new DYRK1A inhibitor scaffold, we constructed a homol. model of DYRK1A in an inactive, DFG-out conformation.  Virtual screening of 2.2 million lead-like compds. from the ZINC database, followed by in vitro testing of selected 68 compds. revealed 8 hits representing 5 different chem. classes.  We chose to focus on one of the hits from the computational screen, thiadiazine 1 which was found to inhibit DYRK1A with IC50 of 9.41 μM (Kd = 7.3 μM).  Optimization of the hit compd. 1, using structure-activity relationship (SAR) anal. and in vitro testing led to the identification of potent thiadiazine analogs with significantly improved binding as compared to the initial hit (Kd = 71-185 nM).  Compd. 3-5 induced human β-cell proliferation at 5 μM while showing selectivity for DYRK1A over DYRK1B and DYRK2 at 10 μM.  This newly developed DYRK1A inhibitor scaffold with unique kinase selectivity profiles has potential to be further optimized as novel therapeutics for diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs8HXnn8ewabVg90H21EOLACvtfcHk0lgLkNsEqYgxVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1ent7vE&md5=026fe0a5ddf42ebeacdea9c5838b0565</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DMan-Un%2BUng%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DAndrews%26aufirst%3DM.%2BK.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DSchlessinger%26aufirst%3DA.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DNovel%2520selective%2520thiadiazine%2520DYRK1A%2520inhibitor%2520lead%2520scaffold%2520with%2520human%2520pancreatic%2520%25CE%25B2-cell%2520proliferation%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D1005%26epage%3D1016%26doi%3D10.1016%2Fj.ejmech.2018.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Development of kinase-selective, harmine-based dYRK1A inhibitors that induce pancreatic human β-cell proliferation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7687</span>– <span class="NLM_lpage">7699</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00658</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00658" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSrsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7687-7699&issue=17&author=K.+Kumarauthor=P.+Wangauthor=R.+Sanchezauthor=E.+A.+Swartzauthor=A.+F.+Stewartauthor=R.+J.+DeVita&title=Development+of+kinase-selective%2C+harmine-based+dYRK1A+inhibitors+that+induce+pancreatic+human+%CE%B2-cell+proliferation&doi=10.1021%2Facs.jmedchem.8b00658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation</span></div><div class="casAuthors">Kumar, Kunal; Wang, Peng; Sanchez, Roberto; Swartz, Ethan A.; Stewart, Andrew F.; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7687-7699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DYRK1A has been implicated as an important drug target in various therapeutic areas, including neurol. disorders and oncol.  DYRK1A has more recently been shown to be involved in pathways regulating human β-cell proliferation, thus making it a potential therapeutic target for both Type 1 and Type 2 diabetes.  Our group, using a high-throughput phenotypic screen identified harmine that is able to induce beta cell proliferation both in vitro and in vivo.  Since harmine has suboptimal kinase selectivity we sought to expand structure-activity relationships for harmine's DYRK1A activity, to enhance selectivity, while retaining human β-cell proliferation capability.  We carried out the optimization of the 1-position of harmine and synthesized 15 harmine analogs.  6 Compds. showed excellent DYRK1A inhibition with IC50 in the range of 49.5-264 nM.  Two compds., 2-2 and 2-8, exhibited excellent human β-cell proliferation at doses of 3-30 μM and compd. 2-2 showed improved kinase selectivity as compared to harmine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmFSDNEicChLVg90H21EOLACvtfcHk0lgLkNsEqYgxVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSrsb7M&md5=e1b748db912ac5b0ef93b8729ad4b13e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00658%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DSwartz%26aufirst%3DE.%2BA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DDevelopment%2520of%2520kinase-selective%252C%2520harmine-based%2520dYRK1A%2520inhibitors%2520that%2520induce%2520pancreatic%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7687%26epage%3D7699%26doi%3D10.1021%2Facs.jmedchem.8b00658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatanic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrouet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamrui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological validation of a harmine-based, central nervous system (CNS)-avoidant, selective, human β-cell regenerative dual-specificity tyrosine phosphorylation-regulated kinase A (DYRK1A) inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2984</span>– <span class="NLM_lpage">3003</span></span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01379" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2984-3003&author=K.+Kumarauthor=P.+Wangauthor=J.+Wilsonauthor=V.+Zlatanicauthor=C.+Berrouetauthor=S.+Khamruiauthor=C.+Secorauthor=E.+A.+Swartzauthor=M.+Lazarusauthor=R.+Sanchezauthor=A.+F.+Stewartauthor=A.+Garcia-Ocanaauthor=R.+J.+DeVita&title=Synthesis+and+biological+validation+of+a+harmine-based%2C+central+nervous+system+%28CNS%29-avoidant%2C+selective%2C+human+%CE%B2-cell+regenerative+dual-specificity+tyrosine+phosphorylation-regulated+kinase+A+%28DYRK1A%29+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01379%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DZlatanic%26aufirst%3DV.%26aulast%3DBerrouet%26aufirst%3DC.%26aulast%3DKhamrui%26aufirst%3DS.%26aulast%3DSecor%26aufirst%3DC.%26aulast%3DSwartz%26aufirst%3DE.%2BA.%26aulast%3DLazarus%26aufirst%3DM.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DSynthesis%2520and%2520biological%2520validation%2520of%2520a%2520harmine-based%252C%2520central%2520nervous%2520system%2520%2528CNS%2529-avoidant%252C%2520selective%252C%2520human%2520%25CE%25B2-cell%2520regenerative%2520dual-specificity%2520tyrosine%2520phosphorylation-regulated%2520kinase%2520A%2520%2528DYRK1A%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2984%26epage%3D3003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursalaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Donato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamireddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loren, J.</span></span> <span> </span><span class="NLM_article-title">A dual inhibitor of DYRK1A and GSK3β for β-cell proliferation: Aminopyrazine derivative GNF4877</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1562</span>– <span class="NLM_lpage">1570</span>, <span class="refDoi"> DOI: 10.1002/cmdc.202000183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1002%2Fcmdc.202000183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=32613743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1yqsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=1562-1570&issue=16&author=Y.+A.+Liuauthor=Q.+Jinauthor=Q.+Dingauthor=X.+Haoauthor=T.+Moauthor=S.+Yanauthor=Y.+Zouauthor=Z.+Huangauthor=X.+Zhangauthor=W.+Gaoauthor=T.+Y.+H.+Wuauthor=C.+Liauthor=B.+Bursalayaauthor=M.+Di+Donatoauthor=Y.-Q.+Zhangauthor=L.+Deatonauthor=W.+Shenauthor=B.+Taylorauthor=A.+Kamireddyauthor=G.+Harbauthor=J.+Liauthor=Y.+Jiaauthor=A.+M.+Schumacherauthor=B.+Laffitteauthor=R.+Glynneauthor=S.+Panauthor=P.+McNamaraauthor=V.+Molteniauthor=J.+Loren&title=A+dual+inhibitor+of+DYRK1A+and+GSK3%CE%B2+for+%CE%B2-cell+proliferation%3A+Aminopyrazine+derivative+GNF4877&doi=10.1002%2Fcmdc.202000183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877</span></div><div class="casAuthors">Liu, Yahu A.; Jin, Qihui; Ding, Qiang; Hao, Xueshi; Mo, Tingting; Yan, Shanshan; Zou, Yefen; Huang, Zhihong; Zhang, Xiaoyue; Gao, Wenqi; Wu, Tom Y.-H.; Li, Chun; Bursalaya, Badry; Di Donato, Michael; Zhang, You-Qing; Deaton, Lisa; Shen, Weijun; Taylor, Brandon; Kamireddy, Anwesh; Harb, George; Li, Jing; Jia, Yong; Schumacher, Andrew M.; Laffitte, Bryan; Glynne, Richard; Pan, Shifeng; McNamara, Peter; Molteni, Valentina; Loren, Jon</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1562-1570</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Loss of β-cell mass and function can lead to insufficient insulin levels and ultimately to hyperglycemia and diabetes mellitus.  The mainstream treatment approach involves regulation of insulin levels; however, approaches intended to increase β-cell mass are less developed.  Promoting β-cell proliferation with low-mol.-wt. inhibitors of dual-specificity tyrosine-regulated kinase 1A (DYRK1A) offers the potential to treat diabetes with oral therapies by restoring β-cell mass, insulin content and glycemic control.  GNF4877, a potent dual inhibitor of DYRK1A and glycogen synthase kinase 3β (GSK3β) was previously reported to induce primary human β-cell proliferation in vitro and in vivo.  Herein, we describe the lead optimization that lead to the identification of GNF4877(I) from an aminopyrazine hit identified in a phenotypic high-throughput screening campaign measuring β-cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq9Ym91j41B7Vg90H21EOLACvtfcHk0limavhSwSIGLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1yqsbrK&md5=4b02cad328225a30bf99eb302e4e177c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.202000183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.202000183%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BA.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DT.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DT.%2BY.%2BH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DBursalaya%26aufirst%3DB.%26aulast%3DDi%2BDonato%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.-Q.%26aulast%3DDeaton%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DTaylor%26aufirst%3DB.%26aulast%3DKamireddy%26aufirst%3DA.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DSchumacher%26aufirst%3DA.%2BM.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DLoren%26aufirst%3DJ.%26atitle%3DA%2520dual%2520inhibitor%2520of%2520DYRK1A%2520and%2520GSK3%25CE%25B2%2520for%2520%25CE%25B2-cell%2520proliferation%253A%2520Aminopyrazine%2520derivative%2520GNF4877%26jtitle%3DChemMedChem%26date%3D2020%26volume%3D15%26issue%3D16%26spage%3D1562%26epage%3D1570%26doi%3D10.1002%2Fcmdc.202000183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrassi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baaten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamireddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeusen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loren, J.</span></span> <span> </span><span class="NLM_article-title">Selective DYRK1A inhibitor for the treatment of type 1 diabetes: discovery of 6-azaindole derivative GNF2133</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2958</span>– <span class="NLM_lpage">2973</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01624</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01624" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlSqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2958-2973&author=Y.+A.+Liuauthor=Q.+Jinauthor=Y.+Zouauthor=Q.+Dingauthor=S.+Yanauthor=Z.+Wangauthor=X.+Haoauthor=B.+Nguyenauthor=X.+Zhangauthor=J.+Panauthor=T.+Moauthor=K.+Jacobsenauthor=T.+Lamauthor=T.+Y.+H.+Wuauthor=H.+M.+Petrassiauthor=B.+Bursulayaauthor=M.+DiDonatoauthor=W.+P.+Gordonauthor=B.+Liuauthor=J.+Baatenauthor=R.+Hillauthor=V.+Nguyen-Tranauthor=M.+Qiuauthor=Y.-Q.+Zhangauthor=A.+Kamireddyauthor=S.+Espinolaauthor=L.+Deatonauthor=S.+Haauthor=G.+Harbauthor=Y.+Jiaauthor=J.+Liauthor=W.+Shenauthor=A.+M.+Schumacherauthor=K.+Colmanauthor=R.+Glynneauthor=S.+Panauthor=P.+McNamaraauthor=B.+Laffitteauthor=S.+Meeusenauthor=V.+Molteniauthor=J.+Loren&title=Selective+DYRK1A+inhibitor+for+the+treatment+of+type+1+diabetes%3A+discovery+of+6-azaindole+derivative+GNF2133&doi=10.1021%2Facs.jmedchem.9b01624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133</span></div><div class="casAuthors">Liu, Yahu A.; Jin, Qihui; Zou, Yefen; Ding, Qiang; Yan, Shanshan; Wang, Zhicheng; Hao, Xueshi; Nguyen, Bao; Zhang, Xiaoyue; Pan, Jianfeng; Mo, Tingting; Jacobsen, Kate; Lam, Thanh; Wu, Tom Y.-H.; Petrassi, H. Michael; Bursulaya, Badry; Di Donato, Michael; Gordon, W. Perry; Liu, Bo; Baaten, Janine; Hill, Robert; Nguyen-Tran, Van; Qiu, Minhua; Zhang, You-Qing; Kamireddy, Anwesh; Espinola, Sheryll; Deaton, Lisa; Ha, Sukwon; Harb, George; Jia, Yong; Li, Jing; Shen, Weijun; Schumacher, Andrew M.; Colman, Karyn; Glynne, Richard; Pan, Shifeng; McNamara, Peter; Laffitte, Bryan; Meeusen, Shelly; Molteni, Valentina; Loren, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2958-2973</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Autoimmune deficiency and destruction in either β-cell mass or function can cause insufficient insulin levels and, as a result, hyperglycemia and diabetes.  Thus, promoting β-cell proliferation could be one approach toward diabetes intervention.  In this report we describe the discovery of a potent and selective DYRK1A inhibitor GNF2133, which was identified through optimization of a 6-azaindole screening hit.  In vitro, GNF2133 is able to proliferate both rodent and human β-cells.  In vivo, GNF2133 demonstrated significant dose-dependent glucose disposal capacity and insulin secretion in response to glucose-potentiated arginine-induced insulin secretion (GPAIS) challenge in rat insulin promoter and diphtheria toxin A (RIP-DTA) mice.  The work described here provides new avenues to disease altering therapeutic interventions in the treatment of type 1 diabetes (T1D).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKP8bWozWpHrVg90H21EOLACvtfcHk0limavhSwSIGLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlSqs7g%253D&md5=0ec2402f79b1b3fa338aab9672b8b669</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01624%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BA.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DT.%26aulast%3DJacobsen%26aufirst%3DK.%26aulast%3DLam%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DT.%2BY.%2BH.%26aulast%3DPetrassi%26aufirst%3DH.%2BM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DBaaten%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%26aulast%3DNguyen-Tran%26aufirst%3DV.%26aulast%3DQiu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.-Q.%26aulast%3DKamireddy%26aufirst%3DA.%26aulast%3DEspinola%26aufirst%3DS.%26aulast%3DDeaton%26aufirst%3DL.%26aulast%3DHa%26aufirst%3DS.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DSchumacher%26aufirst%3DA.%2BM.%26aulast%3DColman%26aufirst%3DK.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DMeeusen%26aufirst%3DS.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DLoren%26aufirst%3DJ.%26atitle%3DSelective%2520DYRK1A%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25201%2520diabetes%253A%2520discovery%2520of%25206-azaindole%2520derivative%2520GNF2133%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2958%26epage%3D2973%26doi%3D10.1021%2Facs.jmedchem.9b01624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeusen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamireddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swafford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursalaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez-Pinzon, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hering, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of DYRK1A and GSK3B induces human β-cell proliferation</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8372</span>, <span class="refDoi"> DOI: 10.1038/ncomms9372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fncomms9372" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26496802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslegu7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8372&author=W.+Shenauthor=B.+Taylorauthor=Q.+Jinauthor=V.+Nguyen-Tranauthor=S.+Meeusenauthor=Y.-Q.+Zhangauthor=A.+Kamireddyauthor=A.+Swaffordauthor=A.+F.+Powersauthor=J.+Walkerauthor=J.+Lambauthor=B.+Bursalayaauthor=M.+DiDonatoauthor=G.+Harbauthor=M.+Qiuauthor=C.+M.+Filippiauthor=L.+Deatonauthor=C.+N.+Turkauthor=W.+L.+Suarez-Pinzonauthor=Y.+Liuauthor=X.+Haoauthor=T.+Moauthor=S.+Yanauthor=J.+Liauthor=A.+E.+Hermanauthor=B.+J.+Heringauthor=T.+Wuauthor=H.+M.+Seidelauthor=P.+McNamaraauthor=R.+Glynneauthor=B.+Laffitte&title=Inhibition+of+DYRK1A+and+GSK3B+induces+human+%CE%B2-cell+proliferation&doi=10.1038%2Fncomms9372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of DYRK1A and GSK3B induces human β-cell proliferation</span></div><div class="casAuthors">Shen, Weijun; Taylor, Brandon; Jin, Qihui; Nguyen-Tran, Van; Meeusen, Shelly; Zhang, You-Qing; Kamireddy, Anwesh; Swafford, Austin; Powers, Andrew F.; Walker, John; Lamb, John; Bursalaya, Badry; DiDonato, Michael; Harb, George; Qiu, Minhua; Filippi, Christophe M.; Deaton, Lisa; Turk, Carolina N.; Suarez-Pinzon, Wilma L.; Liu, Yahu; Hao, Xueshi; Mo, Tingting; Yan, Shanshan; Li, Jing; Herman, Ann E.; Hering, Bernhard J.; Wu, Tom; Seidel, H. Martin; McNamara, Peter; Glynne, Richard; Laffitte, Bryan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8372</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Insufficient pancreatic β-cell mass or function results in diabetes mellitus.  While significant progress has been made in regulating insulin secretion from β-cells in diabetic patients, no pharmacol. agents have been described that increase β-cell replication in humans.  Here we report aminopyrazine compds. that stimulate robust β-cell proliferation in adult primary islets, most likely as a result of combined inhibition of DYRK1A and GSK3B.  Aminopyrazine-treated human islets retain functionality in vitro and after transplantation into diabetic mice.  Oral dosing of these compds. in diabetic mice induces β-cell proliferation, increases β-cell mass and insulin content, and improves glycemic control.  Biochem., genetic and cell biol. data point to Dyrk1a as the key mol. target.  This study supports the feasibility of treating diabetes with an oral therapy to restore β-cell mass, and highlights a tractable pathway for future drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVHzP-VkH5nrVg90H21EOLACvtfcHk0lguOH78rfy_7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslegu7%252FK&md5=5ef960af3bfd2795b9fdce52876e5d59</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fncomms9372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9372%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%26aulast%3DTaylor%26aufirst%3DB.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DNguyen-Tran%26aufirst%3DV.%26aulast%3DMeeusen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.-Q.%26aulast%3DKamireddy%26aufirst%3DA.%26aulast%3DSwafford%26aufirst%3DA.%26aulast%3DPowers%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DJ.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DBursalaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DQiu%26aufirst%3DM.%26aulast%3DFilippi%26aufirst%3DC.%2BM.%26aulast%3DDeaton%26aufirst%3DL.%26aulast%3DTurk%26aufirst%3DC.%2BN.%26aulast%3DSuarez-Pinzon%26aufirst%3DW.%2BL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DT.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHerman%26aufirst%3DA.%2BE.%26aulast%3DHering%26aufirst%3DB.%2BJ.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DLaffitte%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520DYRK1A%2520and%2520GSK3B%2520induces%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8372%26doi%3D10.1038%2Fncomms9372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Perez, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felsenfeld, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivendran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic β-cell replication</span>. <i>Nat. Med. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.1038/nm.3820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnm.3820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=25751815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFOnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=383-388&issue=4&author=P.+Wangauthor=J.-C.+Alvarez-Perezauthor=D.+P.+Felsenfeldauthor=H.+Liuauthor=S.+Sivendranauthor=A.+Benderauthor=A.+Kumarauthor=R.+Sanchezauthor=D.+K.+Scottauthor=A.+Garcia-Ocanaauthor=A.+F.+Stewart&title=A+high-throughput+chemical+screen+reveals+that+harmine-mediated+inhibition+of+DYRK1A+increases+human+pancreatic+%CE%B2-cell+replication&doi=10.1038%2Fnm.3820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication</span></div><div class="casAuthors">Wang, Peng; Alvarez-Perez, Juan-Carlos; Felsenfeld, Dan P.; Liu, Hongtao; Sivendran, Sharmila; Bender, Aaron; Kumar, Anil; Sanchez, Roberto; Scott, Donald K.; Garcia-Ocana, Adolfo; Stewart, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-388</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Types 1 and 2 diabetes affect some 380 million people worldwide.  Both ultimately result from a deficiency of functional pancreatic insulin-producing beta cells.  Beta cells proliferate in humans during a brief temporal window beginning around the time of birth, with a peak percentage (∼2%) engaged in the cell cycle in the first year of life.  In embryonic life and after early childhood, beta cell replication is barely detectable.  Whereas beta cell expansion seems an obvious therapeutic approach to beta cell deficiency, adult human beta cells have proven recalcitrant to such efforts.  Hence, there remains an urgent need for antidiabetic therapeutic agents that can induce regeneration and expansion of adult human beta cells in vivo or ex vivo.  Here, using a high-throughput small-mol. screen (HTS), we find that analogs of the small mol. harmine function as a new class of human beta cell mitogenic compds.  We also define dual-specificity tyrosine-regulated kinase-1a (DYRK1A) as the likely target of harmine and the nuclear factors of activated T cells (NFAT) family of transcription factors as likely mediators of human beta cell proliferation and differentiation.  Using three different mouse and human islet in vivo-based models, we show that harmine is able to induce beta cell proliferation, increase islet mass and improve glycemic control.  These observations suggest that harmine analogs may have unique therapeutic promise for human diabetes therapy.  Enhancing the potency and beta cell specificity of these compds. are important future challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp11xY4tql3VbVg90H21EOLACvtfcHk0lguOH78rfy_7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFOnsr8%253D&md5=32a02c393defd14b8922ac9efff63389</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnm.3820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3820%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DAlvarez-Perez%26aufirst%3DJ.-C.%26aulast%3DFelsenfeld%26aufirst%3DD.%2BP.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSivendran%26aufirst%3DS.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DA%2520high-throughput%2520chemical%2520screen%2520reveals%2520that%2520harmine-mediated%2520inhibition%2520of%2520DYRK1A%2520increases%2520human%2520pancreatic%2520%25CE%25B2-cell%2520replication%26jtitle%3DNat.%2520Med.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2015%26volume%3D21%26issue%3D4%26spage%3D383%26epage%3D388%26doi%3D10.1038%2Fnm.3820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamrui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships and biological evaluation of 7-substituted harmine analogs for human β-cell proliferation</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1983</span>, <span class="refDoi"> DOI: 10.3390/molecules25081983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.3390%2Fmolecules25081983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVekurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=1983&issue=8&author=K.+Kumarauthor=P.+Wangauthor=E.+A.+Swartzauthor=S.+Khamruiauthor=C.+Secorauthor=M.+B.+Lazarusauthor=R.+Sanchezauthor=A.+F.+Stewartauthor=R.+J.+DeVita&title=Structure-activity+relationships+and+biological+evaluation+of+7-substituted+harmine+analogs+for+human+%CE%B2-cell+proliferation&doi=10.3390%2Fmolecules25081983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships and biological evaluation of 7-substituted harmine analogs for human β-cell proliferation</span></div><div class="casAuthors">Kumar, Kunal; Wang, Peng; Swartz, Ethan A.; Khamrui, Susmita; Secor, Cody; Lazarus, Michael B.; Sanchez, Roberto; Stewart, Andrew F.; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1983</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Recently, we have shown that harmine induces β-cell proliferation both in vitro and in vivo, mediated via the DYRK1A-NFAT pathway.  We explore structure-activity relationships of the 7-position of harmine for both DYRK1A kinase inhibition and β-cell proliferation based on our related previous structure-activity relationship studies of harmine in the context of diabetes and β-cell specific targeting strategies.  Thirty three harmine analogs of the 7-position substituent were synthesized and evaluated for biol. activity.  Two novel inhibitors were identified which showed DYRK1A inhibition and human β-cell proliferation capability.  The DYRK1A inhibitor, compd. 3-(7-oxy-1-methyl-9-H-b-carbolin)propionic acid Me ester, induced β-cell proliferation half that of harmine at three times higher concn.  From these studies we can draw the inference that 7-position modification is limited for further harmine optimization focused on β-cell proliferation and cell-specific targeting approach for diabetes therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOP5g7lLBUorVg90H21EOLACvtfcHk0lgmX0fKetCiPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVekurrI&md5=4f8c859f119e45d6b406f11354f4cbe9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25081983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25081983%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DSwartz%26aufirst%3DE.%2BA.%26aulast%3DKhamrui%26aufirst%3DS.%26aulast%3DSecor%26aufirst%3DC.%26aulast%3DLazarus%26aufirst%3DM.%2BB.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DStructure-activity%2520relationships%2520and%2520biological%2520evaluation%2520of%25207-substituted%2520harmine%2520analogs%2520for%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26issue%3D8%26spage%3D1983%26doi%3D10.3390%2Fmolecules25081983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamireddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baaten, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swoboda, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inducer of β cell proliferation identified by high-throughput screening</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1669</span>– <span class="NLM_lpage">1672</span>, <span class="refDoi"> DOI: 10.1021/ja309304m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja309304m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCgu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=1669-1672&issue=5&author=W.+Shenauthor=M.+S.+Tremblayauthor=V.+A.+Deshmukhauthor=W.+Wangauthor=C.+M.+Filippiauthor=G.+Harbauthor=Y.-q.+Zhangauthor=A.+Kamireddyauthor=J.+E.+Baatenauthor=Q.+Jinauthor=T.+Wuauthor=J.+G.+Swobodaauthor=E.+C.+Petersauthor=C.+Y.+Choauthor=J.+Liauthor=B.+A.+Laffitteauthor=P.+McNamaraauthor=R.+Glynneauthor=X.+Wuauthor=A.+E.+Hermanauthor=P.+G.+Schultz&title=Small-molecule+inducer+of+%CE%B2+cell+proliferation+identified+by+high-throughput+screening&doi=10.1021%2Fja309304m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inducer of β Cell Proliferation Identified by High-Throughput Screening</span></div><div class="casAuthors">Shen, Weijun; Tremblay, Matthew S.; Deshmukh, Vishal A.; Wang, Weidong; Filippi, Christophe M.; Harb, George; Zhang, You-qing; Kamireddy, Anwesh; Baaten, Janine E.; Jin, Qihui; Wu, Tom; Swoboda, Jonathan G.; Peters, Eric C.; Cho, Charles Y.; Li, Jing; Laffitte, Bryan A.; McNamara, Peter; Glynne, Richard; Wu, Xu; Herman, Ann E.; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1669-1672</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification of factors that promote β cell proliferation could ultimately move type 1 diabetes treatment away from insulin injection therapy and toward a cure.  We have performed high-throughput, cell-based screens using rodent β cell lines to identify mols. that induce proliferation of β cells.  Herein we report the discovery and characterization of WS6, a novel small mol. that promotes β cell proliferation in rodent and human primary islets.  In the RIP-DTA mouse model of β cell ablation, WS6 normalized blood glucose and induced concomitant increases in β cell proliferation and β cell no.  Affinity pulldown and kinase profiling studies implicate Erb3 binding protein-1 and the IκB kinase pathway in the mechanism of action of WS6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcVnec647SN7Vg90H21EOLACvtfcHk0lgmX0fKetCiPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCgu7w%253D&md5=f7a76c2f8b61e183e171b3343d65543a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fja309304m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja309304m%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%26aulast%3DTremblay%26aufirst%3DM.%2BS.%26aulast%3DDeshmukh%26aufirst%3DV.%2BA.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DFilippi%26aufirst%3DC.%2BM.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.-q.%26aulast%3DKamireddy%26aufirst%3DA.%26aulast%3DBaaten%26aufirst%3DJ.%2BE.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DSwoboda%26aufirst%3DJ.%2BG.%26aulast%3DPeters%26aufirst%3DE.%2BC.%26aulast%3DCho%26aufirst%3DC.%2BY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLaffitte%26aufirst%3DB.%2BA.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DHerman%26aufirst%3DA.%2BE.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DSmall-molecule%2520inducer%2520of%2520%25CE%25B2%2520cell%2520proliferation%2520identified%2520by%2520high-throughput%2520screening%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26issue%3D5%26spage%3D1669%26epage%3D1672%26doi%3D10.1021%2Fja309304m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondegowda, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenutria, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orthofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasavada, R. C.</span></span> <span> </span><span class="NLM_article-title">Osteoprotegerin and Denosumab stimulate human β-cell proliferation through inhibition of the receptor activator of NF-κB ligand pathway</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2015.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2015.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26094891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2lsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=77-85&issue=1&author=N.+G.+Kondegowdaauthor=R.+Fenutriaauthor=I.+R.+Pollackauthor=M.+Orthoferauthor=A.+Garcia-Ocanaauthor=J.+M.+Penningerauthor=R.+C.+Vasavada&title=Osteoprotegerin+and+Denosumab+stimulate+human+%CE%B2-cell+proliferation+through+inhibition+of+the+receptor+activator+of+NF-%CE%BAB+ligand+pathway&doi=10.1016%2Fj.cmet.2015.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway</span></div><div class="casAuthors">Kondegowda, Nagesha Guthalu; Fenutria, Rafael; Pollack, Ilana R.; Orthofer, Michael; Garcia-Ocana, Adolfo; Penninger, Josef M.; Vasavada, Rupangi C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-85</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Diabetes results from a redn. of pancreatic β-cells.  Stimulating replication could normalize β-cell mass.  However, adult human β-cells are recalcitrant to proliferation.  We identified osteoprotegerin, a bone-related decoy receptor, as a β-cell mitogen.  Osteoprotegerin was induced by and required for lactogen-mediated rodent β-cell replication.  Osteoprotegerin enhanced β-cell proliferation in young, aged, and diabetic mice.  This resulted in increased β-cell mass in young mice and significantly delayed hyperglycemia in diabetic mice.  Osteoprotegerin stimulated replication of adult human β-cells, without causing dedifferentiation.  Mechanistically, osteoprotegerin induced human and rodent β-cell replication by modulating CREB and GSK3 pathways, through binding Receptor Activator of NF-κB (RANK) Ligand (RANKL), a brake in β-cell proliferation.  Denosumab, an FDA-approved osteoporosis drug, and RANKL-specific antibody induced human β-cell proliferation in vitro, and in vivo, in humanized mice.  Thus, osteoprotegerin and Denosumab prevent RANKL/RANK interaction to stimulate β-cell replication, highlighting the potential for repurposing an osteoporosis drug to treat diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Jm7_Ycw93rVg90H21EOLACvtfcHk0lgmX0fKetCiPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2lsrjM&md5=42cd0ef9b90a1338312453d2c4b8c4eb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2015.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2015.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DKondegowda%26aufirst%3DN.%2BG.%26aulast%3DFenutria%26aufirst%3DR.%26aulast%3DPollack%26aufirst%3DI.%2BR.%26aulast%3DOrthofer%26aufirst%3DM.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DVasavada%26aufirst%3DR.%2BC.%26atitle%3DOsteoprotegerin%2520and%2520Denosumab%2520stimulate%2520human%2520%25CE%25B2-cell%2520proliferation%2520through%2520inhibition%2520of%2520the%2520receptor%2520activator%2520of%2520NF-%25CE%25BAB%2520ligand%2520pathway%26jtitle%3DCell%2520Metab.%26date%3D2015%26volume%3D22%26issue%3D1%26spage%3D77%26epage%3D85%26doi%3D10.1016%2Fj.cmet.2015.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Ouaamari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirice, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karampelias, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gritsenko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jesus, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, H.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jungtrakoon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfine, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liew, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doria, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remold-O’Donnell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span> <span> </span><span class="NLM_article-title">SerpinB1 promotes pancreatic β cell proliferation</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2015.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2015.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26701651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=194-205&issue=1&author=A.+El%0AOuaamariauthor=E.+Diriceauthor=N.+Gedeonauthor=J.+Huauthor=J.-Y.+Zhouauthor=J.+Shirakawaauthor=L.+Houauthor=J.+Goodmanauthor=C.+Karampeliasauthor=G.+Qiangauthor=J.+Boucherauthor=R.+Martinezauthor=M.+A.+Gritsenkoauthor=D.+F.+De+Jesusauthor=S.+Kahramanauthor=S.+Bhattauthor=R.+D.+Smithauthor=H.-D.+Beerauthor=P.+Jungtrakoonauthor=Y.+Gongauthor=A.+B.+Goldfineauthor=C.+W.+Liewauthor=A.+Doriaauthor=O.+Anderssonauthor=W.-J.+Qianauthor=E.+Remold-O%E2%80%99Donnellauthor=R.+N.+Kulkarni&title=SerpinB1+promotes+pancreatic+%CE%B2+cell+proliferation&doi=10.1016%2Fj.cmet.2015.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">SerpinB1 Promotes Pancreatic β Cell Proliferation</span></div><div class="casAuthors">El Ouaamari, Abdelfattah; Dirice, Ercument; Gedeon, Nicholas; Hu, Jiang; Zhou, Jian-Ying; Shirakawa, Jun; Hou, Lifei; Goodman, Jessica; Karampelias, Christos; Qiang, Guifeng; Boucher, Jeremie; Martinez, Rachael; Gritsenko, Marina A.; De Jesus, Dario F.; Kahraman, Sevim; Bhatt, Shweta; Smith, Richard D.; Beer, Hans-Dietmar; Jungtrakoon, Prapaporn; Gong, Yanping; Goldfine, Allison B.; Liew, Chong Wee; Doria, Alessandro; Andersson, Olov; Qian, Wei-Jun; Remold-O'Donnell, Eileen; Kulkarni, Rohit N.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">194-205</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Although compensatory islet hyperplasia in response to insulin resistance is a recognized feature in diabetes, the factor(s) that promote β cell proliferation have been elusive.  We previously reported that the liver is a source for such factors in the liver insulin receptor knockout (LIRKO) mouse, an insulin resistance model that manifests islet hyperplasia.  Using proteomics we show that serpinB1, a protease inhibitor, which is abundant in the hepatocyte secretome and sera derived from LIRKO mice, is the liver-derived secretory protein that regulates β cell proliferation in humans, mice, and zebrafish.  Small-mol. compds., that partially mimic serpinB1 effects of inhibiting elastase activity, enhanced proliferation of β cells, and mice lacking serpinB1 exhibit attenuated β cell compensation in response to insulin resistance.  Finally, SerpinB1 treatment of islets modulated proteins in growth/survival pathways.  Together, these data implicate serpinB1 as an endogenous protein that can potentially be harnessed to enhance functional β cell mass in patients with diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUF320xRQDVbVg90H21EOLACvtfcHk0lhwlLiE76UGzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVOqtA%253D%253D&md5=23209ce3e3b16faac4f3e235dec481b5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2015.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2015.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BOuaamari%26aufirst%3DA.%26aulast%3DDirice%26aufirst%3DE.%26aulast%3DGedeon%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DJ.-Y.%26aulast%3DShirakawa%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DL.%26aulast%3DGoodman%26aufirst%3DJ.%26aulast%3DKarampelias%26aufirst%3DC.%26aulast%3DQiang%26aufirst%3DG.%26aulast%3DBoucher%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DGritsenko%26aufirst%3DM.%2BA.%26aulast%3DDe%2BJesus%26aufirst%3DD.%2BF.%26aulast%3DKahraman%26aufirst%3DS.%26aulast%3DBhatt%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DR.%2BD.%26aulast%3DBeer%26aufirst%3DH.-D.%26aulast%3DJungtrakoon%26aufirst%3DP.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DGoldfine%26aufirst%3DA.%2BB.%26aulast%3DLiew%26aufirst%3DC.%2BW.%26aulast%3DDoria%26aufirst%3DA.%26aulast%3DAndersson%26aufirst%3DO.%26aulast%3DQian%26aufirst%3DW.-J.%26aulast%3DRemold-O%25E2%2580%2599Donnell%26aufirst%3DE.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26atitle%3DSerpinB1%2520promotes%2520pancreatic%2520%25CE%25B2%2520cell%2520proliferation%26jtitle%3DCell%2520Metab.%26date%3D2016%26volume%3D23%26issue%3D1%26spage%3D194%26epage%3D205%26doi%3D10.1016%2Fj.cmet.2015.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purwana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deurloo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadkase, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasilo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paraskevas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prud’homme, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span> <span> </span><span class="NLM_article-title">GABA promotes human β-cell proliferation and modulates glucose homeostasis</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4197</span>– <span class="NLM_lpage">4205</span>, <span class="refDoi"> DOI: 10.2337/db14-0153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb14-0153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=25008178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCgtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2014&pages=4197-4205&issue=12&author=I.+Purwanaauthor=J.+Zhengauthor=X.+Liauthor=M.+Deurlooauthor=D.+O.+Sonauthor=Z.+Zhangauthor=C.+Liangauthor=E.+Shenauthor=A.+Tadkaseauthor=Z.-P.+Fengauthor=Y.+Liauthor=C.+Hasiloauthor=S.+Paraskevasauthor=R.+Bortellauthor=D.+L.+Greinerauthor=M.+Atkinsonauthor=G.+J.+Prud%E2%80%99hommeauthor=Q.+Wang&title=GABA+promotes+human+%CE%B2-cell+proliferation+and+modulates+glucose+homeostasis&doi=10.2337%2Fdb14-0153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">GABA promotes human β-cell proliferation and modulates glucose homeostasis</span></div><div class="casAuthors">Purwana, Indri; Zheng, Juan; Li, Xiaoming; Deurloo, Marielle; Son, Dong Ok; Zhang, Zhaoyun; Liang, Christie; Shen, Eddie; Tadkase, Akshaya; Feng, Zhong-Ping; Li, Yiming; Hasilo, Craig; Paraskevas, Steven; Bortell, Rita; Greiner, Dale L.; Atkinson, Mark; Prud'homme, Gerald J.; Wang, Qinghua</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4197-4205</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">γ-Aminobutyric acid (GABA) exerts protective and regenerative effects on mouse islet β-cells.  However, in humans it is unknown whether it can increase β-cell mass and improve glucose homeostasis.  To address this question, we transplanted a suboptimal mass of human islets into immunodeficient NOD-scid-γ mice with streptozotocin-induced diabetes.  GABA treatment increased grafted β-cell proliferation, while decreasing apoptosis, leading to enhanced β-cell mass.  This was assocd. with increased circulating human insulin and reduced glucagon levels.  Importantly, GABA administration lowered blood glucose levels and improved glucose excursion rates.  We investigated GABA receptor expression and signaling mechanisms.  In human islets, GABA activated a calcium-dependent signaling pathway through both GABA A receptor and GABA B receptor.  This activated the phosphatidylinositol 3-kinase-Akt and CREB-IRS-2 signaling pathways that convey GABA signals responsible for β-cell proliferation and survival.  Our findings suggest that GABA regulates human β-cell mass and may be beneficial for the treatment of diabetes or improvement of islet transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx0G1KgUS7fbVg90H21EOLACvtfcHk0lhwlLiE76UGzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCgtr7P&md5=27d9ad528f161f68edc4b07d67ff032a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2337%2Fdb14-0153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb14-0153%26sid%3Dliteratum%253Aachs%26aulast%3DPurwana%26aufirst%3DI.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DDeurloo%26aufirst%3DM.%26aulast%3DSon%26aufirst%3DD.%2BO.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DE.%26aulast%3DTadkase%26aufirst%3DA.%26aulast%3DFeng%26aufirst%3DZ.-P.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHasilo%26aufirst%3DC.%26aulast%3DParaskevas%26aufirst%3DS.%26aulast%3DBortell%26aufirst%3DR.%26aulast%3DGreiner%26aufirst%3DD.%2BL.%26aulast%3DAtkinson%26aufirst%3DM.%26aulast%3DPrud%25E2%2580%2599homme%26aufirst%3DG.%2BJ.%26aulast%3DWang%26aufirst%3DQ.%26atitle%3DGABA%2520promotes%2520human%2520%25CE%25B2-cell%2520proliferation%2520and%2520modulates%2520glucose%2520homeostasis%26jtitle%3DDiabetes%26date%3D2014%26volume%3D63%26issue%3D12%26spage%3D4197%26epage%3D4205%26doi%3D10.2337%2Fdb14-0153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of action and therapeutic application of Glucagon-like Peptide-1</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2018.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=29617641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=740-756&issue=4&author=D.+J.+Drucker&title=Mechanisms+of+action+and+therapeutic+application+of+Glucagon-like+Peptide-1&doi=10.1016%2Fj.cmet.2018.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1</span></div><div class="casAuthors">Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-756</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-related glycemic excursions through augmentation of insulin and inhibition of glucagon secretion.  GLP-1 also inhibits gastric emptying and food intake, actions maximizing nutrient absorption while limiting wt. gain.  Here I review the circuits engaged by endogenous vs. pharmacol. GLP-1 action, highlighting key GLP-1 receptor (GLP-1R)-pos. cell types and pathways transducing metabolic and non-glycemic GLP-1 signals.  The role(s) of GLP-1 in the benefits and side effects assocd. with bariatric surgery are discussed and actions of GLP-1 controlling islet function, appetite, inflammation, and cardiovascular pathophysiol. are highlighted.  Refinement of the risk-vs.-benefit profile of GLP-1-based therapies for the treatment of diabetes and obesity has stimulated development of orally bioavailable agonists, allosteric modulators, and unimol. multi-agonists, all targeting the GLP-1R.  This review highlights established and emerging concepts, unanswered questions, and future challenges for development and optimization of GLP-1R agonists in the treatment of metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-w0J5LcxUeLVg90H21EOLACvtfcHk0liFg5ZoBpfoTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqs7k%253D&md5=1bdfca5836ed6bd1d2cf49de109f5e65</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DMechanisms%2520of%2520action%2520and%2520therapeutic%2520application%2520of%2520Glucagon-like%2520Peptide-1%26jtitle%3DCell%2520Metab.%26date%3D2018%26volume%3D27%26issue%3D4%26spage%3D740%26epage%3D756%26doi%3D10.1016%2Fj.cmet.2018.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneyer, A. L.</span></span> <span> </span><span class="NLM_article-title">Emerging roles for the TGFβ family in pancreatic β-cell homeostasis</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1016/j.tem.2010.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.tem.2010.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=20382030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosV2itr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=441-448&issue=7&author=M.+L.+Brownauthor=A.+L.+Schneyer&title=Emerging+roles+for+the+TGF%CE%B2+family+in+pancreatic+%CE%B2-cell+homeostasis&doi=10.1016%2Fj.tem.2010.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging roles for the TGFβ family in pancreatic β-cell homeostasis</span></div><div class="casAuthors">Brown, Melissa L.; Schneyer, Alan L.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">441-448</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Loss of functional β-cells is the primary cause of type 2 diabetes, so that there is an acute need to understand how β-cell no. and function are regulated in the adult under normal physiol. conditions.  Recent studies suggest that members of the transforming growth factor (TGF)-β family regulate β-cell function and glucose homeostasis.  These factors are also likely to influence β-cell proliferation and(or) the incorporation of new β-cells from progenitors in adults.  Sol. TGFβ antagonists also appear to have important roles in maintaining homeostasis, and the coordinated activity of TGFβ family members is likely to regulate the differentiation and function of adult β-cells, raising the possibility of developing new diabetes therapies based on TGFβ agonists or antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcoSl1oLG-GLVg90H21EOLACvtfcHk0liFg5ZoBpfoTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosV2itr4%253D&md5=1b60d74b13d56af3aeb8765338975e38</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2010.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2010.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%2BL.%26aulast%3DSchneyer%26aufirst%3DA.%2BL.%26atitle%3DEmerging%2520roles%2520for%2520the%2520TGF%25CE%25B2%2520family%2520in%2520pancreatic%2520%25CE%25B2-cell%2520homeostasis%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2010%26volume%3D21%26issue%3D7%26spage%3D441%26epage%3D448%26doi%3D10.1016%2Fj.tem.2010.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhawan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirice, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of TGF-β signaling promotes human pancreatic β-cell replication</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1208</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.2337/db15-1331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb15-1331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26936960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWgtLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=1208-1218&issue=5&author=S.+Dhawanauthor=E.+Diriceauthor=R.+N.+Kulkarniauthor=A.+Bhushan&title=Inhibition+of+TGF-%CE%B2+signaling+promotes+human+pancreatic+%CE%B2-cell+replication&doi=10.2337%2Fdb15-1331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of TGF-β signaling promotes human pancreatic β-cell replication</span></div><div class="casAuthors">Dhawan, Sangeeta; Dirice, Ercument; Kulkarni, Rohit N.; Bhushan, Anil</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1208-1218</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Diabetes is assocd. with loss of functional pancreatic β-cells, and restoration of β-cells is a major goal for regenerative therapies.  Endogenous regeneration of β-cells via β-cell replication has the potential to restore cellular mass; however, pharmacol. agents that promote regeneration or expansion of endogenous β-cells have been elusive.  The regenerative capacity of β-cells declines rapidly with age, due to accumulation of p16INK4a, resulting in limited capacity for adult endocrine pancreas regeneration.  Here, we show that transforming growth factor-β (TGF-β) signaling via Smad3 integrates with the trithorax complex to activate and maintain Ink4a expression to prevent β-cell replication.  Importantly, inhibition of TGF-β signaling can result in repression of the Ink4a/Arf locus, resulting in increased β-cell replication in adult mice.  Furthermore, small mol. inhibitors of the TGF-β pathway promote β-cell replication in human islets transplanted into NOD-scid IL-2Rgnull mice.  These data reveal a novel role for TGF-β signaling in the regulation of the Ink4a/Arf locus and highlight the potential of using small mol. inhibitors of TGF-β signaling to promote human β-cell replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppQM9_Rz1R5LVg90H21EOLACvtfcHk0liFg5ZoBpfoTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWgtLrK&md5=b8af25af24c9228f4221fec3b90456f3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2337%2Fdb15-1331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb15-1331%26sid%3Dliteratum%253Aachs%26aulast%3DDhawan%26aufirst%3DS.%26aulast%3DDirice%26aufirst%3DE.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26aulast%3DBhushan%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520TGF-%25CE%25B2%2520signaling%2520promotes%2520human%2520pancreatic%2520%25CE%25B2-cell%2520replication%26jtitle%3DDiabetes%26date%3D2016%26volume%3D65%26issue%3D5%26spage%3D1208%26epage%3D1218%26doi%3D10.2337%2Fdb15-1331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Gohary, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulachan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiersch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasadan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paredes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiota, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gittes, G.</span></span> <span> </span><span class="NLM_article-title">A Smad signaling network regulates islet cell proliferation</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.2337/db13-0432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb13-0432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=24089514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2014&pages=224-236&issue=1&author=Y.+El-Goharyauthor=S.+Tulachanauthor=J.+Wierschauthor=P.+Guoauthor=C.+Welshauthor=K.+Prasadanauthor=J.+Paredesauthor=C.+Shiotaauthor=X.+Xiaoauthor=Y.+Wadaauthor=M.+Diazauthor=G.+Gittes&title=A+Smad+signaling+network+regulates+islet+cell+proliferation&doi=10.2337%2Fdb13-0432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Smad signaling network regulates islet cell proliferation</span></div><div class="casAuthors">El-Gohary, Yousef; Tulachan, Sidhartha; Wiersch, John; Guo, Ping; Welsh, Carey; Prasadan, Krishna; Paredes, Jose; Shiota, Chiyo; Xiao, Xiangwei; Wada, Yoko; Diaz, Marilyn; Gittes, George</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">224-236</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Pancreatic β-cell loss and dysfunction are crit. components of all types of diabetes.  Human and rodent β-cells are able to proliferate, and this proliferation is an important defense against the evolution and progression of diabetes.  Transforming growth factor-β (TGF-β) signaling has been shown to affect β-cell development, proliferation, and function, but β-cell proliferation is thought to be the only source of new β-cells in the adult.  Recently, β-cell dedifferentiation has been shown to be an important contributory mechanism to β-cell failure.  In this study, we tie together these two pathways by showing that a network of intracellular TGF-β regulators, smads 7, 2, and 3, control β-cell proliferation after β-cell loss, and specifically, smad7 is necessary for that β-cell proliferation.  Importantly, this smad7-mediated proliferation appears to entail passing through a transient, nonpathol. dedifferentiation of β-cells to a pancreatic polypeptide-fold hormone-pos. state.  TGF-β receptor II appears to be a receptor important for controlling the status of the smad network in β-cells.  These studies should help our understanding of properly regulated β-cell replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3vhNShoKCo7Vg90H21EOLACvtfcHk0liFg5ZoBpfoTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKrtA%253D%253D&md5=a77b842f007e4aac6421fcf66f889595</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2337%2Fdb13-0432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb13-0432%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Gohary%26aufirst%3DY.%26aulast%3DTulachan%26aufirst%3DS.%26aulast%3DWiersch%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DP.%26aulast%3DWelsh%26aufirst%3DC.%26aulast%3DPrasadan%26aufirst%3DK.%26aulast%3DParedes%26aufirst%3DJ.%26aulast%3DShiota%26aufirst%3DC.%26aulast%3DXiao%26aufirst%3DX.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DDiaz%26aufirst%3DM.%26aulast%3DGittes%26aufirst%3DG.%26atitle%3DA%2520Smad%2520signaling%2520network%2520regulates%2520islet%2520cell%2520proliferation%26jtitle%3DDiabetes%26date%3D2014%26volume%3D63%26issue%3D1%26spage%3D224%26epage%3D236%26doi%3D10.2337%2Fdb13-0432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smart, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apelqvist, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topper, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span> <span> </span><span class="NLM_article-title">Conditional expression of Smad7 in pancreatic β cells disrupts TGF-β signaling and induces reversible diabetes mellitus</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">200</span>– <span class="NLM_lpage">209</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1371%2Fjournal.pbio.0040039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFKmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=200-209&issue=2&author=N.+G.+Smartauthor=A.+A.+Apelqvistauthor=X.+Guauthor=E.+B.+Harmonauthor=J.+N.+Topperauthor=R.+J.+MacDonaldauthor=S.+K.+Kim&title=Conditional+expression+of+Smad7+in+pancreatic+%CE%B2+cells+disrupts+TGF-%CE%B2+signaling+and+induces+reversible+diabetes+mellitus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Conditional expression of Smad7 in pancreatic β cells disrupts TGF-β signaling and induces reversible diabetes mellitus</span></div><div class="casAuthors">Smart, Nora G.; Apelqvist, Asa A.; Gu, Xueying; Harmon, Erin B.; Topper, James N.; MacDonald, Raymond J.; Kim, Seung K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">200-209</span>CODEN:
                <span class="NLM_cas:coden">PBLIBG</span>;
        ISSN:<span class="NLM_cas:issn">1545-7885</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Identification of signaling pathways that maintain and promote adult pancreatic islet functions will accelerate our understanding of organogenesis and improve strategies for treating diseases like diabetes mellitus.  Previous work has implicated transforming growth factor-β (TGF-β) signaling as an important regulator of pancreatic islet development, but has not established whether this signaling pathway is required for essential islet functions in the adult pancreas.  Here we describe a conditional system for expressing Smad7, a potent inhibitor of TGF-β signaling, to identify distinct roles for this pathway in adult and embryonic β cells.  Smad7 expression in Pdx1+ embryonic pancreas cells resulted in striking embryonic β cell hypoplasia and neonatal lethality.  Conditional expression of Smad7 in adult Pdx1+ cells reduced detectable β cell expression of MafA, menin, and other factors that regulate β cell function.  Reduced pancreatic insulin content and hypoinsulinemia produced overt diabetes that was fully reversed upon resumption of islet TGF-β signaling.  Thus, our studies reveal that TGF-β signaling is crucial for establishing and maintaining defining features of mature pancreatic β cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRqdvtCI5rmrVg90H21EOLACvtfcHk0lipKoZanVc_fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFKmtLc%253D&md5=3defebb2d98952fbfd8a5c6768b450d0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.0040039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.0040039%26sid%3Dliteratum%253Aachs%26aulast%3DSmart%26aufirst%3DN.%2BG.%26aulast%3DApelqvist%26aufirst%3DA.%2BA.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DHarmon%26aufirst%3DE.%2BB.%26aulast%3DTopper%26aufirst%3DJ.%2BN.%26aulast%3DMacDonald%26aufirst%3DR.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BK.%26atitle%3DConditional%2520expression%2520of%2520Smad7%2520in%2520pancreatic%2520%25CE%25B2%2520cells%2520disrupts%2520TGF-%25CE%25B2%2520signaling%2520and%2520induces%2520reversible%2520diabetes%2520mellitus%26jtitle%3DPLoS%2520Biol.%26date%3D2006%26volume%3D4%26issue%3D2%26spage%3D200%26epage%3D209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakose, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackeifi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatanic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takane, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">Combined inhibition of DYRK1A, SMAD, and Trithorax pathways synergizes to induce robust replication in adult human β-cells</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">652</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2018.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30581122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2ht7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=638-652&issue=3&author=P.+Wangauthor=E.+Karakoseauthor=H.+Liuauthor=E.+Swartzauthor=C.+Ackeifiauthor=V.+Zlatanicauthor=J.+Wilsonauthor=B.+J.+Gonzalezauthor=A.+Benderauthor=K.+K.+Takaneauthor=L.+Yeauthor=G.+Harbauthor=F.+Pagliucaauthor=D.+Homannauthor=D.+Egliauthor=C.+Argmannauthor=D.+K.+Scottauthor=A.+Garcia-Ocanaauthor=A.+F.+Stewart&title=Combined+inhibition+of+DYRK1A%2C+SMAD%2C+and+Trithorax+pathways+synergizes+to+induce+robust+replication+in+adult+human+%CE%B2-cells&doi=10.1016%2Fj.cmet.2018.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells</span></div><div class="casAuthors">Wang, Peng; Karakose, Esra; Liu, Hongtao; Swartz, Ethan; Ackeifi, Courtney; Zlatanic, Viktor; Wilson, Jessica; Gonzalez, Bryan J.; Bender, Aaron; Takane, Karen K.; Ye, Lillian; Harb, George; Pagliuca, Felicia; Homann, Dirk; Egli, Dieter; Argmann, Carmen; Scott, Donald K.; Garcia-Ocana, Adolfo; Stewart, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">638-652.e5</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of dual-specificity tyrosine-regulated kinase 1A (DYRK1A) induce human beta cells to proliferate, generating a labeling index of 1.5%-3%.  Here, we demonstrate that combined pharmacol. inhibition of DYRK1A and transforming growth factor beta superfamily (TGFβSF)/SMAD signaling generates remarkable further synergistic increases in human beta cell proliferation (av. labeling index, 5%-8%, and as high as 15%-18%), and increases in both mouse and human beta cell nos.  This synergy reflects activation of cyclins and cdks by DYRK1A inhibition, accompanied by simultaneous redns. in key cell-cycle inhibitors (CDKN1C and CDKN1A).  The latter results from interference with the basal Trithorax- and SMAD-mediated transactivation of CDKN1C and CDKN1A.  Notably, combined DYRK1A and TGFβ inhibition allows preservation of beta cell differentiated function.  These beneficial effects extend from normal human beta cells and stem cell-derived human beta cells to those from people with type 2 diabetes, and occur both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTj3UaJV2-V7Vg90H21EOLACvtfcHk0lipKoZanVc_fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2ht7jN&md5=99322b62913a95e1209524c958db8380</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DKarakose%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSwartz%26aufirst%3DE.%26aulast%3DAckeifi%26aufirst%3DC.%26aulast%3DZlatanic%26aufirst%3DV.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DGonzalez%26aufirst%3DB.%2BJ.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DTakane%26aufirst%3DK.%2BK.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DPagliuca%26aufirst%3DF.%26aulast%3DHomann%26aufirst%3DD.%26aulast%3DEgli%26aufirst%3DD.%26aulast%3DArgmann%26aufirst%3DC.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DCombined%2520inhibition%2520of%2520DYRK1A%252C%2520SMAD%252C%2520and%2520Trithorax%2520pathways%2520synergizes%2520to%2520induce%2520robust%2520replication%2520in%2520adult%2520human%2520%25CE%25B2-cells%26jtitle%3DCell%2520Metab.%26date%3D2019%26volume%3D29%26issue%3D3%26spage%3D638%26epage%3D652%26doi%3D10.1016%2Fj.cmet.2018.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schisler, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmeier, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newgard, C. B.</span></span> <span> </span><span class="NLM_article-title">A VGF-derived peptide attenuates development of type 2 diabetes via enhancement of islet β-Cell survival and function</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2012.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2012.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=22768837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFCkur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=33-43&issue=1&author=S.+B.+Stephensauthor=J.+C.+Schislerauthor=H.+E.+Hohmeierauthor=J.+Anauthor=A.+Y.+Sunauthor=G.+S.+Pittauthor=C.+B.+Newgard&title=A+VGF-derived+peptide+attenuates+development+of+type+2+diabetes+via+enhancement+of+islet+%CE%B2-Cell+survival+and+function&doi=10.1016%2Fj.cmet.2012.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A VGF-derived peptide attenuates development of type 2 diabetes via enhancement of islet β-Cell survival and function</span></div><div class="casAuthors">Stephens, Samuel B.; Schisler, Jonathan C.; Hohmeier, Hans E.; An, Jie; Sun, Albert Y.; Pitt, Geoffrey S.; Newgard, Christopher B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-43</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Deterioration of functional islet β-cell mass is the final step in progression to Type 2 diabetes.  We previously reported that overexpression of Nkx6.1 in rat islets has the dual effects of enhancing glucose-stimulated insulin secretion (GSIS) and increasing β-cell replication.  Here we show that Nkx6.1 strongly upregulates the prohormone VGF in rat islets and that VGF is both necessary and sufficient for Nkx6.1-mediated enhancement of GSIS.  Moreover, the VGF-derived peptide TLQP-21 potentiates GSIS in rat and human islets and improves glucose tolerance in vivo.  Chronic injection of TLQP-21 in prediabetic ZDF rats preserves islet mass and slows diabetes onset.  TLQP-21 prevents islet cell apoptosis by a pathway similar to that used by GLP-1, but independent of the GLP-1, GIP, or VIP receptors.  Unlike GLP-1, TLQP-21 does not inhibit gastric emptying or increase heart rate.  We conclude that TLQP-21 is a targeted agent for enhancing islet β-cell survival and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIcnok3bIj3bVg90H21EOLACvtfcHk0lipKoZanVc_fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFCkur0%253D&md5=59107e447935a86fb83a5b1f8b40869b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2012.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2012.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DStephens%26aufirst%3DS.%2BB.%26aulast%3DSchisler%26aufirst%3DJ.%2BC.%26aulast%3DHohmeier%26aufirst%3DH.%2BE.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DA.%2BY.%26aulast%3DPitt%26aufirst%3DG.%2BS.%26aulast%3DNewgard%26aufirst%3DC.%2BB.%26atitle%3DA%2520VGF-derived%2520peptide%2520attenuates%2520development%2520of%2520type%25202%2520diabetes%2520via%2520enhancement%2520of%2520islet%2520%25CE%25B2-Cell%2520survival%2520and%2520function%26jtitle%3DCell%2520Metab.%26date%3D2012%26volume%3D16%26issue%3D1%26spage%3D33%26epage%3D43%26doi%3D10.1016%2Fj.cmet.2012.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robitaille, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rourke, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBane, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, A.M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Screaton, R. A.</span></span> <span> </span><span class="NLM_article-title">High-throughput functional genomics identifies regulators of primary human β-cell proliferation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4614</span>– <span class="NLM_lpage">4625</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.683912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1074%2Fjbc.M115.683912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26740620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1eqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=4614-4625&issue=9&author=K.+Robitailleauthor=J.+L.+Rourkeauthor=J.+E.+McBaneauthor=A.+Fuauthor=S.+Bairdauthor=Q.+Duauthor=T.+Kinauthor=A.M.+J.+Shapiroauthor=R.+A.+Screaton&title=High-throughput+functional+genomics+identifies+regulators+of+primary+human+%CE%B2-cell+proliferation&doi=10.1074%2Fjbc.M115.683912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput functional genomics identifies regulators of primary human beta cell proliferation</span></div><div class="casAuthors">Robitaille, Karine; Rourke, Jillian L.; McBane, Joanne E.; Fu, Accalia; Baird, Stephen; Du, Qiujiang; Kin, Tatsuya; James Shapiro, A. M.; Screaton, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4614-4625</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The expansion of cells for regenerative therapy will require the genetic dissection of complex regulatory mechanisms governing the proliferation of non-transformed human cells.  Here, we report the development of a high-throughput RNAi screening strategy specifically for use in primary cells and demonstrate that silencing the cell cycle-dependent kinase inhibitors CDKN2C/p18 or CDKN1A/p21 facilitates cell cycle entry of quiescent adult human pancreatic beta cells.  This work identifies p18 and p21 as novel targets for promoting proliferation of human beta cells and demonstrates the promise of functional genetic screens for dissecting therapeutically relevant state changes in primary human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuCrU90jJegLVg90H21EOLACvtfcHk0liJcSXZNV77vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1eqsbc%253D&md5=b82a21f4dba273e17baee928caf52f83</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.683912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.683912%26sid%3Dliteratum%253Aachs%26aulast%3DRobitaille%26aufirst%3DK.%26aulast%3DRourke%26aufirst%3DJ.%2BL.%26aulast%3DMcBane%26aufirst%3DJ.%2BE.%26aulast%3DFu%26aufirst%3DA.%26aulast%3DBaird%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DQ.%26aulast%3DKin%26aufirst%3DT.%26aulast%3DShapiro%26aufirst%3DA.M.%2BJ.%26aulast%3DScreaton%26aufirst%3DR.%2BA.%26atitle%3DHigh-throughput%2520functional%2520genomics%2520identifies%2520regulators%2520of%2520primary%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26issue%3D9%26spage%3D4614%26epage%3D4625%26doi%3D10.1074%2Fjbc.M115.683912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Annes, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carolan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollister-Lock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvanites, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melton, D. A.</span></span> <span> </span><span class="NLM_article-title">Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replication</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3915</span>– <span class="NLM_lpage">3920</span>, <span class="refDoi"> DOI: 10.1073/pnas.1201149109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1073%2Fpnas.1201149109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=22345561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38XjvFymtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=3915-3920&issue=10&author=J.+P.+Annesauthor=J.+H.+Ryuauthor=K.+Lamauthor=P.+J.+Carolanauthor=K.+Utzauthor=J.+Hollister-Lockauthor=A.+C.+Arvanitesauthor=L.+L.+Rubinauthor=G.+Weirauthor=D.+A.+Melton&title=Adenosine+kinase+inhibition+selectively+promotes+rodent+and+porcine+islet+%CE%B2-cell+replication&doi=10.1073%2Fpnas.1201149109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replication</span></div><div class="casAuthors">Annes, Justin P.; Ryu, Jennifer Hyoje; Lam, Kelvin; Carolan, Peter J.; Utz, Katrina; Hollister-Lock, Jennifer; Arvanites, Anthony C.; Rubin, Lee L.; Weir, Gordon; Melton, Douglas A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3915-3920</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Diabetes is a pathol. condition characterized by relative insulin deficiency, persistent hyperglycemia, and, consequently, diffuse micro- and macrovascular disease.  One therapeutic strategy is to amplify insulin-secretion capacity by increasing the no. of the insulin-producing β cells without triggering a generalized proliferative response.  Here, we present the development of a small-mol. screening platform for the identification of mols. that increase β-cell replication.  Using this platform, we identify a class of compds. [adenosine kinase inhibitors (ADK-Is)] that promote replication of primary β cells in three species (mouse, rat, and pig).  Furthermore, the replication effect of ADK-Is is cell type-selective: treatment of islet cell cultures with ADK-Is increases replication of β cells but not that of α cells, PP cells, or fibroblasts.  Short-term in vivo treatment with an ADK-I also increases β-cell replication but not exocrine cell or hepatocyte replication.  Therefore, we propose ADK inhibition as a strategy for the treatment of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9d3QakDBpybVg90H21EOLACvtfcHk0liJcSXZNV77vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjvFymtL8%253D&md5=2bec02ff18ef273ec38734a98c9395cb</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1201149109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1201149109%26sid%3Dliteratum%253Aachs%26aulast%3DAnnes%26aufirst%3DJ.%2BP.%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DLam%26aufirst%3DK.%26aulast%3DCarolan%26aufirst%3DP.%2BJ.%26aulast%3DUtz%26aufirst%3DK.%26aulast%3DHollister-Lock%26aufirst%3DJ.%26aulast%3DArvanites%26aufirst%3DA.%2BC.%26aulast%3DRubin%26aufirst%3DL.%2BL.%26aulast%3DWeir%26aufirst%3DG.%26aulast%3DMelton%26aufirst%3DD.%2BA.%26atitle%3DAdenosine%2520kinase%2520inhibition%2520selectively%2520promotes%2520rodent%2520and%2520porcine%2520islet%2520%25CE%25B2-cell%2520replication%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D10%26spage%3D3915%26epage%3D3920%26doi%3D10.1073%2Fpnas.1201149109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span> <span> </span><span class="NLM_article-title">Identification of small-molecule inducers of pancreatic β-cell expansion</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1432</span>, <span class="refDoi"> DOI: 10.1073/pnas.0811848106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1073%2Fpnas.0811848106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=19164755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvV2qtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1427-1432&issue=5&author=W.+Wangauthor=J.+R.+Walkerauthor=X.+Wangauthor=M.+S.+Tremblayauthor=J.+W.+Leeauthor=X.+Wuauthor=P.+G.+Schultz&title=Identification+of+small-molecule+inducers+of+pancreatic+%CE%B2-cell+expansion&doi=10.1073%2Fpnas.0811848106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of small-molecule inducers of pancreatic β-cell expansion</span></div><div class="casAuthors">Wang, Weidong; Walker, John R.; Wang, Xia; Tremblay, Matthew S.; Lee, Jae Wook; Wu, Xu; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1427-1432</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">To identify small mols. that can induce β-cell replication, a large chem. library was screened for proliferation of growth-arrested, reversibly immortalized mouse 1 cells by using an automated high-throughput screening platform.  A no. of structurally diverse, active compds. were identified, including phorbol esters, which likely act through protein kinase C, and a group of thiophene-pyrimidines that stimulate β-cell proliferation by activating the Wnt signaling pathway.  A group of dihydropyridine (DHP) derivs. was also shown to reversibly induce β-cell replication in vitro by activating L-type calcium channels (LTCCs).  Our data suggest that the LTCC agonist 2a affects the expression of genes involved in cell cycle progression and cellular proliferation.  Furthermore, treatment of p cells with both LTCC agonist 2a and the Glp-1 receptor agonist Exendin-4 showed an additive effect on β-cell replication.  The identification of small mols. that induce β-cell proliferation suggests that it may be possible to reversibly expand other quiescent cells to overcome deficits assocd. with degenerative and/or autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzUwmkz4J4CrVg90H21EOLACvtfcHk0liJcSXZNV77vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvV2qtbs%253D&md5=daf6d5e2c1401ac6c1541cd90f88e4c0</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0811848106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0811848106%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTremblay%26aufirst%3DM.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DIdentification%2520of%2520small-molecule%2520inducers%2520of%2520pancreatic%2520%25CE%25B2-cell%2520expansion%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D5%26spage%3D1427%26epage%3D1432%26doi%3D10.1073%2Fpnas.0811848106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goktug, A. N.</span>; <span class="NLM_string-name">Chai, S. C.</span>; <span class="NLM_string-name">Chen, T.</span></span> In  <i>Data analysis approaches in high throughput screening</i>; <span class="NLM_publisher-name">InTech</span>: <span class="NLM_year">2013</span>; pp  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">226</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=201-226&author=A.+N.+Goktug&author=S.+C.+Chai&author=T.+Chen&title=Data+analysis+approaches+in+high+throughput+screening"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGoktug%26aufirst%3DA.%2BN.%26btitle%3DData%2520analysis%2520approaches%2520in%2520high%2520throughput%2520screening%26pub%3DInTech%26date%3D2013%26spage%3D201%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnishi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiramatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kii, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onogi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span> <span> </span><span class="NLM_article-title">Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">86</span>, <span class="refDoi"> DOI: 10.1038/ncomms1090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fncomms1090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=20981014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A280%3ADC%252BC3cbislehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=86&author=Y.+Ogawaauthor=Y.+Nonakaauthor=T.+Gotoauthor=E.+Ohnishiauthor=T.+Hiramatsuauthor=I.+Kiiauthor=M.+Yoshidaauthor=T.+Ikuraauthor=H.+Onogiauthor=H.+Shibuyaauthor=T.+Hosoyaauthor=N.+Itoauthor=M.+Hagiwara&title=Development+of+a+novel+selective+inhibitor+of+the+Down+syndrome-related+kinase+Dyrk1A&doi=10.1038%2Fncomms1090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A</span></div><div class="casAuthors">Ogawa Yasushi; Nonaka Yosuke; Goto Toshiyasu; Ohnishi Eriko; Hiramatsu Toshiyuki; Kii Isao; Yoshida Miyo; Ikura Teikichi; Onogi Hiroshi; Shibuya Hiroshi; Hosoya Takamitsu; Ito Nobutoshi; Hagiwara Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dyrk1A (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A) is a serine/threonine kinase essential for brain development and function, and its excessive activity is considered a pathogenic factor in Down syndrome.  The development of potent, selective inhibitors of Dyrk1A would help to elucidate the molecular mechanisms of normal and diseased brains, and may provide a new lead compound for molecular-targeted drug discovery.  Here, we report a novel Dyrk1A inhibitor, INDY, a benzothiazole derivative showing a potent ATP-competitive inhibitory effect with IC(50) and K(i) values of 0.24 and 0.18 μM, respectively.  X-ray crystallography of the Dyrk1A/INDY complex revealed the binding of INDY in the ATP pocket of the enzyme.  INDY effectively reversed the aberrant tau-phosphorylation and rescued the repressed NFAT (nuclear factor of activated T cell) signalling induced by Dyrk1A overexpression.  Importantly, proINDY, a prodrug of INDY, effectively recovered Xenopus embryos from head malformation induced by Dyrk1A overexpression, resulting in normally developed embryos and demonstrating the utility of proINDY in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOCqf6rsXbPtenUz0lpNqnfW6udTcc2ebWGGRJgCFAtbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbislehtw%253D%253D&md5=ac1d5972bec4085de101bb86194babd1</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fncomms1090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms1090%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DNonaka%26aufirst%3DY.%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DOhnishi%26aufirst%3DE.%26aulast%3DHiramatsu%26aufirst%3DT.%26aulast%3DKii%26aufirst%3DI.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DIkura%26aufirst%3DT.%26aulast%3DOnogi%26aufirst%3DH.%26aulast%3DShibuya%26aufirst%3DH.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DN.%26aulast%3DHagiwara%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520a%2520novel%2520selective%2520inhibitor%2520of%2520the%2520Down%2520syndrome-related%2520kinase%2520Dyrk1A%26jtitle%3DNat.%2520Commun.%26date%3D2010%26volume%3D1%26spage%3D86%26doi%3D10.1038%2Fncomms1090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heit, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apelqvist, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winslow, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neilson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabtree, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span> <span> </span><span class="NLM_article-title">Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function</span>. <i>Nature (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>443</i></span> (<span class="NLM_issue">7109</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1038/nature05097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnature05097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpslaksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=443&publication_year=2006&pages=345-349&issue=7109&author=J.+J.+Heitauthor=A.+A.+Apelqvistauthor=X.+Guauthor=M.+M.+Winslowauthor=J.+R.+Neilsonauthor=G.+R.+Crabtreeauthor=S.+K.+Kim&title=Calcineurin%2FNFAT+signalling+regulates+pancreatic+%CE%B2-cell+growth+and+function&doi=10.1038%2Fnature05097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function</span></div><div class="casAuthors">Heit, Jeremy J.; Apelqvist, Aasa A.; Gu, Xueying; Winslow, Monte M.; Neilson, Joel R.; Crabtree, Gerald R.; Kim, Seung K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">443</span>
        (<span class="NLM_cas:issue">7109</span>),
    <span class="NLM_cas:pages">345-349</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The growth and function of organs such as pancreatic islets adapt to meet physiol. challenges and maintain metabolic balance, but the mechanisms controlling these facultative responses are unclear.  Diabetes in patients treated with calcineurin inhibitors such as cyclosporin A indicates that calcineurin/nuclear factor of activated T-cells (NFAT) signaling might control adaptive islet responses, but the roles of this pathway in β-cells in vivo are not understood.  Here the authors show that mice with a β-cell-specific deletion of the calcineurin phosphatase regulatory subunit, calcineurin b1 (Cnb1), develop age-dependent diabetes characterized by decreased β-cell proliferation and mass, reduced pancreatic insulin content and hypoinsulinemia.  Moreover, β-cells lacking Cnb1 have a reduced expression of established regulators of β-cell proliferation.  Conditional expression of active NFATc1 in Cnb1-deficient β-cells rescues these defects and prevents diabetes.  In normal adult β-cells, conditional NFAT activation promotes the expression of cell-cycle regulators and increases β-cell proliferation and mass, resulting in hyperinsulinemia.  Conditional NFAT activation also induces the expression of genes crit. for β-cell endocrine function, including all six genes mutated in hereditary forms of monogenic type 2 diabetes.  Thus, calcineurin/NFAT signaling regulates multiple factors that control growth and hallmark β-cell functions, revealing unique models for the pathogenesis and therapy of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-AyBy0mjD-rVg90H21EOLACvtfcHk0li_Un6nQQ4vSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpslaksrs%253D&md5=edbb275758f2d117834e96995b313cb5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnature05097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05097%26sid%3Dliteratum%253Aachs%26aulast%3DHeit%26aufirst%3DJ.%2BJ.%26aulast%3DApelqvist%26aufirst%3DA.%2BA.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DWinslow%26aufirst%3DM.%2BM.%26aulast%3DNeilson%26aufirst%3DJ.%2BR.%26aulast%3DCrabtree%26aufirst%3DG.%2BR.%26aulast%3DKim%26aufirst%3DS.%2BK.%26atitle%3DCalcineurin%252FNFAT%2520signalling%2520regulates%2520pancreatic%2520%25CE%25B2-cell%2520growth%2520and%2520function%26jtitle%3DNature%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2006%26volume%3D443%26issue%3D7109%26spage%3D345%26epage%3D349%26doi%3D10.1038%2Fnature05097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodyer, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottino, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabtree, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span> <span> </span><span class="NLM_article-title">Neonatal β cell development in mice and humans is regulated by calcineurin/NFAT</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.devcel.2012.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.devcel.2012.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=22814600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOqu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=21-34&issue=1&author=W.+R.+Goodyerauthor=X.+Guauthor=Y.+Liuauthor=R.+Bottinoauthor=G.+R.+Crabtreeauthor=S.+K.+Kim&title=Neonatal+%CE%B2+cell+development+in+mice+and+humans+is+regulated+by+calcineurin%2FNFAT&doi=10.1016%2Fj.devcel.2012.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Neonatal β Cell Development in Mice and Humans Is Regulated by Calcineurin/NFAT</span></div><div class="casAuthors">Goodyer, William R.; Gu, Xueying; Liu, Yinghua; Bottino, Rita; Crabtree, Gerald R.; Kim, Seung K.</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-34</span>CODEN:
                <span class="NLM_cas:coden">DCEEBE</span>;
        ISSN:<span class="NLM_cas:issn">1534-5807</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Little is known about the mechanisms governing neonatal growth and maturation of organs.  Here we demonstrate that calcineurin/Nuclear Factor of Activated T cells (Cn/NFAT) signaling regulates neonatal pancreatic development in mouse and human islets.  Inactivation of calcineurin b1 (Cnb1) in mouse islets impaired dense core granule biogenesis, decreased insulin secretion, and reduced cell proliferation and mass, culminating in lethal diabetes.  Pancreatic β cells lacking Cnb1 failed to express genes revealed to be direct NFAT targets required for replication, insulin storage, and secretion.  In contrast, glucokinase activation stimulated Cn-dependent expression of these genes.  Calcineurin inhibitors, such as tacrolimus, used for human immunosuppression, induce diabetes.  Tacrolimus exposure reduced Cn/NFAT-dependent expression of factors essential for insulin dense core granule formation and secretion and neonatal β cell proliferation, consistent with our genetic studies.  Discovery of conserved pathways regulating β cell maturation and proliferation suggests new strategies for controlling β cell growth or replacement in human islet diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_D727AJkg_LVg90H21EOLACvtfcHk0li_Un6nQQ4vSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOqu7rE&md5=4526e5fc114232fc996f85383cbcf286</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2012.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2012.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DGoodyer%26aufirst%3DW.%2BR.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBottino%26aufirst%3DR.%26aulast%3DCrabtree%26aufirst%3DG.%2BR.%26aulast%3DKim%26aufirst%3DS.%2BK.%26atitle%3DNeonatal%2520%25CE%25B2%2520cell%2520development%2520in%2520mice%2520and%2520humans%2520is%2520regulated%2520by%2520calcineurin%252FNFAT%26jtitle%3DDev.%2520Cell%26date%3D2012%26volume%3D23%26issue%3D1%26spage%3D21%26epage%3D34%26doi%3D10.1016%2Fj.devcel.2012.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ackeifi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakose, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e132594</span> <span class="refDoi"> DOI: 10.1172/jci.insight.132594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1172%2Fjci.insight.132594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=31821176" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&author=C.+Ackeifiauthor=E.+Swartzauthor=K.+Kumarauthor=H.+Liuauthor=S.+Chaladaauthor=E.+Karakoseauthor=D.+K.+Scottauthor=A.+Garcia-Ocanaauthor=R.+Sanchezauthor=R.+J.+DeVitaauthor=A.+F.+Stewartauthor=P.+Wang&title=Pharmacologic+and+genetic+approaches+define+human+pancreatic+%CE%B2+cell+mitogenic+targets+of+DYRK1A+inhibitors&doi=10.1172%2Fjci.insight.132594"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.132594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.132594%26sid%3Dliteratum%253Aachs%26aulast%3DAckeifi%26aufirst%3DC.%26aulast%3DSwartz%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DChalada%26aufirst%3DS.%26aulast%3DKarakose%26aufirst%3DE.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DPharmacologic%2520and%2520genetic%2520approaches%2520define%2520human%2520pancreatic%2520%25CE%25B2%2520cell%2520mitogenic%2520targets%2520of%2520DYRK1A%2520inhibitors%26jtitle%3DJCI%2520Insight%26date%3D2020%26volume%3D5%26doi%3D10.1172%2Fjci.insight.132594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rachdi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kariyawasam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbones, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabar, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharfmann, R.</span></span> <span> </span><span class="NLM_article-title">Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic β-cell mass</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">960</span>– <span class="NLM_lpage">969</span>, <span class="refDoi"> DOI: 10.1007/s00125-014-3174-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1007%2Fs00125-014-3174-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=24477974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Gltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=960-969&issue=5&author=L.+Rachdiauthor=D.+Kariyawasamauthor=F.+Guezauthor=V.+Aielloauthor=M.+L.+Arbonesauthor=N.+Janelauthor=J.-M.+Delabarauthor=M.+Polakauthor=R.+Scharfmann&title=Dyrk1a+haploinsufficiency+induces+diabetes+in+mice+through+decreased+pancreatic+%CE%B2-cell+mass&doi=10.1007%2Fs00125-014-3174-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass</span></div><div class="casAuthors">Rachdi, Latif; Kariyawasam, Dulanjalee; Guez, Fanny; Aiello, Virginie; Arbones, Maria L.; Janel, Nathalie; Delabar, Jean-Maurice; Polak, Michel; Scharfmann, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">960-969</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aims/hypothesis: Growth factors and nutrients are important regulators of pancreatic beta cell mass and function.  However, the signalling pathways by which these factors modulate these processes have not yet been fully elucidated.  DYRK1A (also named minibrain/MNB) is a member of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family that has been conserved across evolution.  A significant amt. of data implicates DYRK1A in brain growth and function, as well as in neurodegenerative processes in Alzheimer's disease and Down's syndrome.  We investigated here whether DYRK1A would be an attractive candidate for beta cell growth modulation.  Methods: To study the role of DYRK1A in beta cell growth, we used Dyrk1a-deficient mice.  Results: We show that DYRK1A is expressed in pancreatic islets and provide evidence that changes in Dyrk1a gene dosage in mice strongly modulate glycemia and circulating insulin levels.  Specifically, Dyrk1a-haploinsufficient mice show severe glucose intolerance, reduced beta cell mass and decreased beta cell proliferation.  Conclusions/interpretation: Taken together, our data indicate that DYRK1A is a crit. kinase for beta cell growth as Dyrk1a-haploinsufficient mice show a diabetic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpquWxQ9-ygubVg90H21EOLACvtfcHk0lg_MGoBaCI5GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Gltr8%253D&md5=e90679f8effcee39daded5a0b15f94b7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2Fs00125-014-3174-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-014-3174-3%26sid%3Dliteratum%253Aachs%26aulast%3DRachdi%26aufirst%3DL.%26aulast%3DKariyawasam%26aufirst%3DD.%26aulast%3DGuez%26aufirst%3DF.%26aulast%3DAiello%26aufirst%3DV.%26aulast%3DArbones%26aufirst%3DM.%2BL.%26aulast%3DJanel%26aufirst%3DN.%26aulast%3DDelabar%26aufirst%3DJ.-M.%26aulast%3DPolak%26aufirst%3DM.%26aulast%3DScharfmann%26aufirst%3DR.%26atitle%3DDyrk1a%2520haploinsufficiency%2520induces%2520diabetes%2520in%2520mice%2520through%2520decreased%2520pancreatic%2520%25CE%25B2-cell%2520mass%26jtitle%3DDiabetologia%26date%3D2014%26volume%3D57%26issue%3D5%26spage%3D960%26epage%3D969%26doi%3D10.1007%2Fs00125-014-3174-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debdab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreaux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soundararajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babault, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahtouh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baratte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenreich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazureau, J.-P.</span></span> <span> </span><span class="NLM_article-title">Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge Leucettamine B: modulation of alternative pre-RNA splicing</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4172</span>– <span class="NLM_lpage">4186</span>, <span class="refDoi"> DOI: 10.1021/jm200274d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200274d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4172-4186&issue=12&author=M.+Debdabauthor=F.+Carreauxauthor=S.+Renaultauthor=M.+Soundararajanauthor=O.+Fedorovauthor=P.+Filippakopoulosauthor=O.+Lozachauthor=L.+Babaultauthor=T.+Tahtouhauthor=B.+Baratteauthor=Y.+Ogawaauthor=M.+Hagiwaraauthor=A.+Eisenreichauthor=U.+Rauchauthor=S.+Knappauthor=L.+Meijerauthor=J.-P.+Bazureau&title=Leucettines%2C+a+class+of+potent+inhibitors+of+cdc2-like+kinases+and+dual+specificity%2C+tyrosine+phosphorylation+regulated+kinases+derived+from+the+marine+sponge+Leucettamine+B%3A+modulation+of+alternative+pre-RNA+splicing&doi=10.1021%2Fjm200274d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Leucettines, a Class of Potent Inhibitors of cdc2-Like Kinases and Dual Specificity, Tyrosine Phosphorylation Regulated Kinases Derived from the Marine Sponge Leucettamine B: Modulation of Alternative Pre-RNA Splicing</span></div><div class="casAuthors">Debdab, Mansour; Carreaux, Francois; Renault, Steven; Soundararajan, Meera; Fedorov, Oleg; Filippakopoulos, Panagis; Lozach, Olivier; Babault, Lucie; Tahtouh, Tania; Baratte, Blandine; Ogawa, Yasushi; Hagiwara, Masatoshi; Eisenreich, Andreas; Rauch, Ursula; Knapp, Stefan; Meijer, Laurent; Bazureau, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4172-4186</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, optimization, and biol. characterization of leucettines, a family of kinase inhibitors derived from the marine sponge leucettamine B I (R = H, R1 = Me), was reported.  Stepwise synthesis of analogs starting from the natural structure, guided by activity testing on eight purified kinases, led to highly potent inhibitors of CLKs and DYRKs, two families of kinases involved in alternative pre-mRNA splicing and Alzheimer's disease/Down syndrome.  Leucettine L41 I (R = Ph, R1 = H) was cocrystd. with CLK3.  It interacts with key residues located within the ATP-binding pocket of the kinase.  Leucettine L41 inhibited the phosphorylation of serine/arginine-rich proteins (SRp), a family of proteins regulating pre-RNA splicing.  Indeed leucettine L41 was demonstrated to modulate alternative pre-mRNA splicing, in a cell-based reporting system.  Leucettines should be further explored as pharmacol. tools to study and modulate pre-RNA splicing.  Leucettines may also be investigated as potential therapeutic drugs in Alzheimer's disease (AD) and in diseases involving abnormal pre-mRNA splicing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTsnAcfvIJobVg90H21EOLACvtfcHk0lg_MGoBaCI5GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGls7o%253D&md5=a4abd78d51a7a36e03117a1f432e3cae</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm200274d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200274d%26sid%3Dliteratum%253Aachs%26aulast%3DDebdab%26aufirst%3DM.%26aulast%3DCarreaux%26aufirst%3DF.%26aulast%3DRenault%26aufirst%3DS.%26aulast%3DSoundararajan%26aufirst%3DM.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DBabault%26aufirst%3DL.%26aulast%3DTahtouh%26aufirst%3DT.%26aulast%3DBaratte%26aufirst%3DB.%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DM.%26aulast%3DEisenreich%26aufirst%3DA.%26aulast%3DRauch%26aufirst%3DU.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DBazureau%26aufirst%3DJ.-P.%26atitle%3DLeucettines%252C%2520a%2520class%2520of%2520potent%2520inhibitors%2520of%2520cdc2-like%2520kinases%2520and%2520dual%2520specificity%252C%2520tyrosine%2520phosphorylation%2520regulated%2520kinases%2520derived%2520from%2520the%2520marine%2520sponge%2520Leucettamine%2520B%253A%2520modulation%2520of%2520alternative%2520pre-RNA%2520splicing%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D12%26spage%3D4172%26epage%3D4186%26doi%3D10.1021%2Fjm200274d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brierley, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, C.</span></span> <span> </span><span class="NLM_article-title">Developments in harmine pharmacology - Implications for ayahuasca use and drug-dependence treatment</span>. <i>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1016/j.pnpbp.2012.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.pnpbp.2012.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=22691716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVCjsr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=263-272&issue=2&author=D.+I.+Brierleyauthor=C.+Davidson&title=Developments+in+harmine+pharmacology+-+Implications+for+ayahuasca+use+and+drug-dependence+treatment&doi=10.1016%2Fj.pnpbp.2012.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Developments in harmine pharmacology - Implications for ayahuasca use and drug-dependence treatment</span></div><div class="casAuthors">Brierley, Daniel I.; Davidson, Colin</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-272</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Ayahuasca is a hallucinogenic botanical mixt. originating in the Amazon area where it is used ritually, but is now being taken globally.  The 2 main constituents of ayahuasca are N,N-dimethyltryptamine (DMT), a hallucinogen, and harmine, a monoamine oxidase inhibitor (MAOI) which attenuates the breakdown of DMT, which would otherwise be broken down very quickly after oral consumption.  Recent developments in ayahuasca use include the sale of these compds. on the internet and the substitution of related botanical (anahuasca) or synthetic (pharmahuasca) compds. to achieve the same desired hallucinogenic effects.  One intriguing result of ayahuasca use appears to be improved mental health and a redn. in recidivism to alternate (alc., cocaine) drug use.  In this review we discuss the pharmacol. of ayahuasca, with a focus on harmine, and suggest pharmacol. mechanisms for the putative redn. in recidivism to alc. and cocaine misuse.  These pharmacol. mechanisms include MAOI, effects at 5-HT2A and imidazoline receptors and inhibition of dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) and the dopamine transporter.  We also speculate on the therapeutic potential of harmine in other CNS conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBCBZzc81PPLVg90H21EOLACvtfcHk0lg_JhOkPotj8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVCjsr7P&md5=09e343f3b84458c57c6f9a00b3ba96c5</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2012.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2012.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DBrierley%26aufirst%3DD.%2BI.%26aulast%3DDavidson%26aufirst%3DC.%26atitle%3DDevelopments%2520in%2520harmine%2520pharmacology%2520-%2520Implications%2520for%2520ayahuasca%2520use%2520and%2520drug-dependence%2520treatment%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2012%26volume%3D39%26issue%3D2%26spage%3D263%26epage%3D272%26doi%3D10.1016%2Fj.pnpbp.2012.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ung, P. M.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span> <span> </span><span class="NLM_article-title">DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1021/cb500696t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500696t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOjs7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=269-278&issue=1&author=P.+M.-U.+Ungauthor=A.+Schlessinger&title=DFGmodel%3A+predicting+protein+kinase+structures+in+inactive+states+for+structure-based+discovery+of+type-II+inhibitors&doi=10.1021%2Fcb500696t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">DFGmodel: Predicting Protein Kinase Structures in Inactive States for Structure-Based Discovery of Type-II Inhibitors</span></div><div class="casAuthors">Ung, Peter Man-Un; Schlessinger, Avner</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">269-278</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein kinases exist in equil. of active and inactive states, in which the aspartate-phenylalanine-glycine motif in the catalytic domain undergoes conformational changes that are required for function.  Drugs targeting protein kinases typically bind the primary ATP-binding site of an active state (type-I inhibitors) or utilize an allosteric pocket adjacent to the ATP-binding site in the inactive state (type-II inhibitors).  Limited crystallog. data of protein kinases in the inactive state hampers the application of rational drug discovery methods for developing type-II inhibitors.  Here, we present a computational approach to generate structural models of protein kinases in the inactive conformation.  We first perform a comprehensive anal. of all protein kinase structures deposited in the Protein Data Bank.  We then develop DFGmodel, a method that takes either a known structure of a kinase in the active conformation or a sequence of a kinase without a structure, to generate kinase models in the inactive conformation.  Evaluation of DFGmodel's performance using various measures indicates that the inactive kinase models are accurate, exhibiting RMSD of 1.5 Å or lower.  The kinase models also accurately distinguish type-II kinase inhibitors from likely nonbinders (AUC > 0.70), suggesting that they are useful for virtual screening.  Finally, we demonstrate the applicability of our approach with three case studies.  For example, the models are able to capture inhibitors with unintended off-target activity.  Our computational approach provides a structural framework for chem. biologists to characterize kinases in the inactive state and to explore new chem. spaces with structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmlYsMTNeULbVg90H21EOLACvtfcHk0lg_JhOkPotj8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOjs7rE&md5=7478a7e91251c1c8c737ab7be8f9bb75</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fcb500696t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500696t%26sid%3Dliteratum%253Aachs%26aulast%3DUng%26aufirst%3DP.%2BM.-U.%26aulast%3DSchlessinger%26aufirst%3DA.%26atitle%3DDFGmodel%253A%2520predicting%2520protein%2520kinase%2520structures%2520in%2520inactive%2520states%2520for%2520structure-based%2520discovery%2520of%2520type-II%2520inhibitors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26issue%3D1%26spage%3D269%26epage%3D278%26doi%3D10.1021%2Fcb500696t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoegdin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo-Alfredsson, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soederman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormoe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelissen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerning, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for alzheimer’s disease: design, synthesis, and characterization of pyrazines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9107</span>– <span class="NLM_lpage">9119</span>, <span class="refDoi"> DOI: 10.1021/jm201724m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201724m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9107-9119&issue=21&author=S.+Bergauthor=M.+Berghauthor=S.+Hellbergauthor=K.+Hoegdinauthor=Y.+Lo-Alfredssonauthor=P.+Soedermanauthor=S.+von+Bergauthor=T.+Weigeltauthor=M.+Ormoeauthor=Y.+Xueauthor=J.+Tuckerauthor=J.+Neelissenauthor=E.+Jerningauthor=Y.+Nilssonauthor=R.+Bhat&title=Discovery+of+novel+potent+and+highly+selective+glycogen+synthase+kinase-3%CE%B2+%28GSK3%CE%B2%29+inhibitors+for+alzheimer%E2%80%99s+disease%3A+design%2C+synthesis%2C+and+characterization+of+pyrazines&doi=10.1021%2Fjm201724m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3β (GSK3β) Inhibitors for Alzheimer's Disease: Design, Synthesis, and Characterization of Pyrazines</span></div><div class="casAuthors">Berg, Stefan; Bergh, Margareta; Hellberg, Sven; Hoegdin, Katharina; Lo-Alfredsson, Yvonne; Soederman, Peter; von Berg, Stefan; Weigelt, Tatjana; Ormoe, Mats; Xue, Yafeng; Tucker, Julie; Neelissen, Jan; Jerning, Eva; Nilsson, Yvonne; Bhat, Ratan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9107-9119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3β, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metab.  Active forms of GSK3β localize to pretangle pathol. including dystrophic neuritis and neurofibrillary tangles in Alzheimer's disease (AD) brain.  By using a high throughput screening (HTS) approach to search for new chem. series and cocrystn. of key analogs to guide the optimization and synthesis of our pyrazine series, we have developed highly potent and selective inhibitors showing cellular efficacy and blood-brain barrier penetration.  The inhibitors are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDR4w7EMbaI7Vg90H21EOLACvtfcHk0lg_JhOkPotj8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggtrc%253D&md5=f1475e38163a8e81e9ca9a24b271a0be</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm201724m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201724m%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DS.%26aulast%3DBergh%26aufirst%3DM.%26aulast%3DHellberg%26aufirst%3DS.%26aulast%3DHoegdin%26aufirst%3DK.%26aulast%3DLo-Alfredsson%26aufirst%3DY.%26aulast%3DSoederman%26aufirst%3DP.%26aulast%3Dvon%2BBerg%26aufirst%3DS.%26aulast%3DWeigelt%26aufirst%3DT.%26aulast%3DOrmoe%26aufirst%3DM.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DTucker%26aufirst%3DJ.%26aulast%3DNeelissen%26aufirst%3DJ.%26aulast%3DJerning%26aufirst%3DE.%26aulast%3DNilsson%26aufirst%3DY.%26aulast%3DBhat%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520novel%2520potent%2520and%2520highly%2520selective%2520glycogen%2520synthase%2520kinase-3%25CE%25B2%2520%2528GSK3%25CE%25B2%2529%2520inhibitors%2520for%2520alzheimer%25E2%2580%2599s%2520disease%253A%2520design%252C%2520synthesis%252C%2520and%2520characterization%2520of%2520pyrazines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D21%26spage%3D9107%26epage%3D9119%26doi%3D10.1021%2Fjm201724m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mussmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kegel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andag, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burk, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onichtchouk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohrmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austen, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of GSK3 promotes replication and survival of pancreatic β-cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">12030</span>– <span class="NLM_lpage">12037</span>, <span class="refDoi"> DOI: 10.1074/jbc.M609637200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1074%2Fjbc.M609637200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=17242403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktFeltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=12030-12037&issue=16&author=R.+Mussmannauthor=M.+Geeseauthor=F.+Harderauthor=S.+Kegelauthor=U.+Andagauthor=A.+Lomowauthor=U.+Burkauthor=D.+Onichtchoukauthor=C.+Dohrmannauthor=M.+Austen&title=Inhibition+of+GSK3+promotes+replication+and+survival+of+pancreatic+%CE%B2-cells&doi=10.1074%2Fjbc.M609637200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of GSK3 Promotes Replication and Survival of Pancreatic Beta Cells</span></div><div class="casAuthors">Mussmann, Rainer; Geese, Marcus; Harder, Friedrich; Kegel, Simone; Andag, Uwe; Lomow, Alexander; Burk, Ulrike; Onichtchouk, Daria; Dohrmann, Cord; Austen, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">12030-12037</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Recent developments indicate that the regeneration of beta cell function and mass in patients with diabetes is possible.  A regenerative approach may represent an alternative treatment option relative to current diabetes therapies that fail to provide optimal glycemic control.  Here we report that the inactivation of GSK3 by small mol. inhibitors or RNA interference stimulates replication of INS-1E rat insulinoma cells.  Specific and potent GSK3 inhibitors also alleviate the toxic effects of high concns. of glucose and the satd. fatty acid palmitate on INS-1E cells.  Furthermore, treatment of isolated rat islets with structurally diverse small mol. GSK3 inhibitors increases the rate beta cell replication by 2-3-fold relative to controls.  We propose that GSK3 is a regulator of beta cell replication and survival.  Moreover, our results suggest that specific inhibitors of GSK3 may have practical applications in beta cell regenerative therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfuejhr6RNZLVg90H21EOLACvtfcHk0lgE8NEXjSUlGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktFeltro%253D&md5=3a8594690947fa652124d1477a023243</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M609637200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M609637200%26sid%3Dliteratum%253Aachs%26aulast%3DMussmann%26aufirst%3DR.%26aulast%3DGeese%26aufirst%3DM.%26aulast%3DHarder%26aufirst%3DF.%26aulast%3DKegel%26aufirst%3DS.%26aulast%3DAndag%26aufirst%3DU.%26aulast%3DLomow%26aufirst%3DA.%26aulast%3DBurk%26aufirst%3DU.%26aulast%3DOnichtchouk%26aufirst%3DD.%26aulast%3DDohrmann%26aufirst%3DC.%26aulast%3DAusten%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520GSK3%2520promotes%2520replication%2520and%2520survival%2520of%2520pancreatic%2520%25CE%25B2-cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26issue%3D16%26spage%3D12030%26epage%3D12037%26doi%3D10.1074%2Fjbc.M609637200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span> <span> </span><span class="NLM_article-title">GSK3 inhibitors: development and therapeutic potential</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1038/nrd1415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrd1415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=15173837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=479-487&issue=6&author=P.+Cohenauthor=M.+Goedert&title=GSK3+inhibitors%3A+development+and+therapeutic+potential&doi=10.1038%2Fnrd1415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 inhibitors: development and therapeutic potential</span></div><div class="casAuthors">Cohen, Philip; Goedert, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">479-487</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metab.  In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics.  Here, we describe the biol. of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL3ua5xi0_qrVg90H21EOLACvtfcHk0lgE8NEXjSUlGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D&md5=165d1354bf11faa6021ac4dba797fda2</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnrd1415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1415%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DGoedert%26aufirst%3DM.%26atitle%3DGSK3%2520inhibitors%253A%2520development%2520and%2520therapeutic%2520potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D6%26spage%3D479%26epage%3D487%26doi%3D10.1038%2Fnrd1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baaten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeusen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-(3,4-difluorophenyl)-3-(pyrazol-4-yl)-7-azaindole (GNF3809) for β-cell survival in type 1 diabetes</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">3571</span>– <span class="NLM_lpage">3581</span>, <span class="refDoi"> DOI: 10.1021/acsomega.8b03050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.8b03050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=3571-3581&issue=2&author=Z.+Huangauthor=M.+S.+Tremblayauthor=T.+Y.+H.+Wuauthor=Q.+Dingauthor=X.+Haoauthor=J.+Baatenauthor=R.+Hillauthor=B.+Liuauthor=S.+Meeusenauthor=Y.+Zouauthor=S.+Yanauthor=Y.+Jiaauthor=V.+Nguyen-Tranauthor=W.+Shenauthor=G.+Bhatauthor=R.+Glynneauthor=B.+Laffitteauthor=J.+Liauthor=V.+Molteniauthor=Y.+A.+Liu&title=Discovery+of+5-%283%2C4-difluorophenyl%29-3-%28pyrazol-4-yl%29-7-azaindole+%28GNF3809%29+for+%CE%B2-cell+survival+in+type+1+diabetes&doi=10.1021%2Facsomega.8b03050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-(3,4-Difluorophenyl)-3-(pyrazol-4-yl)-7-azaindole (GNF3809) for β-Cell Survival in Type 1 Diabetes</span></div><div class="casAuthors">Huang, Zhihong; Tremblay, Matthew S.; Wu, Tom Y.-H.; Ding, Qiang; Hao, Xueshi; Baaten, Janine; Hill, Robert; Liu, Bo; Meeusen, Shelly; Zou, Yefen; Yan, Shanshan; Jia, Yong; Nguyen-Tran, Van; Shen, Weijun; Bhat, Ganesh; Glynne, Richard; Laffitte, Bryan; Li, Jing; Molteni, Valentina; Liu, Yahu A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">3571-3581</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pancreatic beta cell apoptosis, a hallmark of the development of type 1 diabetes (T1D), is assocd. with increased levels of pro-inflammatory cytokines.  Thus, an agent protecting beta cells from cytokine-induced stress should have an impact on maintaining functional beta cell mass in T1D.  Screening of a ∼2 million-compd. library identified a series of 7-azaindole derivs. as capable of protecting rat insulinoma (INS-1E) beta cells from death induced by pro-inflammatory cytokines.  The screening hits were optimized to result in GNF3809, a compd. which preserves insulin content and viability of beta cells in both rodent and human islets under stress induced by cytokines.  In vivo, orally bioavailable GNF3809 prevented elevated blood glucose level and improved oral glucose tolerance in a nonobese diabetic (NOD) mouse model.  This work lays the foundation for development of a new class of therapeutic interventions for T1D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6UVxw6m-JQrVg90H21EOLACvtfcHk0lgE8NEXjSUlGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyms74%253D&md5=af22eae54a0159416e25c7c4cdd53992</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facsomega.8b03050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.8b03050%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DTremblay%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DT.%2BY.%2BH.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DBaaten%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DMeeusen%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DNguyen-Tran%26aufirst%3DV.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DBhat%26aufirst%3DG.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DY.%2BA.%26atitle%3DDiscovery%2520of%25205-%25283%252C4-difluorophenyl%2529-3-%2528pyrazol-4-yl%2529-7-azaindole%2520%2528GNF3809%2529%2520for%2520%25CE%25B2-cell%2520survival%2520in%2520type%25201%2520diabetes%26jtitle%3DACS%2520Omega%26date%3D2019%26volume%3D4%26issue%3D2%26spage%3D3571%26epage%3D3581%26doi%3D10.1021%2Facsomega.8b03050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banasavadi-Siddegowda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nardini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobol, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornblum, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waclaw, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beullens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, I.</span></span> <span> </span><span class="NLM_article-title">MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells</span>. <i>Stem Cells (Durham, NC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1051</span>– <span class="NLM_lpage">1063</span>, <span class="refDoi"> DOI: 10.1002/stem.1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1002%2Fstem.1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=23404835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1Gjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1051-1063&issue=6&author=K.+Joshiauthor=Y.+Banasavadi-Siddegowdaauthor=X.+Moauthor=S.-H.+Kimauthor=P.+Maoauthor=C.+Kigauthor=D.+Nardiniauthor=R.+W.+Sobolauthor=L.+M.+L.+Chowauthor=H.+I.+Kornblumauthor=R.+Waclawauthor=M.+Beullensauthor=I.+Nakano&title=MELK-dependent+FOXM1+phosphorylation+is+essential+for+proliferation+of+glioma+stem+cells&doi=10.1002%2Fstem.1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells</span></div><div class="casAuthors">Joshi, Kaushal; Banasavadi-Siddegowda, Yeshavanth; Mo, Xiaokui; Kim, Sung-Hak; Mao, Ping; Kig, Cenk; Nardini, Diana; Sobol, Robert W.; Chow, Lionel M. L.; Kornblum, Harley I.; Waclaw, Ronald; Beullens, Monique; Nakano, Ichiro</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cells (Durham, NC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1051-1063</span>CODEN:
                <span class="NLM_cas:coden">STCEEJ</span>;
        ISSN:<span class="NLM_cas:issn">1066-5099</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is a life-threatening brain tumor.  Accumulating evidence suggests that eradication of glioma stem-like cells (GSCs) in GBM is essential to achieve cure.  The transcription factor FOXM1 has recently gained attention as a master regulator of mitotic progression of cancer cells in various organs.  Here, we demonstrate that FOXM1 forms a protein complex with the mitotic kinase MELK in GSCs, leading to phosphorylation and activation of FOXM1 in a MELK kinase-dependent manner.  This MELK-dependent activation of FOXM1 results in a subsequent increase in mitotic regulatory genes in GSCs.  MELK-driven FOXM1 activation is regulated by the binding and subsequent trans-phosphorylation of FOXM1 by another kinase PLK1.  Using mouse neural progenitor cells (NPCs), we found that transgenic expression of FOXM1 enhances, while siRNA-mediated gene silencing diminishes neurosphere formation, suggesting that FOXM1 is required for NPC growth.  During tumorigenesis, FOXM1 expression sequentially increases as cells progress from NPCs, to pretumorigenic progenitors and GSCs.  The antibiotic Siomycin A disrupts MELK-mediated FOXM1 signaling with a greater sensitivity in GSC compared to neural stem cell.  Treatment with the first-line chemotherapy agent for GBM, Temozolomide, paradoxically enriches for both FOXM1 (+) and MELK (+) cells in GBM cells, and addn. of Siomycin A to Temozolomide treatment in mice harboring GSC-derived intracranial tumors enhances the effects of the latter.  Collectively, our data indicate that FOXM1 signaling through its direct interaction with MELK regulates key mitotic genes in GSCs in a PLK1-dependent manner and thus, this protein complex is a potential therapeutic target for GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnuNcHO-aJSrVg90H21EOLACvtfcHk0lhr4cbTfUPDEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1Gjtbg%253D&md5=c1fff162527daa625cfdb99d814daa77</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fstem.1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fstem.1358%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%26aulast%3DBanasavadi-Siddegowda%26aufirst%3DY.%26aulast%3DMo%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DMao%26aufirst%3DP.%26aulast%3DKig%26aufirst%3DC.%26aulast%3DNardini%26aufirst%3DD.%26aulast%3DSobol%26aufirst%3DR.%2BW.%26aulast%3DChow%26aufirst%3DL.%2BM.%2BL.%26aulast%3DKornblum%26aufirst%3DH.%2BI.%26aulast%3DWaclaw%26aufirst%3DR.%26aulast%3DBeullens%26aufirst%3DM.%26aulast%3DNakano%26aufirst%3DI.%26atitle%3DMELK-dependent%2520FOXM1%2520phosphorylation%2520is%2520essential%2520for%2520proliferation%2520of%2520glioma%2520stem%2520cells%26jtitle%3DStem%2520Cells%2520%2528Durham%252C%2520NC%252C%2520U.%2520S.%2529%26date%3D2013%26volume%3D31%26issue%3D6%26spage%3D1051%26epage%3D1063%26doi%3D10.1002%2Fstem.1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maulis, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadi, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osipovich, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gannon, M.</span></span> <span> </span><span class="NLM_article-title">Activation of FoxM1 revitalizes the replicative potential of aged β-cells in male mice and enhances insulin secretion</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3829</span>– <span class="NLM_lpage">3838</span>, <span class="refDoi"> DOI: 10.2337/db15-0465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb15-0465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26251404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1Klt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=3829-3838&issue=11&author=M.+L.+Golsonauthor=J.+C.+Dunnauthor=M.+F.+Maulisauthor=P.+K.+Dadiauthor=A.+B.+Osipovichauthor=M.+A.+Magnusonauthor=D.+A.+Jacobsonauthor=M.+Gannon&title=Activation+of+FoxM1+revitalizes+the+replicative+potential+of+aged+%CE%B2-cells+in+male+mice+and+enhances+insulin+secretion&doi=10.2337%2Fdb15-0465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of FoxM1 revitalizes the replicative potential of aged β-cells in male mice and enhances insulin secretion</span></div><div class="casAuthors">Golson, Maria L.; Dunn, Jennifer C.; Maulis, Matthew F.; Dadi, Prasanna K.; Osipovich, Anna B.; Magnuson, Mark A.; Jacobson, David A.; Gannon, Maureen</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3829-3838</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Type 2 diabetes incidence increases with age, while β-cell replication declines.  The transcription factor FoxM1 is required for β-cell replication in various situations, and its expression declines with age.  We hypothesized that increased FoxM1 activity in aged β-cells would rejuvenate proliferation.  Induction of an activated form of FoxM1 was sufficient to increase β-cell mass and proliferation in 12-mo-old male mice after just 2 wk.  Unexpectedly, at 2 mo of age, induction of activated FoxM1 in male mice improved glucose homeostasis with unchanged β-cell mass.  Cells expressing activated FoxM1 demonstrated enhanced glucose-stimulated Ca2+ influx, which resulted in improved glucose tolerance through enhanced β-cell function.  Conversely, our lab. has previously demonstrated that mice lacking FoxM1 in the pancreas display glucose intolerance or diabetes with only a 60% redn. in β-cell mass, suggesting that the loss of FoxM1 is detrimental to β-cell function.  Ex vivo insulin secretion was therefore examd. in size-matched islets from young mice lacking FoxM1 in β-cells.  Foxm1-deficient islets indeed displayed reduced insulin secretion.  Our studies reveal that activated FoxM1 increases β-cell replication while simultaneously enhancing insulin secretion and improving glucose homeostasis, making FoxM1 an attractive therapeutic target for diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe3qKKriOoNrVg90H21EOLACvtfcHk0lhr4cbTfUPDEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1Klt74%253D&md5=7b00512bbf1abe7b4d2546603751a242</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2337%2Fdb15-0465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb15-0465%26sid%3Dliteratum%253Aachs%26aulast%3DGolson%26aufirst%3DM.%2BL.%26aulast%3DDunn%26aufirst%3DJ.%2BC.%26aulast%3DMaulis%26aufirst%3DM.%2BF.%26aulast%3DDadi%26aufirst%3DP.%2BK.%26aulast%3DOsipovich%26aufirst%3DA.%2BB.%26aulast%3DMagnuson%26aufirst%3DM.%2BA.%26aulast%3DJacobson%26aufirst%3DD.%2BA.%26aulast%3DGannon%26aufirst%3DM.%26atitle%3DActivation%2520of%2520FoxM1%2520revitalizes%2520the%2520replicative%2520potential%2520of%2520aged%2520%25CE%25B2-cells%2520in%2520male%2520mice%2520and%2520enhances%2520insulin%2520secretion%26jtitle%3DDiabetes%26date%3D2015%26volume%3D64%26issue%3D11%26spage%3D3829%26epage%3D3838%26doi%3D10.2337%2Fdb15-0465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alachkar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutonga, M. B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malnassy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzeler, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiddemann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, Y.</span></span> <span> </span><span class="NLM_article-title">Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">12371</span>– <span class="NLM_lpage">12382</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.18632%2Foncotarget.2642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=25365263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A280%3ADC%252BC2M3lt1ejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=12371-12382&issue=23&author=H.+Alachkarauthor=M.+B.+G.+Mutongaauthor=N.+Fultonauthor=G.+Malnassyauthor=W.+Stockauthor=Y.+Nakamuraauthor=K.+H.+Metzelerauthor=T.+Heroldauthor=K.+Spiekermannauthor=W.+Hiddemannauthor=S.+K.+Bohlanderauthor=Y.+Matsuo&title=Preclinical+efficacy+of+maternal+embryonic+leucine-zipper+kinase+%28MELK%29+inhibition+in+acute+myeloid+leukemia&doi=10.18632%2Foncotarget.2642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia</span></div><div class="casAuthors">Alachkar Houda; Mutonga Martin B G; Fulton Noreen; Malnassy Gregory; Stock Wendy; Nakamura Yusuke; Metzeler Klaus H; Herold Tobias; Spiekermann Karsten; Hiddemann Wolfgang; Bohlander Stefan K; Matsuo Yo</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">12371-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Maternal embryonic leucine-zipper kinase (MELK), which was reported to be frequently up-regulated in various types of solid cancer, plays critical roles in formation and maintenance of cancer stem cells.  However, little is known about the relevance of this kinase in hematologic malignancies.  Here we report characterization of possible roles of MELK in acute myeloid leukemia (AML).  MELK is expressed in AML cell lines and AML blasts with higher levels in less differentiated cells.  MELK is frequently upregulated in AML with complex karyotypes and is associated with worse clinical outcome.  MELK knockdown resulted in growth inhibition and apoptosis of leukemic cells.  Hence, we investigated the potent anti-leukemia activity of OTS167, a small molecule MELK kinase inhibitor, in AML, and found that the compound induced cell differentiation and apoptosis as well as decreased migration of AML cells.  MELK expression was positively correlated with the expression of FOXM1 as well as its downstream target genes.  Furthermore, MELK inhibition resulted in downregulation of FOXM1 activity and the expression of its downstream targets.  Taken together, and given that OTS167 is undergoing a phase I clinical trial in solid cancer, our study warrants clinical evaluation of this compound as a novel targeted therapy for AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1IkpC-K_Eonp3bfzSLaX5fW6udTcc2ebMmRt_KBylZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3lt1ejsQ%253D%253D&md5=f7a207e2593cedd69fc2864a3e3311ca</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2642%26sid%3Dliteratum%253Aachs%26aulast%3DAlachkar%26aufirst%3DH.%26aulast%3DMutonga%26aufirst%3DM.%2BB.%2BG.%26aulast%3DFulton%26aufirst%3DN.%26aulast%3DMalnassy%26aufirst%3DG.%26aulast%3DStock%26aufirst%3DW.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DMetzeler%26aufirst%3DK.%2BH.%26aulast%3DHerold%26aufirst%3DT.%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DHiddemann%26aufirst%3DW.%26aulast%3DBohlander%26aufirst%3DS.%2BK.%26aulast%3DMatsuo%26aufirst%3DY.%26atitle%3DPreclinical%2520efficacy%2520of%2520maternal%2520embryonic%2520leucine-zipper%2520kinase%2520%2528MELK%2529%2520inhibition%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26issue%3D23%26spage%3D12371%26epage%3D12382%26doi%3D10.18632%2Foncotarget.2642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horton, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allegretti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annes, J. P.</span></span> <span> </span><span class="NLM_article-title">Zinc-chelating small molecules preferentially accumulate and function within pancreatic β cells</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.chembiol.2018.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30527998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVChs77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=213-222&issue=2&author=T.+M.+Hortonauthor=P.+A.+Allegrettiauthor=S.+Leeauthor=H.+P.+Moellerauthor=M.+Smithauthor=J.+P.+Annes&title=Zinc-chelating+small+molecules+preferentially+accumulate+and+function+within+pancreatic+%CE%B2+cells&doi=10.1016%2Fj.chembiol.2018.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc-Chelating Small Molecules Preferentially Accumulate and Function within Pancreatic β Cells</span></div><div class="casAuthors">Horton, Timothy M.; Allegretti, Paul A.; Lee, Sooyeon; Moeller, Hannah P.; Smith, Mark; Annes, Justin P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-222.e6</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Diabetes is a hyperglycemic condition characterized by pancreatic β-cell dysfunction and depletion.  Whereas methods for monitoring β-cell function in vivo exist, methods to deliver therapeutics to β cells are lacking.  We leveraged the rare ability of β cells to conc. zinc to preferentially trap zinc-binding mols. within β cells, resulting in β-cell-targeted compd. delivery.  We detd. that zinc-rich β cells and islets preferentially accumulated TSQ (6-methoxy-8-p-toluenesulfonamido-quinoline) in a zinc-dependent manner compared with exocrine pancreas.  Next, we asked whether appending a zinc-chelating moiety onto a β-cell replication-inducing compd. was sufficient to confer preferential β-cell accumulation and activity.  Indeed, the hybrid compd. preferentially accumulated within rodent and human islets in a zinc-dependent manner and increased the selectivity of replication-promoting activity toward β cells.  These data resolve the fundamental question of whether intracellular accumulation of zinc-chelating compds. is influenced by zinc content.  Furthermore, application of this principle yielded a proof-of-concept method for β-cell-targeted drug delivery and bioactivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrUmxdaubO7Vg90H21EOLACvtfcHk0lhVnhou8ezH8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVChs77L&md5=284270ac8b527adcc6987f4aa60c0244</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DHorton%26aufirst%3DT.%2BM.%26aulast%3DAllegretti%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DMoeller%26aufirst%3DH.%2BP.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DAnnes%26aufirst%3DJ.%2BP.%26atitle%3DZinc-chelating%2520small%2520molecules%2520preferentially%2520accumulate%2520and%2520function%2520within%2520pancreatic%2520%25CE%25B2%2520cells%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D2%26spage%3D213%26epage%3D222%26doi%3D10.1016%2Fj.chembiol.2018.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakose, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inabnet, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libutti, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambertini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ranvier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takane, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antipin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzilov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reva, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Losic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">Insights into β-cell regeneration for diabetes via integration of molecular landscapes in human insulinomas</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fs41467-017-01662-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=28232747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2gtrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1-15&issue=1&author=H.+Wangauthor=A.+Benderauthor=P.+Wangauthor=E.+Karakoseauthor=W.+B.+Inabnetauthor=S.+K.+Libuttiauthor=A.+Arnoldauthor=L.+Lambertiniauthor=M.+Stangauthor=H.+Chenauthor=Y.+Kasaiauthor=M.+Mahajanauthor=Y.+Kinoshitaauthor=G.+Fernandez-Ranvierauthor=T.+C.+Beckerauthor=K.+K.+Takaneauthor=L.+A.+Walkerauthor=S.+Saulauthor=R.+Chenauthor=D.+K.+Scottauthor=J.+Ferrerauthor=Y.+Antipinauthor=M.+Donovanauthor=A.+V.+Uzilovauthor=B.+Revaauthor=E.+E.+Schadtauthor=B.+Losicauthor=C.+Argmannauthor=A.+F.+Stewart&title=Insights+into+%CE%B2-cell+regeneration+for+diabetes+via+integration+of+molecular+landscapes+in+human+insulinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Fast kinetics of magnesium monochloride cations in interlayer-expanded titanium disulfide for magnesium rechargeable batteries</span></div><div class="casAuthors">Yoo, Hyun Deog; Liang, Yanliang; Dong, Hui; Lin, Junhao; Wang, Hua; Liu, Yisheng; Ma, Lu; Wu, Tianpin; Li, Yifei; Ru, Qiang; Jing, Yan; An, Qinyou; Zhou, Wu; Guo, Jinghua; Lu, Jun; Pantelides, Sokrates T.; Qian, Xiaofeng; Yao, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Magnesium rechargeable batteries potentially offer high-energy d., safety, and low cost due to the ability to employ divalent, dendrite-free, and earth-abundant magnesium metal anode.  Despite recent progress, further development remains stagnated mainly due to the sluggish scission of magnesium-chloride bond and slow diffusion of divalent magnesium cations in cathodes.  Here we report a battery chem. that utilizes magnesium monochloride cations in expanded titanium disulfide.  Combined theor. modeling, spectroscopic anal., and electrochem. study reveal fast diffusion kinetics of magnesium monochloride cations without scission of magnesium-chloride bond.  The battery demonstrates the reversible intercalation of 1 and 1.7 magnesium monochloride cations per titanium at 25 and 60°C, resp., corresponding to up to 400 mAh g-1 capacity based on the mass of titanium disulfide.  The large capacity accompanies with excellent rate and cycling performances even at room temp., opening up possibilities for a variety of effective intercalation hosts for multivalent-ion batteries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYULYh8ggm57Vg90H21EOLACvtfcHk0lhVnhou8ezH8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2gtrvE&md5=289dffaf7f3f59a3be62c35d7f8a03ef</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-01662-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-01662-6%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DKarakose%26aufirst%3DE.%26aulast%3DInabnet%26aufirst%3DW.%2BB.%26aulast%3DLibutti%26aufirst%3DS.%2BK.%26aulast%3DArnold%26aufirst%3DA.%26aulast%3DLambertini%26aufirst%3DL.%26aulast%3DStang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DKasai%26aufirst%3DY.%26aulast%3DMahajan%26aufirst%3DM.%26aulast%3DKinoshita%26aufirst%3DY.%26aulast%3DFernandez-Ranvier%26aufirst%3DG.%26aulast%3DBecker%26aufirst%3DT.%2BC.%26aulast%3DTakane%26aufirst%3DK.%2BK.%26aulast%3DWalker%26aufirst%3DL.%2BA.%26aulast%3DSaul%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DFerrer%26aufirst%3DJ.%26aulast%3DAntipin%26aufirst%3DY.%26aulast%3DDonovan%26aufirst%3DM.%26aulast%3DUzilov%26aufirst%3DA.%2BV.%26aulast%3DReva%26aufirst%3DB.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DLosic%26aufirst%3DB.%26aulast%3DArgmann%26aufirst%3DC.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DInsights%2520into%2520%25CE%25B2-cell%2520regeneration%2520for%2520diabetes%2520via%2520integration%2520of%2520molecular%2520landscapes%2520in%2520human%2520insulinomas%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D1%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aemmaelae, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drury, W. J.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knerr, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlstedt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillemark-Billton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennberg-Huldt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeur, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson-Loefmark, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundstroem, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claesson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monia, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, S.</span></span> <span> </span><span class="NLM_article-title">Targeted delivery of antisense oligonucleotides to pancreatic β-cells</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">10</span>), <span class="NLM_elocation-id">eaat3386</span> <span class="refDoi"> DOI: 10.1126/sciadv.aat3386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1126%2Fsciadv.aat3386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30345352" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&issue=10&author=C.+Aemmaelaeauthor=W.+J.+Druryauthor=L.+Knerrauthor=I.+Ahlstedtauthor=P.+Stillemark-Billtonauthor=C.+Wennberg-Huldtauthor=E.+M.+Anderssonauthor=E.+Valeurauthor=R.+Jansson-Loefmarkauthor=D.+Janzenauthor=L.+Sundstroemauthor=J.+Meullerauthor=J.+Claessonauthor=P.+Anderssonauthor=C.+Johanssonauthor=R.+G.+Leeauthor=T.+P.+Prakashauthor=P.+P.+Sethauthor=B.+P.+Moniaauthor=S.+Andersson&title=Targeted+delivery+of+antisense+oligonucleotides+to+pancreatic+%CE%B2-cells&doi=10.1126%2Fsciadv.aat3386"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aat3386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aat3386%26sid%3Dliteratum%253Aachs%26aulast%3DAemmaelae%26aufirst%3DC.%26aulast%3DDrury%26aufirst%3DW.%2BJ.%26aulast%3DKnerr%26aufirst%3DL.%26aulast%3DAhlstedt%26aufirst%3DI.%26aulast%3DStillemark-Billton%26aufirst%3DP.%26aulast%3DWennberg-Huldt%26aufirst%3DC.%26aulast%3DAndersson%26aufirst%3DE.%2BM.%26aulast%3DValeur%26aufirst%3DE.%26aulast%3DJansson-Loefmark%26aufirst%3DR.%26aulast%3DJanzen%26aufirst%3DD.%26aulast%3DSundstroem%26aufirst%3DL.%26aulast%3DMeuller%26aufirst%3DJ.%26aulast%3DClaesson%26aufirst%3DJ.%26aulast%3DAndersson%26aufirst%3DP.%26aulast%3DJohansson%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DR.%2BG.%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26aulast%3DMonia%26aufirst%3DB.%2BP.%26aulast%3DAndersson%26aufirst%3DS.%26atitle%3DTargeted%2520delivery%2520of%2520antisense%2520oligonucleotides%2520to%2520pancreatic%2520%25CE%25B2-cells%26jtitle%3DSci.%2520Adv.%26date%3D2018%26volume%3D4%26issue%3D10%26doi%3D10.1126%2Fsciadv.aat3386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aramandla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poffenberger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goff, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virostko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shostak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnahan, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevigny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, A. C.</span></span> <span> </span><span class="NLM_article-title">Ectonucleoside triphosphate diphosphohydrolase-3 antibody targets adult human pancreatic β cells for in vitro and in vivo analysis</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2018.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30449685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1WltrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=745-754&issue=3&author=D.+C.+Saundersauthor=M.+Brissovaauthor=N.+Phillipsauthor=S.+Shresthaauthor=J.+T.+Walkerauthor=R.+Aramandlaauthor=G.+Poffenbergerauthor=D.+K.+Flahertyauthor=K.+P.+Wellerauthor=J.+Pelletierauthor=T.+Cooperauthor=M.+T.+Goffauthor=J.+Virostkoauthor=A.+Shostakauthor=E.+D.+Deanauthor=D.+L.+Greinerauthor=L.+D.+Shultzauthor=N.+Prasadauthor=S.+E.+Levyauthor=R.+H.+Carnahanauthor=C.+Daiauthor=J.+Sevignyauthor=A.+C.+Powers&title=Ectonucleoside+triphosphate+diphosphohydrolase-3+antibody+targets+adult+human+pancreatic+%CE%B2+cells+for+in+vitro+and+in+vivo+analysis&doi=10.1016%2Fj.cmet.2018.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Ectonucleoside Triphosphate Diphosphohydrolase-3 Antibody Targets Adult Human Pancreatic β Cells for In Vitro and In Vivo Analysis</span></div><div class="casAuthors">Saunders, Diane C.; Brissova, Marcela; Phillips, Neil; Shrestha, Shristi; Walker, John T.; Aramandla, Radhika; Poffenberger, Greg; Flaherty, David K.; Weller, Kevin P.; Pelletier, Julie; Cooper, Tracy; Goff, Matt T.; Virostko, John; Shostak, Alena; Dean, E. Danielle; Greiner, Dale L.; Shultz, Leonard D.; Prasad, Nripesh; Levy, Shawn E.; Carnahan, Robert H.; Dai, Chunhua; Sevigny, Jean; Powers, Alvin C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">745-754.e4</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Identification of cell-surface markers specific to human pancreatic β cells would allow in vivo anal. and imaging.  Here we introduce a biomarker, ectonucleoside triphosphate diphosphohydrolase-3 (NTPDase3), that is expressed on the cell surface of essentially all adult human β cells, including those from individuals with type 1 or type 2 diabetes.  NTPDase3 is expressed dynamically during postnatal human pancreas development, appearing first in acinar cells at birth, but several months later its expression declines in acinar cells while concurrently emerging in islet β cells.  Given its specificity and membrane localization, we utilized an NTPDase3 antibody for purifn. of live human β cells as confirmed by transcriptional profiling, and, in addn., for in vivo imaging of transplanted human β cells.  Thus, NTPDase3 is a cell-surface biomarker of adult human β cells, and the antibody directed to this protein should be a useful new reagent for β cell sorting, in vivo imaging, and targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRe1GNU808ybVg90H21EOLACvtfcHk0lggscIdJsUKrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1WltrnP&md5=4902bddf1d3ba4fcfc62ebadb2ea117a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DSaunders%26aufirst%3DD.%2BC.%26aulast%3DBrissova%26aufirst%3DM.%26aulast%3DPhillips%26aufirst%3DN.%26aulast%3DShrestha%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DJ.%2BT.%26aulast%3DAramandla%26aufirst%3DR.%26aulast%3DPoffenberger%26aufirst%3DG.%26aulast%3DFlaherty%26aufirst%3DD.%2BK.%26aulast%3DWeller%26aufirst%3DK.%2BP.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DCooper%26aufirst%3DT.%26aulast%3DGoff%26aufirst%3DM.%2BT.%26aulast%3DVirostko%26aufirst%3DJ.%26aulast%3DShostak%26aufirst%3DA.%26aulast%3DDean%26aufirst%3DE.%2BD.%26aulast%3DGreiner%26aufirst%3DD.%2BL.%26aulast%3DShultz%26aufirst%3DL.%2BD.%26aulast%3DPrasad%26aufirst%3DN.%26aulast%3DLevy%26aufirst%3DS.%2BE.%26aulast%3DCarnahan%26aufirst%3DR.%2BH.%26aulast%3DDai%26aufirst%3DC.%26aulast%3DSevigny%26aufirst%3DJ.%26aulast%3DPowers%26aufirst%3DA.%2BC.%26atitle%3DEctonucleoside%2520triphosphate%2520diphosphohydrolase-3%2520antibody%2520targets%2520adult%2520human%2520pancreatic%2520%25CE%25B2%2520cells%2520for%2520in%2520vitro%2520and%2520in%2520vivo%2520analysis%26jtitle%3DCell%2520Metab.%26date%3D2019%26volume%3D29%26issue%3D3%26spage%3D745%26epage%3D754%26doi%3D10.1016%2Fj.cmet.2018.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ackeifi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakose, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning Fox, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrouet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorens, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">530</span>), <span class="NLM_elocation-id">eaaw9996</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aaw9996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1126%2Fscitranslmed.aaw9996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=32051230" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&issue=530&author=C.+Ackeifiauthor=P.+Wangauthor=E.+Karakoseauthor=J.+E.+Manning+Foxauthor=B.+J.+Gonzalezauthor=H.+Liuauthor=J.+Wilsonauthor=E.+Swartzauthor=C.+Berrouetauthor=Y.+Liauthor=K.+Kumarauthor=P.+E.+MacDonaldauthor=R.+Sanchezauthor=B.+Thorensauthor=R.+DeVitaauthor=D.+Homannauthor=D.+Egliauthor=D.+K.+Scottauthor=A.+Garcia-Ocanaauthor=A.+F.+Stewart&title=GLP-1+receptor+agonists+synergize+with+DYRK1A+inhibitors+to+potentiate+functional+human+%CE%B2+cell+regeneration&doi=10.1126%2Fscitranslmed.aaw9996"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaw9996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaw9996%26sid%3Dliteratum%253Aachs%26aulast%3DAckeifi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DKarakose%26aufirst%3DE.%26aulast%3DManning%2BFox%26aufirst%3DJ.%2BE.%26aulast%3DGonzalez%26aufirst%3DB.%2BJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DSwartz%26aufirst%3DE.%26aulast%3DBerrouet%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DMacDonald%26aufirst%3DP.%2BE.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DThorens%26aufirst%3DB.%26aulast%3DDeVita%26aufirst%3DR.%26aulast%3DHomann%26aufirst%3DD.%26aulast%3DEgli%26aufirst%3DD.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DGLP-1%2520receptor%2520agonists%2520synergize%2520with%2520DYRK1A%2520inhibitors%2520to%2520potentiate%2520functional%2520human%2520%25CE%25B2%2520cell%2520regeneration%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26issue%3D530%26doi%3D10.1126%2Fscitranslmed.aaw9996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosado-Olivieri, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenty, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melton, D. A.</span></span> <span> </span><span class="NLM_article-title">YAP inhibition enhances the differentiation of functional stem cell-derived insulin-producing β cells</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fs41467-019-09404-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30602773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXoslGks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1-11&issue=1&author=E.+A.+Rosado-Olivieriauthor=K.+Andersonauthor=J.+H.+Kentyauthor=D.+A.+Melton&title=YAP+inhibition+enhances+the+differentiation+of+functional+stem+cell-derived+insulin-producing+%CE%B2+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">YAP inhibition enhances the differentiation of functional stem cell-derived insulin-producing β cells</span></div><div class="casAuthors">Rosado-Olivieri, Edwin A.; Anderson, Kendall; Kenty, Jennifer H.; Melton, Douglas A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Stem cell-derived insulin-producing beta cells (SC-β) offer an inexhaustible supply of functional β cells for cell replacement therapies and disease modeling for diabetes.  While successful directed differentiation protocols for this cell type have been described, the mechanisms controlling its differentiation and function are not fully understood.  Here we report that the Hippo pathway controls the proliferation and specification of pancreatic progenitors into the endocrine lineage.  Downregulation of YAP, an effector of the pathway, enhances endocrine progenitor differentiation and the generation of SC-β cells with improved insulin secretion.  A chem. inhibitor of YAP acts as an inducer of endocrine differentiation and reduces the presence of proliferative progenitor cells.  Conversely, sustained activation of YAP results in impaired differentiation, blunted glucose-stimulated insulin secretion, and increased proliferation of SC-β cells.  Together these results support a role for YAP in controlling the self-renewal and differentiation balance of pancreatic progenitors and limiting endocrine differentiation in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVP8NOk_IoyLVg90H21EOLACvtfcHk0lgfJ_XGw3x94g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXoslGks7w%253D&md5=bb11ed4559fd6c8236fb325d389ebba1</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-09404-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-09404-6%26sid%3Dliteratum%253Aachs%26aulast%3DRosado-Olivieri%26aufirst%3DE.%2BA.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DKenty%26aufirst%3DJ.%2BH.%26aulast%3DMelton%26aufirst%3DD.%2BA.%26atitle%3DYAP%2520inhibition%2520enhances%2520the%2520differentiation%2520of%2520functional%2520stem%2520cell-derived%2520insulin-producing%2520%25CE%25B2%2520cells%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosado-Olivieri, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aigha, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenty, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melton, D. A.</span></span> <span> </span><span class="NLM_article-title">Identification of a LIF-responsive, replication-competent subpopulation of human β cells</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2019.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2019.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=31928884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpt1Cjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=327-338&issue=2&author=E.+A.+Rosado-Olivieriauthor=I.+I.+Aighaauthor=J.+H.+Kentyauthor=D.+A.+Melton&title=Identification+of+a+LIF-responsive%2C+replication-competent+subpopulation+of+human+%CE%B2+cells&doi=10.1016%2Fj.cmet.2019.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a LIF-Responsive, Replication-Competent Subpopulation of Human β Cells</span></div><div class="casAuthors">Rosado-Olivieri, Edwin A.; Aigha, Idil I.; Kenty, Jennifer H.; Melton, Douglas A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-338.e6</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The beta (β)-cell mass formed during embryogenesis is amplified by cell replication during fetal and early postnatal development.  Thereafter, β cells become functionally mature, and their mass is maintained by a low rate of replication.  For those few β cells that replicate in adult life, it is not known how replication is initiated nor whether this occurs in a specialized subset of β cells.  We capitalized on a YAP overexpression system to induce replication of stem-cell-derived β cells and, by single-cell RNA sequencing, identified an upregulation of the leukemia inhibitory factor (LIF) pathway.  Activation of the LIF pathway induces replication of human β cells in vitro and in vivo.  The expression of the LIF receptor is restricted to a subset of transcriptionally distinct human β cells with increased proliferative capacity.  This study delineates novel genetic networks that control the replication of LIF-responsive, replication-competent human β cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh8W5YE4mVybVg90H21EOLACvtfcHk0lgfJ_XGw3x94g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpt1Cjsw%253D%253D&md5=8fd407c003ab85af255c990336fd540a</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2019.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2019.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DRosado-Olivieri%26aufirst%3DE.%2BA.%26aulast%3DAigha%26aufirst%3DI.%2BI.%26aulast%3DKenty%26aufirst%3DJ.%2BH.%26aulast%3DMelton%26aufirst%3DD.%2BA.%26atitle%3DIdentification%2520of%2520a%2520LIF-responsive%252C%2520replication-competent%2520subpopulation%2520of%2520human%2520%25CE%25B2%2520cells%26jtitle%3DCell%2520Metab.%26date%3D2020%26volume%3D31%26issue%3D2%26spage%3D327%26epage%3D338%26doi%3D10.1016%2Fj.cmet.2019.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicola, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babon, J. J.</span></span> <span> </span><span class="NLM_article-title">Leukemia inhibitory factor (LIF)</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cytogfr.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26187859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOksrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=533-544&issue=5&author=N.+A.+Nicolaauthor=J.+J.+Babon&title=Leukemia+inhibitory+factor+%28LIF%29&doi=10.1016%2Fj.cytogfr.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Leukemia inhibitory factor (LIF)</span></div><div class="casAuthors">Nicola, Nicos A.; Babon, Jeffrey J.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">533-544</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Leukemia inhibitory factor (LIF) is the most pleiotropic member of the interleukin-6 family of cytokines.  It utilizes a receptor that consists of the LIF receptor β and gp130 and this receptor complex is also used by ciliary neurotrophic growth factor (CNTF), oncostatin M, cardiotrophin 1 (CT1) and cardiotrophin-like cytokine (CLC).  Despite common signal transduction mechanisms (JAK/STAT, MAPK and PI3K) LIF can have paradoxically opposite effects in different cell types including stimulating or inhibiting each of cell proliferation, differentiation and survival.  While LIF can act on a wide range of cell types, LIF knockout mice have revealed that many of these actions are not apparent during ordinary development and that they may be the result of induced LIF expression during tissue damage or injury.  Nevertheless LIF does appear to have non-redundant actions in maternal receptivity to blastocyst implantation, placental formation and in the development of the nervous system.  LIF has also found practical use in the maintenance of self-renewal and totipotency of embryonic stem cells and induced pluripotent stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox2V6NiD3P87Vg90H21EOLACvtfcHk0lgfJ_XGw3x94g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOksrfL&md5=f1352a4bb21486e040194456f862fe25</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DNicola%26aufirst%3DN.%2BA.%26aulast%3DBabon%26aufirst%3DJ.%2BJ.%26atitle%3DLeukemia%2520inhibitory%2520factor%2520%2528LIF%2529%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2015%26volume%3D26%26issue%3D5%26spage%3D533%26epage%3D544%26doi%3D10.1016%2Fj.cytogfr.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetsch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvaïa, N.</span></span> <span> </span><span class="NLM_article-title">Strategies and challenges for the next generation of antibody–drug conjugates</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrd.2016.268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=28303026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=315-337&issue=5&author=A.+Beckauthor=L.+Goetschauthor=C.+Dumontetauthor=N.+Corva%C3%AFa&title=Strategies+and+challenges+for+the+next+generation+of+antibody%E2%80%93drug+conjugates&doi=10.1038%2Fnrd.2016.268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies and challenges for the next generation of antibody-drug conjugates</span></div><div class="casAuthors">Beck, Alain; Goetsch, Liliane; Dumontet, Charles; Corvaia, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-337</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncol. therapeutics.  After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clin. trials that are evaluating more than 60 further ADC candidates.  The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody.  Furthermore, lessons learned during the past decade are now being used in the development of third-generation ADCs.  In this Review, we discuss strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues.  The selection and engineering of antibodies for site-specific drug conjugation, which will result in higher homogeneity and increased stability, as well as the quest for new conjugation chemistries and mechanisms of action, are priorities in ADC research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP7lV63Ws8rbVg90H21EOLACvtfcHk0lhQqWocYXJOkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D&md5=7358b6080dd1aed1d21e98c078cd9ef1</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.268%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DGoetsch%26aufirst%3DL.%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DCorva%25C3%25AFa%26aufirst%3DN.%26atitle%3DStrategies%2520and%2520challenges%2520for%2520the%2520next%2520generation%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D5%26spage%3D315%26epage%3D337%26doi%3D10.1038%2Fnrd.2016.268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span> <span> </span><span class="NLM_article-title">Site-specific antibody drug conjugates for cancer therapy</span>. <i>mAbs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.4161/mabs.27022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.4161%2Fmabs.27022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=24423619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A280%3ADC%252BC2cvnslaltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=34-45&issue=1&author=S.+Panowskiauthor=S.+Bhaktaauthor=H.+Raabauthor=P.+Polakisauthor=J.+R.+Junutula&title=Site-specific+antibody+drug+conjugates+for+cancer+therapy&doi=10.4161%2Fmabs.27022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific antibody drug conjugates for cancer therapy</span></div><div class="casAuthors">Panowski Siler; Bhakta Sunil; Raab Helga; Polakis Paul; Junutula Jagath R</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibody therapeutics have revolutionized the treatment of cancer over the past two decades.  Antibodies that specifically bind tumor surface antigens can be effective therapeutics; however, many unmodified antibodies lack therapeutic activity.  These antibodies can instead be applied successfully as guided missiles to deliver potent cytotoxic drugs in the form of antibody drug conjugates (ADCs).  The success of ADCs is dependent on four factors--target antigen, antibody, linker, and payload.  The field has made great progress in these areas, marked by the recent approval by the US Food and Drug Administration of two ADCs, brentuximab vedotin (Adcetris) and ado-trastuzumab emtansine (Kadcyla).  However, the therapeutic window for many ADCs that are currently in pre-clinical or clinical development remains narrow and further improvements may be required to enhance the therapeutic potential of these ADCs.  Production of ADCs is an area where improvement is needed because current methods yield heterogeneous mixtures that may include 0-8 drug species per antibody molecule.  Site-specific conjugation has been recently shown to eliminate heterogeneity, improve conjugate stability, and increase the therapeutic window.  Here, we review and describe various site-specific conjugation strategies that are currently used for the production of ADCs, including use of engineered cysteine residues, unnatural amino acids, and enzymatic conjugation through glycotransferases and transglutaminases.  In addition, we also summarize differences among these methods and highlight critical considerations when building next-generation ADC therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXMRlj6bTH0hOk4JA3soTqfW6udTcc2eYpER8xgDBPdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvnslaltw%253D%253D&md5=9da883692122c03303f785e61f6c5db7</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.4161%2Fmabs.27022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fmabs.27022%26sid%3Dliteratum%253Aachs%26aulast%3DPanowski%26aufirst%3DS.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DSite-specific%2520antibody%2520drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DmAbs%26date%3D2014%26volume%3D6%26issue%3D1%26spage%3D34%26epage%3D45%26doi%3D10.4161%2Fmabs.27022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdollahpour-Alitappeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotfinia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharibi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardaneh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farhadihosseinabadi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larki, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faghfourian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepehr, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbaszadeh-Goudarzi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbaszadeh-Goudarzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johari, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zali, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagheri, N.</span></span> <span> </span><span class="NLM_article-title">Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">5628</span>– <span class="NLM_lpage">5642</span>, <span class="refDoi"> DOI: 10.1002/jcp.27419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1002%2Fjcp.27419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30478951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSgs77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=5628-5642&issue=5&author=M.+Abdollahpour-Alitappehauthor=M.+Lotfiniaauthor=T.+Gharibiauthor=J.+Mardanehauthor=B.+Farhadihosseinabadiauthor=P.+Larkiauthor=B.+Faghfourianauthor=K.+S.+Sepehrauthor=K.+Abbaszadeh-Goudarziauthor=G.+Abbaszadeh-Goudarziauthor=B.+Johariauthor=M.+R.+Zaliauthor=N.+Bagheri&title=Antibody%E2%80%93drug+conjugates+%28ADCs%29+for+cancer+therapy%3A+Strategies%2C+challenges%2C+and+successes&doi=10.1002%2Fjcp.27419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes</span></div><div class="casAuthors">Abdollahpour-Alitappeh, Meghdad; Lotfinia, Majid; Gharibi, Tohid; Mardaneh, Jalal; Farhadihosseinabadi, Behrouz; Larki, Pegah; Faghfourian, Babak; Sepehr, Koushan Sineh; Abbaszadeh-Goudarzi, Kazem; Abbaszadeh-Goudarzi, Ghasem; Johari, Behrooz; Zali, Mohammad Reza; Bagheri, Nader</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">5628-5642</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Targeted delivery of therapeutic mols. into cancer cells is considered as a promising strategy to tackle cancer.  Antibody-drug conjugates (ADCs), in which a monoclonal antibody (mAb) is conjugated to biol. active drugs through chem. linkers, have emerged as a promising class of anticancer treatment agents, being one of the fastest growing fields in cancer therapy.  The failure of early ADCs led researchers to explore strategies to develop more effective and improved ADCs with lower levels of unconjugated mAbs and more-stable linkers between the drug and the antibody, which show improved pharmacokinetic properties, therapeutic indexes, and safety profiles.  Such improvements resulted in the US Food and Drug Administration approvals of brentuximab vedotin, trastuzumab emtansine, and, more recently, inotuzumab ozogamicin.  In addn., recent clin. outcomes have sparked addnl. interest, which leads to the dramatically increased no. of ADCs in clin. development.  The present review explores ADCs, their main characteristics, and new research developments, as well as discusses strategies for the selection of the most appropriate target antigens, mAbs, cytotoxic drugs, linkers, and conjugation chemistries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYkf-vg9w2KbVg90H21EOLACvtfcHk0lhQqWocYXJOkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSgs77I&md5=56789e8e2935cebae1392511c4cf497f</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fjcp.27419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.27419%26sid%3Dliteratum%253Aachs%26aulast%3DAbdollahpour-Alitappeh%26aufirst%3DM.%26aulast%3DLotfinia%26aufirst%3DM.%26aulast%3DGharibi%26aufirst%3DT.%26aulast%3DMardaneh%26aufirst%3DJ.%26aulast%3DFarhadihosseinabadi%26aufirst%3DB.%26aulast%3DLarki%26aufirst%3DP.%26aulast%3DFaghfourian%26aufirst%3DB.%26aulast%3DSepehr%26aufirst%3DK.%2BS.%26aulast%3DAbbaszadeh-Goudarzi%26aufirst%3DK.%26aulast%3DAbbaszadeh-Goudarzi%26aufirst%3DG.%26aulast%3DJohari%26aufirst%3DB.%26aulast%3DZali%26aufirst%3DM.%2BR.%26aulast%3DBagheri%26aufirst%3DN.%26atitle%3DAntibody%25E2%2580%2593drug%2520conjugates%2520%2528ADCs%2529%2520for%2520cancer%2520therapy%253A%2520Strategies%252C%2520challenges%252C%2520and%2520successes%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26issue%3D5%26spage%3D5628%26epage%3D5642%26doi%3D10.1002%2Fjcp.27419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehar, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajihara, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandlen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePalatis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazenbos, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiroshi Morisaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darwish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyet, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalfin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plise, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strandh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koefoed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wah Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariathasan, S.</span></span> <span> </span><span class="NLM_article-title">Novel antibody–antibiotic conjugate eliminates intracellular S. aureus</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>527</i></span> (<span class="NLM_issue">7578</span>),  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1038/nature16057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnature16057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26536114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOrtLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=527&publication_year=2015&pages=323-328&issue=7578&author=S.+M.+Leharauthor=T.+Pillowauthor=M.+Xuauthor=L.+Stabenauthor=K.+K.+Kajiharaauthor=R.+Vandlenauthor=L.+DePalatisauthor=H.+Raabauthor=W.+L.+Hazenbosauthor=J.+Hiroshi+Morisakiauthor=J.+Kimauthor=S.+Parkauthor=M.+Darwishauthor=B.-C.+Leeauthor=H.+Hernandezauthor=K.+M.+Loyetauthor=P.+Lupardusauthor=R.+Fongauthor=D.+Yanauthor=C.+Chalouniauthor=E.+Luisauthor=Y.+Khalfinauthor=E.+Pliseauthor=J.+Cheongauthor=J.+P.+Lyssikatosauthor=M.+Strandhauthor=K.+Koefoedauthor=P.+S.+Andersenauthor=J.+A.+Flygareauthor=M.+Wah+Tanauthor=E.+J.+Brownauthor=S.+Mariathasan&title=Novel+antibody%E2%80%93antibiotic+conjugate+eliminates+intracellular+S.+aureus&doi=10.1038%2Fnature16057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Novel antibody-antibiotic conjugate eliminates intracellular S. aureus</span></div><div class="casAuthors">Lehar, Sophie M.; Pillow, Thomas; Xu, Min; Staben, Leanna; Kajihara, Kimberly K.; Vandlen, Richard; De Palatis, Laura; Raab, Helga; Hazenbos, Wouter L.; Hiroshi Morisaki, J.; Kim, Janice; Park, Summer; Darwish, Martine; Lee, Byoung-Chul; Hernandez, Hilda; Loyet, Kelly M.; Lupardus, Patrick; Fong, Rina; Yan, Donghong; Chalouni, Cecile; Luis, Elizabeth; Khalfin, Yana; Plise, Emile; Cheong, Jonathan; Lyssikatos, Joseph P.; Strandh, Magnus; Koefoed, Klaus; Andersen, Peter S.; Flygare, John A.; Tan, Man Wah; Brown, Eric J.; Mariathasan, Sanjeev</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">527</span>
        (<span class="NLM_cas:issue">7578</span>),
    <span class="NLM_cas:pages">323-328</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Staphylococcus aureus is considered to be an extracellular pathogen.  However, survival of S. aureus within host cells may provide a reservoir relatively protected from antibiotics, thus enabling long-term colonization of the host and explaining clin. failures and relapses after antibiotic therapy.  Here we confirm that intracellular reservoirs of S. aureus in mice comprise a virulent subset of bacteria that can establish infection even in the presence of vancomycin, and we introduce a novel therapeutic that effectively kills intracellular S. aureus.  This antibody-antibiotic conjugate consists of an anti-S. aureus antibody conjugated to a highly efficacious antibiotic that is activated only after it is released in the proteolytic environment of the phagolysosome.  The antibody-antibiotic conjugate is superior to vancomycin for treatment of bacteremia and provides direct evidence that intracellular S. aureus represents an important component of invasive infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9cwgfxu2hErVg90H21EOLACvtfcHk0libyGdBPOmDiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOrtLfP&md5=09cc42906a456aaa772530d69c36aa50</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnature16057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16057%26sid%3Dliteratum%253Aachs%26aulast%3DLehar%26aufirst%3DS.%2BM.%26aulast%3DPillow%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DStaben%26aufirst%3DL.%26aulast%3DKajihara%26aufirst%3DK.%2BK.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DDePalatis%26aufirst%3DL.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DHazenbos%26aufirst%3DW.%2BL.%26aulast%3DHiroshi%2BMorisaki%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DDarwish%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DB.-C.%26aulast%3DHernandez%26aufirst%3DH.%26aulast%3DLoyet%26aufirst%3DK.%2BM.%26aulast%3DLupardus%26aufirst%3DP.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DLuis%26aufirst%3DE.%26aulast%3DKhalfin%26aufirst%3DY.%26aulast%3DPlise%26aufirst%3DE.%26aulast%3DCheong%26aufirst%3DJ.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26aulast%3DStrandh%26aufirst%3DM.%26aulast%3DKoefoed%26aufirst%3DK.%26aulast%3DAndersen%26aufirst%3DP.%2BS.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DWah%2BTan%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DE.%2BJ.%26aulast%3DMariathasan%26aufirst%3DS.%26atitle%3DNovel%2520antibody%25E2%2580%2593antibiotic%2520conjugate%2520eliminates%2520intracellular%2520S.%2520aureus%26jtitle%3DNature%26date%3D2015%26volume%3D527%26issue%3D7578%26spage%3D323%26epage%3D328%26doi%3D10.1038%2Fnature16057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weglarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampton, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollong, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambaldo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. S.</span></span> <span> </span><span class="NLM_article-title">Targeted delivery of an anti-inflammatory PDE4 inhibitor to immune cells via an antibody–drug conjugate</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2078</span>– <span class="NLM_lpage">2089</span>, <span class="refDoi"> DOI: 10.1038/mt.2016.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fmt.2016.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=27731313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKgtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2078-2089&issue=12&author=S.+Yuauthor=A.+D.+Pearsonauthor=R.+K.+V.+Limauthor=D.+T.+Rodgersauthor=S.+Liauthor=H.+B.+Parkerauthor=M.+Weglarzauthor=E.+N.+Hamptonauthor=M.+J.+Bollongauthor=J.+Shenauthor=C.+Zambaldoauthor=D.+Wangauthor=A.+K.+Woodsauthor=T.+M.+Wrightauthor=P.+G.+Schultzauthor=S.+A.+Kazaneauthor=T.+S.+Youngauthor=M.+S.+Tremblay&title=Targeted+delivery+of+an+anti-inflammatory+PDE4+inhibitor+to+immune+cells+via+an+antibody%E2%80%93drug+conjugate&doi=10.1038%2Fmt.2016.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate</span></div><div class="casAuthors">Yu, Shan; Pearson, Aaron D.; Lim, Reyna K. V.; Rodgers, David T.; Li, Sijia; Parker, Holly B.; Weglarz, Meredith; Hampton, Eric N.; Bollong, Michael J.; Shen, Jiayin; Zambaldo, Claudio; Wang, Danling; Woods, Ashley K.; Wright, Timothy M.; Schultz, Peter G.; Kazane, Stephanie A.; Young, Travis S.; Tremblay, Matthew S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2078-2089</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4) inhibitors are approved for the treatment of some moderate to severe inflammatory conditions.  However, dose-limiting side effects in the central nervous system and gastrointestinal tract, including nausea, emesis, headache, and diarrhea, have impeded the broader therapeutic application of PDE4 inhibitors.  We sought to exploit the wealth of validation surrounding PDE4 inhibition by improving the therapeutic index through generation of an antibody-drug conjugate (ADC) that selectively targets immune cells through the CD11a antigen.  The resulting ADC consisted of a human αCD11a antibody (based on efalizumab clone hu1124) conjugated to an analog of the highly potent PDE4 inhibitor GSK256066.  Both the human αCD11a ADC and a mouse surrogate αCD11a ADC (based on the M17 clone) rapidly internalized into immune cells and suppressed lipopolysaccharide (LPS)-induced TNFα secretion in primary human monocytes and mouse peritoneal cells, resp.  In a carrageenan-induced air pouch inflammation mouse model, treatment with the ADC significantly reduced inflammatory cytokine prodn. in the air pouch exudate.  Overall, these results provide compelling evidence for the feasibility of delivering drugs with anti-inflammatory activity selectively to the immune compartment via CD11a and the development of tissue-targeted PDE4 inhibitors as a promising therapeutic modality for treating inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTURNcWDw-37Vg90H21EOLACvtfcHk0libyGdBPOmDiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKgtL7I&md5=82964396c796f6cfda7cf938e55bcc72</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fmt.2016.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2016.175%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DS.%26aulast%3DPearson%26aufirst%3DA.%2BD.%26aulast%3DLim%26aufirst%3DR.%2BK.%2BV.%26aulast%3DRodgers%26aufirst%3DD.%2BT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DH.%2BB.%26aulast%3DWeglarz%26aufirst%3DM.%26aulast%3DHampton%26aufirst%3DE.%2BN.%26aulast%3DBollong%26aufirst%3DM.%2BJ.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZambaldo%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DA.%2BK.%26aulast%3DWright%26aufirst%3DT.%2BM.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DKazane%26aufirst%3DS.%2BA.%26aulast%3DYoung%26aufirst%3DT.%2BS.%26aulast%3DTremblay%26aufirst%3DM.%2BS.%26atitle%3DTargeted%2520delivery%2520of%2520an%2520anti-inflammatory%2520PDE4%2520inhibitor%2520to%2520immune%2520cells%2520via%2520an%2520antibody%25E2%2580%2593drug%2520conjugate%26jtitle%3DMol.%2520Ther.%26date%3D2016%26volume%3D24%26issue%3D12%26spage%3D2078%26epage%3D2089%26doi%3D10.1038%2Fmt.2016.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazane, S. A.</span></span> <span> </span><span class="NLM_article-title">Targeted delivery of LXR agonist using a site-specific antibody–drug conjugate</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2216</span>– <span class="NLM_lpage">2222</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.5b00203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.5b00203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslGhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2216-2222&issue=11&author=R.+K.+V.+Limauthor=S.+Yuauthor=B.+Chengauthor=S.+Liauthor=N.-J.+Kimauthor=Y.+Caoauthor=V.+Chiauthor=J.+Y.+Kimauthor=A.+K.+Chatterjeeauthor=P.+G.+Schultzauthor=M.+S.+Tremblayauthor=S.+A.+Kazane&title=Targeted+delivery+of+LXR+agonist+using+a+site-specific+antibody%E2%80%93drug+conjugate&doi=10.1021%2Facs.bioconjchem.5b00203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted delivery of LXR agonist using a site-specific antibody-drug conjugate</span></div><div class="casAuthors">Lim, Reyna K. V.; Yu, Shan; Cheng, Bo; Li, Sijia; Kim, Nam-Jung; Cao, Yu; Chi, Victor; Kim, Ji Young; Chatterjee, Arnab K.; Schultz, Peter G.; Tremblay, Matthew S.; Kazane, Stephanie A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2216-2222</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Liver X receptor (LXR) agonists have been explored as potential treatments for atherosclerosis and other diseases based on their ability to induce reverse cholesterol transport and suppress inflammation.  However, this therapeutic potential has been hindered by on-target adverse effects in the liver mediated by excessive lipogenesis.  Herein, we report a novel site-specific antibody-drug conjugate (ADC) that selectively delivers a LXR agonist to monocytes/macrophages while sparing hepatocytes.  The unnatural amino acid para-acetylphenylalanine (pAcF) was site-specifically incorporated into anti-CD11a IgG, which binds the α-chain component of the lymphocyte function-assocd. antigen 1 (LFA-1) expressed on nearly all monocytes and macrophages.  An aminooxy-modified LXR agonist was conjugated to anti-CD11a IgG through a stable, cathepsin B cleavable oxime linkage to afford a chem. defined ADC.  The anti-CD11a IgG-LXR agonist ADC induced LXR activation specifically in human THP-1 monocyte/macrophage cells in vitro (EC50-27 nM), but had no significant effect in hepatocytes, indicating that payload delivery is CD11a-mediated.  Moreover, the ADC exhibited higher-fold activation compared to a conventional synthetic LXR agonist T0901317 (Tularik) (3-fold).  This novel ADC represents a fundamentally different strategy that uses tissue targeting to overcome the limitations of LXR agonists for potential use in treating atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFsgPuuioq9LVg90H21EOLACvtfcHk0libyGdBPOmDiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslGhurw%253D&md5=970224ffc9f452632dae3b8b2a2224e6</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.5b00203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.5b00203%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DR.%2BK.%2BV.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DN.-J.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DChi%26aufirst%3DV.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DTremblay%26aufirst%3DM.%2BS.%26aulast%3DKazane%26aufirst%3DS.%2BA.%26atitle%3DTargeted%2520delivery%2520of%2520LXR%2520agonist%2520using%2520a%2520site-specific%2520antibody%25E2%2580%2593drug%2520conjugate%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26issue%3D11%26spage%3D2216%26epage%3D2222%26doi%3D10.1021%2Facs.bioconjchem.5b00203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueberberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schechinger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinturk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, S.</span></span> <span> </span><span class="NLM_article-title">In vitro phage display in a rat β-cell line: a simple approach for the generation of a single-chain antibody targeting a novel β-cell-specific epitope</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1384</span>– <span class="NLM_lpage">1394</span>, <span class="refDoi"> DOI: 10.1007/s00125-010-1725-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1007%2Fs00125-010-1725-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=20369222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsFyrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1384-1394&issue=7&author=S.+Ueberbergauthor=D.+Zieglerauthor=W.+Schechingerauthor=J.+W.+Dietrichauthor=S.+Akinturkauthor=H.+H.+Kleinauthor=S.+Schneider&title=In+vitro+phage+display+in+a+rat+%CE%B2-cell+line%3A+a+simple+approach+for+the+generation+of+a+single-chain+antibody+targeting+a+novel+%CE%B2-cell-specific+epitope&doi=10.1007%2Fs00125-010-1725-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro phage display in a rat beta cell line: a simple approach for the generation of a single-chain antibody targeting a novel beta cell-specific epitope</span></div><div class="casAuthors">Ueberberg, S.; Ziegler, D.; Schechinger, W.; Dietrich, J. W.; Akinturk, S.; Klein, H. H.; Schneider, S.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1384-1394</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aims/hypothesis: The aim of the present study was to evaluate in vitro phage display in a beta cell line as a novel strategy for the isolation of beta cell-specific agents/biomarkers.  Methods: A single-chain antibody (SCA) library was pre-incubated with AR42J cells in order to eliminate SCAs with exocrine binding properties.  It was then panned against INS-1 cells to select beta cell-targeted antibodies.  Results: By these means, we isolated a novel antibody, SCA B5, that binds rapidly (6.0 min) and with a 450-fold higher specificity to beta cells relative to exocrine cells.  We estd. for SCA B5 a binding affinity in the low μmol/l range and 858 binding sites per beta cell.  Confocal microscopy showed binding to the beta cell surface and confirmed subsequent internalization.  Moreover, staining of rat and human pancreatic tissue sections with SCA B5 suggests that the target epitope is presented in pancreatic beta cells of different origins.  IR imaging revealed that labeling of beta cells with tracer SCA B5 is strictly dependent on beta cell mass.  With competition assays we excluded insulin, glutamate decarboxylase, C-peptide and islet amyloid polypeptide as SCA B5 targets.  In accordance with these predictions, SCA B5 homed in vivo highly selectively to normal beta cells and dysfunctional beta cells of diabetic rats.  Moreover, accumulation of radioactively labeled SCA B5 in the pancreas was reduced by 80% after pre-injection with unlabeled SCA B5, thereby confirming the specific uptake in the pancreas.  Conclusions/interpretation: We report a simple strategy for the generation of an SCA targeting a novel beta cell-specific epitope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxUWVKlwj24bVg90H21EOLACvtfcHk0lhMkdDAFx4qhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsFyrsrs%253D&md5=4a0a2cc022760d948184e88a5c375805</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2Fs00125-010-1725-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-010-1725-9%26sid%3Dliteratum%253Aachs%26aulast%3DUeberberg%26aufirst%3DS.%26aulast%3DZiegler%26aufirst%3DD.%26aulast%3DSchechinger%26aufirst%3DW.%26aulast%3DDietrich%26aufirst%3DJ.%2BW.%26aulast%3DAkinturk%26aufirst%3DS.%26aulast%3DKlein%26aufirst%3DH.%2BH.%26aulast%3DSchneider%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520phage%2520display%2520in%2520a%2520rat%2520%25CE%25B2-cell%2520line%253A%2520a%2520simple%2520approach%2520for%2520the%2520generation%2520of%2520a%2520single-chain%2520antibody%2520targeting%2520a%2520novel%2520%25CE%25B2-cell-specific%2520epitope%26jtitle%3DDiabetologia%26date%3D2010%26volume%3D53%26issue%3D7%26spage%3D1384%26epage%3D1394%26doi%3D10.1007%2Fs00125-010-1725-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khvorova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J. K.</span></span> <span> </span><span class="NLM_article-title">The chemical evolution of oligonucleotide therapies of clinical utility</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1038/nbt.3765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnbt.3765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=28244990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlalurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=238-248&issue=3&author=A.+Khvorovaauthor=J.+K.+Watts&title=The+chemical+evolution+of+oligonucleotide+therapies+of+clinical+utility&doi=10.1038%2Fnbt.3765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The chemical evolution of oligonucleotide therapies of clinical utility</span></div><div class="casAuthors">Khvorova, Anastasia; Watts, Jonathan K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">238-248</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">After nearly 40 years of development, oligonucleotide therapeutics are nearing meaningful clin. productivity.  One of the key advantages of oligonucleotide drugs is that their delivery and potency are derived primarily from the chem. structure of the oligonucleotide whereas their target is defined by the base sequence.  Thus, as oligonucleotides with a particular chem. design show appropriate distribution and safety profiles for clin. gene silencing in a particular tissue, this will open the door to the rapid development of addnl. drugs targeting other disease-assocd. genes in the same tissue.  To achieve clin. productivity, the chem. architecture of the oligonucleotide needs to be optimized with a combination of sugar, backbone, nucleobase, and 3'- and 5'-terminal modifications.  A portfolio of chemistries can be used to confer drug-like properties onto the oligonucleotide as a whole, with minor chem. changes often translating into major improvements in clin. efficacy.  One outstanding challenge in oligonucleotide chem. development is the optimization of chem. architectures to ensure long-term safety.  There are multiple designs that enable effective targeting of the liver, but a second challenge is to develop architectures that enable robust clin. efficacy in addnl. tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhUFUW0teh-rVg90H21EOLACvtfcHk0lhMkdDAFx4qhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlalurc%253D&md5=d6c3f3ec136632eee79a63fc0be0bbfc</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fnbt.3765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.3765%26sid%3Dliteratum%253Aachs%26aulast%3DKhvorova%26aufirst%3DA.%26aulast%3DWatts%26aufirst%3DJ.%2BK.%26atitle%3DThe%2520chemical%2520evolution%2520of%2520oligonucleotide%2520therapies%2520of%2520clinical%2520utility%26jtitle%3DNat.%2520Biotechnol.%26date%3D2017%26volume%3D35%26issue%3D3%26spage%3D238%26epage%3D248%26doi%3D10.1038%2Fnbt.3765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jabs, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, P. D.</span></span> <span> </span><span class="NLM_article-title">Fomivirsen for the treatment of cytomegalovirus retinitis11Internet Advance publication at ajo.com Feb 8, 2002</span>. <i>Am. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>133</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1016/S0002-9394(02)01325-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2FS0002-9394%2802%2901325-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=11931791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD38XisV2rtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2002&pages=552-556&issue=4&author=D.+A.+Jabsauthor=P.+D.+Griffiths&title=Fomivirsen+for+the+treatment+of+cytomegalovirus+retinitis11Internet+Advance+publication+at+ajo.com+Feb+8%2C+2002&doi=10.1016%2FS0002-9394%2802%2901325-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Fomivirsen for the treatment of cytomegalovirus retinitis</span></div><div class="casAuthors">Jabs, Douglas A.; Griffiths, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Ophthalmology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">552-556</span>CODEN:
                <span class="NLM_cas:coden">AJOPAA</span>;
        ISSN:<span class="NLM_cas:issn">0002-9394</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The authors provide an editorial describing articles found in this publication on dose comparison trials for induction and maintenance fomivirsen therapy in humans with small peripheral cytomegalovirus retinitis lesions, two treatment regimens for humans with relapsed retinitis, and safety profile and adverse effects among humans treated with fomivirsen for cytomegalovirus retinitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorMucTWqlXYrVg90H21EOLACvtfcHk0lhMkdDAFx4qhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisV2rtLk%253D&md5=b4158cc7d5a9bfb041964c9599ee0e02</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0002-9394%2802%2901325-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9394%252802%252901325-9%26sid%3Dliteratum%253Aachs%26aulast%3DJabs%26aufirst%3DD.%2BA.%26aulast%3DGriffiths%26aufirst%3DP.%2BD.%26atitle%3DFomivirsen%2520for%2520the%2520treatment%2520of%2520cytomegalovirus%2520retinitis11Internet%2520Advance%2520publication%2520at%2520ajo.com%2520Feb%25208%252C%25202002%26jtitle%3DAm.%2520J.%2520Ophthalmol.%26date%3D2002%26volume%3D133%26issue%3D4%26spage%3D552%26epage%3D556%26doi%3D10.1016%2FS0002-9394%2802%2901325-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanotto, D.</span></span> <span> </span><span class="NLM_article-title">FDA-approved aligonucleotide therapies in 2017</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1075</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2017.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.ymthe.2017.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=28366767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFeltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1069-1075&issue=5&author=C.+A.+Steinauthor=D.+Castanotto&title=FDA-approved+aligonucleotide+therapies+in+2017&doi=10.1016%2Fj.ymthe.2017.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-Approved Oligonucleotide Therapies in 2017</span></div><div class="casAuthors">Stein, Cy A.; Castanotto, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1069-1075</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oligonucleotides (oligos) have been under clin. development for approx. the past 30 years, beginning with antisense oligonucleotides (ASOs) and apatmers and followed about 15 years ago by siRNAs.  During that lengthy period of time, numerous clin. trials have been performed and thousands of trial participants accrued onto studies.  Of all the mols. evaluated as of Jan. 2017, the regulatory authorities assessed that six provided clear clin. benefit in rigorously controlled trials.  The story of these six is given in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNtVeb7iVOxrVg90H21EOLACvtfcHk0lgN32cMSdYPpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFeltLs%253D&md5=d9f556e813d1070c6af77b34fe051fd2</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2017.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2017.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DC.%2BA.%26aulast%3DCastanotto%26aufirst%3DD.%26atitle%3DFDA-approved%2520aligonucleotide%2520therapies%2520in%25202017%26jtitle%3DMol.%2520Ther.%26date%3D2017%26volume%3D25%26issue%3D5%26spage%3D1069%26epage%3D1075%26doi%3D10.1016%2Fj.ymthe.2017.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riches, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kernan, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochstein, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mineishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Termuhlen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemecek, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giralt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champlin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajwa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Agostino, R. B.,  Sr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massaro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miloslavsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hume, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejadnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannah, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soiffer, R. J.</span></span> <span> </span><span class="NLM_article-title">Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1656</span>– <span class="NLM_lpage">1665</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-10-676924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1182%2Fblood-2015-10-676924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26825712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ehurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=1656-1665&issue=13&author=P.+G.+Richardsonauthor=M.+L.+Richesauthor=N.+A.+Kernanauthor=J.+A.+Brochsteinauthor=S.+Mineishiauthor=A.+M.+Termuhlenauthor=S.+Araiauthor=S.+A.+Gruppauthor=E.+C.+Guinanauthor=P.+L.+Martinauthor=G.+Steinbachauthor=A.+Krishnanauthor=E.+R.+Nemecekauthor=S.+Giraltauthor=T.+Rodriguezauthor=R.+Duerstauthor=J.+Doyleauthor=J.+H.+Antinauthor=A.+Smithauthor=L.+Lehmannauthor=R.+Champlinauthor=A.+Gillioauthor=R.+Bajwaauthor=R.+B.+D%E2%80%99Agostinoauthor=J.+Massaroauthor=D.+Warrenauthor=M.+Miloslavskyauthor=R.+L.+Humeauthor=M.+Iacobelliauthor=B.+Nejadnikauthor=A.+L.+Hannahauthor=R.+J.+Soiffer&title=Phase+3+trial+of+defibrotide+for+the+treatment+of+severe+veno-occlusive+disease+and+multi-organ+failure&doi=10.1182%2Fblood-2015-10-676924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure</span></div><div class="casAuthors">Richardson, Paul G.; Riches, Marcie L.; Kernan, Nancy A.; Brochstein, Joel A.; Mineishi, Shin; Termuhlen, Amanda M.; Arai, Sally; Grupp, Stephan A.; Guinan, Eva C.; Martin, Paul L.; Steinbach, Gideon; Krishnan, Amrita; Nemecek, Eneida R.; Giralt, Sergio; Rodriguez, Tulio; Duerst, Reggie; Doyle, John; Antin, Joseph H.; Smith, Angela; Lehmann, Leslie; Champlin, Richard; Gillio, Alfred; Bajwa, Rajinder; Sr, Ralph B. D'Agostino; Massaro, Joseph; Warren, Diane; Miloslavsky, Maja; Hume, Robin L.; Iacobelli, Massimo; Nejadnik, Bijan; Hannah, Alison L.; Soiffer, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1656-1665</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Hepatic veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome (SOS), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT).  Untreated hepatic VOD/SOS with multi-organ failure (MOF) is assocd. with >80% mortality.  Defibrotide has shown promising efficacy treating hepatic VOD/SOS with MOF in phase 2 studies.  This phase 3 study investigated safety and efficacy of defibrotide in patients with established hepatic VOD/SOS and advanced MOF.  Patients (n 5 102) given defibrotide 25 mg/kg per day were compared with 32 historical controls identified out of 6867 medical charts of HSCT patients by blinded independent reviewers.  Baseline characteristics between groups were well balanced.  The primary endpoint was survival at day + 100 post-HSCT; obsd. rates equaled 38.2% in the defibrotide group and 25% in the controls (23% estd. difference; 95.1% confidence interval [CI], 5.2-40.8; P = .0109, using a propensity adjusted anal.).  Obsd. day 1100 complete response (CR) rates equaled 25.5% for defibrotide and 12.5% for controls (19% difference using similar methodol.; 95.1% CI, 3.5-34.6; P = .0160).  Defibrotide was generally well tolerated with manageable toxicity.  Related adverse events (AEs) included hemorrhage or hypotension; incidence of common hemorrhagic AEs (including pulmonary alveolar [11.8% and 15.6%] and gastrointestinal bleeding [7.8%and 9.4%])was similar between the defibrotide and control groups, resp.  Defibrotide was assocd. with significant improvement in day +100 survival and CR rate.  The historical-control methodol. offers a novel, meaningful approach for phase 3 evaluation of orphan diseases assocd. with high mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWcb9S-yNTwrVg90H21EOLACvtfcHk0lgN32cMSdYPpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ehurrN&md5=59b5053e3cc6a6f48253080485aa56c7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-10-676924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-10-676924%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DRiches%26aufirst%3DM.%2BL.%26aulast%3DKernan%26aufirst%3DN.%2BA.%26aulast%3DBrochstein%26aufirst%3DJ.%2BA.%26aulast%3DMineishi%26aufirst%3DS.%26aulast%3DTermuhlen%26aufirst%3DA.%2BM.%26aulast%3DArai%26aufirst%3DS.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26aulast%3DGuinan%26aufirst%3DE.%2BC.%26aulast%3DMartin%26aufirst%3DP.%2BL.%26aulast%3DSteinbach%26aufirst%3DG.%26aulast%3DKrishnan%26aufirst%3DA.%26aulast%3DNemecek%26aufirst%3DE.%2BR.%26aulast%3DGiralt%26aufirst%3DS.%26aulast%3DRodriguez%26aufirst%3DT.%26aulast%3DDuerst%26aufirst%3DR.%26aulast%3DDoyle%26aufirst%3DJ.%26aulast%3DAntin%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DLehmann%26aufirst%3DL.%26aulast%3DChamplin%26aufirst%3DR.%26aulast%3DGillio%26aufirst%3DA.%26aulast%3DBajwa%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Agostino%26aufirst%3DR.%2BB.%26aulast%3DMassaro%26aufirst%3DJ.%26aulast%3DWarren%26aufirst%3DD.%26aulast%3DMiloslavsky%26aufirst%3DM.%26aulast%3DHume%26aufirst%3DR.%2BL.%26aulast%3DIacobelli%26aufirst%3DM.%26aulast%3DNejadnik%26aufirst%3DB.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DSoiffer%26aufirst%3DR.%2BJ.%26atitle%3DPhase%25203%2520trial%2520of%2520defibrotide%2520for%2520the%2520treatment%2520of%2520severe%2520veno-occlusive%2520disease%2520and%2520multi-organ%2520failure%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26issue%3D13%26spage%3D1656%26epage%3D1665%26doi%3D10.1182%2Fblood-2015-10-676924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, D. R.</span></span> <span> </span><span class="NLM_article-title">Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1584</span>– <span class="NLM_lpage">1600</span>, <span class="refDoi"> DOI: 10.1093/nar/gkx1239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1093%2Fnar%2Fgkx1239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=29240946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGisb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1584-1600&issue=4&author=X.+Shenauthor=D.+R.+Corey&title=Chemistry%2C+mechanism+and+clinical+status+of+antisense+oligonucleotides+and+duplex+RNAs&doi=10.1093%2Fnar%2Fgkx1239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs</span></div><div class="casAuthors">Shen, Xiulong; Corey, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1584-1600</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  RNA plays a central role in the expression of all genes.  Because any sequence within RNA can be recognized by complementary base pairing, synthetic oligonucleotides and oligonucleotide mimics offer a general strategy for controlling processes that affect disease.  The two primary antisense approaches for regulating expression through recognition of cellular RNAs are single-stranded antisense oligonucleotides and duplex RNAs.  This review will discuss the chem. modifications and mol. mechanisms that make synthetic nucleic acid drugs possible.  Lessons learned from recent clin. trials will be summarized.  Ongoing clin. trials are likely to decisively test the adequacy of our current generation of antisense nucleic acid technologies and highlight areas where more basic research is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHfDaQwcmtD7Vg90H21EOLACvtfcHk0lgN32cMSdYPpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGisb7F&md5=b5bdec984635f12162386b6f8a6f6fe0</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx1239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx1239%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DX.%26aulast%3DCorey%26aufirst%3DD.%2BR.%26atitle%3DChemistry%252C%2520mechanism%2520and%2520clinical%2520status%2520of%2520antisense%2520oligonucleotides%2520and%2520duplex%2520RNAs%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2018%26volume%3D46%26issue%3D4%26spage%3D1584%26epage%3D1600%26doi%3D10.1093%2Fnar%2Fgkx1239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geary, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2015.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.addr.2015.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=25666165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVOqsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=46-51&author=R.+S.+Gearyauthor=D.+Norrisauthor=R.+Yuauthor=C.+F.+Bennett&title=Pharmacokinetics%2C+biodistribution+and+cell+uptake+of+antisense+oligonucleotides&doi=10.1016%2Fj.addr.2015.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides</span></div><div class="casAuthors">Geary, Richard S.; Norris, Daniel; Yu, Rosie; Bennett, C. Frank</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-51</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pharmacokinetic properties of oligonucleotides are largely driven by chem. of the backbone and thus are sequence independent within a chem. class.  Tissue bioavailability (% of administered dose) is assisted by plasma protein binding that limits glomerular filtration and ultimate urinary excretion of oligonucleotides.  The substitution of one non-bridging oxygen with the more hydrophobic sulfur atom (phosphorothioate) increases both plasma stability and plasma protein binding and thus, ultimately, tissue bioavailability.  Addnl. modifications of the sugar at the 2' position, increase RNA binding affinity and significantly increase potency, tissue half-life and prolong RNA inhibitory activity.  Oligonucleotides modified in this manner consistently exhibit the highest tissue bioavailability (> 90%).  Systemic biodistribution is broad, and organs typically with highest concns. are liver and kidney followed by bone marrow, adipocytes, and lymph nodes.  Cell uptake is predominantly mediated by endocytosis.  Both size and charge for most oligonucleotides prevents distribution across the blood brain barrier.  However, modified single-strand oligonucleotides administered by intrathecal injection into the CSF distribute broadly in the CNS.  The majority of intracellular oligonucleotide distribution following systemic or local administration occurs rapidly in just a few hours following administration and is facilitated by rapid endocytotic uptake mechanisms.  Further understanding of the intracellular trafficking of oligonucleotides may provide further enhancements in design and ultimate potency of antisense oligonucleotides in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ2gcLkd_4t7Vg90H21EOLACvtfcHk0lgzesFcMrjZsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVOqsb4%253D&md5=20b700e0b591b2708180f651ff940173</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2015.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2015.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DGeary%26aufirst%3DR.%2BS.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DBennett%26aufirst%3DC.%2BF.%26atitle%3DPharmacokinetics%252C%2520biodistribution%2520and%2520cell%2520uptake%2520of%2520antisense%2520oligonucleotides%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2015%26volume%3D87%26spage%3D46%26epage%3D51%26doi%3D10.1016%2Fj.addr.2015.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Peptide conjugates with small molecules designed to enhance efficacy and safety</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1855</span>, <span class="refDoi"> DOI: 10.3390/molecules24101855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.3390%2Fmolecules24101855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFagtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1855&issue=10&author=R.+Heauthor=B.+Finanauthor=J.+P.+Mayerauthor=R.+D.+DiMarchi&title=Peptide+conjugates+with+small+molecules+designed+to+enhance+efficacy+and+safety&doi=10.3390%2Fmolecules24101855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide conjugates with small molecules designed to enhance efficacy and safety</span></div><div class="casAuthors">He, Rongjun; Finan, Brian; Mayer, John P.; DiMarchi, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1855</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Peptides constitute mol. diversity with unique mol. mechanisms of action that are proven indispensable in the management of many human diseases, but of only a mere fraction relative to more traditional small mol.-based medicines.  The integration of these two therapeutic modalities o ers the potential to enhance and broaden pharmacol. while minimizing dose-dependent toxicol.  This review summarizes numerous advances in drug design, synthesis and development that provide direction for next-generation research endeavors in this field.  Medicinal studies in this area have largely focused upon the application of peptides to selectively enhance small mol. cytotoxicity to more effectively treat multiple oncol. diseases.  To a lesser and steadily emerging extent peptides are being therapeutically employed to complement and diversify the pharmacol. of small mol. drugs in diseases other than just cancer.  No matter the disease, the purpose of the mol. integration remains const. and it is to achieve superior therapeutic outcomes with diminished adverse effects.  We review linker technol. and conjugation chemistries that have enabled integrated and targeted pharmacol. with controlled release.  Finally, we offer our perspective on opportunities and obstacles in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_IMrSi0d7urVg90H21EOLACvtfcHk0lgzesFcMrjZsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFagtb%252FM&md5=da04d398164460a08977abcdcefdc230</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24101855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24101855%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DR.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DMayer%26aufirst%3DJ.%2BP.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DPeptide%2520conjugates%2520with%2520small%2520molecules%2520designed%2520to%2520enhance%2520efficacy%2520and%2520safety%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26issue%3D10%26spage%3D1855%26doi%3D10.3390%2Fmolecules24101855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaway, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, C.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habegger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schriever, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Caceres, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabra, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hembree, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raver, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irmler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabe de Angelis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiano, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauvais-Jarvis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfluger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschoep, M. H.</span></span> <span> </span><span class="NLM_article-title">Targeted estrogen delivery reverses the metabolic syndrome</span>. <i>Nat. Med. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1847</span>– <span class="NLM_lpage">1856</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnm.3009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=23142820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1CktL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1847-1856&issue=12&author=B.+Finanauthor=B.+Yangauthor=N.+Ottawayauthor=K.+Stemmerauthor=T.+D.+Muellerauthor=C.-X.+Yiauthor=K.+Habeggerauthor=S.+C.+Schrieverauthor=C.+Garcia-Caceresauthor=D.+G.+Kabraauthor=J.+Hembreeauthor=J.+Hollandauthor=C.+Raverauthor=R.+J.+Seeleyauthor=W.+Hansauthor=M.+Irmlerauthor=J.+Beckersauthor=M.+Hrabe+de+Angelisauthor=J.+P.+Tianoauthor=F.+Mauvais-Jarvisauthor=D.+Perez-Tilveauthor=P.+Pflugerauthor=L.+Zhangauthor=V.+Gelfanovauthor=R.+D.+DiMarchiauthor=M.+H.+Tschoep&title=Targeted+estrogen+delivery+reverses+the+metabolic+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted estrogen delivery reverses the metabolic syndrome</span></div><div class="casAuthors">Finan, Brian; Yang, Bin; Ottaway, Nickki; Stemmer, Kerstin; Mueller, Timo D.; Yi, Chun-Xia; Habegger, Kirk; Schriever, Sonja C.; Garcia-Caceres, Cristina; Kabra, Dhiraj G.; Hembree, Jazzminn; Holland, Jenna; Raver, Christine; Seeley, Randy J.; Hans, Wolfgang; Irmler, Martin; Beckers, Johannes; Hrabe de Angelis, Martin; Tiano, Joseph P.; Mauvais-Jarvis, Franck; Perez-Tilve, Diego; Pfluger, Paul; Zhang, Lianshan; Gelfanov, Vasily; DiMarchi, Richard D.; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1847-1856</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the development of a new combinatorial approach that allows for peptide-mediated selective tissue targeting of nuclear hormone pharmacol. while eliminating adverse effects in other tissues.  Specifically, we report the development of a glucagon-like peptide-1 (GLP-1)-estrogen conjugate that has superior sex-independent efficacy over either of the individual hormones alone to correct obesity, hyperglycemia and dyslipidemia in mice.  The therapeutic benefits are driven by pleiotropic dual hormone action to improve energy, glucose and lipid metab., as shown by loss-of-function models and genetic action profiling.  Notably, the peptide-based targeting strategy also prevents hallmark side effects of estrogen in male and female mice, such as reproductive endocrine toxicity and oncogenicity.  Collectively, selective activation of estrogen receptors in GLP-1-targeted tissues produces unprecedented efficacy to enhance the metabolic benefits of GLP-1 agonism.  This example of targeting the metabolic syndrome represents the discovery of a new class of therapeutics that enables synergistic co-agonism through peptide-based selective delivery of small mols.  Although our observations with the GLP-1-estrogen conjugate justify translational studies for diabetes and obesity, the multitude of other possible combinations of peptides and small mols. may offer equal promise for other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQGspuH3IemrVg90H21EOLACvtfcHk0lgzesFcMrjZsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1CktL7F&md5=7c080cb982964af88163a9c505d0ee83</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fnm.3009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3009%26sid%3Dliteratum%253Aachs%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DStemmer%26aufirst%3DK.%26aulast%3DMueller%26aufirst%3DT.%2BD.%26aulast%3DYi%26aufirst%3DC.-X.%26aulast%3DHabegger%26aufirst%3DK.%26aulast%3DSchriever%26aufirst%3DS.%2BC.%26aulast%3DGarcia-Caceres%26aufirst%3DC.%26aulast%3DKabra%26aufirst%3DD.%2BG.%26aulast%3DHembree%26aufirst%3DJ.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DRaver%26aufirst%3DC.%26aulast%3DSeeley%26aufirst%3DR.%2BJ.%26aulast%3DHans%26aufirst%3DW.%26aulast%3DIrmler%26aufirst%3DM.%26aulast%3DBeckers%26aufirst%3DJ.%26aulast%3DHrabe%2Bde%2BAngelis%26aufirst%3DM.%26aulast%3DTiano%26aufirst%3DJ.%2BP.%26aulast%3DMauvais-Jarvis%26aufirst%3DF.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DPfluger%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTschoep%26aufirst%3DM.%2BH.%26atitle%3DTargeted%2520estrogen%2520delivery%2520reverses%2520the%2520metabolic%2520syndrome%26jtitle%3DNat.%2520Med.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2012%26volume%3D18%26issue%3D12%26spage%3D1847%26epage%3D1856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Va, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. Y. H.</span></span> <span> </span><span class="NLM_article-title">Pancreas-specific delivery of β-cell proliferating small molecules</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1132</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1002%2Fcmdc.201600116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=27095073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtlSit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1129-1132&issue=11&author=X.+Haoauthor=Q.+Jinauthor=P.+Vaauthor=C.+Liauthor=W.+Shenauthor=B.+Laffitteauthor=T.+Y.+H.+Wu&title=Pancreas-specific+delivery+of+%CE%B2-cell+proliferating+small+molecules&doi=10.1002%2Fcmdc.201600116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Pancreas-Specific Delivery of β-Cell Proliferating Small Molecules</span></div><div class="casAuthors">Hao, Xueshi; Jin, Qihui; Va, Porino; Li, Chun; Shen, Weijun; Laffitte, Bryan; Wu, Tom Y.-H.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1129-1132</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Our research groups recently described a series of small-mol. inducers of β-cell proliferation that could be used to increase β-cell mass.  To mitigate the risk of nonspecific proliferation of other cell types, we devised a delivery strategy built on the tissue specificity obsd. in the exptl. β-cell imaging agent (+)-dihydrotetrabenazine (DTBZ).  The β-cell proliferator agent aminopyrazine (AP) was covalently linked with (+)-DTBZ to afford conjugates that retain both the proliferation activity and binding affinity for vesicular monoamine transporter-2 (VMAT2).  In vivo mouse tissue distribution studies of a prototypical AP-DTBZ conjugate showed 15-fold pancreas exposure over plasma.  Tissue-to-plasma ratios in liver and kidneys were two- and five-fold, resp.  This work is the first demonstration of enhanced delivery of β-cell-proliferating mols. to the pancreas by leveraging the intrinsic tissue specificity of a β-cell imaging agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVn8pxJAObf7Vg90H21EOLACvtfcHk0ljjiZtVdDzMZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtlSit70%253D&md5=ef7f9c60a865d219a57a247a852b400a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600116%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DVa%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%2BY.%2BH.%26atitle%3DPancreas-specific%2520delivery%2520of%2520%25CE%25B2-cell%2520proliferating%2520small%2520molecules%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D11%26spage%3D1129%26epage%3D1132%26doi%3D10.1002%2Fcmdc.201600116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. V.</span></span> <span> </span><span class="NLM_article-title">Zinc and insulin in pancreatic beta-cells</span>. <i>Endocrine</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1007/s12020-013-0032-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1007%2Fs12020-013-0032-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=23979673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlansrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2014&pages=178-189&issue=2&author=Y.+V.+Li&title=Zinc+and+insulin+in+pancreatic+beta-cells&doi=10.1007%2Fs12020-013-0032-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc and insulin in pancreatic beta-cells</span></div><div class="casAuthors">Li, Yang V.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">EOCRE5</span>;
        ISSN:<span class="NLM_cas:issn">1355-008X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Zinc (Zn2+) is an essential element crucial for growth and development, and also plays a role in cell signaling for cellular processes like cell division and apoptosis.  In the mammalian pancreas, Zn2+ is essential for the correct processing, storage, secretion, and action of insulin in beta (β)-cells.  Insulin is stored inside secretory vesicles or granules, where two Zn2+ ions coordinate six insulin monomers to form the hexameric-structure on which maturated insulin crystals are based.  The total Zn2+ content of the mammalian pancreas is among the highest in the body, and Zn2+ concn. reach millimolar levels in the interior of the dense-core granule.  Changes in Zn2+ levels in the pancreas have been found to be assocd. with diabetes.  Hence, the relationship between co-stored Zn2+ and insulin undoubtedly is crit. to normal β-cell function.  The advances in the field of Zn2+ biol. over the last decade have facilitated our understanding of Zn2+ trafficking, its intracellular distribution and its storage.  When exocytosis of insulin occurs, insulin granules fuse with the β-cell plasma membrane and release their contents, i.e., insulin as well as substantial amt. of free Zn2+, into the extracellular space and the local circulation.  Studies increasingly indicate that secreted Zn2+ has autocrine or paracrine signaling in β-cells or the neighboring cells.  This review discusses the Zn2+ homeostasis in β-cells with emphasis on the potential signaling role of Zn2+ to islet biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXit9l5NHEXrVg90H21EOLACvtfcHk0ljjiZtVdDzMZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlansrrJ&md5=eeef17ab5ae5a1ed01ca3e27aa5d64c6</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2Fs12020-013-0032-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12020-013-0032-x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BV.%26atitle%3DZinc%2520and%2520insulin%2520in%2520pancreatic%2520beta-cells%26jtitle%3DEndocrine%26date%3D2014%26volume%3D45%26issue%3D2%26spage%3D178%26epage%3D189%26doi%3D10.1007%2Fs12020-013-0032-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A. E.</span></span> <span> </span><span class="NLM_article-title">Techniques for measuring cellular zinc</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>611</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2016.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.abb.2016.08.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=27580940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOqurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=611&publication_year=2016&pages=20-29&author=M.+C.+Carpenterauthor=M.+N.+Loauthor=A.+E.+Palmer&title=Techniques+for+measuring+cellular+zinc&doi=10.1016%2Fj.abb.2016.08.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Techniques for measuring cellular zinc</span></div><div class="casAuthors">Carpenter, Margaret C.; Lo, Maria N.; Palmer, Amy E.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">611</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-29</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development and improvement of fluorescent Zn2+ sensors and Zn2+ imaging techniques have increased our insight into this biol. important ion.  Application of these tools has identified an intracellular labile Zn2+ pool and cultivated further interest in defining the distribution and dynamics of labile Zn2+.  The study of Zn2+ in live cells in real time using sensors is a powerful way to answer complex biol. questions.  In this review, we highlight newly engineered Zn2+ sensors, methods to test whether the sensors are accessing labile Zn2+, and recent studies that point to the challenges of using such sensors.  Elemental mapping techniques can complement and strengthen data collected with sensors.  Both mass spectrometry-based and X-ray fluorescence-based techniques yield highly specific, sensitive, and spatially resolved snapshots of metal distribution in cells.  The study of Zn2+ has already led to new insight into all phases of life from fertilization of the egg to life-threatening cancers.  In order to continue building new knowledge about Zn2+ biol. it remains important to critically assess the available toolset for this endeavor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS3pvhyccECrVg90H21EOLACvtfcHk0ljjiZtVdDzMZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOqurfJ&md5=e0c83d48f35e627a03888a23d4c11fd5</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2016.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2016.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DM.%2BC.%26aulast%3DLo%26aufirst%3DM.%2BN.%26aulast%3DPalmer%26aufirst%3DA.%2BE.%26atitle%3DTechniques%2520for%2520measuring%2520cellular%2520zinc%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2016%26volume%3D611%26spage%3D20%26epage%3D29%26doi%3D10.1016%2Fj.abb.2016.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNary, W. F.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Zinc-dithizone reaction of pancreatic islets</span>. <i>J. Histochem. Cytochem.</i> <span class="NLM_year" style="font-weight: bold;">1954</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1177/2.3.185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1177%2F2.3.185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=13163393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADyaG2cXnvVSrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1954&pages=185-193&author=W.+F.+McNary&title=Zinc-dithizone+reaction+of+pancreatic+islets&doi=10.1177%2F2.3.185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc-dithizone reaction of pancreatic islets</span></div><div class="casAuthors">McNary, Wm. F., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">1954</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">185-93</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    </div><div class="casAbstract">Zinc was demonstrated by means of the Okamoto diphenylthiocarbazone technique in the pancreas islet cells of the rabbit, rat, dog, mouse, monkey, and human, but not in the guinea pig.  Diffusion is a source of error owing to the soly. of the zinc-contg. cellular materials in the solvents of the Okamoto technique.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo27ZUBFXLXm7Vg90H21EOLACvtfcHk0ljjiZtVdDzMZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG2cXnvVSrtA%253D%253D&md5=54e554b2b6bc529f60a2542f9dbb5e8d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1177%2F2.3.185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2.3.185%26sid%3Dliteratum%253Aachs%26aulast%3DMcNary%26aufirst%3DW.%2BF.%26atitle%3DZinc-dithizone%2520reaction%2520of%2520pancreatic%2520islets%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D1954%26volume%3D2%26spage%3D185%26epage%3D193%26doi%3D10.1177%2F2.3.185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gee, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, R.</span></span> <span> </span><span class="NLM_article-title">Detection and imaging of zinc secretion from pancreatic β-cells using a new fluorescent zinc indicator</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">778</span>, <span class="refDoi"> DOI: 10.1021/ja011774y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja011774y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1Sisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=776-778&issue=5&author=K.+R.+Geeauthor=Z.-L.+Zhouauthor=W.-J.+Qianauthor=R.+Kennedy&title=Detection+and+imaging+of+zinc+secretion+from+pancreatic+%CE%B2-cells+using+a+new+fluorescent+zinc+indicator&doi=10.1021%2Fja011774y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Detection and imaging of zinc secretion from pancreatic β-cells using a new fluorescent zinc indicator</span></div><div class="casAuthors">Gee, Kyle R.; Zhou, Zhang-Lin; Qian, Wei-Jun; Kennedy, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">776-778</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel Zn2+-selective visible wavelength fluoroionophore (FluoZin-3, 9) was synthesized.  The chelating portion of the mol. resembles known EGTA-based Ca2+-selective fluoroionophores, except that one of the N-acetic acid moieties has been deleted in 9. FluoZin-3 is virtually non-fluorescent in the absence of Zn2+, and exhibits a several hundred-fold fluorescence increase upon satn. with Zn2+(~100 nM), with a Kd = 15±2 nM.  A 1:1 binding stoichiometry of 9:Zn2+ was detd., and the fluorescence of the complex is pH-independent at pH > 6. FluoZin-3 was used to monitor Zn2+ that was co-secreted with insulin from pancreatic β-cells by exocytosis following stimulation with glucose.  The total Zn2+ concn. near the cells reached 600 nM, and Zn2+ was detectable at least 15 μm away from secreting cells.  Heterogeneity in secretion among cells was indicated in that some cells in a cluster did not release Zn2+.  Also, within secreting cells some regions of the cell membrane gave rise to secretion while others did not, suggesting active zones of secretion on the cell surface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5rRMroNlviLVg90H21EOLACvtfcHk0lgcg8i_BbXVuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1Sisw%253D%253D&md5=3c23d26c7f3545a4dbf872d165b63ec3</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fja011774y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja011774y%26sid%3Dliteratum%253Aachs%26aulast%3DGee%26aufirst%3DK.%2BR.%26aulast%3DZhou%26aufirst%3DZ.-L.%26aulast%3DQian%26aufirst%3DW.-J.%26aulast%3DKennedy%26aufirst%3DR.%26atitle%3DDetection%2520and%2520imaging%2520of%2520zinc%2520secretion%2520from%2520pancreatic%2520%25CE%25B2-cells%2520using%2520a%2520new%2520fluorescent%2520zinc%2520indicator%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26issue%3D5%26spage%3D776%26epage%3D778%26doi%3D10.1021%2Fja011774y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lukowiak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandewalle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riachy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr-Conte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmyr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belaich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattou, F.</span></span> <span> </span><span class="NLM_article-title">Identification and purification of functional human β-cells by a new specific zinc-fluorescent probe</span>. <i>J. Histochem. Cytochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1177/002215540104900412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1177%2F002215540104900412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=11259455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFKgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2001&pages=519-527&issue=4&author=B.+Lukowiakauthor=B.+Vandewalleauthor=R.+Riachyauthor=J.+Kerr-Conteauthor=V.+Gmyrauthor=S.+Belaichauthor=J.+Lefebvreauthor=F.+Pattou&title=Identification+and+purification+of+functional+human+%CE%B2-cells+by+a+new+specific+zinc-fluorescent+probe&doi=10.1177%2F002215540104900412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and purification of functional human β-cells by a new specific zinc-fluorescent probe</span></div><div class="casAuthors">Lukowiak, Bruno; Vandewalle, Brigitte; Riachy, Rita; Kerr-Conte, Julie; Gmyr, Valery; Belaich, Sandrine; Lefebvre, Jean; Pattou, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-527</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Histochemical Society, Inc.</span>)
        </div><div class="casAbstract">Pancreatic β-cells contain large amts. of zinc.  We took advantage of this to try to localize, quantify, and isolate insulin-producing cells from islet prepns.  Our study was designed to identify a non-toxic zinc-sensitive fluorescent probe able to selectively label labile zinc in viable β-cells and to exhibit excitation and emission wavelengths in the visible spectrum, making this technique exploitable by most instruments.  We tested Newport Green, a probe excitable at 485 nm with a dissocn. const. in the micromolar range corresponding to a low affinity for zinc.  The loading of the lipophilic esterified form of Newport Green was easy, rapid, specific, and non-toxic to cells.  Confocal microscopy highlighted an intense fluorescence assocd. with secretory granules.  Regression analyses showed a good relationship between zinc fluorescence and islet no. (r=0.98) and between zinc fluorescence and insulin content (r=0.81).  The detn. of Zn fluorescence per DNA enabled us to assess the quality of the different islet prepns. intended for islet allografting in terms of both purity and viability.  Cell sorting of dissocd. Newport Green-labeled cells resulted in a clear sepn. of β-cells, as judged by insulin content per DNA and immunocytochem. anal.  This zinc probe, the first able to specifically label living cells in the visible spectrum, appears very promising for β-cell experimentation, both clin. and for basic research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb9bbdhU9XerVg90H21EOLACvtfcHk0lgcg8i_BbXVuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFKgtrs%253D&md5=d71bddbb05e93bb149b4a305ec3b3e90</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1177%2F002215540104900412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F002215540104900412%26sid%3Dliteratum%253Aachs%26aulast%3DLukowiak%26aufirst%3DB.%26aulast%3DVandewalle%26aufirst%3DB.%26aulast%3DRiachy%26aufirst%3DR.%26aulast%3DKerr-Conte%26aufirst%3DJ.%26aulast%3DGmyr%26aufirst%3DV.%26aulast%3DBelaich%26aufirst%3DS.%26aulast%3DLefebvre%26aufirst%3DJ.%26aulast%3DPattou%26aufirst%3DF.%26atitle%3DIdentification%2520and%2520purification%2520of%2520functional%2520human%2520%25CE%25B2-cells%2520by%2520a%2520new%2520specific%2520zinc-fluorescent%2520probe%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D2001%26volume%3D49%26issue%3D4%26spage%3D519%26epage%3D527%26doi%3D10.1177%2F002215540104900412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jindal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmeraldo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span> <span> </span><span class="NLM_article-title">A new method for quantification of islets by measurement of zinc content</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1056</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.2337/diabetes.41.9.1056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdiab.41.9.1056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1499858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADyaK38XlvVOmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1992&pages=1056-1062&issue=9&author=R.+M.+Jindalauthor=R.+P.+Taylorauthor=D.+W.+R.+Grayauthor=R.+Esmeraldoauthor=P.+J.+Morris&title=A+new+method+for+quantification+of+islets+by+measurement+of+zinc+content&doi=10.2337%2Fdiabetes.41.9.1056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">A new method for quantification of islets by measurement of zinc content</span></div><div class="casAuthors">Jindal, Rahul M.; Taylor, Richard P.; Gray, Derek W. R.; Esmeraldo, Ronaldo; Morris, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1056-62</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    </div><div class="casAbstract">The ability to quantify the yield of pancreatic islet tissue after isolation is important for interlab. comparisons and for the assessment of islet yield prior to clin. transplantation.  Because pancreatic islets contain a much higher concn. of zinc than other tissues, the authors investigated the anal. of zinc as a measure of islet tissue yield.  Rat islets of std. diam. 250 μm were handpicked into samples contg. 10-80 islets.  The zinc content was measured by EAAS and showed a linear correlation with islet no.  A zinc binding fluorescent dye, TSQ, was investigated as a way of simplifying the zinc measurement for routine use.  Samples of 10-80 islets of 250 μm were sonicated in 3 mL zinc-free water, 0.18 μmol TSQ was added, and the TSQ-zinc fluorescence was measured at 480 nm.  A linear correlation was obsd.  Exocrine contamination up to 50% barely affected the results.  Islet zinc content also was shown to be correlated linearly with islet no. for freshly isolated human islets.  Measurement of zinc by TSQ fluorescence is a rapid, cheap, and objective measure of islet tissue content.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUeFEzJ9x6_LVg90H21EOLACvtfcHk0lgcg8i_BbXVuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvVOmurk%253D&md5=0ec793ab59b1ba6b4e65984b05bcabbf</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.2337%2Fdiab.41.9.1056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiab.41.9.1056%26sid%3Dliteratum%253Aachs%26aulast%3DJindal%26aufirst%3DR.%2BM.%26aulast%3DTaylor%26aufirst%3DR.%2BP.%26aulast%3DGray%26aufirst%3DD.%2BW.%2BR.%26aulast%3DEsmeraldo%26aufirst%3DR.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26atitle%3DA%2520new%2520method%2520for%2520quantification%2520of%2520islets%2520by%2520measurement%2520of%2520zinc%2520content%26jtitle%3DDiabetes%26date%3D1992%26volume%3D41%26issue%3D9%26spage%3D1056%26epage%3D1062%26doi%3D10.2337%2Fdiabetes.41.9.1056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellomo, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarasov, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.-h.</span></span> <span> </span><span class="NLM_article-title">Imaging dynamic insulin release using a fluorescent zinc indicator for monitoring induced exocytotic release (ZIMIR)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">52</span>),  <span class="NLM_fpage">21063</span>– <span class="NLM_lpage">21068</span>, <span class="refDoi"> DOI: 10.1073/pnas.1109773109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1073%2Fpnas.1109773109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=22160693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVGjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=21063-21068&issue=52&author=D.+Liauthor=S.+Chenauthor=E.+A.+Bellomoauthor=A.+I.+Tarasovauthor=C.+Kautauthor=G.+A.+Rutterauthor=W.-h.+Li&title=Imaging+dynamic+insulin+release+using+a+fluorescent+zinc+indicator+for+monitoring+induced+exocytotic+release+%28ZIMIR%29&doi=10.1073%2Fpnas.1109773109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging dynamic insulin release using a fluorescent zinc indicator for monitoring induced exocytotic release (ZIMIR)</span></div><div class="casAuthors">Li, Daliang; Chen, Shiuhwei; Bellomo, Elisa A.; Tarasov, Andrei I.; Kaut, Callan; Rutter, Guy A.; Li, Wen-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">21063-21068, S21063/1-S21063/13</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Current methods of monitoring insulin secretion lack the required spatial and temporal resoln. to adequately map the dynamics of exocytosis of native insulin granules in intact cell populations in three dimensions.  Exploiting the fact that insulin granules contain a high level of Zn2+, and that Zn2+ is coreleased with insulin during secretion, we have developed a fluorescent, cell surface-targeted zinc indicator for monitoring induced exocytotic release (ZIMIR).  ZIMIR displayed a robust fluorescence enhancement on Zn2+ chelation and bound Zn2+ with high selectivity against Ca2+ and Mg2+.  When added to cultured β cells or intact pancreatic islets at low micromolar concns., ZIMIR labeled cells rapidly,. noninvasively, and stably, and it reliably reported changes in Zn2+ concn. near the sites of granule fusion with high sensitivity that correlated well with membrane capacitance measurement.  Fluorescence imaging of ZIMIR-labeled β cells followed the dynamics of exocytotic activity at subcellular resoln., even when using simple epifluorescence microscopy, and located the chief sites of insulin release to intercellular junctions.  Moreover, ZIMIR imaging of intact rat islets revealed that Zn2+/insulin release occurred largely in small groups of adjacent β cells, with each forming a "secretory unit".  Concurrent imaging of ZIMIR and Fura-2 showed that the amplitude of cytosolic Ca2+ elevation did not necessarily correlate with insulin secretion activity, suggesting that events downstream of Ca2+ signaling underlie the cell-cell heterogeneity in insulin release.  In addn. to studying stimulation-secretion coupling in cells with Zn2+-contg. granules, ZIMIR may find applications in β-cell engineering and screening for mols. regulating insulin secretion on high-throughput platforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNJA5_1YArHrVg90H21EOLACvtfcHk0lgEq0PwGTAs-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVGjug%253D%253D&md5=850cf8ab3152beaf9d8715f45d0a5672</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1109773109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1109773109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBellomo%26aufirst%3DE.%2BA.%26aulast%3DTarasov%26aufirst%3DA.%2BI.%26aulast%3DKaut%26aufirst%3DC.%26aulast%3DRutter%26aufirst%3DG.%2BA.%26aulast%3DLi%26aufirst%3DW.-h.%26atitle%3DImaging%2520dynamic%2520insulin%2520release%2520using%2520a%2520fluorescent%2520zinc%2520indicator%2520for%2520monitoring%2520induced%2520exocytotic%2520release%2520%2528ZIMIR%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26issue%3D52%26spage%3D21063%26epage%3D21068%26doi%3D10.1073%2Fpnas.1109773109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maji, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elgamal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, A.</span></span> <span> </span><span class="NLM_article-title">Native zinc catalyzes selective and traceless release of small molecules in β-cells</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6477</span>– <span class="NLM_lpage">6482</span>, <span class="refDoi"> DOI: 10.1021/jacs.0c00099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.0c00099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVKksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=6477-6482&issue=14&author=M.+Leeauthor=B.+Majiauthor=D.+Mannaauthor=S.+Kahramanauthor=R.+M.+Elgamalauthor=J.+Smallauthor=P.+Kokkondaauthor=A.+Vetereauthor=J.+M.+Goldbergauthor=S.+J.+Lippardauthor=R.+N.+Kulkarniauthor=B.+K.+Wagnerauthor=A.+Choudhary&title=Native+zinc+catalyzes+selective+and+traceless+release+of+small+molecules+in+%CE%B2-cells&doi=10.1021%2Fjacs.0c00099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Native Zinc Catalyzes Selective and Traceless Release of Small Molecules in β-Cells</span></div><div class="casAuthors">Lee, Miseon; Maji, Basudeb; Manna, Debasish; Kahraman, Sevim; Elgamal, Ruth M.; Small, Jonnell; Kokkonda, Praveen; Vetere, Amedeo; Goldberg, Jacob M.; Lippard, Stephen J.; Kulkarni, Rohit N.; Wagner, Bridget K.; Choudhary, Amit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6477-6482</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The loss of insulin-producing β-cells is the central pathol. event in type 1 and 2 diabetes, which has led to efforts to identify mols. to promote β-cell proliferation, protection, and imaging.  However, the lack of β-cell specificity of these mols. jeopardizes their therapeutic potential.  A general platform for selective release of small-mol. cargoes in β-cells over other islet cells ex vivo or other cell-types in an organismal context will be immensely valuable in advancing diabetes research and therapeutic development.  Here, we leverage the unusually high Zn(II) concn. in β-cells to develop a Zn(II)-based prodrug system to selectively and tracelessly deliver bioactive small mols. and fluorophores to β-cells.  The Zn(II)-targeting mechanism enriches the inactive cargo in β-cells as compared to other pancreatic cells; importantly, Zn(II)-mediated hydrolysis triggers cargo activation.  This prodrug system, with modular components that allow for fine-tuning selectivity, should enable the safer and more effective targeting of β-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8PBBj0fuUarVg90H21EOLACvtfcHk0lgEq0PwGTAs-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVKksr0%253D&md5=fd7bc8705bf5eb48ef45dce4c708954a</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjacs.0c00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.0c00099%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%26aulast%3DMaji%26aufirst%3DB.%26aulast%3DManna%26aufirst%3DD.%26aulast%3DKahraman%26aufirst%3DS.%26aulast%3DElgamal%26aufirst%3DR.%2BM.%26aulast%3DSmall%26aufirst%3DJ.%26aulast%3DKokkonda%26aufirst%3DP.%26aulast%3DVetere%26aufirst%3DA.%26aulast%3DGoldberg%26aufirst%3DJ.%2BM.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DChoudhary%26aufirst%3DA.%26atitle%3DNative%2520zinc%2520catalyzes%2520selective%2520and%2520traceless%2520release%2520of%2520small%2520molecules%2520in%2520%25CE%25B2-cells%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26issue%3D14%26spage%3D6477%26epage%3D6482%26doi%3D10.1021%2Fjacs.0c00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, S.</span></span> <span> </span><span class="NLM_article-title">Induced pluripotent stem cell technology: a decade of progress</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrd.2016.245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=27980341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsl2lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=115-130&issue=2&author=Y.+Shiauthor=H.+Inoueauthor=J.+C.+Wuauthor=S.+Yamanaka&title=Induced+pluripotent+stem+cell+technology%3A+a+decade+of+progress&doi=10.1038%2Fnrd.2016.245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Induced pluripotent stem cell technology: a decade of progress</span></div><div class="casAuthors">Shi, Yanhong; Inoue, Haruhisa; Wu, Joseph C.; Yamanaka, Shinya</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-130</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Since the advent of induced pluripotent stem cell (iPSC) technol. a decade ago, enormous progress has been made in stem cell biol. and regenerative medicine.  Human iPSCs have been widely used for disease modeling, drug discovery and cell therapy development.  Novel pathol. mechanisms have been elucidated, new drugs originating from iPSC screens are in the pipeline and the first clin. trial using human iPSC-derived products has been initiated.  In particular, the combination of human iPSC technol. with recent developments in gene editing and 3D organoids makes iPSC-based platforms even more powerful in each area of their application, including precision medicine.  In this Review, we discuss the progress in applications of iPSC technol. that are particularly relevant to drug discovery and regenerative medicine, and consider the remaining challenges and the emerging opportunities in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosBuEbSJ5V5bVg90H21EOLACvtfcHk0lgEq0PwGTAs-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsl2lsg%253D%253D&md5=e6884f9743341369ab8e24e872990761</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.245%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DYamanaka%26aufirst%3DS.%26atitle%3DInduced%2520pluripotent%2520stem%2520cell%2520technology%253A%2520a%2520decade%2520of%2520progress%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D2%26spage%3D115%26epage%3D130%26doi%3D10.1038%2Fnrd.2016.245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manolagas, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, M.</span></span> <span> </span><span class="NLM_article-title">The role of estrogen and androgen receptors in bone health and disease</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2013.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrendo.2013.179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=24042328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVynu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=699-712&issue=12&author=S.+C.+Manolagasauthor=C.+A.+O%E2%80%99Brienauthor=M.+Almeida&title=The+role+of+estrogen+and+androgen+receptors+in+bone+health+and+disease&doi=10.1038%2Fnrendo.2013.179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The role of estrogen and androgen receptors in bone health and disease</span></div><div class="casAuthors">Manolagas, Stavros C.; O'Brien, Charles A.; Almeida, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">699-712</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mouse models with cell-specific deletion of the estrogen receptor (ER) α, the androgen receptor (AR) or the receptor activator of nuclear factor κB ligand (RANKL), as well as cascade-selective estrogenic compds. have provided novel insights into the function and signalling of ERα and AR.  The studies reveal that the effects of estrogens on trabecular vs. cortical bone mass are mediated by direct effects on osteoclasts and osteoblasts, resp.  The protection of cortical bone mass by estrogens is mediated via ERα, using a non-nucleus-initiated mechanism.  By contrast, the AR of mature osteoblasts is indispensable for the maintenance of trabecular bone mass in male mammals, but not required for the anabolic effects of androgens on cortical bone.  Most unexpectedly, and independently of estrogens, ERα in osteoblast progenitors stimulates Wnt signalling and periosteal bone accrual in response to mech. strain.  RANKL expression in B lymphocytes, but not T lymphocytes, contributes to the loss of trabecular bone caused by estrogen deficiency.  In this Review, we summarize this evidence and discuss its implications for understanding the regulation of trabecular and cortical bone mass; the integration of hormonal and mech. signals; the relative importance of estrogens vs. androgens in the male skeleton; and, finally, the pathogenesis and treatment of osteoporosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXOwr_v3mjKbVg90H21EOLACvtfcHk0lhAJ4uVy9Q7Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVynu77I&md5=fbda8ee8c9962a695f33c1ec3130d15d</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2013.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2013.179%26sid%3Dliteratum%253Aachs%26aulast%3DManolagas%26aufirst%3DS.%2BC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%2BA.%26aulast%3DAlmeida%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520estrogen%2520and%2520androgen%2520receptors%2520in%2520bone%2520health%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2013%26volume%3D9%26issue%3D12%26spage%3D699%26epage%3D712%26doi%3D10.1038%2Fnrendo.2013.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briquez, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. R.</span></span> <span> </span><span class="NLM_article-title">Engineering growth factors for regenerative medicine applications</span>. <i>Acta Biomater.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.actbio.2015.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.actbio.2015.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26555377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWlur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1-12&author=A.+C.+Mitchellauthor=P.+S.+Briquezauthor=J.+A.+Hubbellauthor=J.+R.+Cochran&title=Engineering+growth+factors+for+regenerative+medicine+applications&doi=10.1016%2Fj.actbio.2015.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering growth factors for regenerative medicine applications</span></div><div class="casAuthors">Mitchell, Aaron C.; Briquez, Priscilla S.; Hubbell, Jeffrey A.; Cochran, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Biomaterialia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">ABCICB</span>;
        ISSN:<span class="NLM_cas:issn">1742-7061</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Growth factors are important morphogenetic proteins that instruct cell behavior and guide tissue repair and renewal.  Although their therapeutic potential holds great promise in regenerative medicine applications, translation of growth factors into clin. treatments has been hindered by limitations including poor protein stability, low recombinant expression yield, and suboptimal efficacy.  This review highlights current tools, technologies, and approaches to design integrated and effective growth factor-based therapies for regenerative medicine applications.  The first section describes rational and combinatorial protein engineering approaches that have been utilized to improve growth factor stability, expression yield, biodistribution, and serum half-life, or alter their cell trafficking behavior or receptor binding affinity.  The second section highlights elegant biomaterial-based systems, inspired by the natural extracellular matrix milieu, that have been developed for effective spatial and temporal delivery of growth factors to cell surface receptors.  Although appearing distinct, these two approaches are highly complementary and involve principles of mol. design and engineering to be considered in parallel when developing optimal materials for clin. applications.  Growth factors are promising therapeutic proteins that have the ability to modulate morphogenetic behaviors, including cell survival, proliferation, migration and differentiation.  However, the translation of growth factors into clin. therapies has been hindered by properties such as poor protein stability, low recombinant expression yield, and non-physiol. delivery, which lead to suboptimal efficacy and adverse side effects.  To address these needs, researchers are employing clever mol. and material engineering and design strategies to both improve the intrinsic properties of growth factors and effectively control their delivery into tissue.  This review highlights examples of interdisciplinary tools and technologies used to augment the therapeutic potential of growth factors for clin. applications in regenerative medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0W98k2-jDm7Vg90H21EOLACvtfcHk0lhAJ4uVy9Q7Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWlur%252FK&md5=d04bfadd38b7372647cdb2fb406331bc</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.actbio.2015.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.actbio.2015.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DA.%2BC.%26aulast%3DBriquez%26aufirst%3DP.%2BS.%26aulast%3DHubbell%26aufirst%3DJ.%2BA.%26aulast%3DCochran%26aufirst%3DJ.%2BR.%26atitle%3DEngineering%2520growth%2520factors%2520for%2520regenerative%2520medicine%2520applications%26jtitle%3DActa%2520Biomater.%26date%3D2016%26volume%3D30%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.actbio.2015.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wojda, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donahue, S. W.</span></span> <span> </span><span class="NLM_article-title">Parathyroid hormone for bone regeneration</span>. <i>J. Orthop. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2586</span>– <span class="NLM_lpage">2594</span>, <span class="refDoi"> DOI: 10.1002/jor.24075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1002%2Fjor.24075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=29926970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVKhtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=2586-2594&issue=10&author=S.+J.+Wojdaauthor=S.+W.+Donahue&title=Parathyroid+hormone+for+bone+regeneration&doi=10.1002%2Fjor.24075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Parathyroid hormone for bone regeneration</span></div><div class="casAuthors">Wojda, Samantha J.; Donahue, Seth W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Orthopaedic Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2586-2594</span>CODEN:
                <span class="NLM_cas:coden">JOREDR</span>;
        ISSN:<span class="NLM_cas:issn">0736-0266</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Delayed healing and/or non-union occur in approx. 5-10% of the fractures that occur annually in the United States.  Segmental bone loss increases the probability of non-union.  Though grafting can be an effective treatment for segmental bone loss, autografting is limited for large defects since a limited amt. of bone is available for harvest.  Parathyroid hormone (PTH) is a key regulator of calcium homeostasis in the body and plays an important role in bone metab.  Presently PTH is FDA approved for use as an anabolic treatment for osteoporosis.  The anabolic effect PTH has on bone has led to research on its use for bone regeneration applications.  Numerous studies in animal models have indicated enhanced fracture healing as a result of once daily injections of PTH.  Similarly, in a human case study, non-union persisted despite treatment attempts with internal fixation, external fixation, and autograft in combination with BMP-7, until off label use of PTH1-84 was utilized.  Use of a biomaterial scaffold to locally deliver PTH to a defect site has also been shown to improve bone formation and healing around dental implants in dogs and drill defects in sheep.  Thus, PTH may be used to promote bone regeneration and provide an alternative to autograft and BMP for the treatment of large segmental defects and non-unions.  This review briefly summarizes the unmet clin. need for improved bone regeneration techniques and how PTH may help fill that void by both systemically and locally delivered PTH for bone regeneration applications. © 2018 Orthopaedic Research Society.  Published by Wiley Periodicals, Inc.  J Orthop Res 36:2586-2594, 2018.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWvcGNijGjG7Vg90H21EOLACvtfcHk0lhAJ4uVy9Q7Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVKhtb%252FI&md5=8ae183f3ff0e092c2b4c17267a745d94</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fjor.24075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjor.24075%26sid%3Dliteratum%253Aachs%26aulast%3DWojda%26aufirst%3DS.%2BJ.%26aulast%3DDonahue%26aufirst%3DS.%2BW.%26atitle%3DParathyroid%2520hormone%2520for%2520bone%2520regeneration%26jtitle%3DJ.%2520Orthop.%2520Res.%26date%3D2018%26volume%3D36%26issue%3D10%26spage%3D2586%26epage%3D2594%26doi%3D10.1002%2Fjor.24075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okajima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemoto, S.</span></span> <span> </span><span class="NLM_article-title">Current state and future evolution of pancreatic islet transplantation</span>. <i>Ann. Gastroenterol Surg</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1002/ags3.12214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1002%2Fags3.12214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30697608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A280%3ADC%252BB3cjmvVChuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=34-42&issue=1&author=T.+Anazawaauthor=H.+Okajimaauthor=T.+Masuiauthor=S.+Uemoto&title=Current+state+and+future+evolution+of+pancreatic+islet+transplantation&doi=10.1002%2Fags3.12214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Current state and future evolution of pancreatic islet transplantation</span></div><div class="casAuthors">Anazawa Takayuki; Okajima Hideaki; Masui Toshihiko; Uemoto Shinji</div><div class="citationInfo"><span class="NLM_cas:title">Annals of gastroenterological surgery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pancreatic islet transplantation provides an effective treatment option for patients with type 1 diabetes (T1D) with intractable impaired awareness of hypoglycemia and severe hypoglycemic events.  Currently, the primary goal of islet transplantation should be excellent glycemic control without severe hypoglycemia, rather than insulin independence.  Islet transplant recipients were less likely to achieve insulin independence, whereas solid pancreas transplant recipients substantially had greater procedure-related morbidity.  Excellent therapeutic effects of islet transplantation as a result of accurate blood glucose level-reactive insulin secretion, which cannot be reproduced by current drug therapy, have been confirmed.  Recent improvement of islet transplantation outcome has been achieved by refinement of the pancreatic islet isolation technique, improvement of islet engraftment method, and introduction of effective immunosuppressive therapy.  A disadvantage of islet transplantation is that donors are essential, and donor shortage has become a hindrance to its development.  With the development of alternative transplantation sites and new cell sources, including porcine islet cells and embryonic stem/induced pluripotent stem (ES/iPS)-derived β cells, "On-demand" and "Unlimited" cell therapy for T1D can be established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSftIHOVdtXIyCEBeYuoi7AfW6udTcc2ea-VG9eeSxUorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjmvVChuw%253D%253D&md5=10b1cb41cb78387d67af0a4b762fcdd6</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2Fags3.12214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fags3.12214%26sid%3Dliteratum%253Aachs%26aulast%3DAnazawa%26aufirst%3DT.%26aulast%3DOkajima%26aufirst%3DH.%26aulast%3DMasui%26aufirst%3DT.%26aulast%3DUemoto%26aufirst%3DS.%26atitle%3DCurrent%2520state%2520and%2520future%2520evolution%2520of%2520pancreatic%2520islet%2520transplantation%26jtitle%3DAnn.%2520Gastroenterol%2520Surg%26date%3D2019%26volume%3D3%26issue%3D1%26spage%3D34%26epage%3D42%26doi%3D10.1002%2Fags3.12214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shahjalal, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayem, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, T.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.-G.</span></span> <span> </span><span class="NLM_article-title">Generation of pancreatic β cells for treatment of diabetes: advances and challenges</span>. <i>Stem Cell Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">355</span>, <span class="refDoi"> DOI: 10.1186/s13287-018-1099-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1186%2Fs13287-018-1099-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30594258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFGkurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=355&author=H.+M.+Shahjalalauthor=A.+A.+Dayemauthor=K.+M.+Limauthor=T.-i.+Jeonauthor=S.-G.+Cho&title=Generation+of+pancreatic+%CE%B2+cells+for+treatment+of+diabetes%3A+advances+and+challenges&doi=10.1186%2Fs13287-018-1099-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of pancreatic β cells for treatment of diabetes: advances and challenges</span></div><div class="casAuthors">Shahjalal, Hussain Md.; Dayem, Ahmed Abdal; Lim, Kyung Min; Jeon, Tak-il; Cho, Ssang-Goo</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Research & Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">355</span>CODEN:
                <span class="NLM_cas:coden">SCRTEK</span>;
        ISSN:<span class="NLM_cas:issn">1757-6512</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC) are considered attractive sources of pancreatic β cells and islet organoids.  Recently, several reports presented that hESC/iPSC-derived cells enriched with specific transcription factors can form glucose-responsive insulin-secreting cells in vitro and transplantation of these cells ameliorates hyperglycemia in diabetic mice.  However, the glucose-stimulated insulin-secreting capacity of these cells is lower than that of endogenous islets, suggesting the need to improve induction procedures.  One of the crit. problems facing in vivo maturation of hESC/iPSC-derived cells is their low survival rate after transplantation, although this rate increases when the implanted pancreatic cells are encapsulated to avoid the immune response.  Several groups have also reported on the generation of hESC/iPSC-derived islet-like organoids, but development of techniques for complete islet structures with the eventual generation of vascularized constructs remains a major challenge to their application in regenerative therapies.  Many issues also need to be addressed before the successful clin. application of hESC/iPSC-derived cells or islet organoids.  In this review, we summarize advances in the generation of hESC/iPSC-derived pancreatic β cells or islet organoids and discuss the limitations and challenges for their successful therapeutic application in diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1q13PgE1c07Vg90H21EOLACvtfcHk0ljXKsGzTULiqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFGkurvN&md5=8e0a3342ea874dfd7e6c7485d46c67b2</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1186%2Fs13287-018-1099-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13287-018-1099-3%26sid%3Dliteratum%253Aachs%26aulast%3DShahjalal%26aufirst%3DH.%2BM.%26aulast%3DDayem%26aufirst%3DA.%2BA.%26aulast%3DLim%26aufirst%3DK.%2BM.%26aulast%3DJeon%26aufirst%3DT.-i.%26aulast%3DCho%26aufirst%3DS.-G.%26atitle%3DGeneration%2520of%2520pancreatic%2520%25CE%25B2%2520cells%2520for%2520treatment%2520of%2520diabetes%253A%2520advances%2520and%2520challenges%26jtitle%3DStem%2520Cell%2520Res.%2520Ther.%26date%3D2018%26volume%3D9%26spage%3D355%26doi%3D10.1186%2Fs13287-018-1099-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span> <span> </span><span class="NLM_article-title">The De-, Re-, and trans-differentiation of β-cells: Regulation and function</span>. <i>Semin. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1016/j.semcdb.2020.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.semcdb.2020.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=31948775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A280%3ADC%252BB38%252Fht1ahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2020&pages=68-75&author=J.+Zhangauthor=F.+Liu&title=The+De-%2C+Re-%2C+and+trans-differentiation+of+%CE%B2-cells%3A+Regulation+and+function&doi=10.1016%2Fj.semcdb.2020.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">The De-, Re-, and trans-differentiation of β-cells: Regulation and function</span></div><div class="casAuthors">Zhang Jingjing; Liu Feng</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in cell & developmental biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diabetes is a serious, costly, and major health problem worldwide.  Whereas diabetes could be alleviated by medication, this disease could not be fully cured at the present time due to the lack of effective therapeutic treatment for β-cell loss and/or dysfunction.  Increased β-cell mass or volume could be achieved via differentiation of embryonic stem (ES) cells or pluripotent stem cells or through β-cell renewal, including proliferation, redifferentiation, and transdifferentiation.  Data cumulated over the past several years suggest that increased β-cell dedifferentiation plays a crucial role in the progression of diabetes, shedding new light on potential targets for β-cell replacement therapy.  In this review, we summarize current views on β-cell dedifferentiation, redifferentiation, and transdifferentiation.  We also discuss potential mechanisms regulating these key processes to maintain β-cell homeostasis.  Understanding pancreatic β-cell differentiation and dedifferentiation could be provide important information on developing effective strategies to cure diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA48EmrnerrVWTCLT8lX9SfW6udTcc2eZcTk9oL_qrWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252Fht1ahuw%253D%253D&md5=4bb6ba69a506317ad893de0ca7710833</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2020.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2020.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DF.%26atitle%3DThe%2520De-%252C%2520Re-%252C%2520and%2520trans-differentiation%2520of%2520%25CE%25B2-cells%253A%2520Regulation%2520and%2520function%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26date%3D2020%26volume%3D103%26spage%3D68%26epage%3D75%26doi%3D10.1016%2Fj.semcdb.2020.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simao, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barroso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristovao, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallardo, E.</span></span> <span> </span><span class="NLM_article-title">Toxicological aspects and determination of the main components of ayahuasca: a critical review</span>. <i>Medicines</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">106</span>, <span class="refDoi"> DOI: 10.3390/medicines6040106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.3390%2Fmedicines6040106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslekur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=106&issue=4&author=A.+Y.+Simaoauthor=J.+Goncalvesauthor=A.+P.+Duarteauthor=M.+Barrosoauthor=A.+C.+Cristovaoauthor=E.+Gallardo&title=Toxicological+aspects+and+determination+of+the+main+components+of+ayahuasca%3A+a+critical+review&doi=10.3390%2Fmedicines6040106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicological aspects and determination of the main components of ayahuasca: a critical review</span></div><div class="casAuthors">Simao, Ana Y.; Goncalves, Joana; Duarte, Ana Paula; Barroso, Mario; Cristovao, Ana Clara; Gallardo, Eugenia</div><div class="citationInfo"><span class="NLM_cas:title">Medicines</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">106</span>CODEN:
                <span class="NLM_cas:coden">MEDICX</span>;
        ISSN:<span class="NLM_cas:issn">2305-6320</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Ayahuasca is a psychoactive beverage prepd. traditionally from a mixt. of the leaves and stems of Psychotria viridis and Banisteriopsis caapi, resp., being originally consumed by indigenous Amazonian tribes for ritual and medicinal purposes.  Over the years, its use has spread to other populations as a means to personal growth and spiritual connection.  Also, the recreational use of its isolated compds. has become prominent.  The main compds. of this tea-like prepn. are N,N-dimethyltryptamine (DMT), β-Carbolines, and harmala alkaloids, such as harmine, tetrahydroharmine, and harmaline.  The latter are monoamine-oxidase inhibitors and are responsible for DMT psychoactive and hallucinogenic effects on the central nervous system.  Although consumers defend its use, its metabolic effects and those on the central nervous system are not fully understood yet.  The majority of studies regarding the effects of this beverage and of its individual compds. are based on in vivo expts., clin. trials, and even surveys.  This paper will not only address the toxicol. aspects of the ayahuasca compds. but also perform a comprehensive and crit. review on the anal. methods available for their detn. in biol. and non-biol. specimens, with special focus on instrumental developments and sample prepn. approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCVD50AnXcybVg90H21EOLACvtfcHk0ljXKsGzTULiqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslekur7O&md5=7af469d0df539b2b19da8b51a380f12b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.3390%2Fmedicines6040106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmedicines6040106%26sid%3Dliteratum%253Aachs%26aulast%3DSimao%26aufirst%3DA.%2BY.%26aulast%3DGoncalves%26aufirst%3DJ.%26aulast%3DDuarte%26aufirst%3DA.%2BP.%26aulast%3DBarroso%26aufirst%3DM.%26aulast%3DCristovao%26aufirst%3DA.%2BC.%26aulast%3DGallardo%26aufirst%3DE.%26atitle%3DToxicological%2520aspects%2520and%2520determination%2520of%2520the%2520main%2520components%2520of%2520ayahuasca%253A%2520a%2520critical%2520review%26jtitle%3DMedicines%26date%3D2019%26volume%3D6%26issue%3D4%26spage%3D106%26doi%3D10.3390%2Fmedicines6040106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maji, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elgamal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, A.</span></span> <span> </span><span class="NLM_article-title">Native zinc catalyzes selective and traceless release of small molecules in β-cells</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6477</span>– <span class="NLM_lpage">6482</span>, <span class="refDoi"> DOI: 10.1021/jacs.0c00099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.0c00099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVKksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=6477-6482&issue=14&author=M.+Leeauthor=B.+Majiauthor=D.+Mannaauthor=S.+Kahramanauthor=R.+M.+Elgamalauthor=J.+Smallauthor=P.+Kokkondaauthor=A.+Vetereauthor=J.+M.+Goldbergauthor=S.+J.+Lippardauthor=R.+N.+Kulkarniauthor=B.+K.+Wagnerauthor=A.+Choudhary&title=Native+zinc+catalyzes+selective+and+traceless+release+of+small+molecules+in+%CE%B2-cells&doi=10.1021%2Fjacs.0c00099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Native Zinc Catalyzes Selective and Traceless Release of Small Molecules in β-Cells</span></div><div class="casAuthors">Lee, Miseon; Maji, Basudeb; Manna, Debasish; Kahraman, Sevim; Elgamal, Ruth M.; Small, Jonnell; Kokkonda, Praveen; Vetere, Amedeo; Goldberg, Jacob M.; Lippard, Stephen J.; Kulkarni, Rohit N.; Wagner, Bridget K.; Choudhary, Amit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6477-6482</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The loss of insulin-producing β-cells is the central pathol. event in type 1 and 2 diabetes, which has led to efforts to identify mols. to promote β-cell proliferation, protection, and imaging.  However, the lack of β-cell specificity of these mols. jeopardizes their therapeutic potential.  A general platform for selective release of small-mol. cargoes in β-cells over other islet cells ex vivo or other cell-types in an organismal context will be immensely valuable in advancing diabetes research and therapeutic development.  Here, we leverage the unusually high Zn(II) concn. in β-cells to develop a Zn(II)-based prodrug system to selectively and tracelessly deliver bioactive small mols. and fluorophores to β-cells.  The Zn(II)-targeting mechanism enriches the inactive cargo in β-cells as compared to other pancreatic cells; importantly, Zn(II)-mediated hydrolysis triggers cargo activation.  This prodrug system, with modular components that allow for fine-tuning selectivity, should enable the safer and more effective targeting of β-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8PBBj0fuUarVg90H21EOLACvtfcHk0li35XxaKLCTmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVKksr0%253D&md5=fd7bc8705bf5eb48ef45dce4c708954a</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjacs.0c00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.0c00099%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%26aulast%3DMaji%26aufirst%3DB.%26aulast%3DManna%26aufirst%3DD.%26aulast%3DKahraman%26aufirst%3DS.%26aulast%3DElgamal%26aufirst%3DR.%2BM.%26aulast%3DSmall%26aufirst%3DJ.%26aulast%3DKokkonda%26aufirst%3DP.%26aulast%3DVetere%26aufirst%3DA.%26aulast%3DGoldberg%26aufirst%3DJ.%2BM.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DChoudhary%26aufirst%3DA.%26atitle%3DNative%2520zinc%2520catalyzes%2520selective%2520and%2520traceless%2520release%2520of%2520small%2520molecules%2520in%2520%25CE%25B2-cells%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26issue%3D14%26spage%3D6477%26epage%3D6482%26doi%3D10.1021%2Fjacs.0c00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naparstek, Y.</span></span> <span> </span><span class="NLM_article-title">Immune modulation for prevention of type 1 diabetes mellitus</span>. <i>Trends Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.tibtech.2005.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.tibtech.2005.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=15734555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsleiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=128-134&issue=3&author=I.+Razauthor=R.+Eldorauthor=Y.+Naparstek&title=Immune+modulation+for+prevention+of+type+1+diabetes+mellitus&doi=10.1016%2Fj.tibtech.2005.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Immune modulation for prevention of type 1 diabetes mellitus</span></div><div class="casAuthors">Raz, Itamar; Eldor, Roy; Naparstek, Yaakov</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">128-134</span>CODEN:
                <span class="NLM_cas:coden">TRBIDM</span>;
        ISSN:<span class="NLM_cas:issn">0167-7799</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Prevention of type 1 diabetes mellitus requires early intervention in the autoimmune process directed against β cells of the pancreatic islets of Langerhans.  This autoimmune inflammatory process is thought to be caused by the effect of Th1 cells and their secreted cytokines (e.g. interferon) and to be suppressed by Th2-secreted anti-inflammatory cytokines (e.g. IL-4, IL-10).  Various methods aimed specifically at halting or modulating this response have been attempted.  An alternative method is the re-induction of tolerance towards the putative self antigen that causes the disease.  Proposed antigens such as insulin, glutamic acid decarboxylase (GAD) and the heat shock protein 60 (Hsp60)-derived peptide 277 have been used successfully in murine diabetes models and in initial clin. trials in early diabetes patients.  Here, we review the results of these trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5RGvDHjKu2bVg90H21EOLACvtfcHk0li35XxaKLCTmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsleiur8%253D&md5=60e4fad8f948d37bfa806d4762d10356</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.tibtech.2005.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibtech.2005.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DRaz%26aufirst%3DI.%26aulast%3DEldor%26aufirst%3DR.%26aulast%3DNaparstek%26aufirst%3DY.%26atitle%3DImmune%2520modulation%2520for%2520prevention%2520of%2520type%25201%2520diabetes%2520mellitus%26jtitle%3DTrends%2520Biotechnol.%26date%3D2005%26volume%3D23%26issue%3D3%26spage%3D128%26epage%3D134%26doi%3D10.1016%2Fj.tibtech.2005.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roep, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tree, T. I. M.</span></span> <span> </span><span class="NLM_article-title">Immune modulation in humans: implications for type 1 diabetes mellitus</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2014.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrendo.2014.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=24468651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsF2qsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=229-242&issue=4&author=B.+O.+Roepauthor=T.+I.+M.+Tree&title=Immune+modulation+in+humans%3A+implications+for+type+1+diabetes+mellitus&doi=10.1038%2Fnrendo.2014.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Immune modulation in humans: implications for type 1 diabetes mellitus</span></div><div class="casAuthors">Roep, Bart O.; Tree, Timothy I. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">229-242</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Type 1 diabetes mellitus (T1DM) is the result of autoimmune destruction of pancreatic β cells in genetically predisposed individuals with impaired immune regulation.  The insufficiency in the modulation of immune attacks on the β cells might be partly due to genetic causes; indeed, several of the genetic variants that predispose individuals to T1DM have functional features of impaired immune regulation.  While defects in immune regulation in patients with T1DM have been identified, many patients seem to have immune regulatory capacities that are indistinguishable from those of healthy individuals.  Insight into the regulation of islet autoimmunity might enable us to restore immune imbalances with therapeutic interventions.  In this Review, we discuss the current knowledge on immune regulation and dysfunction in humans that is the basis of tissue-specific immune regulation as an alternative to generalized immune suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQCg2ICr_McrVg90H21EOLACvtfcHk0li35XxaKLCTmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsF2qsL0%253D&md5=a9263cce17235d3a06e064676054dd46</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2014.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2014.2%26sid%3Dliteratum%253Aachs%26aulast%3DRoep%26aufirst%3DB.%2BO.%26aulast%3DTree%26aufirst%3DT.%2BI.%2BM.%26atitle%3DImmune%2520modulation%2520in%2520humans%253A%2520implications%2520for%2520type%25201%2520diabetes%2520mellitus%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2014%26volume%3D10%26issue%3D4%26spage%3D229%26epage%3D242%26doi%3D10.1038%2Fnrendo.2014.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herold, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluestone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Meglio, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufort, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitelman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsley, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skyler, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsalikian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wherrett, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, A.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenbaum, C. J.</span></span> <span> </span><span class="NLM_article-title">An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1902226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1056%2FNEJMoa1902226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=31180194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1GqsbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=603-613&issue=7&author=K.+C.+Heroldauthor=B.+N.+Bundyauthor=S.+A.+Longauthor=J.+A.+Bluestoneauthor=L.+A.+Di+Meglioauthor=M.+J.+Dufortauthor=S.+E.+Gitelmanauthor=P.+A.+Gottliebauthor=J.+P.+Krischerauthor=P.+S.+Linsleyauthor=J.+B.+Marksauthor=W.+Mooreauthor=A.+Moranauthor=H.+Rodriguezauthor=W.+E.+Russellauthor=D.+Schatzauthor=J.+S.+Skylerauthor=E.+Tsalikianauthor=D.+K.+Wherrettauthor=A.-G.+Zieglerauthor=C.+J.+Greenbaum&title=An+anti-CD3+antibody%2C+teplizumab%2C+in+relatives+at+risk+for+type+1+diabetes&doi=10.1056%2FNEJMoa1902226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes</span></div><div class="casAuthors">Herold, Kevan C.; Bundy, Brian N.; Long, S. Alice; Bluestone, Jeffrey A.; Di Meglio, Linda A.; Dufort, Matthew J.; Gitelman, Stephen E.; Gottlieb, Peter A.; Krischer, Jeffrey P.; Linsley, Peter S.; Marks, Jennifer B.; Moore, Wayne; Moran, Antoinette; Rodriguez, Henry; Russell, William E.; Schatz, Desmond; Skyler, Jay S.; Tsalikian, Eva; Wherrett, Diane K.; Ziegler, Anette-Gabriele; Greenbaum, Carla J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">603-613</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1 diabetes who did not have diabetes but were at high risk for development of clin. disease.  Patients were randomly assigned to a single 14-day course of teplizumab or placebo, and follow-up for progression to clin. type 1 diabetes was performed with the use of oral glucose-tolerance tests at 6-mo intervals. results A total of 76 participants (55 [72%] of whom were ≤18 years of age) underwent randomization - 44 to the teplizumab group and 32 to the placebo group.  The median time to the diagnosis of type 1 diabetes was 48.4 mo in the teplizumab group and 24.4 mo in the placebo group; the disease was diagnosed in 19 (43%) of the participants who received teplizumab and in 23 (72%) of those who received placebo.  The hazard ratio for the diagnosis of type 1 diabetes (teplizumab vs. placebo) was 0.41 (95% confidence interval, 0.22 to 0.78; P = 0.006 by adjusted Cox proportional-hazards model).  The annualized rates of diagnosis of diabetes were 14.9% per yr in the teplizumab group and 35.9% per yr in the placebo group.  There were expected adverse events of rash and transient lymphopenia.  KLRG1 + TIGIT + CD8+ T cells were more common in the teplizumab group than in the placebo group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwpYoP4iqOS7Vg90H21EOLACvtfcHk0li35XxaKLCTmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1GqsbbN&md5=a91854229de7210f9bba44953cce713d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1902226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1902226%26sid%3Dliteratum%253Aachs%26aulast%3DHerold%26aufirst%3DK.%2BC.%26aulast%3DBundy%26aufirst%3DB.%2BN.%26aulast%3DLong%26aufirst%3DS.%2BA.%26aulast%3DBluestone%26aufirst%3DJ.%2BA.%26aulast%3DDi%2BMeglio%26aufirst%3DL.%2BA.%26aulast%3DDufort%26aufirst%3DM.%2BJ.%26aulast%3DGitelman%26aufirst%3DS.%2BE.%26aulast%3DGottlieb%26aufirst%3DP.%2BA.%26aulast%3DKrischer%26aufirst%3DJ.%2BP.%26aulast%3DLinsley%26aufirst%3DP.%2BS.%26aulast%3DMarks%26aufirst%3DJ.%2BB.%26aulast%3DMoore%26aufirst%3DW.%26aulast%3DMoran%26aufirst%3DA.%26aulast%3DRodriguez%26aufirst%3DH.%26aulast%3DRussell%26aufirst%3DW.%2BE.%26aulast%3DSchatz%26aufirst%3DD.%26aulast%3DSkyler%26aufirst%3DJ.%2BS.%26aulast%3DTsalikian%26aufirst%3DE.%26aulast%3DWherrett%26aufirst%3DD.%2BK.%26aulast%3DZiegler%26aufirst%3DA.-G.%26aulast%3DGreenbaum%26aufirst%3DC.%2BJ.%26atitle%3DAn%2520anti-CD3%2520antibody%252C%2520teplizumab%252C%2520in%2520relatives%2520at%2520risk%2520for%2520type%25201%2520diabetes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26issue%3D7%26spage%3D603%26epage%3D613%26doi%3D10.1056%2FNEJMoa1902226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Register, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann-Petersen, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehdizadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colon-Negron, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meza-Acevedo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backes, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluestone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papa, F. R.</span></span> <span> </span><span class="NLM_article-title">Targeting ABL-IRE1α signaling spares ER-stressed pancreatic β cells to reverse autoimmune diabetes</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">897</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2017.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2017.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=28380378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1ylsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=883-897&issue=4&author=S.+Moritaauthor=S.+A.+Villaltaauthor=H.+C.+Feldmanauthor=A.+C.+Registerauthor=W.+Rosenthalauthor=I.+T.+Hoffmann-Petersenauthor=M.+Mehdizadehauthor=R.+Ghoshauthor=L.+Wangauthor=K.+Colon-Negronauthor=R.+Meza-Acevedoauthor=B.+J.+Backesauthor=D.+J.+Malyauthor=J.+A.+Bluestoneauthor=F.+R.+Papa&title=Targeting+ABL-IRE1%CE%B1+signaling+spares+ER-stressed+pancreatic+%CE%B2+cells+to+reverse+autoimmune+diabetes&doi=10.1016%2Fj.cmet.2017.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes</span></div><div class="casAuthors">Morita, Shuhei; Villalta, S. Armando; Feldman, Hannah C.; Register, Ames C.; Rosenthal, Wendy; Hoffmann-Petersen, Ingeborg T.; Mehdizadeh, Morvarid; Ghosh, Rajarshi; Wang, Likun; Colon-Negron, Kevin; Meza-Acevedo, Rosa; Backes, Bradley J.; Maly, Dustin J.; Bluestone, Jeffrey A.; Papa, Feroz R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">883-897.e8</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">In cells experiencing unrelieved endoplasmic reticulum (ER) stress, the ER transmembrane kinase/endoribonuclease (RNase)-IRE1α-endonucleolytically degrades ER-localized mRNAs to promote apoptosis.  Here we find that the ABL family of tyrosine kinases rheostatically enhances IRE1α's enzymic activities, thereby potentiating ER stress-induced apoptosis.  During ER stress, cytosolic ABL kinases localize to the ER membrane, where they bind, scaffold, and hyperactivate IRE1α's RNase.  Imatinib-an anti-cancer tyrosine kinase inhibitor-antagonizes the ABL-IRE1α interaction, blunts IRE1α RNase hyperactivity, reduces pancreatic β cell apoptosis, and reverses type 1 diabetes (T1D) in the non-obese diabetic (NOD) mouse model.  A mono-selective kinase inhibitor that allosterically attenuates IRE1α's RNase-KIRA8-also efficaciously reverses established diabetes in NOD mice by sparing β cells and preserving their physiol. function.  Our data support a model wherein ER-stressed β cells contribute to their own demise during T1D pathogenesis and implicate the ABL-IRE1α axis as a drug target for the treatment of an autoimmune disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGZtS35KHrIrVg90H21EOLACvtfcHk0liVz8veflqslw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1ylsbg%253D&md5=be7692b3c222ac9eb9b1d1ca68a77e47</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2017.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2017.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DVillalta%26aufirst%3DS.%2BA.%26aulast%3DFeldman%26aufirst%3DH.%2BC.%26aulast%3DRegister%26aufirst%3DA.%2BC.%26aulast%3DRosenthal%26aufirst%3DW.%26aulast%3DHoffmann-Petersen%26aufirst%3DI.%2BT.%26aulast%3DMehdizadeh%26aufirst%3DM.%26aulast%3DGhosh%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DColon-Negron%26aufirst%3DK.%26aulast%3DMeza-Acevedo%26aufirst%3DR.%26aulast%3DBackes%26aufirst%3DB.%2BJ.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26aulast%3DBluestone%26aufirst%3DJ.%2BA.%26aulast%3DPapa%26aufirst%3DF.%2BR.%26atitle%3DTargeting%2520ABL-IRE1%25CE%25B1%2520signaling%2520spares%2520ER-stressed%2520pancreatic%2520%25CE%25B2%2520cells%2520to%2520reverse%2520autoimmune%2520diabetes%26jtitle%3DCell%2520Metab.%26date%3D2017%26volume%3D25%26issue%3D4%26spage%3D883%26epage%3D897%26doi%3D10.1016%2Fj.cmet.2017.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dayan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, K. C.</span></span> <span> </span><span class="NLM_article-title">Changing the landscape for type 1 diabetes: the first step to prevention</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>394</i></span> (<span class="NLM_issue">10205</span>),  <span class="NLM_fpage">1286</span>– <span class="NLM_lpage">1296</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)32127-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2FS0140-6736%2819%2932127-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=31533907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSgtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2019&pages=1286-1296&issue=10205&author=C.+M.+Dayanauthor=M.+Korahauthor=D.+Tatovicauthor=B.+N.+Bundyauthor=K.+C.+Herold&title=Changing+the+landscape+for+type+1+diabetes%3A+the+first+step+to+prevention&doi=10.1016%2FS0140-6736%2819%2932127-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Changing the landscape for type 1 diabetes: the first step to prevention</span></div><div class="casAuthors">Dayan, Colin M.; Korah, Maria; Tatovic, Danijela; Bundy, Brian N.; Herold, Kevan C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">10205</span>),
    <span class="NLM_cas:pages">1286-1296</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Over several decades, studies have described the progression of autoimmune diabetes, from the first appearance of autoantibodies until, and after, the diagnosis of clin. disease with hyperglycemia and insulin dependence.  Despite the improved management of type 1 diabetes with exogenous insulin, most patients do not meet clin. glycemic goals, and diabetes remains an important medical problem that affects children and adults.  Clin. and preclin. studies have suggested strategies to prevent the diagnosis of type 1 diabetes in people at risk, but the outcomes of previous clin. trials have not met their primary endpoints of disease prevention or delay.  The results from the TN-10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a FcR non-binding monoclonal antibody to CD3 in people at high risk for disease.  This Series paper discusses how this clin. achievement raises new questions about for whom, and when, immunol. strategies might be developed to prevent type 1 diabetes, and how to achieve this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp85ZTak7FRELVg90H21EOLACvtfcHk0liVz8veflqslw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSgtrzP&md5=db7b8f06453481f7d06fd50dacf84c37</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2932127-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252932127-0%26sid%3Dliteratum%253Aachs%26aulast%3DDayan%26aufirst%3DC.%2BM.%26aulast%3DKorah%26aufirst%3DM.%26aulast%3DTatovic%26aufirst%3DD.%26aulast%3DBundy%26aufirst%3DB.%2BN.%26aulast%3DHerold%26aufirst%3DK.%2BC.%26atitle%3DChanging%2520the%2520landscape%2520for%2520type%25201%2520diabetes%253A%2520the%2520first%2520step%2520to%2520prevention%26jtitle%3DLancet%26date%3D2019%26volume%3D394%26issue%3D10205%26spage%3D1286%26epage%3D1296%26doi%3D10.1016%2FS0140-6736%2819%2932127-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenwu  Liu</span>, <span class="hlFld-ContribAuthor ">Xin  Liu</span>, <span class="hlFld-ContribAuthor ">Liting  Tian</span>, <span class="hlFld-ContribAuthor ">Yaping  Gao</span>, <span class="hlFld-ContribAuthor ">Wenjie  Liu</span>, <span class="hlFld-ContribAuthor ">Huanhua  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaowen  Jiang</span>, <span class="hlFld-ContribAuthor ">Zihua  Xu</span>, <span class="hlFld-ContribAuthor ">Huaiwei  Ding</span>, <span class="hlFld-ContribAuthor ">Qingchun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113554. <a href="https://doi.org/10.1016/j.ejmech.2021.113554" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113554</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113554%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bharmine%252Bderivatives%252Bas%252Bpotent%252BGSK-3%2525CE%2525B2%25252FDYRK1A%252Bdual%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252BAlzheimer%252527s%252Bdisease%26aulast%3DLiu%26aufirst%3DWenwu%26date%3D2021%26volume%3D222%26spage%3D113554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mengzhu  Zheng</span>, <span class="hlFld-ContribAuthor ">Qingzhe  Zhang</span>, <span class="hlFld-ContribAuthor ">Chengliang  Zhang</span>, <span class="hlFld-ContribAuthor ">Canrong  Wu</span>, <span class="hlFld-ContribAuthor ">Kaiyin  Yang</span>, <span class="hlFld-ContribAuthor ">Zhuorui  Song</span>, <span class="hlFld-ContribAuthor ">Qiqi  Wang</span>, <span class="hlFld-ContribAuthor ">Chen  Li</span>, <span class="hlFld-ContribAuthor ">Yirong  Zhou</span>, <span class="hlFld-ContribAuthor ">Jiachun  Chen</span>, <span class="hlFld-ContribAuthor ">Hua  Li</span>, <span class="hlFld-ContribAuthor ">Lixia  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">A natural DYRK1A inhibitor as a potential stimulator for β‐cell proliferation in diabetes. </span><span class="cited-content_cbyCitation_journal-name">Clinical and Translational Medicine</span><span> <strong>2021,</strong> <em>11 </em>
                                    (7)
                                     <a href="https://doi.org/10.1002/ctm2.494" title="DOI URL">https://doi.org/10.1002/ctm2.494</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ctm2.494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fctm2.494%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520and%2520Translational%2520Medicine%26atitle%3DA%252Bnatural%252BDYRK1A%252Binhibitor%252Bas%252Ba%252Bpotential%252Bstimulator%252Bfor%252B%2525CE%2525B2%2525E2%252580%252590cell%252Bproliferation%252Bin%252Bdiabetes%26aulast%3DZheng%26aufirst%3DMengzhu%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mattias F.  Lindberg</span>, <span class="hlFld-ContribAuthor ">Laurent  Meijer</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (11)
                                     , 6047. <a href="https://doi.org/10.3390/ijms22116047" title="DOI URL">https://doi.org/10.3390/ijms22116047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22116047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22116047%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDual-Specificity%25252C%252BTyrosine%252BPhosphorylation-Regulated%252BKinases%252B%252528DYRKs%252529%252Band%252Bcdc2-Like%252BKinases%252B%252528CLKs%252529%252Bin%252BHuman%252BDisease%25252C%252Ban%252BOverview%26aulast%3DLindberg%26aufirst%3DMattias%2BF.%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D11%26spage%3D6047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of DYRK1A inhibitors that induce human β-cell proliferation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Mechanism of DYRK1A-NFAT mediated human β-cell proliferation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. SAR study of harmine analogues and crystal structure of harmine bound to DYRK1A (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ANR">3ANR</a>) showing key interactions with Lys188 and Leu241.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. SAR study of 1,3,4-thiadiazines as DYRK1A inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Optimization of aminopyrazine <b>13</b> toward discovery of GNF4877 (<b>16</b>)</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Optimization and SAR studies of 7-azaindoles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Optimization and SAR studies of 1,5-naphthyridine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mechanism of synergistic effect of <b>1</b> and TGFβ inhibitor on human β-cell proliferation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Structure of eGLP1–ASO (<b>26</b>) with fluorescent tag. (B) Structure of amino pyrazine (<b>13</b>) β-cell proliferation inducer, DTBZ (<b>27</b>), and AP-DTBZ conjugate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/medium/jm0c02050_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Structures of GNF4877-EXT-DPA (<b>29</b>) and (B) structures of prodrug ZnPD5 (<b>30</b>) and its Zn(II) mediated ester cleavage products ZP1 (<b>31</b>) and <b>16</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02050/20210319/images/large/jm0c02050_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02050&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i31">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08156" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08156" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 103 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <i>Executive Summary Global
Reports on Diabetes</i>; <span class="NLM_publisher-name">World Health Organization</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Executive+Summary+Global%0AReports+on+Diabetes%3B+World+Health+Organization%2C+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DExecutive%2520Summary%2520Global%250AReports%2520on%2520Diabetes%26pub%3DWorld%2520Health%2520Organization%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span> <i>National Diabetes Satistics
Report</i>; <span class="NLM_publisher-name">Center
for Disease Control and Prevention (CDC)</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+National+Diabetes+Satistics%0AReport%3B+Center%0Afor+Disease+Control+and+Prevention+%28CDC%29%2C+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DNational%2520Diabetes%2520Satistics%250AReport%26pub%3DCenter%250Afor%2520Disease%2520Control%2520and%2520Prevention%2520%2528CDC%2529%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bluestone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbarth, G.</span></span> <span> </span><span class="NLM_article-title">Genetics, pathogenesis and clinical interventions in type 1 diabetes</span>. <i>Nature (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span> (<span class="NLM_issue">7293</span>),  <span class="NLM_fpage">1293</span>– <span class="NLM_lpage">1300</span>, <span class="refDoi"> DOI: 10.1038/nature08933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnature08933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltl2ltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=1293-1300&issue=7293&author=J.+A.+Bluestoneauthor=K.+Heroldauthor=G.+Eisenbarth&title=Genetics%2C+pathogenesis+and+clinical+interventions+in+type+1+diabetes&doi=10.1038%2Fnature08933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Genetics, pathogenesis and clinical interventions in type 1 diabetes</span></div><div class="casAuthors">Bluestone, Jeffrey A.; Herold, Kevan; Eisenbarth, George</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7293</span>),
    <span class="NLM_cas:pages">1293-1300</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Type 1 diabetes is an autoimmune disorder afflicting millions of people worldwide.  Once diagnosed, patients require lifelong insulin treatment and can experience numerous disease-assocd. complications.  The last decade has seen tremendous advances in elucidating the causes and treatment of the disease based on extensive research both in rodent models of spontaneous diabetes and in humans.  Integrating these advances has led to the recognition that the balance between regulatory and effector T cells dets. disease risk, timing of disease activation, and disease tempo.  Here the authors describe current progress, the challenges ahead and the new interventions that are being tested to address the unmet need for preventative or curative therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrinJVAyiy2CbVg90H21EOLACvtfcHk0lhTPbOi6mmPVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltl2ltr8%253D&md5=c5de4f26364038119187cd1cc364711f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature08933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08933%26sid%3Dliteratum%253Aachs%26aulast%3DBluestone%26aufirst%3DJ.%2BA.%26aulast%3DHerold%26aufirst%3DK.%26aulast%3DEisenbarth%26aufirst%3DG.%26atitle%3DGenetics%252C%2520pathogenesis%2520and%2520clinical%2520interventions%2520in%2520type%25201%2520diabetes%26jtitle%3DNature%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2010%26volume%3D464%26issue%3D7293%26spage%3D1293%26epage%3D1300%26doi%3D10.1038%2Fnature08933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrannini, E.</span></span> <span> </span><span class="NLM_article-title">The stunned β cell: a brief history</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2010.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2010.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=20444416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtleis7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=349-352&issue=5&author=E.+Ferrannini&title=The+stunned+%CE%B2+cell%3A+a+brief+history&doi=10.1016%2Fj.cmet.2010.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The stunned β cell: a brief history</span></div><div class="casAuthors">Ferrannini, Ele</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-352</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  β Cell dysfunction is sufficient to cause hyperglycemia; β cell loss is not necessary but, if severe, can be sufficient and may be accompanied by intrinsic β cell dysfunction.  Clin. testing can differentiate β cell capacity from β cell glucose sensitivity but cannot ascribe either to relative changes in β cell mass vs. function.  However, longitudinal and intervention studies indicate that β cell glucose insensitivity (stunning) closely tracks with hyperglycemia and is, at least in part, reversible.  Rescuing stunned β cells is a key therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3OBfJdbqmjbVg90H21EOLACvtfcHk0lhTPbOi6mmPVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtleis7o%253D&md5=418ba1462e578d7d0ed2e847cbba4a9c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2010.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2010.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DFerrannini%26aufirst%3DE.%26atitle%3DThe%2520stunned%2520%25CE%25B2%2520cell%253A%2520a%2520brief%2520history%26jtitle%3DCell%2520Metab.%26date%3D2010%26volume%3D11%26issue%3D5%26spage%3D349%26epage%3D352%26doi%3D10.1016%2Fj.cmet.2010.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meier, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizza, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, P. C.</span></span> <span> </span><span class="NLM_article-title">Sustained β-cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2221</span>– <span class="NLM_lpage">2228</span>, <span class="refDoi"> DOI: 10.1007/s00125-005-1949-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1007%2Fs00125-005-1949-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=16205882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Skt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2221-2228&issue=11&author=J.+J.+Meierauthor=A.+Bhushanauthor=A.+E.+Butlerauthor=R.+A.+Rizzaauthor=P.+C.+Butler&title=Sustained+%CE%B2-cell+apoptosis+in+patients+with+long-standing+type+1+diabetes%3A+indirect+evidence+for+islet+regeneration%3F&doi=10.1007%2Fs00125-005-1949-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?</span></div><div class="casAuthors">Meier, J. J.; Bhushan, A.; Butler, A. E.; Rizza, R. A.; Butler, P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2221-2228</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Aims/hypothesis: Type 1 diabetes is widely held to result from an irreversible loss of insulin-secreting beta cells.  However, insulin secretion is detectable in some people with long-standing type 1 diabetes, indicating either a small population of surviving beta cells or continued renewal of beta cells subject to ongoing autoimmune destruction.  The aim of the present study was to evaluate these possibilities.  Materials and methods: Pancreatic sections from 42 individuals with type 1 diabetes and 14 non-diabetic individuals were evaluated for the presence of beta cells, beta cell apoptosis and replication, T lymphocytes and macrophages.  The presence and extent of periductal fibrosis was also quantified.  Results: Beta cells were identified in 88% of individuals with type 1 diabetes.  The no. of beta cells was unrelated to duration of disease (range 4-67 years) or age at death (range 14-77 years), but was higher (p<0.05) in individuals with lower mean blood glucose.  Beta cell apoptosis was twice as frequent in type 1 diabetes as in control subjects (p<0.001), but beta cell replication was rare in both groups.  The increased beta cell apoptosis in type 1 diabetes was accompanied by both increased macrophages and T lymphocytes and a marked increase in periductal fibrosis (p<0.001), implying chronic inflammation over many years, consistent with an ongoing supply of beta cells.  Conclusions/interpretation: Most people with long-standing type 1 diabetes have beta cells that continue to be destroyed.  The mechanisms underlying increased beta cell death may involve both ongoing autoimmunity and glucose toxicity.  The presence of beta cells despite ongoing apoptosis implies, by definition, that concomitant new beta cell formation must be occurring, even after long-standing type 1 diabetes.  We conclude that type 1 diabetes may be reversed by targeted inhibition of beta cell destruction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqLVyfuuqQ_LVg90H21EOLACvtfcHk0lhTPbOi6mmPVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Skt7vJ&md5=089daf7c1358b2e1c8abc9fa57581408</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs00125-005-1949-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-005-1949-2%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26aulast%3DBhushan%26aufirst%3DA.%26aulast%3DButler%26aufirst%3DA.%2BE.%26aulast%3DRizza%26aufirst%3DR.%2BA.%26aulast%3DButler%26aufirst%3DP.%2BC.%26atitle%3DSustained%2520%25CE%25B2-cell%2520apoptosis%2520in%2520patients%2520with%2520long-standing%2520type%25201%2520diabetes%253A%2520indirect%2520evidence%2520for%2520islet%2520regeneration%253F%26jtitle%3DDiabetologia%26date%3D2005%26volume%3D48%26issue%3D11%26spage%3D2221%26epage%3D2228%26doi%3D10.1007%2Fs00125-005-1949-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiaschi-Taesch, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasavada, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">Diabetes mellitus-advances and challenges in human β-cell proliferation</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2015.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrendo.2015.9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=25687999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivFWktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=201-212&issue=4&author=P.+Wangauthor=N.+M.+Fiaschi-Taeschauthor=R.+C.+Vasavadaauthor=D.+K.+Scottauthor=A.+Garcia-Ocanaauthor=A.+F.+Stewart&title=Diabetes+mellitus-advances+and+challenges+in+human+%CE%B2-cell+proliferation&doi=10.1038%2Fnrendo.2015.9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetes mellitus-advances and challenges in human β-cell proliferation</span></div><div class="casAuthors">Wang, Peng; Fiaschi-Taesch, Nathalie M.; Vasavada, Rupangi C.; Scott, Donald K.; Garcia-Ocana, Adolfo; Stewart, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">201-212</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The treatment of diabetes mellitus represents one of the greatest medical challenges of our era.  Diabetes results from a deficiency or functional impairment of insulin-producing β cells, alone or in combination with insulin resistance.  It logically follows that the replacement or regeneration of β cells should reverse the progression of diabetes and, indeed, this seems to be the case in humans and rodents.  This concept has prompted attempts in many labs. to create new human β cells using stem-cell strategies to transdifferentiate or reprogram non-β cells into β cells or to discover small mols. or other compds. that can induce proliferation of human β cells.  This latter approach has shown promise, but has also proven particularly challenging to implement.  In this Review, we discuss the physiol. of normal human β-cell replication, the mol. mechanisms that regulate the cell cycle in human β cells, the upstream intracellular signalling pathways that connect them to cell surface receptors on β cells, the epigenetic mechanisms that control human β-cell proliferation and unbiased approaches for discovering novel mols. that can drive human β-cell proliferation.  Finally, we discuss the potential and challenges of implementing strategies that replace or regenerate β cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyZARqiz5cV7Vg90H21EOLACvtfcHk0lhGpBlmP-xG5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivFWktL4%253D&md5=32e771cd720d326dacf886def4ae87ed</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2015.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2015.9%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DFiaschi-Taesch%26aufirst%3DN.%2BM.%26aulast%3DVasavada%26aufirst%3DR.%2BC.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DDiabetes%2520mellitus-advances%2520and%2520challenges%2520in%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2015%26volume%3D11%26issue%3D4%26spage%3D201%26epage%3D212%26doi%3D10.1038%2Fnrendo.2015.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, W. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, L. G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, T. N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, E. S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattamisra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candasamy, M.</span></span> <span> </span><span class="NLM_article-title">Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention</span>. <i>Diabetes Metab Syndr</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1016/j.dsx.2018.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.dsx.2018.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30641727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A280%3ADC%252BB3cjht1OisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=364-372&issue=1&author=S.+Y.+Tanauthor=W.+J.+L.+Meiauthor=Y.+J.+Simauthor=S.+S.+Wongauthor=S.+H.+Tanauthor=L.+G.+P.+Lingauthor=T.+N.+W.+Rongauthor=N.+C.+Annanauthor=E.+S.+A.+Mohamedauthor=S.+K.+Bhattamisraauthor=M.+Candasamy&title=Type+1+and+2+diabetes+mellitus%3A+A+review+on+current+treatment+approach+and+gene+therapy+as+potential+intervention&doi=10.1016%2Fj.dsx.2018.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention</span></div><div class="casAuthors">Tan Sin Yee; Mei Wong Joyce Ling; Sim Yan Jinn; Wong Su Sie; Tan Sean Hong; Ling Lim Grace Pei; Rong Tay Nicole Wuen; Annan Naveenya Chetty; Mohamed Elhassan Safa Abdelgadir; Bhattamisra Subrat Kumar; Candasamy Mayuren</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes & metabolic syndrome</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">364-372</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type 1 and type 2 diabetes mellitus is a serious and lifelong condition commonly characterised by abnormally elevated blood glucose levels due to a failure in insulin production or a decrease in insulin sensitivity and function.  Over the years, prevalence of diabetes has increased globally and it is classified as one of the leading cause of high mortality and morbidity rate.  Furthermore, diabetes confers a huge economic burden due to its management costs as well as its complications are skyrocketing.  The conventional medications in diabetes treatment focusing on insulin secretion and insulin sensitisation cause unwanted side effects to patients and lead to incompliance as well as treatment failure.  Besides insulin and oral hypoglycaemic agents, other treatments such as gene therapy and induced β-cells regeneration have not been widely introduced to manage diabetes.  Therefore, this review aims to deliver an overview of the current conventional medications in diabetes, discovery of newer pharmacological drugs and gene therapy as a potential intervention of diabetes in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9gChR5MMa5N0Q2ypr7jHkfW6udTcc2eZoUWdi0lQhQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjht1OisA%253D%253D&md5=d46edec4547793fc86f34eeb8e7a3262</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.dsx.2018.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dsx.2018.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DS.%2BY.%26aulast%3DMei%26aufirst%3DW.%2BJ.%2BL.%26aulast%3DSim%26aufirst%3DY.%2BJ.%26aulast%3DWong%26aufirst%3DS.%2BS.%26aulast%3DTan%26aufirst%3DS.%2BH.%26aulast%3DLing%26aufirst%3DL.%2BG.%2BP.%26aulast%3DRong%26aufirst%3DT.%2BN.%2BW.%26aulast%3DAnnan%26aufirst%3DN.%2BC.%26aulast%3DMohamed%26aufirst%3DE.%2BS.%2BA.%26aulast%3DBhattamisra%26aufirst%3DS.%2BK.%26aulast%3DCandasamy%26aufirst%3DM.%26atitle%3DType%25201%2520and%25202%2520diabetes%2520mellitus%253A%2520A%2520review%2520on%2520current%2520treatment%2520approach%2520and%2520gene%2520therapy%2520as%2520potential%2520intervention%26jtitle%3DDiabetes%2520Metab%2520Syndr%26date%3D2019%26volume%3D13%26issue%3D1%26spage%3D364%26epage%3D372%26doi%3D10.1016%2Fj.dsx.2018.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner-Weir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritzel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizza, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, P. C.</span></span> <span> </span><span class="NLM_article-title">β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.2337/diabetes.52.1.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdiabetes.52.1.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=12502499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVaisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2003&pages=102-110&issue=1&author=A.+E.+Butlerauthor=J.+Jansonauthor=S.+Bonner-Weirauthor=R.+Ritzelauthor=R.+A.+Rizzaauthor=P.+C.+Butler&title=%CE%B2-cell+deficit+and+increased+%CE%B2-cell+apoptosis+in+humans+with+type+2+diabetes&doi=10.2337%2Fdiabetes.52.1.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes</span></div><div class="casAuthors">Butler, Alexandra E.; Janson, Juliette; Bonner-Weir, Susan; Ritzel, Robert; Rizza, Robert A.; Butler, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-110</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">Type 2 diabetes is characterized by impaired insulin secretion.  Some but not all studies suggest that a decrease in β-cell mass contributes to this.  We examd. pancreatic tissue from 124 autopsies: 91 obese cases (BMI >27 kg/m2; 41 with type 2 diabetes, 15 with impaired fasting glucose [IFG], and 35 nondiabetic subjects) and 33 lean cases (BMI <25 kg/m2; 16 type 2 diabetic and 17 nondiabetic subjects).  We measured relative β-cell vol., frequency of β-cell apoptosis and replication, and new islet formation from exocrine ducts (neogenesis).  Relative β-cell vol. was increased in obese vs. lean nondiabetic cases (P = 0.05) through the mechanism of increased neogenesis (P < 0.05).  Obese humans with IFG and type 2 diabetes had a 40% (P < 0.05) and 63% (P < 0.01) deficit and lean cases of type 2 diabetes had a 41% deficit (P < 0.05) in relative β-cell vol. compared with nondiabetic obese and lean cases, resp.  The frequency of β-cell replication was very low in all cases and no different among groups.  Neogenesis, while increased with obesity, was comparable in obese type 2 diabetic, IFG, or nondiabetic subjects and in lean type 2 diabetic or nondiabetic subjects.  However, the frequency of β-cell apoptosis was increased 10-fold in lean and 3-fold in obese cases of type 2 diabetes compared with their resp. nondiabetic control group (P < 0.05).  We conclude that β-cell mass is decreased in type 2 diabetes and that the mechanism underlying this is increased β-cell apoptosis.  Since the major defect leading to a decrease in β-cell mass in type 2 diabetes is increased apoptosis, while new islet formation and β-cell replication are normal, therapeutic approaches designed to arrest apoptosis could be a significant new development in the management of type 2 diabetes, because this approach might actually reverse the disease to a degree rather than just palliate glycemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVcyE2o6KAcbVg90H21EOLACvtfcHk0lhGpBlmP-xG5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVaisA%253D%253D&md5=ce00b44af8145b182dd17131a75e14ae</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.52.1.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.52.1.102%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DA.%2BE.%26aulast%3DJanson%26aufirst%3DJ.%26aulast%3DBonner-Weir%26aufirst%3DS.%26aulast%3DRitzel%26aufirst%3DR.%26aulast%3DRizza%26aufirst%3DR.%2BA.%26aulast%3DButler%26aufirst%3DP.%2BC.%26atitle%3D%25CE%25B2-cell%2520deficit%2520and%2520increased%2520%25CE%25B2-cell%2520apoptosis%2520in%2520humans%2520with%2520type%25202%2520diabetes%26jtitle%3DDiabetes%26date%3D2003%26volume%3D52%26issue%3D1%26spage%3D102%26epage%3D110%26doi%3D10.2337%2Fdiabetes.52.1.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell-Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaddis, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserfall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugliese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M. A.</span></span> <span> </span><span class="NLM_article-title">Insulitis and β-cell mass in the natural history of type 1 diabetes</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.2337/db15-0779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb15-0779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26581594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKltLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=719-731&issue=3&author=M.+Campbell-Thompsonauthor=A.+Fuauthor=J.+S.+Kaddisauthor=C.+Wasserfallauthor=D.+A.+Schatzauthor=A.+Puglieseauthor=M.+A.+Atkinson&title=Insulitis+and+%CE%B2-cell+mass+in+the+natural+history+of+type+1+diabetes&doi=10.2337%2Fdb15-0779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Insulitis and β-cell mass in the natural history of type 1 diabetes</span></div><div class="casAuthors">Campbell-Thompson, Martha; Fu, Ann; Kaddis, John S.; Wasserfall, Clive; Schatz, Desmond A.; Pugliese, Alberto; Atkinson, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">719-731</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Descriptions of insulitis in human islets throughout the natural history of type 1 diabetes are limited.  We detd. insulitis frequency (the percent of islets displaying insulitis to total islets), infiltrating leukocyte subtypes, and β-cell and α-cell mass in pancreata recov- ered from organ donors with type 1 diabetes (n = 80), as well as from donors without diabetes, both with islet au- toantibodies (AAb-, n = 18) and without islet autoanti- bodies (AAb-, n = 61).  Insulitis was obsd. in four of four donors (100%) with type 1 diabetes duration of ≤1 yr and two AAb- donors (2 of 18 donors, 11%).  Insulitis frequency showed a significant but limited inverse corre- lation with diabetes duration (r = -0.58, P = 0.01) but not with age at disease onset.  Residual β-cells were obsd. in all type 1 diabetes donors with insulitis, while β-cell area and mass were significantly higher in type 1 diabetes do- nors with insulitis compared with those without insulitis.  Insulitis affected 33% of insulin' islets compared with 2% of insulin islets in donors with type 1 diabetes.  A signifi- cant correlation was obsd. between insulitis frequency and CD45+, CD+, CD4+, CD8+, and CD20+ cell nos. within the insulitis (r = 0.53-0.73, P = 0.004-0.04), but not CD68+ or CD11c+ cells.  The presence of β-cells as well as insulitis several years after diagnosis in children and young adults suggests that the chronicity of islet autoimmunity extends well into the postdiagnosis period.  This informa- tion should aid considerations of therapeutic strategies seeking type 1 diabetes prevention and reversal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFzD4FuUdazrVg90H21EOLACvtfcHk0liJ7PDEDetCIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKltLfM&md5=536b4f6374259c00b7b1c80f2c9aeac0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2337%2Fdb15-0779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb15-0779%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell-Thompson%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DA.%26aulast%3DKaddis%26aufirst%3DJ.%2BS.%26aulast%3DWasserfall%26aufirst%3DC.%26aulast%3DSchatz%26aufirst%3DD.%2BA.%26aulast%3DPugliese%26aufirst%3DA.%26aulast%3DAtkinson%26aufirst%3DM.%2BA.%26atitle%3DInsulitis%2520and%2520%25CE%25B2-cell%2520mass%2520in%2520the%2520natural%2520history%2520of%2520type%25201%2520diabetes%26jtitle%3DDiabetes%26date%3D2016%26volume%3D65%26issue%3D3%26spage%3D719%26epage%3D731%26doi%3D10.2337%2Fdb15-0779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.-M.</span></span> <span> </span><span class="NLM_article-title">Cellular signaling pathways regulating β-cell proliferation as a promising therapeutic target in the treatment of diabetes (review)</span>. <i>Exp. Ther. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlWmtrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=1-11&issue=4&author=W.-J.+Jiangauthor=Y.-C.+Pengauthor=K.-M.+Yang&title=Cellular+signaling+pathways+regulating+%CE%B2-cell+proliferation+as+a+promising+therapeutic+target+in+the+treatment+of+diabetes+%28review%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelial stem cells attenuate cardiac apoptosis via downregulating cardiac microRNA-146a in a rat model of coronary heart disease</span></div><div class="casAuthors">Fang, Yeqing; Chen, Shaoyuan; Liu, Zhenguo; Ai, Wen; He, Xiaofang; Wang, Lei; Xie, Peiyi; Jiang, Bimei; Fang, Hongcheng</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Therapeutic Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">ETMXA2</span>;
        ISSN:<span class="NLM_cas:issn">1792-1015</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Coronary artery disease (CAD) is one of the main causes of hospitalization worldwide and has high morbidity.  It has previously been demonstrated that stem cells serve an important role in improving myocardial function.  MicroRNA (miRNA)-146a downregulation has been reported to inhibit vascular smooth muscle cell apoptosis in a rat model of coronary heart disease.  The aim of the present study was to investigate the mechanisms underlying the effects of endothelial stem cell (ESC)-derived paracrine factors and cardiac miRNAs in CAD.  Acute myocardial infarction was induced in 20 rats.  Autologous ESCs (n=10; exptl. group) or PBS (n=10; control group) were injected in the border zone.  Reverse transcription-quantitativepolymerase chain reaction, ELISA and immunohistochem. assays were performed to analyze the therapeutic effects of ESCs in rats with coronary heart disease rats.  Serum interleukin (IL)-1, IL-17 and tumor necrosis factor-α were reduced in the exptl. group compared with control rats, as was the no. of circulating proatherogenic cells.  The results demonstrated that ESC transplantation markedly downregulatedmiRNA-146a expression and decreased apoptosis in the myocardium compared with the control group.  Rats in the exptl. group also had higher levels of vascular endothelial growth factor compared with the control group.  In addn., it was demonstrated that miRNA-146 knockdown reduced cardiac apoptosis and increased VEGF expression.  Furthermore, the infarct area in the border zone or rats with CAD was reduced in the exptl. group compared with the control group.  In conclusion, these results suggest that ESC transplantation may improve cardiac function via downregulating miR-146a, which may be have potential as a treatment for CAD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpba9Xas-bqwrVg90H21EOLACvtfcHk0liJ7PDEDetCIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlWmtrvK&md5=c8d7d920ced4952b1558ec822f70b88b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DW.-J.%26aulast%3DPeng%26aufirst%3DY.-C.%26aulast%3DYang%26aufirst%3DK.-M.%26atitle%3DCellular%2520signaling%2520pathways%2520regulating%2520%25CE%25B2-cell%2520proliferation%2520as%2520a%2520promising%2520therapeutic%2520target%2520in%2520the%2520treatment%2520of%2520diabetes%2520%2528review%2529%26jtitle%3DExp.%2520Ther.%2520Med.%26date%3D2018%26volume%3D16%26issue%3D4%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karakose, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackeifi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">Advances in drug discovery for human β-cell regeneration</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1693</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1007/s00125-018-4639-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1007%2Fs00125-018-4639-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=29770834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFyhs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1693-1699&issue=8&author=E.+Karakoseauthor=C.+Ackeifiauthor=P.+Wangauthor=A.+F.+Stewart&title=Advances+in+drug+discovery+for+human+%CE%B2-cell+regeneration&doi=10.1007%2Fs00125-018-4639-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in drug discovery for human beta cell regeneration</span></div><div class="casAuthors">Karakose, Esra; Ackeifi, Courtney; Wang, Peng; Stewart, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1693-1699</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The nos. of insulin-secreting pancreatic beta cells are reduced in people with type 1 and type 2 diabetes.  Driving beta cell regeneration in the pancreases of people with diabetes would be an attractive approach to reversing diabetes.  While adult human beta cells have long been believed to be terminally differentiated and, therefore, irreversibly quiescent, it has become clear over recent years that this is not true.  More specifically, both candidate and unbiased high-throughput screen approaches have revealed several classes of mols. that are clearly able to induce human beta cell proliferation.  Here, we review recent approaches and accomplishments in human beta cell regenerative drug discovery.  We also list the challenges that this rapidly moving field must confront to translate beta cell regenerative therapy from the lab. to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwrd9iOZ9UrLVg90H21EOLACvtfcHk0liJ7PDEDetCIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFyhs7w%253D&md5=6e9b8f40e4e07a3cd6b8eba1af284856</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs00125-018-4639-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-018-4639-6%26sid%3Dliteratum%253Aachs%26aulast%3DKarakose%26aufirst%3DE.%26aulast%3DAckeifi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DAdvances%2520in%2520drug%2520discovery%2520for%2520human%2520%25CE%25B2-cell%2520regeneration%26jtitle%3DDiabetologia%26date%3D2018%26volume%3D61%26issue%3D8%26spage%3D1693%26epage%3D1699%26doi%3D10.1007%2Fs00125-018-4639-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirakawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span> <span> </span><span class="NLM_article-title">Novel factors modulating human β-cell proliferation</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">S1</span>),  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1111/dom.12731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1111%2Fdom.12731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=27615134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyltr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=71-77&issue=S1&author=J.+Shirakawaauthor=R.+N.+Kulkarni&title=Novel+factors+modulating+human+%CE%B2-cell+proliferation&doi=10.1111%2Fdom.12731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Novel factors modulating human β-cell proliferation</span></div><div class="casAuthors">Shirakawa, J.; Kulkarni, R. N.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">71-77</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">β-Cell dysfunction in type 1 and type 2 diabetes is accompanied by a progressive loss of β-cells, and an understanding of the cellular mechanism(s) that regulate β-cell mass will enable approaches to enhance hormone secretion.  It is becoming increasingly recognized that enhancement of human β-cell proliferation is one potential approach to restore β-cell mass to prevent and/or cure type 1 and type 2 diabetes.  While several reports describe the factor(s) that enhance β-cell replication in animal models or cell lines, promoting effective human β-cell proliferation continues to be a challenge in the field.  In this review, we discuss recent studies reporting successful human β-cell proliferation including WS6, an IkB kinase and EBP1 inhibitor; harmine and 5-IT, both DYRK1A inhibitors; GNF7156 and GNF4877, GSK-3β and DYRK1A inhibitors; osteoprotegrin and Denosmab, receptor activator of NF-kB (RANK) inhibitors; and SerpinB1, a protease inhibitor.  These studies provide important examples of proteins and pathways that may prove useful for designing therapeutic strategies to counter the different forms of human diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9FUo37-cG7bVg90H21EOLACvtfcHk0lg-44L7_EIv-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyltr3E&md5=aa02d20a9e03ee38c74ef3af2d0e5f6a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fdom.12731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12731%26sid%3Dliteratum%253Aachs%26aulast%3DShirakawa%26aufirst%3DJ.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26atitle%3DNovel%2520factors%2520modulating%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2016%26volume%3D18%26issue%3DS1%26spage%3D71%26epage%3D77%26doi%3D10.1111%2Fdom.12731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vetere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the pancreatic β-cell to treat diabetes</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1038/nrd4231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrd4231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=24525781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFSht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=278-289&issue=4&author=A.+Vetereauthor=A.+Choudharyauthor=S.+M.+Burnsauthor=B.+K.+Wagner&title=Targeting+the+pancreatic+%CE%B2-cell+to+treat+diabetes&doi=10.1038%2Fnrd4231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the pancreatic β-cell to treat diabetes</span></div><div class="casAuthors">Vetere, Amedeo; Choudhary, Amit; Burns, Sean M.; Wagner, Bridget K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">278-289</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Diabetes is a leading cause of morbidity and mortality worldwide, and predicted to affect over 500 million people by 2030.  However, this growing burden of disease has not been met with a comparable expansion in therapeutic options.  The appreciation of the pancreatic β-cell as a central player in the pathogenesis of both type 1 and type 2 diabetes has renewed focus on ways to improve glucose homeostasis by preserving, expanding and improving the function of this key cell type.  Here, we provide an overview of the latest developments in this field, with an emphasis on the most promising strategies identified to date for treating diabetes by targeting the β-cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9e3CEl2cNAbVg90H21EOLACvtfcHk0lg-44L7_EIv-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFSht7Y%253D&md5=703d2104e872c969a1acbad3e92d61fb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd4231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4231%26sid%3Dliteratum%253Aachs%26aulast%3DVetere%26aufirst%3DA.%26aulast%3DChoudhary%26aufirst%3DA.%26aulast%3DBurns%26aufirst%3DS.%2BM.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26atitle%3DTargeting%2520the%2520pancreatic%2520%25CE%25B2-cell%2520to%2520treat%2520diabetes%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26issue%3D4%26spage%3D278%26epage%3D289%26doi%3D10.1038%2Fnrd4231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregg, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demozay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, C. J.</span></span> <span> </span><span class="NLM_article-title">Formation of a human β-cell population within pancreatic islets is set early in life</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>97</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3197</span>– <span class="NLM_lpage">3206</span>, <span class="refDoi"> DOI: 10.1210/jc.2012-1206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1210%2Fjc.2012-1206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=22745242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtlymu7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=3197-3206&issue=9&author=B.+E.+Greggauthor=P.+C.+Mooreauthor=D.+Demozayauthor=B.+A.+Hallauthor=M.+Liauthor=A.+Husainauthor=A.+J.+Wrightauthor=M.+A.+Atkinsonauthor=C.+J.+Rhodes&title=Formation+of+a+human+%CE%B2-cell+population+within+pancreatic+islets+is+set+early+in+life&doi=10.1210%2Fjc.2012-1206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Formation of a human β-cell population within pancreatic islets is set early in life</span></div><div class="casAuthors">Gregg, Brigid E.; Moore, Patrick C.; Demozay, Damien; Hall, Ben A.; Li, Mei; Husain, Aliya; Wright, Amy J.; Atkinson, Mark A.; Rhodes, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3197-3206</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Context: Insulin resistance can be compensated by increased functional pancreatic β-cell mass; otherwise, diabetes ensues.  Such compensation depends not only on environmental and genetic factors but also on the baseline β-cell mass from which the expansion originates.  Objective: Little is known about assembly of a baseline β-cell mass in humans.  Here, we examd. formation of β-cell populations relative to other pancreatic islet cell types and assocd. neurons throughout the normal human lifespan.  Design and Methods: Human pancreatic sections derived from normal cadavers aged 24 wk premature to 72 yr were examd. by immunofluorescence.  Insulin, glucagon, and somatostatin were used as markers for β-, α-, and δ-cells, resp.  Cytokeratin-19 marked ductal cells, Ki67 cell proliferation, and Tuj1 (neuronal class III β-tubulin) marked neurons.  Results: Most β-cell neogenesis was obsd. preterm with a burst of β-cell proliferation peaking within the first 2 yr of life.  Thereafter, little indication of β-cell growth was obsd.  Postnatal proliferation of α- and δ-cells was rarely seen, but a wave of ductal cell proliferation was found mostly assocd. with exocrine cell expansion.  The β-cell to α-cell ratio doubled neonatally, reflecting increased growth of β-cells, but during childhood, there was a 7-fold change in the β-cell to δ-cell ratio, reflecting an addnl. loss of δ-cells.  A close assocn. of neurons to pancreatic islets was noted developmentally and retained throughout adulthood.  Negligible neuronal assocn. to exocrine pancreas was obsd.  Conclusion: Human baseline β-cell population and appropriate assocn. with other islet cell types is established before 5 yr of age.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3K2h2ve0i07Vg90H21EOLACvtfcHk0lg-44L7_EIv-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtlymu7vJ&md5=e71533f2d6e1a26f3a98e82ae5126ca9</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1210%2Fjc.2012-1206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2012-1206%26sid%3Dliteratum%253Aachs%26aulast%3DGregg%26aufirst%3DB.%2BE.%26aulast%3DMoore%26aufirst%3DP.%2BC.%26aulast%3DDemozay%26aufirst%3DD.%26aulast%3DHall%26aufirst%3DB.%2BA.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHusain%26aufirst%3DA.%26aulast%3DWright%26aufirst%3DA.%2BJ.%26aulast%3DAtkinson%26aufirst%3DM.%2BA.%26aulast%3DRhodes%26aufirst%3DC.%2BJ.%26atitle%3DFormation%2520of%2520a%2520human%2520%25CE%25B2-cell%2520population%2520within%2520pancreatic%2520islets%2520is%2520set%2520early%2520in%2520life%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2012%26volume%3D97%26issue%3D9%26spage%3D3197%26epage%3D3206%26doi%3D10.1210%2Fjc.2012-1206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meier, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saisho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monchamp, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizza, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, P. C.</span></span> <span> </span><span class="NLM_article-title">β-Cell replication is the primary mechanism subserving the postnatal expansion of β-cell mass in humans</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1584</span>– <span class="NLM_lpage">1594</span>, <span class="refDoi"> DOI: 10.2337/db07-1369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb07-1369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=18334605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsF2isr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2008&pages=1584-1594&issue=6&author=J.+J.+Meierauthor=A.+E.+Butlerauthor=Y.+Saishoauthor=T.+Monchampauthor=R.+Galassoauthor=A.+Bhushanauthor=R.+A.+Rizzaauthor=P.+C.+Butler&title=%CE%B2-Cell+replication+is+the+primary+mechanism+subserving+the+postnatal+expansion+of+%CE%B2-cell+mass+in+humans&doi=10.2337%2Fdb07-1369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">β-Cell replication is the primary mechanism subserving the postnatal expansion of β-cell mass in humans</span></div><div class="casAuthors">Meier, Juris J.; Butler, Alexandra E.; Saisho, Yoshifumi; Monchamp, Travis; Galasso, Ryan; Bhushan, Anil; Rizza, Robert A.; Butler, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1584-1594</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Little is known about the capacity, mechanisms, or timing of growth in β-cell mass in humans.  We sought to establish if the predominant expansion of β-cell mass in humans occurs in early childhood and if, as in rodents, this coincides with relatively abundant β-cell replication.  We also sought to establish if there is a secondary growth in β-cell mass coincident with the accelerated somatic growth in adolescence.  To address these questions, pancreas vol. was detd. from abdominal computer tomogs. in 135 children aged 4 wk to 20 years, and morphometric analyses were performed in human pancreatic tissue obtained at autopsy from 46 children aged 2 wk to 21 years.  We report that (1) β-cell mass expands by several-fold from birth to adulthood, (2) islets grow in size rather than in no. during this transition, (3) the relative rate of β-cell growth is highest in infancy and gradually declines thereafter to adulthood with no secondary accelerated growth phase during adolescence, (4) β-cell mass (and presumably growth) is highly variable between individuals, and (5) a high rate of β-cell replication is coincident with the major postnatal expansion of β-cell mass.  These data imply that regulation of β-cell replication during infancy plays a major role in β-cell mass in adult humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7r0YX6A1w-7Vg90H21EOLACvtfcHk0lg-44L7_EIv-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsF2isr0%253D&md5=e07d494d4a1c440c8ee18bc2fff4652a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2337%2Fdb07-1369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb07-1369%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26aulast%3DButler%26aufirst%3DA.%2BE.%26aulast%3DSaisho%26aufirst%3DY.%26aulast%3DMonchamp%26aufirst%3DT.%26aulast%3DGalasso%26aufirst%3DR.%26aulast%3DBhushan%26aufirst%3DA.%26aulast%3DRizza%26aufirst%3DR.%2BA.%26aulast%3DButler%26aufirst%3DP.%2BC.%26atitle%3D%25CE%25B2-Cell%2520replication%2520is%2520the%2520primary%2520mechanism%2520subserving%2520the%2520postnatal%2520expansion%2520of%2520%25CE%25B2-cell%2520mass%2520in%2520humans%26jtitle%3DDiabetes%26date%3D2008%26volume%3D57%26issue%3D6%26spage%3D1584%26epage%3D1594%26doi%3D10.2337%2Fdb07-1369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdolazimi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allegretti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCutcheon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalizi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annes, J. P.</span></span> <span> </span><span class="NLM_article-title">CC-401 promotes β-cell replication via pleiotropic consequences of DYRK1A/B inhibition</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>159</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3143</span>– <span class="NLM_lpage">3157</span>, <span class="refDoi"> DOI: 10.1210/en.2018-00083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1210%2Fen.2018-00083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=29514186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCgu7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2018&pages=3143-3157&issue=9&author=Y.+Abdolazimiauthor=Z.+Zhaoauthor=S.+Leeauthor=H.+Xuauthor=P.+Allegrettiauthor=T.+M.+Hortonauthor=B.+Yehauthor=H.+P.+Moellerauthor=R.+J.+Nicholsauthor=D.+McCutcheonauthor=A.+Shaliziauthor=M.+Smithauthor=N.+A.+Armstrongauthor=J.+P.+Annes&title=CC-401+promotes+%CE%B2-cell+replication+via+pleiotropic+consequences+of+DYRK1A%2FB+inhibition&doi=10.1210%2Fen.2018-00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">CC-401 promotes β-cell replication via pleiotropic consequences of DYRK1A/B inhibition</span></div><div class="casAuthors">Abdolazimi, Yassan; Zhao, Zhengshan; Lee, Sooyeon; Xu, Haixia; Allegretti, Paul; Horton, Timothy M.; Yeh, Benjamin; Moeller, Hannah P.; Nichols, Robert J.; McCutcheon, David; Shalizi, Aryaman; Smith, Mark; Armstrong, Neali A.; Annes, Justin P.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3143-3157</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">1945-7170</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Pharmacol. expansion of endogenous β cells is a promising therapeutic strategy for diabetes.  To elucidate the mol. pathways that control β-cell growth we screened ∼2400 bioactive compds. for rat β-cell replication-modulating activity.  Numerous hit compds. impaired or promoted rat β-cell replication, including CC-401, an advanced clin. candidate previously characterized as a c-Jun N-terminal kinase inhibitor.  Surprisingly, CC-401 induced rodent (in vitro and in vivo) and human (in vitro) β-cell replication via dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) 1A and 1B inhibition.  In contrast to rat β cells, which were broadly growth responsive to compd. treatment, human β-cell replication was only consistently induced by DYRK1A/B inhibitors.  This effect was enhanced by simultaneous glycogen synthase kinase-3β (GSK-3β) or activin A receptor type II-like kinase/transforming growth factor-β (ALK5/TGF-β) inhibition.  Prior work emphasized DYRK1A/B inhibition-dependent activation of nuclear factor of activated T cells (NFAT) as the primary mechanism of human β-cell-replication induction.  However, inhibition of NFAT activity had limited effect on CC-401-induced β-cell replication.  Consequently, we investigated addnl. effects of CC-401-dependent DYRK1A/B inhibition.  Indeed, CC-401 inhibited DYRK1A-dependent phosphorylation/stabilization of the β-cell-replication inhibitor p27Kip1.  Addnl., CC-401 increased expression of numerous replication-promoting genes normally suppressed by the dimerization partner, RB-like, E2F and multivulval class B (DREAM) complex, which depends upon DYRK1A/B activity for integrity, including MYBL2 and FOXM1.  In summary, we present a compendium of compds. as a valuable resource for manipulating the signaling pathways that control β-cell replication and leverage a DYRK1A/B inhibitor (CC-401) to expand our understanding of the mol. pathways that control β-cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0bClqAWU1ZLVg90H21EOLACvtfcHk0ljTmA2fO03gpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCgu7rP&md5=35cb7f0245f44f2d8a66eae8a78b390e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1210%2Fen.2018-00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2018-00083%26sid%3Dliteratum%253Aachs%26aulast%3DAbdolazimi%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DAllegretti%26aufirst%3DP.%26aulast%3DHorton%26aufirst%3DT.%2BM.%26aulast%3DYeh%26aufirst%3DB.%26aulast%3DMoeller%26aufirst%3DH.%2BP.%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26aulast%3DMcCutcheon%26aufirst%3DD.%26aulast%3DShalizi%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DN.%2BA.%26aulast%3DAnnes%26aufirst%3DJ.%2BP.%26atitle%3DCC-401%2520promotes%2520%25CE%25B2-cell%2520replication%2520via%2520pleiotropic%2520consequences%2520of%2520DYRK1A%252FB%2520inhibition%26jtitle%3DEndocrinology%26date%3D2018%26volume%3D159%26issue%3D9%26spage%3D3143%26epage%3D3157%26doi%3D10.1210%2Fen.2018-00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allegretti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdolazimi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caffet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annes, J. P.</span></span> <span> </span><span class="NLM_article-title">Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115193</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.bmc.2019.115193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=31757680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1amsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115193&author=P.+A.+Allegrettiauthor=T.+M.+Hortonauthor=Y.+Abdolazimiauthor=H.+P.+Moellerauthor=B.+Yehauthor=M.+Caffetauthor=G.+Michelauthor=M.+Smithauthor=J.+P.+Annes&title=Generation+of+highly+potent+DYRK1A-dependent+inducers+of+human+%CE%B2-Cell+replication+via+Multi-Dimensional+compound+optimization&doi=10.1016%2Fj.bmc.2019.115193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization</span></div><div class="casAuthors">Allegretti, Paul A.; Horton, Timothy M.; Abdolazimi, Yassan; Moeller, Hannah P.; Yeh, Benjamin; Caffet, Matthew; Michel, Guillermina; Smith, Mark; Annes, Justin P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115193</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Small mol. stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes.  Although chem. inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replication, current lead compds. have inadequate cellular potency for in vivo application.  Herein, we report the clin. stage anti-cancer kinase inhibitor OTS167 as a structurally novel, remarkably potent DYRK1A inhibitor and inducer of human β-cell replication.  Unfortunately, OTS167's target promiscuity and cytotoxicity curtails utility.  To tailor kinase selectivity towards DYRK1A and reduce cytotoxicity we designed a library of fifty-one OTS167 derivs. based upon a modeled structure of the DYRK1A-OTS167 complex.  Indeed, deriv. characterization yielded several leads with exceptional DYRK1A inhibition and human β-cell replication promoting potencies but substantially reduced cytotoxicity.  These compds. are the most potent human β-cell replication-promoting compds. yet described and exemplify the potential to purposefully leverage off-target activities of advanced stage compds. for a desired application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1KYUl2Lp-FrVg90H21EOLACvtfcHk0ljTmA2fO03gpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1amsLvL&md5=e01d93661157162b14a0995c19c5b6f2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115193%26sid%3Dliteratum%253Aachs%26aulast%3DAllegretti%26aufirst%3DP.%2BA.%26aulast%3DHorton%26aufirst%3DT.%2BM.%26aulast%3DAbdolazimi%26aufirst%3DY.%26aulast%3DMoeller%26aufirst%3DH.%2BP.%26aulast%3DYeh%26aufirst%3DB.%26aulast%3DCaffet%26aufirst%3DM.%26aulast%3DMichel%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DAnnes%26aufirst%3DJ.%2BP.%26atitle%3DGeneration%2520of%2520highly%2520potent%2520DYRK1A-dependent%2520inducers%2520of%2520human%2520%25CE%25B2-Cell%2520replication%2520via%2520Multi-Dimensional%2520compound%2520optimization%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115193%26doi%3D10.1016%2Fj.bmc.2019.115193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dirice, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpita, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dancik, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of DYRK1A stimulates human beta-cell proliferation</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1660</span>– <span class="NLM_lpage">1671</span>, <span class="refDoi"> DOI: 10.2337/db15-1127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb15-1127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26953159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWns7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=1660-1671&issue=6&author=E.+Diriceauthor=D.+Walpitaauthor=A.+Vetereauthor=B.+C.+Meierauthor=S.+Kahramanauthor=J.+Huauthor=V.+Dancikauthor=S.+M.+Burnsauthor=T.+J.+Gilbertauthor=D.+E.+Olsonauthor=P.+A.+Clemonsauthor=R.+N.+Kulkarniauthor=B.+K.+Wagner&title=Inhibition+of+DYRK1A+stimulates+human+beta-cell+proliferation&doi=10.2337%2Fdb15-1127"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of DYRK1A stimulates human beta-cell proliferation</span></div><div class="casAuthors">Dirice, Ercument; Walpita, Deepika; Vetere, Amedeo; Meier, Bennett C.; Kahraman, Sevim; Hu, Jiang; Dancik, Vlado; Burns, Sean M.; Gilbert, Tamara J.; Olson, David E.; Clemons, Paul A.; Kulkarni, Rohit N.; Wagner, Bridget K.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1660-1671</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Restoring functional β-cell mass is an important therapeutic goal for both type 1 and type 2 diabetes (1).  While proliferation of existing β-cells is the primary means of β-cell replacement in rodents (2), it is unclear whether a similar principle applies to humans, as human β-cells are remarkably resistant to stimulation of division (3,4).  Here, we show that 5-iodotubercidin (5-IT), an annotated adenosine kinase inhibitor previously reported to increase proliferation in rodent and porcine islets (5), strongly and selectively increases human β-cell proliferation in vitro and in vivo.  Remarkably, 5-IT also increased glucose-dependent insulin secretion after prolonged treatment.  Kinome profiling revealed 5-IT to be a potent and selective inhibitor of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) and cell division cycle-like kinase families.  Induction of β-cell proliferation by either 5-IT or harmine, another natural product DYRK1A inhibitor, was suppressed by coincubation with the calcineurin inhibitor FK506, suggesting involvement of DYRK1A and nuclear factor of activated T cells signaling.  Gene expression profiling in whole islets treated with 5-IT revealed induction of proliferation- and cell cycle-related genes, suggesting that true proliferation is induced by 5-IT.  Furthermore, 5-IT promotes β-cell proliferation in human islets grafted under the kidney capsule of NOD-scid IL2Rgnull mice.  These results point to inhibition of DYRK1A as a therapeutic strategy to increase human β-cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqLKPVi2wkdrVg90H21EOLACvtfcHk0ljTmA2fO03gpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWns7vP&md5=c383c8d1f2c1739252ad3cfe4361585c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2337%2Fdb15-1127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb15-1127%26sid%3Dliteratum%253Aachs%26aulast%3DDirice%26aufirst%3DE.%26aulast%3DWalpita%26aufirst%3DD.%26aulast%3DVetere%26aufirst%3DA.%26aulast%3DMeier%26aufirst%3DB.%2BC.%26aulast%3DKahraman%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DDancik%26aufirst%3DV.%26aulast%3DBurns%26aufirst%3DS.%2BM.%26aulast%3DGilbert%26aufirst%3DT.%2BJ.%26aulast%3DOlson%26aufirst%3DD.%2BE.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26atitle%3DInhibition%2520of%2520DYRK1A%2520stimulates%2520human%2520beta-cell%2520proliferation%26jtitle%3DDiabetes%26date%3D2016%26volume%3D65%26issue%3D6%26spage%3D1660%26epage%3D1671%26doi%3D10.2337%2Fdb15-1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jarhad, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashelkar, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, L. S.</span></span> <span> </span><span class="NLM_article-title">Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) inhibitors as potential therapeutics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">9791</span>– <span class="NLM_lpage">9810</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00185</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12jsLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9791-9810&issue=22&author=D.+B.+Jarhadauthor=K.+K.+Mashelkarauthor=H.-R.+Kimauthor=M.+Nohauthor=L.+S.+Jeong&title=Dual-Specificity+Tyrosine+Phosphorylation-Regulated+Kinase+1A+%28DYRK1A%29+inhibitors+as+potential+therapeutics&doi=10.1021%2Facs.jmedchem.8b00185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics</span></div><div class="casAuthors">Jarhad, Dnyandev B.; Mashelkar, Karishma K.; Kim, Hong-Rae; Noh, Minsoo; Jeong, Lak Shin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9791-9810</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a member of an evolutionarily conserved family of protein kinases that belongs to the CMGC group of kinases.  DYRK1A, encoded by a gene located in the human chromosome 21q22.2 region, has attracted attention due to its assocn. with both neuropathol. phenotypes and cancer susceptibility in patients with Down syndrome (DS).  Inhibition of DYRK1A attenuates cognitive dysfunctions in animal models for both DS and Alzheimer's disease (AD).  Furthermore, DYRK1A has been studied as a potential cancer therapeutic target because of its role in the regulation of cell cycle progression by affecting both tumor suppressors and oncogenes.  Consequently, selective synthetic inhibitors have been developed to det. the role of DYRK1A in various human diseases.  Our perspective includes a comprehensive review of potent and selective DYRK1A inhibitors and their forthcoming therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYrGtCZLBQ77Vg90H21EOLACvtfcHk0ljwbZPf7pumeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12jsLvO&md5=6ffb927f58fc34f16f19c5e5b8beebcf</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00185%26sid%3Dliteratum%253Aachs%26aulast%3DJarhad%26aufirst%3DD.%2BB.%26aulast%3DMashelkar%26aufirst%3DK.%2BK.%26aulast%3DKim%26aufirst%3DH.-R.%26aulast%3DNoh%26aufirst%3DM.%26aulast%3DJeong%26aufirst%3DL.%2BS.%26atitle%3DDual-Specificity%2520Tyrosine%2520Phosphorylation-Regulated%2520Kinase%25201A%2520%2528DYRK1A%2529%2520inhibitors%2520as%2520potential%2520therapeutics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D22%26spage%3D9791%26epage%3D9810%26doi%3D10.1021%2Facs.jmedchem.8b00185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man-Un Ung, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1016</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.ejmech.2018.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30170319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1ent7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=1005-1016&author=K.+Kumarauthor=P.+Man-Un+Ungauthor=P.+Wangauthor=H.+Wangauthor=H.+Liauthor=M.+K.+Andrewsauthor=A.+F.+Stewartauthor=A.+Schlessingerauthor=R.+J.+DeVita&title=Novel+selective+thiadiazine+DYRK1A+inhibitor+lead+scaffold+with+human+pancreatic+%CE%B2-cell+proliferation+activity&doi=10.1016%2Fj.ejmech.2018.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity</span></div><div class="casAuthors">Kumar, Kunal; Man-Un Ung, Peter; Wang, Peng; Wang, Hui; Li, Hailing; Andrews, Mary K.; Stewart, Andrew F.; Schlessinger, Avner; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1005-1016</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) is an enzyme that has been implicated as an important drug target in various therapeutic areas, including neurol. disorders (Down syndrome, Alzheimer's disease), oncol., and diabetes (pancreatic β-cell expansion).  Current small mol. DYRK1A inhibitors are ATP-competitive inhibitors that bind to the kinase in an active conformation.  As a result, these inhibitors are promiscuous, resulting in pharmacol. side effects that limit their therapeutic applications.  None are in clin. trials at this time.  In order to identify a new DYRK1A inhibitor scaffold, we constructed a homol. model of DYRK1A in an inactive, DFG-out conformation.  Virtual screening of 2.2 million lead-like compds. from the ZINC database, followed by in vitro testing of selected 68 compds. revealed 8 hits representing 5 different chem. classes.  We chose to focus on one of the hits from the computational screen, thiadiazine 1 which was found to inhibit DYRK1A with IC50 of 9.41 μM (Kd = 7.3 μM).  Optimization of the hit compd. 1, using structure-activity relationship (SAR) anal. and in vitro testing led to the identification of potent thiadiazine analogs with significantly improved binding as compared to the initial hit (Kd = 71-185 nM).  Compd. 3-5 induced human β-cell proliferation at 5 μM while showing selectivity for DYRK1A over DYRK1B and DYRK2 at 10 μM.  This newly developed DYRK1A inhibitor scaffold with unique kinase selectivity profiles has potential to be further optimized as novel therapeutics for diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs8HXnn8ewabVg90H21EOLACvtfcHk0ljwbZPf7pumeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1ent7vE&md5=026fe0a5ddf42ebeacdea9c5838b0565</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DMan-Un%2BUng%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DAndrews%26aufirst%3DM.%2BK.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DSchlessinger%26aufirst%3DA.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DNovel%2520selective%2520thiadiazine%2520DYRK1A%2520inhibitor%2520lead%2520scaffold%2520with%2520human%2520pancreatic%2520%25CE%25B2-cell%2520proliferation%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D1005%26epage%3D1016%26doi%3D10.1016%2Fj.ejmech.2018.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Development of kinase-selective, harmine-based dYRK1A inhibitors that induce pancreatic human β-cell proliferation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7687</span>– <span class="NLM_lpage">7699</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00658</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00658" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSrsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7687-7699&issue=17&author=K.+Kumarauthor=P.+Wangauthor=R.+Sanchezauthor=E.+A.+Swartzauthor=A.+F.+Stewartauthor=R.+J.+DeVita&title=Development+of+kinase-selective%2C+harmine-based+dYRK1A+inhibitors+that+induce+pancreatic+human+%CE%B2-cell+proliferation&doi=10.1021%2Facs.jmedchem.8b00658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation</span></div><div class="casAuthors">Kumar, Kunal; Wang, Peng; Sanchez, Roberto; Swartz, Ethan A.; Stewart, Andrew F.; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7687-7699</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">DYRK1A has been implicated as an important drug target in various therapeutic areas, including neurol. disorders and oncol.  DYRK1A has more recently been shown to be involved in pathways regulating human β-cell proliferation, thus making it a potential therapeutic target for both Type 1 and Type 2 diabetes.  Our group, using a high-throughput phenotypic screen identified harmine that is able to induce beta cell proliferation both in vitro and in vivo.  Since harmine has suboptimal kinase selectivity we sought to expand structure-activity relationships for harmine's DYRK1A activity, to enhance selectivity, while retaining human β-cell proliferation capability.  We carried out the optimization of the 1-position of harmine and synthesized 15 harmine analogs.  6 Compds. showed excellent DYRK1A inhibition with IC50 in the range of 49.5-264 nM.  Two compds., 2-2 and 2-8, exhibited excellent human β-cell proliferation at doses of 3-30 μM and compd. 2-2 showed improved kinase selectivity as compared to harmine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmFSDNEicChLVg90H21EOLACvtfcHk0ljwbZPf7pumeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSrsb7M&md5=e1b748db912ac5b0ef93b8729ad4b13e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00658%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DSwartz%26aufirst%3DE.%2BA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DDevelopment%2520of%2520kinase-selective%252C%2520harmine-based%2520dYRK1A%2520inhibitors%2520that%2520induce%2520pancreatic%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7687%26epage%3D7699%26doi%3D10.1021%2Facs.jmedchem.8b00658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatanic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrouet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamrui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological validation of a harmine-based, central nervous system (CNS)-avoidant, selective, human β-cell regenerative dual-specificity tyrosine phosphorylation-regulated kinase A (DYRK1A) inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2984</span>– <span class="NLM_lpage">3003</span></span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01379" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2984-3003&author=K.+Kumarauthor=P.+Wangauthor=J.+Wilsonauthor=V.+Zlatanicauthor=C.+Berrouetauthor=S.+Khamruiauthor=C.+Secorauthor=E.+A.+Swartzauthor=M.+Lazarusauthor=R.+Sanchezauthor=A.+F.+Stewartauthor=A.+Garcia-Ocanaauthor=R.+J.+DeVita&title=Synthesis+and+biological+validation+of+a+harmine-based%2C+central+nervous+system+%28CNS%29-avoidant%2C+selective%2C+human+%CE%B2-cell+regenerative+dual-specificity+tyrosine+phosphorylation-regulated+kinase+A+%28DYRK1A%29+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01379%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DZlatanic%26aufirst%3DV.%26aulast%3DBerrouet%26aufirst%3DC.%26aulast%3DKhamrui%26aufirst%3DS.%26aulast%3DSecor%26aufirst%3DC.%26aulast%3DSwartz%26aufirst%3DE.%2BA.%26aulast%3DLazarus%26aufirst%3DM.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DSynthesis%2520and%2520biological%2520validation%2520of%2520a%2520harmine-based%252C%2520central%2520nervous%2520system%2520%2528CNS%2529-avoidant%252C%2520selective%252C%2520human%2520%25CE%25B2-cell%2520regenerative%2520dual-specificity%2520tyrosine%2520phosphorylation-regulated%2520kinase%2520A%2520%2528DYRK1A%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2984%26epage%3D3003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursalaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Donato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamireddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loren, J.</span></span> <span> </span><span class="NLM_article-title">A dual inhibitor of DYRK1A and GSK3β for β-cell proliferation: Aminopyrazine derivative GNF4877</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1562</span>– <span class="NLM_lpage">1570</span>, <span class="refDoi"> DOI: 10.1002/cmdc.202000183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1002%2Fcmdc.202000183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=32613743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1yqsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=1562-1570&issue=16&author=Y.+A.+Liuauthor=Q.+Jinauthor=Q.+Dingauthor=X.+Haoauthor=T.+Moauthor=S.+Yanauthor=Y.+Zouauthor=Z.+Huangauthor=X.+Zhangauthor=W.+Gaoauthor=T.+Y.+H.+Wuauthor=C.+Liauthor=B.+Bursalayaauthor=M.+Di+Donatoauthor=Y.-Q.+Zhangauthor=L.+Deatonauthor=W.+Shenauthor=B.+Taylorauthor=A.+Kamireddyauthor=G.+Harbauthor=J.+Liauthor=Y.+Jiaauthor=A.+M.+Schumacherauthor=B.+Laffitteauthor=R.+Glynneauthor=S.+Panauthor=P.+McNamaraauthor=V.+Molteniauthor=J.+Loren&title=A+dual+inhibitor+of+DYRK1A+and+GSK3%CE%B2+for+%CE%B2-cell+proliferation%3A+Aminopyrazine+derivative+GNF4877&doi=10.1002%2Fcmdc.202000183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877</span></div><div class="casAuthors">Liu, Yahu A.; Jin, Qihui; Ding, Qiang; Hao, Xueshi; Mo, Tingting; Yan, Shanshan; Zou, Yefen; Huang, Zhihong; Zhang, Xiaoyue; Gao, Wenqi; Wu, Tom Y.-H.; Li, Chun; Bursalaya, Badry; Di Donato, Michael; Zhang, You-Qing; Deaton, Lisa; Shen, Weijun; Taylor, Brandon; Kamireddy, Anwesh; Harb, George; Li, Jing; Jia, Yong; Schumacher, Andrew M.; Laffitte, Bryan; Glynne, Richard; Pan, Shifeng; McNamara, Peter; Molteni, Valentina; Loren, Jon</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1562-1570</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Loss of β-cell mass and function can lead to insufficient insulin levels and ultimately to hyperglycemia and diabetes mellitus.  The mainstream treatment approach involves regulation of insulin levels; however, approaches intended to increase β-cell mass are less developed.  Promoting β-cell proliferation with low-mol.-wt. inhibitors of dual-specificity tyrosine-regulated kinase 1A (DYRK1A) offers the potential to treat diabetes with oral therapies by restoring β-cell mass, insulin content and glycemic control.  GNF4877, a potent dual inhibitor of DYRK1A and glycogen synthase kinase 3β (GSK3β) was previously reported to induce primary human β-cell proliferation in vitro and in vivo.  Herein, we describe the lead optimization that lead to the identification of GNF4877(I) from an aminopyrazine hit identified in a phenotypic high-throughput screening campaign measuring β-cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq9Ym91j41B7Vg90H21EOLACvtfcHk0lifkcPna_WVWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1yqsbrK&md5=4b02cad328225a30bf99eb302e4e177c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.202000183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.202000183%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BA.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DT.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DT.%2BY.%2BH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DBursalaya%26aufirst%3DB.%26aulast%3DDi%2BDonato%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.-Q.%26aulast%3DDeaton%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DTaylor%26aufirst%3DB.%26aulast%3DKamireddy%26aufirst%3DA.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DSchumacher%26aufirst%3DA.%2BM.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DLoren%26aufirst%3DJ.%26atitle%3DA%2520dual%2520inhibitor%2520of%2520DYRK1A%2520and%2520GSK3%25CE%25B2%2520for%2520%25CE%25B2-cell%2520proliferation%253A%2520Aminopyrazine%2520derivative%2520GNF4877%26jtitle%3DChemMedChem%26date%3D2020%26volume%3D15%26issue%3D16%26spage%3D1562%26epage%3D1570%26doi%3D10.1002%2Fcmdc.202000183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrassi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baaten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamireddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeusen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loren, J.</span></span> <span> </span><span class="NLM_article-title">Selective DYRK1A inhibitor for the treatment of type 1 diabetes: discovery of 6-azaindole derivative GNF2133</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2958</span>– <span class="NLM_lpage">2973</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01624</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01624" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlSqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2958-2973&author=Y.+A.+Liuauthor=Q.+Jinauthor=Y.+Zouauthor=Q.+Dingauthor=S.+Yanauthor=Z.+Wangauthor=X.+Haoauthor=B.+Nguyenauthor=X.+Zhangauthor=J.+Panauthor=T.+Moauthor=K.+Jacobsenauthor=T.+Lamauthor=T.+Y.+H.+Wuauthor=H.+M.+Petrassiauthor=B.+Bursulayaauthor=M.+DiDonatoauthor=W.+P.+Gordonauthor=B.+Liuauthor=J.+Baatenauthor=R.+Hillauthor=V.+Nguyen-Tranauthor=M.+Qiuauthor=Y.-Q.+Zhangauthor=A.+Kamireddyauthor=S.+Espinolaauthor=L.+Deatonauthor=S.+Haauthor=G.+Harbauthor=Y.+Jiaauthor=J.+Liauthor=W.+Shenauthor=A.+M.+Schumacherauthor=K.+Colmanauthor=R.+Glynneauthor=S.+Panauthor=P.+McNamaraauthor=B.+Laffitteauthor=S.+Meeusenauthor=V.+Molteniauthor=J.+Loren&title=Selective+DYRK1A+inhibitor+for+the+treatment+of+type+1+diabetes%3A+discovery+of+6-azaindole+derivative+GNF2133&doi=10.1021%2Facs.jmedchem.9b01624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133</span></div><div class="casAuthors">Liu, Yahu A.; Jin, Qihui; Zou, Yefen; Ding, Qiang; Yan, Shanshan; Wang, Zhicheng; Hao, Xueshi; Nguyen, Bao; Zhang, Xiaoyue; Pan, Jianfeng; Mo, Tingting; Jacobsen, Kate; Lam, Thanh; Wu, Tom Y.-H.; Petrassi, H. Michael; Bursulaya, Badry; Di Donato, Michael; Gordon, W. Perry; Liu, Bo; Baaten, Janine; Hill, Robert; Nguyen-Tran, Van; Qiu, Minhua; Zhang, You-Qing; Kamireddy, Anwesh; Espinola, Sheryll; Deaton, Lisa; Ha, Sukwon; Harb, George; Jia, Yong; Li, Jing; Shen, Weijun; Schumacher, Andrew M.; Colman, Karyn; Glynne, Richard; Pan, Shifeng; McNamara, Peter; Laffitte, Bryan; Meeusen, Shelly; Molteni, Valentina; Loren, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2958-2973</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Autoimmune deficiency and destruction in either β-cell mass or function can cause insufficient insulin levels and, as a result, hyperglycemia and diabetes.  Thus, promoting β-cell proliferation could be one approach toward diabetes intervention.  In this report we describe the discovery of a potent and selective DYRK1A inhibitor GNF2133, which was identified through optimization of a 6-azaindole screening hit.  In vitro, GNF2133 is able to proliferate both rodent and human β-cells.  In vivo, GNF2133 demonstrated significant dose-dependent glucose disposal capacity and insulin secretion in response to glucose-potentiated arginine-induced insulin secretion (GPAIS) challenge in rat insulin promoter and diphtheria toxin A (RIP-DTA) mice.  The work described here provides new avenues to disease altering therapeutic interventions in the treatment of type 1 diabetes (T1D).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKP8bWozWpHrVg90H21EOLACvtfcHk0lifkcPna_WVWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlSqs7g%253D&md5=0ec2402f79b1b3fa338aab9672b8b669</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01624%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%2BA.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DT.%26aulast%3DJacobsen%26aufirst%3DK.%26aulast%3DLam%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DT.%2BY.%2BH.%26aulast%3DPetrassi%26aufirst%3DH.%2BM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DBaaten%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%26aulast%3DNguyen-Tran%26aufirst%3DV.%26aulast%3DQiu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.-Q.%26aulast%3DKamireddy%26aufirst%3DA.%26aulast%3DEspinola%26aufirst%3DS.%26aulast%3DDeaton%26aufirst%3DL.%26aulast%3DHa%26aufirst%3DS.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DSchumacher%26aufirst%3DA.%2BM.%26aulast%3DColman%26aufirst%3DK.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DMeeusen%26aufirst%3DS.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DLoren%26aufirst%3DJ.%26atitle%3DSelective%2520DYRK1A%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25201%2520diabetes%253A%2520discovery%2520of%25206-azaindole%2520derivative%2520GNF2133%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2958%26epage%3D2973%26doi%3D10.1021%2Facs.jmedchem.9b01624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeusen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamireddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swafford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursalaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez-Pinzon, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hering, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of DYRK1A and GSK3B induces human β-cell proliferation</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8372</span>, <span class="refDoi"> DOI: 10.1038/ncomms9372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fncomms9372" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26496802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslegu7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=8372&author=W.+Shenauthor=B.+Taylorauthor=Q.+Jinauthor=V.+Nguyen-Tranauthor=S.+Meeusenauthor=Y.-Q.+Zhangauthor=A.+Kamireddyauthor=A.+Swaffordauthor=A.+F.+Powersauthor=J.+Walkerauthor=J.+Lambauthor=B.+Bursalayaauthor=M.+DiDonatoauthor=G.+Harbauthor=M.+Qiuauthor=C.+M.+Filippiauthor=L.+Deatonauthor=C.+N.+Turkauthor=W.+L.+Suarez-Pinzonauthor=Y.+Liuauthor=X.+Haoauthor=T.+Moauthor=S.+Yanauthor=J.+Liauthor=A.+E.+Hermanauthor=B.+J.+Heringauthor=T.+Wuauthor=H.+M.+Seidelauthor=P.+McNamaraauthor=R.+Glynneauthor=B.+Laffitte&title=Inhibition+of+DYRK1A+and+GSK3B+induces+human+%CE%B2-cell+proliferation&doi=10.1038%2Fncomms9372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of DYRK1A and GSK3B induces human β-cell proliferation</span></div><div class="casAuthors">Shen, Weijun; Taylor, Brandon; Jin, Qihui; Nguyen-Tran, Van; Meeusen, Shelly; Zhang, You-Qing; Kamireddy, Anwesh; Swafford, Austin; Powers, Andrew F.; Walker, John; Lamb, John; Bursalaya, Badry; DiDonato, Michael; Harb, George; Qiu, Minhua; Filippi, Christophe M.; Deaton, Lisa; Turk, Carolina N.; Suarez-Pinzon, Wilma L.; Liu, Yahu; Hao, Xueshi; Mo, Tingting; Yan, Shanshan; Li, Jing; Herman, Ann E.; Hering, Bernhard J.; Wu, Tom; Seidel, H. Martin; McNamara, Peter; Glynne, Richard; Laffitte, Bryan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8372</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Insufficient pancreatic β-cell mass or function results in diabetes mellitus.  While significant progress has been made in regulating insulin secretion from β-cells in diabetic patients, no pharmacol. agents have been described that increase β-cell replication in humans.  Here we report aminopyrazine compds. that stimulate robust β-cell proliferation in adult primary islets, most likely as a result of combined inhibition of DYRK1A and GSK3B.  Aminopyrazine-treated human islets retain functionality in vitro and after transplantation into diabetic mice.  Oral dosing of these compds. in diabetic mice induces β-cell proliferation, increases β-cell mass and insulin content, and improves glycemic control.  Biochem., genetic and cell biol. data point to Dyrk1a as the key mol. target.  This study supports the feasibility of treating diabetes with an oral therapy to restore β-cell mass, and highlights a tractable pathway for future drug discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVHzP-VkH5nrVg90H21EOLACvtfcHk0ljPoj3OUcSNww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslegu7%252FK&md5=5ef960af3bfd2795b9fdce52876e5d59</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fncomms9372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms9372%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%26aulast%3DTaylor%26aufirst%3DB.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DNguyen-Tran%26aufirst%3DV.%26aulast%3DMeeusen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.-Q.%26aulast%3DKamireddy%26aufirst%3DA.%26aulast%3DSwafford%26aufirst%3DA.%26aulast%3DPowers%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DJ.%26aulast%3DLamb%26aufirst%3DJ.%26aulast%3DBursalaya%26aufirst%3DB.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DQiu%26aufirst%3DM.%26aulast%3DFilippi%26aufirst%3DC.%2BM.%26aulast%3DDeaton%26aufirst%3DL.%26aulast%3DTurk%26aufirst%3DC.%2BN.%26aulast%3DSuarez-Pinzon%26aufirst%3DW.%2BL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DT.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHerman%26aufirst%3DA.%2BE.%26aulast%3DHering%26aufirst%3DB.%2BJ.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DLaffitte%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520DYRK1A%2520and%2520GSK3B%2520induces%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D8372%26doi%3D10.1038%2Fncomms9372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Perez, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felsenfeld, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivendran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic β-cell replication</span>. <i>Nat. Med. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">388</span>, <span class="refDoi"> DOI: 10.1038/nm.3820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnm.3820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=25751815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFOnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=383-388&issue=4&author=P.+Wangauthor=J.-C.+Alvarez-Perezauthor=D.+P.+Felsenfeldauthor=H.+Liuauthor=S.+Sivendranauthor=A.+Benderauthor=A.+Kumarauthor=R.+Sanchezauthor=D.+K.+Scottauthor=A.+Garcia-Ocanaauthor=A.+F.+Stewart&title=A+high-throughput+chemical+screen+reveals+that+harmine-mediated+inhibition+of+DYRK1A+increases+human+pancreatic+%CE%B2-cell+replication&doi=10.1038%2Fnm.3820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication</span></div><div class="casAuthors">Wang, Peng; Alvarez-Perez, Juan-Carlos; Felsenfeld, Dan P.; Liu, Hongtao; Sivendran, Sharmila; Bender, Aaron; Kumar, Anil; Sanchez, Roberto; Scott, Donald K.; Garcia-Ocana, Adolfo; Stewart, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">383-388</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Types 1 and 2 diabetes affect some 380 million people worldwide.  Both ultimately result from a deficiency of functional pancreatic insulin-producing beta cells.  Beta cells proliferate in humans during a brief temporal window beginning around the time of birth, with a peak percentage (∼2%) engaged in the cell cycle in the first year of life.  In embryonic life and after early childhood, beta cell replication is barely detectable.  Whereas beta cell expansion seems an obvious therapeutic approach to beta cell deficiency, adult human beta cells have proven recalcitrant to such efforts.  Hence, there remains an urgent need for antidiabetic therapeutic agents that can induce regeneration and expansion of adult human beta cells in vivo or ex vivo.  Here, using a high-throughput small-mol. screen (HTS), we find that analogs of the small mol. harmine function as a new class of human beta cell mitogenic compds.  We also define dual-specificity tyrosine-regulated kinase-1a (DYRK1A) as the likely target of harmine and the nuclear factors of activated T cells (NFAT) family of transcription factors as likely mediators of human beta cell proliferation and differentiation.  Using three different mouse and human islet in vivo-based models, we show that harmine is able to induce beta cell proliferation, increase islet mass and improve glycemic control.  These observations suggest that harmine analogs may have unique therapeutic promise for human diabetes therapy.  Enhancing the potency and beta cell specificity of these compds. are important future challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp11xY4tql3VbVg90H21EOLACvtfcHk0ljPoj3OUcSNww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFOnsr8%253D&md5=32a02c393defd14b8922ac9efff63389</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnm.3820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3820%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DAlvarez-Perez%26aufirst%3DJ.-C.%26aulast%3DFelsenfeld%26aufirst%3DD.%2BP.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSivendran%26aufirst%3DS.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DA%2520high-throughput%2520chemical%2520screen%2520reveals%2520that%2520harmine-mediated%2520inhibition%2520of%2520DYRK1A%2520increases%2520human%2520pancreatic%2520%25CE%25B2-cell%2520replication%26jtitle%3DNat.%2520Med.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2015%26volume%3D21%26issue%3D4%26spage%3D383%26epage%3D388%26doi%3D10.1038%2Fnm.3820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khamrui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships and biological evaluation of 7-substituted harmine analogs for human β-cell proliferation</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1983</span>, <span class="refDoi"> DOI: 10.3390/molecules25081983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.3390%2Fmolecules25081983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVekurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=1983&issue=8&author=K.+Kumarauthor=P.+Wangauthor=E.+A.+Swartzauthor=S.+Khamruiauthor=C.+Secorauthor=M.+B.+Lazarusauthor=R.+Sanchezauthor=A.+F.+Stewartauthor=R.+J.+DeVita&title=Structure-activity+relationships+and+biological+evaluation+of+7-substituted+harmine+analogs+for+human+%CE%B2-cell+proliferation&doi=10.3390%2Fmolecules25081983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships and biological evaluation of 7-substituted harmine analogs for human β-cell proliferation</span></div><div class="casAuthors">Kumar, Kunal; Wang, Peng; Swartz, Ethan A.; Khamrui, Susmita; Secor, Cody; Lazarus, Michael B.; Sanchez, Roberto; Stewart, Andrew F.; DeVita, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1983</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Recently, we have shown that harmine induces β-cell proliferation both in vitro and in vivo, mediated via the DYRK1A-NFAT pathway.  We explore structure-activity relationships of the 7-position of harmine for both DYRK1A kinase inhibition and β-cell proliferation based on our related previous structure-activity relationship studies of harmine in the context of diabetes and β-cell specific targeting strategies.  Thirty three harmine analogs of the 7-position substituent were synthesized and evaluated for biol. activity.  Two novel inhibitors were identified which showed DYRK1A inhibition and human β-cell proliferation capability.  The DYRK1A inhibitor, compd. 3-(7-oxy-1-methyl-9-H-b-carbolin)propionic acid Me ester, induced β-cell proliferation half that of harmine at three times higher concn.  From these studies we can draw the inference that 7-position modification is limited for further harmine optimization focused on β-cell proliferation and cell-specific targeting approach for diabetes therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOP5g7lLBUorVg90H21EOLACvtfcHk0lj8CHJLGP9Ifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVekurrI&md5=4f8c859f119e45d6b406f11354f4cbe9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25081983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25081983%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DSwartz%26aufirst%3DE.%2BA.%26aulast%3DKhamrui%26aufirst%3DS.%26aulast%3DSecor%26aufirst%3DC.%26aulast%3DLazarus%26aufirst%3DM.%2BB.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26atitle%3DStructure-activity%2520relationships%2520and%2520biological%2520evaluation%2520of%25207-substituted%2520harmine%2520analogs%2520for%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26issue%3D8%26spage%3D1983%26doi%3D10.3390%2Fmolecules25081983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamireddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baaten, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swoboda, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inducer of β cell proliferation identified by high-throughput screening</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1669</span>– <span class="NLM_lpage">1672</span>, <span class="refDoi"> DOI: 10.1021/ja309304m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja309304m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCgu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=1669-1672&issue=5&author=W.+Shenauthor=M.+S.+Tremblayauthor=V.+A.+Deshmukhauthor=W.+Wangauthor=C.+M.+Filippiauthor=G.+Harbauthor=Y.-q.+Zhangauthor=A.+Kamireddyauthor=J.+E.+Baatenauthor=Q.+Jinauthor=T.+Wuauthor=J.+G.+Swobodaauthor=E.+C.+Petersauthor=C.+Y.+Choauthor=J.+Liauthor=B.+A.+Laffitteauthor=P.+McNamaraauthor=R.+Glynneauthor=X.+Wuauthor=A.+E.+Hermanauthor=P.+G.+Schultz&title=Small-molecule+inducer+of+%CE%B2+cell+proliferation+identified+by+high-throughput+screening&doi=10.1021%2Fja309304m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inducer of β Cell Proliferation Identified by High-Throughput Screening</span></div><div class="casAuthors">Shen, Weijun; Tremblay, Matthew S.; Deshmukh, Vishal A.; Wang, Weidong; Filippi, Christophe M.; Harb, George; Zhang, You-qing; Kamireddy, Anwesh; Baaten, Janine E.; Jin, Qihui; Wu, Tom; Swoboda, Jonathan G.; Peters, Eric C.; Cho, Charles Y.; Li, Jing; Laffitte, Bryan A.; McNamara, Peter; Glynne, Richard; Wu, Xu; Herman, Ann E.; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1669-1672</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification of factors that promote β cell proliferation could ultimately move type 1 diabetes treatment away from insulin injection therapy and toward a cure.  We have performed high-throughput, cell-based screens using rodent β cell lines to identify mols. that induce proliferation of β cells.  Herein we report the discovery and characterization of WS6, a novel small mol. that promotes β cell proliferation in rodent and human primary islets.  In the RIP-DTA mouse model of β cell ablation, WS6 normalized blood glucose and induced concomitant increases in β cell proliferation and β cell no.  Affinity pulldown and kinase profiling studies implicate Erb3 binding protein-1 and the IκB kinase pathway in the mechanism of action of WS6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcVnec647SN7Vg90H21EOLACvtfcHk0lj8CHJLGP9Ifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCgu7w%253D&md5=f7a76c2f8b61e183e171b3343d65543a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fja309304m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja309304m%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%26aulast%3DTremblay%26aufirst%3DM.%2BS.%26aulast%3DDeshmukh%26aufirst%3DV.%2BA.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DFilippi%26aufirst%3DC.%2BM.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.-q.%26aulast%3DKamireddy%26aufirst%3DA.%26aulast%3DBaaten%26aufirst%3DJ.%2BE.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DSwoboda%26aufirst%3DJ.%2BG.%26aulast%3DPeters%26aufirst%3DE.%2BC.%26aulast%3DCho%26aufirst%3DC.%2BY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLaffitte%26aufirst%3DB.%2BA.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DHerman%26aufirst%3DA.%2BE.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DSmall-molecule%2520inducer%2520of%2520%25CE%25B2%2520cell%2520proliferation%2520identified%2520by%2520high-throughput%2520screening%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26issue%3D5%26spage%3D1669%26epage%3D1672%26doi%3D10.1021%2Fja309304m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondegowda, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenutria, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orthofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasavada, R. C.</span></span> <span> </span><span class="NLM_article-title">Osteoprotegerin and Denosumab stimulate human β-cell proliferation through inhibition of the receptor activator of NF-κB ligand pathway</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2015.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2015.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26094891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2lsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=77-85&issue=1&author=N.+G.+Kondegowdaauthor=R.+Fenutriaauthor=I.+R.+Pollackauthor=M.+Orthoferauthor=A.+Garcia-Ocanaauthor=J.+M.+Penningerauthor=R.+C.+Vasavada&title=Osteoprotegerin+and+Denosumab+stimulate+human+%CE%B2-cell+proliferation+through+inhibition+of+the+receptor+activator+of+NF-%CE%BAB+ligand+pathway&doi=10.1016%2Fj.cmet.2015.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway</span></div><div class="casAuthors">Kondegowda, Nagesha Guthalu; Fenutria, Rafael; Pollack, Ilana R.; Orthofer, Michael; Garcia-Ocana, Adolfo; Penninger, Josef M.; Vasavada, Rupangi C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-85</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Diabetes results from a redn. of pancreatic β-cells.  Stimulating replication could normalize β-cell mass.  However, adult human β-cells are recalcitrant to proliferation.  We identified osteoprotegerin, a bone-related decoy receptor, as a β-cell mitogen.  Osteoprotegerin was induced by and required for lactogen-mediated rodent β-cell replication.  Osteoprotegerin enhanced β-cell proliferation in young, aged, and diabetic mice.  This resulted in increased β-cell mass in young mice and significantly delayed hyperglycemia in diabetic mice.  Osteoprotegerin stimulated replication of adult human β-cells, without causing dedifferentiation.  Mechanistically, osteoprotegerin induced human and rodent β-cell replication by modulating CREB and GSK3 pathways, through binding Receptor Activator of NF-κB (RANK) Ligand (RANKL), a brake in β-cell proliferation.  Denosumab, an FDA-approved osteoporosis drug, and RANKL-specific antibody induced human β-cell proliferation in vitro, and in vivo, in humanized mice.  Thus, osteoprotegerin and Denosumab prevent RANKL/RANK interaction to stimulate β-cell replication, highlighting the potential for repurposing an osteoporosis drug to treat diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Jm7_Ycw93rVg90H21EOLACvtfcHk0lj8CHJLGP9Ifw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2lsrjM&md5=42cd0ef9b90a1338312453d2c4b8c4eb</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2015.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2015.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DKondegowda%26aufirst%3DN.%2BG.%26aulast%3DFenutria%26aufirst%3DR.%26aulast%3DPollack%26aufirst%3DI.%2BR.%26aulast%3DOrthofer%26aufirst%3DM.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DVasavada%26aufirst%3DR.%2BC.%26atitle%3DOsteoprotegerin%2520and%2520Denosumab%2520stimulate%2520human%2520%25CE%25B2-cell%2520proliferation%2520through%2520inhibition%2520of%2520the%2520receptor%2520activator%2520of%2520NF-%25CE%25BAB%2520ligand%2520pathway%26jtitle%3DCell%2520Metab.%26date%3D2015%26volume%3D22%26issue%3D1%26spage%3D77%26epage%3D85%26doi%3D10.1016%2Fj.cmet.2015.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Ouaamari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirice, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gedeon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karampelias, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gritsenko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jesus, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, H.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jungtrakoon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfine, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liew, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doria, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remold-O’Donnell, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span> <span> </span><span class="NLM_article-title">SerpinB1 promotes pancreatic β cell proliferation</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2015.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2015.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26701651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=194-205&issue=1&author=A.+El%0AOuaamariauthor=E.+Diriceauthor=N.+Gedeonauthor=J.+Huauthor=J.-Y.+Zhouauthor=J.+Shirakawaauthor=L.+Houauthor=J.+Goodmanauthor=C.+Karampeliasauthor=G.+Qiangauthor=J.+Boucherauthor=R.+Martinezauthor=M.+A.+Gritsenkoauthor=D.+F.+De+Jesusauthor=S.+Kahramanauthor=S.+Bhattauthor=R.+D.+Smithauthor=H.-D.+Beerauthor=P.+Jungtrakoonauthor=Y.+Gongauthor=A.+B.+Goldfineauthor=C.+W.+Liewauthor=A.+Doriaauthor=O.+Anderssonauthor=W.-J.+Qianauthor=E.+Remold-O%E2%80%99Donnellauthor=R.+N.+Kulkarni&title=SerpinB1+promotes+pancreatic+%CE%B2+cell+proliferation&doi=10.1016%2Fj.cmet.2015.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">SerpinB1 Promotes Pancreatic β Cell Proliferation</span></div><div class="casAuthors">El Ouaamari, Abdelfattah; Dirice, Ercument; Gedeon, Nicholas; Hu, Jiang; Zhou, Jian-Ying; Shirakawa, Jun; Hou, Lifei; Goodman, Jessica; Karampelias, Christos; Qiang, Guifeng; Boucher, Jeremie; Martinez, Rachael; Gritsenko, Marina A.; De Jesus, Dario F.; Kahraman, Sevim; Bhatt, Shweta; Smith, Richard D.; Beer, Hans-Dietmar; Jungtrakoon, Prapaporn; Gong, Yanping; Goldfine, Allison B.; Liew, Chong Wee; Doria, Alessandro; Andersson, Olov; Qian, Wei-Jun; Remold-O'Donnell, Eileen; Kulkarni, Rohit N.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">194-205</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Although compensatory islet hyperplasia in response to insulin resistance is a recognized feature in diabetes, the factor(s) that promote β cell proliferation have been elusive.  We previously reported that the liver is a source for such factors in the liver insulin receptor knockout (LIRKO) mouse, an insulin resistance model that manifests islet hyperplasia.  Using proteomics we show that serpinB1, a protease inhibitor, which is abundant in the hepatocyte secretome and sera derived from LIRKO mice, is the liver-derived secretory protein that regulates β cell proliferation in humans, mice, and zebrafish.  Small-mol. compds., that partially mimic serpinB1 effects of inhibiting elastase activity, enhanced proliferation of β cells, and mice lacking serpinB1 exhibit attenuated β cell compensation in response to insulin resistance.  Finally, SerpinB1 treatment of islets modulated proteins in growth/survival pathways.  Together, these data implicate serpinB1 as an endogenous protein that can potentially be harnessed to enhance functional β cell mass in patients with diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUF320xRQDVbVg90H21EOLACvtfcHk0lgWKPxxmako-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVOqtA%253D%253D&md5=23209ce3e3b16faac4f3e235dec481b5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2015.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2015.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BOuaamari%26aufirst%3DA.%26aulast%3DDirice%26aufirst%3DE.%26aulast%3DGedeon%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DJ.-Y.%26aulast%3DShirakawa%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DL.%26aulast%3DGoodman%26aufirst%3DJ.%26aulast%3DKarampelias%26aufirst%3DC.%26aulast%3DQiang%26aufirst%3DG.%26aulast%3DBoucher%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DGritsenko%26aufirst%3DM.%2BA.%26aulast%3DDe%2BJesus%26aufirst%3DD.%2BF.%26aulast%3DKahraman%26aufirst%3DS.%26aulast%3DBhatt%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DR.%2BD.%26aulast%3DBeer%26aufirst%3DH.-D.%26aulast%3DJungtrakoon%26aufirst%3DP.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DGoldfine%26aufirst%3DA.%2BB.%26aulast%3DLiew%26aufirst%3DC.%2BW.%26aulast%3DDoria%26aufirst%3DA.%26aulast%3DAndersson%26aufirst%3DO.%26aulast%3DQian%26aufirst%3DW.-J.%26aulast%3DRemold-O%25E2%2580%2599Donnell%26aufirst%3DE.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26atitle%3DSerpinB1%2520promotes%2520pancreatic%2520%25CE%25B2%2520cell%2520proliferation%26jtitle%3DCell%2520Metab.%26date%3D2016%26volume%3D23%26issue%3D1%26spage%3D194%26epage%3D205%26doi%3D10.1016%2Fj.cmet.2015.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purwana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deurloo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadkase, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasilo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paraskevas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prud’homme, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span> <span> </span><span class="NLM_article-title">GABA promotes human β-cell proliferation and modulates glucose homeostasis</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4197</span>– <span class="NLM_lpage">4205</span>, <span class="refDoi"> DOI: 10.2337/db14-0153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb14-0153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=25008178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCgtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2014&pages=4197-4205&issue=12&author=I.+Purwanaauthor=J.+Zhengauthor=X.+Liauthor=M.+Deurlooauthor=D.+O.+Sonauthor=Z.+Zhangauthor=C.+Liangauthor=E.+Shenauthor=A.+Tadkaseauthor=Z.-P.+Fengauthor=Y.+Liauthor=C.+Hasiloauthor=S.+Paraskevasauthor=R.+Bortellauthor=D.+L.+Greinerauthor=M.+Atkinsonauthor=G.+J.+Prud%E2%80%99hommeauthor=Q.+Wang&title=GABA+promotes+human+%CE%B2-cell+proliferation+and+modulates+glucose+homeostasis&doi=10.2337%2Fdb14-0153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">GABA promotes human β-cell proliferation and modulates glucose homeostasis</span></div><div class="casAuthors">Purwana, Indri; Zheng, Juan; Li, Xiaoming; Deurloo, Marielle; Son, Dong Ok; Zhang, Zhaoyun; Liang, Christie; Shen, Eddie; Tadkase, Akshaya; Feng, Zhong-Ping; Li, Yiming; Hasilo, Craig; Paraskevas, Steven; Bortell, Rita; Greiner, Dale L.; Atkinson, Mark; Prud'homme, Gerald J.; Wang, Qinghua</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4197-4205</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">γ-Aminobutyric acid (GABA) exerts protective and regenerative effects on mouse islet β-cells.  However, in humans it is unknown whether it can increase β-cell mass and improve glucose homeostasis.  To address this question, we transplanted a suboptimal mass of human islets into immunodeficient NOD-scid-γ mice with streptozotocin-induced diabetes.  GABA treatment increased grafted β-cell proliferation, while decreasing apoptosis, leading to enhanced β-cell mass.  This was assocd. with increased circulating human insulin and reduced glucagon levels.  Importantly, GABA administration lowered blood glucose levels and improved glucose excursion rates.  We investigated GABA receptor expression and signaling mechanisms.  In human islets, GABA activated a calcium-dependent signaling pathway through both GABA A receptor and GABA B receptor.  This activated the phosphatidylinositol 3-kinase-Akt and CREB-IRS-2 signaling pathways that convey GABA signals responsible for β-cell proliferation and survival.  Our findings suggest that GABA regulates human β-cell mass and may be beneficial for the treatment of diabetes or improvement of islet transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx0G1KgUS7fbVg90H21EOLACvtfcHk0lgWKPxxmako-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCgtr7P&md5=27d9ad528f161f68edc4b07d67ff032a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2337%2Fdb14-0153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb14-0153%26sid%3Dliteratum%253Aachs%26aulast%3DPurwana%26aufirst%3DI.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DDeurloo%26aufirst%3DM.%26aulast%3DSon%26aufirst%3DD.%2BO.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DE.%26aulast%3DTadkase%26aufirst%3DA.%26aulast%3DFeng%26aufirst%3DZ.-P.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHasilo%26aufirst%3DC.%26aulast%3DParaskevas%26aufirst%3DS.%26aulast%3DBortell%26aufirst%3DR.%26aulast%3DGreiner%26aufirst%3DD.%2BL.%26aulast%3DAtkinson%26aufirst%3DM.%26aulast%3DPrud%25E2%2580%2599homme%26aufirst%3DG.%2BJ.%26aulast%3DWang%26aufirst%3DQ.%26atitle%3DGABA%2520promotes%2520human%2520%25CE%25B2-cell%2520proliferation%2520and%2520modulates%2520glucose%2520homeostasis%26jtitle%3DDiabetes%26date%3D2014%26volume%3D63%26issue%3D12%26spage%3D4197%26epage%3D4205%26doi%3D10.2337%2Fdb14-0153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of action and therapeutic application of Glucagon-like Peptide-1</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2018.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=29617641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=740-756&issue=4&author=D.+J.+Drucker&title=Mechanisms+of+action+and+therapeutic+application+of+Glucagon-like+Peptide-1&doi=10.1016%2Fj.cmet.2018.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1</span></div><div class="casAuthors">Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-756</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-related glycemic excursions through augmentation of insulin and inhibition of glucagon secretion.  GLP-1 also inhibits gastric emptying and food intake, actions maximizing nutrient absorption while limiting wt. gain.  Here I review the circuits engaged by endogenous vs. pharmacol. GLP-1 action, highlighting key GLP-1 receptor (GLP-1R)-pos. cell types and pathways transducing metabolic and non-glycemic GLP-1 signals.  The role(s) of GLP-1 in the benefits and side effects assocd. with bariatric surgery are discussed and actions of GLP-1 controlling islet function, appetite, inflammation, and cardiovascular pathophysiol. are highlighted.  Refinement of the risk-vs.-benefit profile of GLP-1-based therapies for the treatment of diabetes and obesity has stimulated development of orally bioavailable agonists, allosteric modulators, and unimol. multi-agonists, all targeting the GLP-1R.  This review highlights established and emerging concepts, unanswered questions, and future challenges for development and optimization of GLP-1R agonists in the treatment of metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-w0J5LcxUeLVg90H21EOLACvtfcHk0lgWKPxxmako-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqs7k%253D&md5=1bdfca5836ed6bd1d2cf49de109f5e65</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DMechanisms%2520of%2520action%2520and%2520therapeutic%2520application%2520of%2520Glucagon-like%2520Peptide-1%26jtitle%3DCell%2520Metab.%26date%3D2018%26volume%3D27%26issue%3D4%26spage%3D740%26epage%3D756%26doi%3D10.1016%2Fj.cmet.2018.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneyer, A. L.</span></span> <span> </span><span class="NLM_article-title">Emerging roles for the TGFβ family in pancreatic β-cell homeostasis</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1016/j.tem.2010.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.tem.2010.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=20382030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosV2itr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=441-448&issue=7&author=M.+L.+Brownauthor=A.+L.+Schneyer&title=Emerging+roles+for+the+TGF%CE%B2+family+in+pancreatic+%CE%B2-cell+homeostasis&doi=10.1016%2Fj.tem.2010.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging roles for the TGFβ family in pancreatic β-cell homeostasis</span></div><div class="casAuthors">Brown, Melissa L.; Schneyer, Alan L.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">441-448</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Loss of functional β-cells is the primary cause of type 2 diabetes, so that there is an acute need to understand how β-cell no. and function are regulated in the adult under normal physiol. conditions.  Recent studies suggest that members of the transforming growth factor (TGF)-β family regulate β-cell function and glucose homeostasis.  These factors are also likely to influence β-cell proliferation and(or) the incorporation of new β-cells from progenitors in adults.  Sol. TGFβ antagonists also appear to have important roles in maintaining homeostasis, and the coordinated activity of TGFβ family members is likely to regulate the differentiation and function of adult β-cells, raising the possibility of developing new diabetes therapies based on TGFβ agonists or antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcoSl1oLG-GLVg90H21EOLACvtfcHk0li4TQAnNm-4mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosV2itr4%253D&md5=1b60d74b13d56af3aeb8765338975e38</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2010.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2010.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%2BL.%26aulast%3DSchneyer%26aufirst%3DA.%2BL.%26atitle%3DEmerging%2520roles%2520for%2520the%2520TGF%25CE%25B2%2520family%2520in%2520pancreatic%2520%25CE%25B2-cell%2520homeostasis%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2010%26volume%3D21%26issue%3D7%26spage%3D441%26epage%3D448%26doi%3D10.1016%2Fj.tem.2010.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhawan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirice, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhushan, A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of TGF-β signaling promotes human pancreatic β-cell replication</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1208</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.2337/db15-1331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb15-1331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26936960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWgtLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2016&pages=1208-1218&issue=5&author=S.+Dhawanauthor=E.+Diriceauthor=R.+N.+Kulkarniauthor=A.+Bhushan&title=Inhibition+of+TGF-%CE%B2+signaling+promotes+human+pancreatic+%CE%B2-cell+replication&doi=10.2337%2Fdb15-1331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of TGF-β signaling promotes human pancreatic β-cell replication</span></div><div class="casAuthors">Dhawan, Sangeeta; Dirice, Ercument; Kulkarni, Rohit N.; Bhushan, Anil</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1208-1218</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Diabetes is assocd. with loss of functional pancreatic β-cells, and restoration of β-cells is a major goal for regenerative therapies.  Endogenous regeneration of β-cells via β-cell replication has the potential to restore cellular mass; however, pharmacol. agents that promote regeneration or expansion of endogenous β-cells have been elusive.  The regenerative capacity of β-cells declines rapidly with age, due to accumulation of p16INK4a, resulting in limited capacity for adult endocrine pancreas regeneration.  Here, we show that transforming growth factor-β (TGF-β) signaling via Smad3 integrates with the trithorax complex to activate and maintain Ink4a expression to prevent β-cell replication.  Importantly, inhibition of TGF-β signaling can result in repression of the Ink4a/Arf locus, resulting in increased β-cell replication in adult mice.  Furthermore, small mol. inhibitors of the TGF-β pathway promote β-cell replication in human islets transplanted into NOD-scid IL-2Rgnull mice.  These data reveal a novel role for TGF-β signaling in the regulation of the Ink4a/Arf locus and highlight the potential of using small mol. inhibitors of TGF-β signaling to promote human β-cell replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppQM9_Rz1R5LVg90H21EOLACvtfcHk0li4TQAnNm-4mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWgtLrK&md5=b8af25af24c9228f4221fec3b90456f3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2337%2Fdb15-1331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb15-1331%26sid%3Dliteratum%253Aachs%26aulast%3DDhawan%26aufirst%3DS.%26aulast%3DDirice%26aufirst%3DE.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26aulast%3DBhushan%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520TGF-%25CE%25B2%2520signaling%2520promotes%2520human%2520pancreatic%2520%25CE%25B2-cell%2520replication%26jtitle%3DDiabetes%26date%3D2016%26volume%3D65%26issue%3D5%26spage%3D1208%26epage%3D1218%26doi%3D10.2337%2Fdb15-1331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Gohary, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulachan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiersch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasadan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paredes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiota, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gittes, G.</span></span> <span> </span><span class="NLM_article-title">A Smad signaling network regulates islet cell proliferation</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.2337/db13-0432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb13-0432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=24089514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2014&pages=224-236&issue=1&author=Y.+El-Goharyauthor=S.+Tulachanauthor=J.+Wierschauthor=P.+Guoauthor=C.+Welshauthor=K.+Prasadanauthor=J.+Paredesauthor=C.+Shiotaauthor=X.+Xiaoauthor=Y.+Wadaauthor=M.+Diazauthor=G.+Gittes&title=A+Smad+signaling+network+regulates+islet+cell+proliferation&doi=10.2337%2Fdb13-0432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Smad signaling network regulates islet cell proliferation</span></div><div class="casAuthors">El-Gohary, Yousef; Tulachan, Sidhartha; Wiersch, John; Guo, Ping; Welsh, Carey; Prasadan, Krishna; Paredes, Jose; Shiota, Chiyo; Xiao, Xiangwei; Wada, Yoko; Diaz, Marilyn; Gittes, George</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">224-236</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Pancreatic β-cell loss and dysfunction are crit. components of all types of diabetes.  Human and rodent β-cells are able to proliferate, and this proliferation is an important defense against the evolution and progression of diabetes.  Transforming growth factor-β (TGF-β) signaling has been shown to affect β-cell development, proliferation, and function, but β-cell proliferation is thought to be the only source of new β-cells in the adult.  Recently, β-cell dedifferentiation has been shown to be an important contributory mechanism to β-cell failure.  In this study, we tie together these two pathways by showing that a network of intracellular TGF-β regulators, smads 7, 2, and 3, control β-cell proliferation after β-cell loss, and specifically, smad7 is necessary for that β-cell proliferation.  Importantly, this smad7-mediated proliferation appears to entail passing through a transient, nonpathol. dedifferentiation of β-cells to a pancreatic polypeptide-fold hormone-pos. state.  TGF-β receptor II appears to be a receptor important for controlling the status of the smad network in β-cells.  These studies should help our understanding of properly regulated β-cell replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3vhNShoKCo7Vg90H21EOLACvtfcHk0li4TQAnNm-4mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKrtA%253D%253D&md5=a77b842f007e4aac6421fcf66f889595</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2337%2Fdb13-0432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb13-0432%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Gohary%26aufirst%3DY.%26aulast%3DTulachan%26aufirst%3DS.%26aulast%3DWiersch%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DP.%26aulast%3DWelsh%26aufirst%3DC.%26aulast%3DPrasadan%26aufirst%3DK.%26aulast%3DParedes%26aufirst%3DJ.%26aulast%3DShiota%26aufirst%3DC.%26aulast%3DXiao%26aufirst%3DX.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DDiaz%26aufirst%3DM.%26aulast%3DGittes%26aufirst%3DG.%26atitle%3DA%2520Smad%2520signaling%2520network%2520regulates%2520islet%2520cell%2520proliferation%26jtitle%3DDiabetes%26date%3D2014%26volume%3D63%26issue%3D1%26spage%3D224%26epage%3D236%26doi%3D10.2337%2Fdb13-0432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smart, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apelqvist, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topper, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span> <span> </span><span class="NLM_article-title">Conditional expression of Smad7 in pancreatic β cells disrupts TGF-β signaling and induces reversible diabetes mellitus</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">200</span>– <span class="NLM_lpage">209</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1371%2Fjournal.pbio.0040039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFKmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=200-209&issue=2&author=N.+G.+Smartauthor=A.+A.+Apelqvistauthor=X.+Guauthor=E.+B.+Harmonauthor=J.+N.+Topperauthor=R.+J.+MacDonaldauthor=S.+K.+Kim&title=Conditional+expression+of+Smad7+in+pancreatic+%CE%B2+cells+disrupts+TGF-%CE%B2+signaling+and+induces+reversible+diabetes+mellitus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Conditional expression of Smad7 in pancreatic β cells disrupts TGF-β signaling and induces reversible diabetes mellitus</span></div><div class="casAuthors">Smart, Nora G.; Apelqvist, Asa A.; Gu, Xueying; Harmon, Erin B.; Topper, James N.; MacDonald, Raymond J.; Kim, Seung K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">200-209</span>CODEN:
                <span class="NLM_cas:coden">PBLIBG</span>;
        ISSN:<span class="NLM_cas:issn">1545-7885</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Identification of signaling pathways that maintain and promote adult pancreatic islet functions will accelerate our understanding of organogenesis and improve strategies for treating diseases like diabetes mellitus.  Previous work has implicated transforming growth factor-β (TGF-β) signaling as an important regulator of pancreatic islet development, but has not established whether this signaling pathway is required for essential islet functions in the adult pancreas.  Here we describe a conditional system for expressing Smad7, a potent inhibitor of TGF-β signaling, to identify distinct roles for this pathway in adult and embryonic β cells.  Smad7 expression in Pdx1+ embryonic pancreas cells resulted in striking embryonic β cell hypoplasia and neonatal lethality.  Conditional expression of Smad7 in adult Pdx1+ cells reduced detectable β cell expression of MafA, menin, and other factors that regulate β cell function.  Reduced pancreatic insulin content and hypoinsulinemia produced overt diabetes that was fully reversed upon resumption of islet TGF-β signaling.  Thus, our studies reveal that TGF-β signaling is crucial for establishing and maintaining defining features of mature pancreatic β cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRqdvtCI5rmrVg90H21EOLACvtfcHk0liRe5HrgxfKGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFKmtLc%253D&md5=3defebb2d98952fbfd8a5c6768b450d0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.0040039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.0040039%26sid%3Dliteratum%253Aachs%26aulast%3DSmart%26aufirst%3DN.%2BG.%26aulast%3DApelqvist%26aufirst%3DA.%2BA.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DHarmon%26aufirst%3DE.%2BB.%26aulast%3DTopper%26aufirst%3DJ.%2BN.%26aulast%3DMacDonald%26aufirst%3DR.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BK.%26atitle%3DConditional%2520expression%2520of%2520Smad7%2520in%2520pancreatic%2520%25CE%25B2%2520cells%2520disrupts%2520TGF-%25CE%25B2%2520signaling%2520and%2520induces%2520reversible%2520diabetes%2520mellitus%26jtitle%3DPLoS%2520Biol.%26date%3D2006%26volume%3D4%26issue%3D2%26spage%3D200%26epage%3D209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakose, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackeifi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatanic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takane, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">Combined inhibition of DYRK1A, SMAD, and Trithorax pathways synergizes to induce robust replication in adult human β-cells</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">652</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2018.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30581122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisF2ht7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=638-652&issue=3&author=P.+Wangauthor=E.+Karakoseauthor=H.+Liuauthor=E.+Swartzauthor=C.+Ackeifiauthor=V.+Zlatanicauthor=J.+Wilsonauthor=B.+J.+Gonzalezauthor=A.+Benderauthor=K.+K.+Takaneauthor=L.+Yeauthor=G.+Harbauthor=F.+Pagliucaauthor=D.+Homannauthor=D.+Egliauthor=C.+Argmannauthor=D.+K.+Scottauthor=A.+Garcia-Ocanaauthor=A.+F.+Stewart&title=Combined+inhibition+of+DYRK1A%2C+SMAD%2C+and+Trithorax+pathways+synergizes+to+induce+robust+replication+in+adult+human+%CE%B2-cells&doi=10.1016%2Fj.cmet.2018.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells</span></div><div class="casAuthors">Wang, Peng; Karakose, Esra; Liu, Hongtao; Swartz, Ethan; Ackeifi, Courtney; Zlatanic, Viktor; Wilson, Jessica; Gonzalez, Bryan J.; Bender, Aaron; Takane, Karen K.; Ye, Lillian; Harb, George; Pagliuca, Felicia; Homann, Dirk; Egli, Dieter; Argmann, Carmen; Scott, Donald K.; Garcia-Ocana, Adolfo; Stewart, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">638-652.e5</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Small-mol. inhibitors of dual-specificity tyrosine-regulated kinase 1A (DYRK1A) induce human beta cells to proliferate, generating a labeling index of 1.5%-3%.  Here, we demonstrate that combined pharmacol. inhibition of DYRK1A and transforming growth factor beta superfamily (TGFβSF)/SMAD signaling generates remarkable further synergistic increases in human beta cell proliferation (av. labeling index, 5%-8%, and as high as 15%-18%), and increases in both mouse and human beta cell nos.  This synergy reflects activation of cyclins and cdks by DYRK1A inhibition, accompanied by simultaneous redns. in key cell-cycle inhibitors (CDKN1C and CDKN1A).  The latter results from interference with the basal Trithorax- and SMAD-mediated transactivation of CDKN1C and CDKN1A.  Notably, combined DYRK1A and TGFβ inhibition allows preservation of beta cell differentiated function.  These beneficial effects extend from normal human beta cells and stem cell-derived human beta cells to those from people with type 2 diabetes, and occur both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTj3UaJV2-V7Vg90H21EOLACvtfcHk0liRe5HrgxfKGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisF2ht7jN&md5=99322b62913a95e1209524c958db8380</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DKarakose%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DSwartz%26aufirst%3DE.%26aulast%3DAckeifi%26aufirst%3DC.%26aulast%3DZlatanic%26aufirst%3DV.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DGonzalez%26aufirst%3DB.%2BJ.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DTakane%26aufirst%3DK.%2BK.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DHarb%26aufirst%3DG.%26aulast%3DPagliuca%26aufirst%3DF.%26aulast%3DHomann%26aufirst%3DD.%26aulast%3DEgli%26aufirst%3DD.%26aulast%3DArgmann%26aufirst%3DC.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DCombined%2520inhibition%2520of%2520DYRK1A%252C%2520SMAD%252C%2520and%2520Trithorax%2520pathways%2520synergizes%2520to%2520induce%2520robust%2520replication%2520in%2520adult%2520human%2520%25CE%25B2-cells%26jtitle%3DCell%2520Metab.%26date%3D2019%26volume%3D29%26issue%3D3%26spage%3D638%26epage%3D652%26doi%3D10.1016%2Fj.cmet.2018.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schisler, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmeier, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newgard, C. B.</span></span> <span> </span><span class="NLM_article-title">A VGF-derived peptide attenuates development of type 2 diabetes via enhancement of islet β-Cell survival and function</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2012.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2012.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=22768837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFCkur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=33-43&issue=1&author=S.+B.+Stephensauthor=J.+C.+Schislerauthor=H.+E.+Hohmeierauthor=J.+Anauthor=A.+Y.+Sunauthor=G.+S.+Pittauthor=C.+B.+Newgard&title=A+VGF-derived+peptide+attenuates+development+of+type+2+diabetes+via+enhancement+of+islet+%CE%B2-Cell+survival+and+function&doi=10.1016%2Fj.cmet.2012.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A VGF-derived peptide attenuates development of type 2 diabetes via enhancement of islet β-Cell survival and function</span></div><div class="casAuthors">Stephens, Samuel B.; Schisler, Jonathan C.; Hohmeier, Hans E.; An, Jie; Sun, Albert Y.; Pitt, Geoffrey S.; Newgard, Christopher B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-43</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Deterioration of functional islet β-cell mass is the final step in progression to Type 2 diabetes.  We previously reported that overexpression of Nkx6.1 in rat islets has the dual effects of enhancing glucose-stimulated insulin secretion (GSIS) and increasing β-cell replication.  Here we show that Nkx6.1 strongly upregulates the prohormone VGF in rat islets and that VGF is both necessary and sufficient for Nkx6.1-mediated enhancement of GSIS.  Moreover, the VGF-derived peptide TLQP-21 potentiates GSIS in rat and human islets and improves glucose tolerance in vivo.  Chronic injection of TLQP-21 in prediabetic ZDF rats preserves islet mass and slows diabetes onset.  TLQP-21 prevents islet cell apoptosis by a pathway similar to that used by GLP-1, but independent of the GLP-1, GIP, or VIP receptors.  Unlike GLP-1, TLQP-21 does not inhibit gastric emptying or increase heart rate.  We conclude that TLQP-21 is a targeted agent for enhancing islet β-cell survival and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIcnok3bIj3bVg90H21EOLACvtfcHk0liRe5HrgxfKGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFCkur0%253D&md5=59107e447935a86fb83a5b1f8b40869b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2012.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2012.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DStephens%26aufirst%3DS.%2BB.%26aulast%3DSchisler%26aufirst%3DJ.%2BC.%26aulast%3DHohmeier%26aufirst%3DH.%2BE.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DA.%2BY.%26aulast%3DPitt%26aufirst%3DG.%2BS.%26aulast%3DNewgard%26aufirst%3DC.%2BB.%26atitle%3DA%2520VGF-derived%2520peptide%2520attenuates%2520development%2520of%2520type%25202%2520diabetes%2520via%2520enhancement%2520of%2520islet%2520%25CE%25B2-Cell%2520survival%2520and%2520function%26jtitle%3DCell%2520Metab.%26date%3D2012%26volume%3D16%26issue%3D1%26spage%3D33%26epage%3D43%26doi%3D10.1016%2Fj.cmet.2012.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robitaille, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rourke, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBane, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, A.M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Screaton, R. A.</span></span> <span> </span><span class="NLM_article-title">High-throughput functional genomics identifies regulators of primary human β-cell proliferation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4614</span>– <span class="NLM_lpage">4625</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.683912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1074%2Fjbc.M115.683912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26740620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1eqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=4614-4625&issue=9&author=K.+Robitailleauthor=J.+L.+Rourkeauthor=J.+E.+McBaneauthor=A.+Fuauthor=S.+Bairdauthor=Q.+Duauthor=T.+Kinauthor=A.M.+J.+Shapiroauthor=R.+A.+Screaton&title=High-throughput+functional+genomics+identifies+regulators+of+primary+human+%CE%B2-cell+proliferation&doi=10.1074%2Fjbc.M115.683912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput functional genomics identifies regulators of primary human beta cell proliferation</span></div><div class="casAuthors">Robitaille, Karine; Rourke, Jillian L.; McBane, Joanne E.; Fu, Accalia; Baird, Stephen; Du, Qiujiang; Kin, Tatsuya; James Shapiro, A. M.; Screaton, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4614-4625</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The expansion of cells for regenerative therapy will require the genetic dissection of complex regulatory mechanisms governing the proliferation of non-transformed human cells.  Here, we report the development of a high-throughput RNAi screening strategy specifically for use in primary cells and demonstrate that silencing the cell cycle-dependent kinase inhibitors CDKN2C/p18 or CDKN1A/p21 facilitates cell cycle entry of quiescent adult human pancreatic beta cells.  This work identifies p18 and p21 as novel targets for promoting proliferation of human beta cells and demonstrates the promise of functional genetic screens for dissecting therapeutically relevant state changes in primary human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuCrU90jJegLVg90H21EOLACvtfcHk0lh4uXwjbaOHjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1eqsbc%253D&md5=b82a21f4dba273e17baee928caf52f83</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.683912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.683912%26sid%3Dliteratum%253Aachs%26aulast%3DRobitaille%26aufirst%3DK.%26aulast%3DRourke%26aufirst%3DJ.%2BL.%26aulast%3DMcBane%26aufirst%3DJ.%2BE.%26aulast%3DFu%26aufirst%3DA.%26aulast%3DBaird%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DQ.%26aulast%3DKin%26aufirst%3DT.%26aulast%3DShapiro%26aufirst%3DA.M.%2BJ.%26aulast%3DScreaton%26aufirst%3DR.%2BA.%26atitle%3DHigh-throughput%2520functional%2520genomics%2520identifies%2520regulators%2520of%2520primary%2520human%2520%25CE%25B2-cell%2520proliferation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26issue%3D9%26spage%3D4614%26epage%3D4625%26doi%3D10.1074%2Fjbc.M115.683912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Annes, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carolan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollister-Lock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvanites, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melton, D. A.</span></span> <span> </span><span class="NLM_article-title">Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replication</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">3915</span>– <span class="NLM_lpage">3920</span>, <span class="refDoi"> DOI: 10.1073/pnas.1201149109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1073%2Fpnas.1201149109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=22345561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38XjvFymtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=3915-3920&issue=10&author=J.+P.+Annesauthor=J.+H.+Ryuauthor=K.+Lamauthor=P.+J.+Carolanauthor=K.+Utzauthor=J.+Hollister-Lockauthor=A.+C.+Arvanitesauthor=L.+L.+Rubinauthor=G.+Weirauthor=D.+A.+Melton&title=Adenosine+kinase+inhibition+selectively+promotes+rodent+and+porcine+islet+%CE%B2-cell+replication&doi=10.1073%2Fpnas.1201149109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replication</span></div><div class="casAuthors">Annes, Justin P.; Ryu, Jennifer Hyoje; Lam, Kelvin; Carolan, Peter J.; Utz, Katrina; Hollister-Lock, Jennifer; Arvanites, Anthony C.; Rubin, Lee L.; Weir, Gordon; Melton, Douglas A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3915-3920</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Diabetes is a pathol. condition characterized by relative insulin deficiency, persistent hyperglycemia, and, consequently, diffuse micro- and macrovascular disease.  One therapeutic strategy is to amplify insulin-secretion capacity by increasing the no. of the insulin-producing β cells without triggering a generalized proliferative response.  Here, we present the development of a small-mol. screening platform for the identification of mols. that increase β-cell replication.  Using this platform, we identify a class of compds. [adenosine kinase inhibitors (ADK-Is)] that promote replication of primary β cells in three species (mouse, rat, and pig).  Furthermore, the replication effect of ADK-Is is cell type-selective: treatment of islet cell cultures with ADK-Is increases replication of β cells but not that of α cells, PP cells, or fibroblasts.  Short-term in vivo treatment with an ADK-I also increases β-cell replication but not exocrine cell or hepatocyte replication.  Therefore, we propose ADK inhibition as a strategy for the treatment of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9d3QakDBpybVg90H21EOLACvtfcHk0lh4uXwjbaOHjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjvFymtL8%253D&md5=2bec02ff18ef273ec38734a98c9395cb</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1201149109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1201149109%26sid%3Dliteratum%253Aachs%26aulast%3DAnnes%26aufirst%3DJ.%2BP.%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DLam%26aufirst%3DK.%26aulast%3DCarolan%26aufirst%3DP.%2BJ.%26aulast%3DUtz%26aufirst%3DK.%26aulast%3DHollister-Lock%26aufirst%3DJ.%26aulast%3DArvanites%26aufirst%3DA.%2BC.%26aulast%3DRubin%26aufirst%3DL.%2BL.%26aulast%3DWeir%26aufirst%3DG.%26aulast%3DMelton%26aufirst%3DD.%2BA.%26atitle%3DAdenosine%2520kinase%2520inhibition%2520selectively%2520promotes%2520rodent%2520and%2520porcine%2520islet%2520%25CE%25B2-cell%2520replication%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D10%26spage%3D3915%26epage%3D3920%26doi%3D10.1073%2Fpnas.1201149109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span> <span> </span><span class="NLM_article-title">Identification of small-molecule inducers of pancreatic β-cell expansion</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1427</span>– <span class="NLM_lpage">1432</span>, <span class="refDoi"> DOI: 10.1073/pnas.0811848106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1073%2Fpnas.0811848106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=19164755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvV2qtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1427-1432&issue=5&author=W.+Wangauthor=J.+R.+Walkerauthor=X.+Wangauthor=M.+S.+Tremblayauthor=J.+W.+Leeauthor=X.+Wuauthor=P.+G.+Schultz&title=Identification+of+small-molecule+inducers+of+pancreatic+%CE%B2-cell+expansion&doi=10.1073%2Fpnas.0811848106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of small-molecule inducers of pancreatic β-cell expansion</span></div><div class="casAuthors">Wang, Weidong; Walker, John R.; Wang, Xia; Tremblay, Matthew S.; Lee, Jae Wook; Wu, Xu; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1427-1432</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">To identify small mols. that can induce β-cell replication, a large chem. library was screened for proliferation of growth-arrested, reversibly immortalized mouse 1 cells by using an automated high-throughput screening platform.  A no. of structurally diverse, active compds. were identified, including phorbol esters, which likely act through protein kinase C, and a group of thiophene-pyrimidines that stimulate β-cell proliferation by activating the Wnt signaling pathway.  A group of dihydropyridine (DHP) derivs. was also shown to reversibly induce β-cell replication in vitro by activating L-type calcium channels (LTCCs).  Our data suggest that the LTCC agonist 2a affects the expression of genes involved in cell cycle progression and cellular proliferation.  Furthermore, treatment of p cells with both LTCC agonist 2a and the Glp-1 receptor agonist Exendin-4 showed an additive effect on β-cell replication.  The identification of small mols. that induce β-cell proliferation suggests that it may be possible to reversibly expand other quiescent cells to overcome deficits assocd. with degenerative and/or autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzUwmkz4J4CrVg90H21EOLACvtfcHk0lh4uXwjbaOHjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvV2qtbs%253D&md5=daf6d5e2c1401ac6c1541cd90f88e4c0</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0811848106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0811848106%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTremblay%26aufirst%3DM.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DIdentification%2520of%2520small-molecule%2520inducers%2520of%2520pancreatic%2520%25CE%25B2-cell%2520expansion%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D5%26spage%3D1427%26epage%3D1432%26doi%3D10.1073%2Fpnas.0811848106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goktug, A. N.</span>; <span class="NLM_string-name">Chai, S. C.</span>; <span class="NLM_string-name">Chen, T.</span></span> In  <i>Data analysis approaches in high throughput screening</i>; <span class="NLM_publisher-name">InTech</span>: <span class="NLM_year">2013</span>; pp  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">226</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=201-226&author=A.+N.+Goktug&author=S.+C.+Chai&author=T.+Chen&title=Data+analysis+approaches+in+high+throughput+screening"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGoktug%26aufirst%3DA.%2BN.%26btitle%3DData%2520analysis%2520approaches%2520in%2520high%2520throughput%2520screening%26pub%3DInTech%26date%3D2013%26spage%3D201%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohnishi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiramatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kii, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onogi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span> <span> </span><span class="NLM_article-title">Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">86</span>, <span class="refDoi"> DOI: 10.1038/ncomms1090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fncomms1090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=20981014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A280%3ADC%252BC3cbislehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=86&author=Y.+Ogawaauthor=Y.+Nonakaauthor=T.+Gotoauthor=E.+Ohnishiauthor=T.+Hiramatsuauthor=I.+Kiiauthor=M.+Yoshidaauthor=T.+Ikuraauthor=H.+Onogiauthor=H.+Shibuyaauthor=T.+Hosoyaauthor=N.+Itoauthor=M.+Hagiwara&title=Development+of+a+novel+selective+inhibitor+of+the+Down+syndrome-related+kinase+Dyrk1A&doi=10.1038%2Fncomms1090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A</span></div><div class="casAuthors">Ogawa Yasushi; Nonaka Yosuke; Goto Toshiyasu; Ohnishi Eriko; Hiramatsu Toshiyuki; Kii Isao; Yoshida Miyo; Ikura Teikichi; Onogi Hiroshi; Shibuya Hiroshi; Hosoya Takamitsu; Ito Nobutoshi; Hagiwara Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dyrk1A (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A) is a serine/threonine kinase essential for brain development and function, and its excessive activity is considered a pathogenic factor in Down syndrome.  The development of potent, selective inhibitors of Dyrk1A would help to elucidate the molecular mechanisms of normal and diseased brains, and may provide a new lead compound for molecular-targeted drug discovery.  Here, we report a novel Dyrk1A inhibitor, INDY, a benzothiazole derivative showing a potent ATP-competitive inhibitory effect with IC(50) and K(i) values of 0.24 and 0.18 μM, respectively.  X-ray crystallography of the Dyrk1A/INDY complex revealed the binding of INDY in the ATP pocket of the enzyme.  INDY effectively reversed the aberrant tau-phosphorylation and rescued the repressed NFAT (nuclear factor of activated T cell) signalling induced by Dyrk1A overexpression.  Importantly, proINDY, a prodrug of INDY, effectively recovered Xenopus embryos from head malformation induced by Dyrk1A overexpression, resulting in normally developed embryos and demonstrating the utility of proINDY in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOCqf6rsXbPtenUz0lpNqnfW6udTcc2eZVYU_E9JDxyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbislehtw%253D%253D&md5=ac1d5972bec4085de101bb86194babd1</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fncomms1090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms1090%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DNonaka%26aufirst%3DY.%26aulast%3DGoto%26aufirst%3DT.%26aulast%3DOhnishi%26aufirst%3DE.%26aulast%3DHiramatsu%26aufirst%3DT.%26aulast%3DKii%26aufirst%3DI.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DIkura%26aufirst%3DT.%26aulast%3DOnogi%26aufirst%3DH.%26aulast%3DShibuya%26aufirst%3DH.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DN.%26aulast%3DHagiwara%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520a%2520novel%2520selective%2520inhibitor%2520of%2520the%2520Down%2520syndrome-related%2520kinase%2520Dyrk1A%26jtitle%3DNat.%2520Commun.%26date%3D2010%26volume%3D1%26spage%3D86%26doi%3D10.1038%2Fncomms1090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heit, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apelqvist, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winslow, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neilson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabtree, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span> <span> </span><span class="NLM_article-title">Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function</span>. <i>Nature (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>443</i></span> (<span class="NLM_issue">7109</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1038/nature05097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnature05097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpslaksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=443&publication_year=2006&pages=345-349&issue=7109&author=J.+J.+Heitauthor=A.+A.+Apelqvistauthor=X.+Guauthor=M.+M.+Winslowauthor=J.+R.+Neilsonauthor=G.+R.+Crabtreeauthor=S.+K.+Kim&title=Calcineurin%2FNFAT+signalling+regulates+pancreatic+%CE%B2-cell+growth+and+function&doi=10.1038%2Fnature05097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function</span></div><div class="casAuthors">Heit, Jeremy J.; Apelqvist, Aasa A.; Gu, Xueying; Winslow, Monte M.; Neilson, Joel R.; Crabtree, Gerald R.; Kim, Seung K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">443</span>
        (<span class="NLM_cas:issue">7109</span>),
    <span class="NLM_cas:pages">345-349</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The growth and function of organs such as pancreatic islets adapt to meet physiol. challenges and maintain metabolic balance, but the mechanisms controlling these facultative responses are unclear.  Diabetes in patients treated with calcineurin inhibitors such as cyclosporin A indicates that calcineurin/nuclear factor of activated T-cells (NFAT) signaling might control adaptive islet responses, but the roles of this pathway in β-cells in vivo are not understood.  Here the authors show that mice with a β-cell-specific deletion of the calcineurin phosphatase regulatory subunit, calcineurin b1 (Cnb1), develop age-dependent diabetes characterized by decreased β-cell proliferation and mass, reduced pancreatic insulin content and hypoinsulinemia.  Moreover, β-cells lacking Cnb1 have a reduced expression of established regulators of β-cell proliferation.  Conditional expression of active NFATc1 in Cnb1-deficient β-cells rescues these defects and prevents diabetes.  In normal adult β-cells, conditional NFAT activation promotes the expression of cell-cycle regulators and increases β-cell proliferation and mass, resulting in hyperinsulinemia.  Conditional NFAT activation also induces the expression of genes crit. for β-cell endocrine function, including all six genes mutated in hereditary forms of monogenic type 2 diabetes.  Thus, calcineurin/NFAT signaling regulates multiple factors that control growth and hallmark β-cell functions, revealing unique models for the pathogenesis and therapy of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-AyBy0mjD-rVg90H21EOLACvtfcHk0ligRI22vfiliQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpslaksrs%253D&md5=edbb275758f2d117834e96995b313cb5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnature05097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05097%26sid%3Dliteratum%253Aachs%26aulast%3DHeit%26aufirst%3DJ.%2BJ.%26aulast%3DApelqvist%26aufirst%3DA.%2BA.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DWinslow%26aufirst%3DM.%2BM.%26aulast%3DNeilson%26aufirst%3DJ.%2BR.%26aulast%3DCrabtree%26aufirst%3DG.%2BR.%26aulast%3DKim%26aufirst%3DS.%2BK.%26atitle%3DCalcineurin%252FNFAT%2520signalling%2520regulates%2520pancreatic%2520%25CE%25B2-cell%2520growth%2520and%2520function%26jtitle%3DNature%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2006%26volume%3D443%26issue%3D7109%26spage%3D345%26epage%3D349%26doi%3D10.1038%2Fnature05097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodyer, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottino, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabtree, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span> <span> </span><span class="NLM_article-title">Neonatal β cell development in mice and humans is regulated by calcineurin/NFAT</span>. <i>Dev. Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.devcel.2012.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.devcel.2012.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=22814600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOqu7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=21-34&issue=1&author=W.+R.+Goodyerauthor=X.+Guauthor=Y.+Liuauthor=R.+Bottinoauthor=G.+R.+Crabtreeauthor=S.+K.+Kim&title=Neonatal+%CE%B2+cell+development+in+mice+and+humans+is+regulated+by+calcineurin%2FNFAT&doi=10.1016%2Fj.devcel.2012.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Neonatal β Cell Development in Mice and Humans Is Regulated by Calcineurin/NFAT</span></div><div class="casAuthors">Goodyer, William R.; Gu, Xueying; Liu, Yinghua; Bottino, Rita; Crabtree, Gerald R.; Kim, Seung K.</div><div class="citationInfo"><span class="NLM_cas:title">Developmental Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-34</span>CODEN:
                <span class="NLM_cas:coden">DCEEBE</span>;
        ISSN:<span class="NLM_cas:issn">1534-5807</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Little is known about the mechanisms governing neonatal growth and maturation of organs.  Here we demonstrate that calcineurin/Nuclear Factor of Activated T cells (Cn/NFAT) signaling regulates neonatal pancreatic development in mouse and human islets.  Inactivation of calcineurin b1 (Cnb1) in mouse islets impaired dense core granule biogenesis, decreased insulin secretion, and reduced cell proliferation and mass, culminating in lethal diabetes.  Pancreatic β cells lacking Cnb1 failed to express genes revealed to be direct NFAT targets required for replication, insulin storage, and secretion.  In contrast, glucokinase activation stimulated Cn-dependent expression of these genes.  Calcineurin inhibitors, such as tacrolimus, used for human immunosuppression, induce diabetes.  Tacrolimus exposure reduced Cn/NFAT-dependent expression of factors essential for insulin dense core granule formation and secretion and neonatal β cell proliferation, consistent with our genetic studies.  Discovery of conserved pathways regulating β cell maturation and proliferation suggests new strategies for controlling β cell growth or replacement in human islet diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_D727AJkg_LVg90H21EOLACvtfcHk0lh0wYqGdxcVSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOqu7rE&md5=4526e5fc114232fc996f85383cbcf286</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.devcel.2012.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.devcel.2012.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DGoodyer%26aufirst%3DW.%2BR.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBottino%26aufirst%3DR.%26aulast%3DCrabtree%26aufirst%3DG.%2BR.%26aulast%3DKim%26aufirst%3DS.%2BK.%26atitle%3DNeonatal%2520%25CE%25B2%2520cell%2520development%2520in%2520mice%2520and%2520humans%2520is%2520regulated%2520by%2520calcineurin%252FNFAT%26jtitle%3DDev.%2520Cell%26date%3D2012%26volume%3D23%26issue%3D1%26spage%3D21%26epage%3D34%26doi%3D10.1016%2Fj.devcel.2012.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ackeifi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakose, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e132594</span> <span class="refDoi"> DOI: 10.1172/jci.insight.132594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1172%2Fjci.insight.132594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=31821176" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&author=C.+Ackeifiauthor=E.+Swartzauthor=K.+Kumarauthor=H.+Liuauthor=S.+Chaladaauthor=E.+Karakoseauthor=D.+K.+Scottauthor=A.+Garcia-Ocanaauthor=R.+Sanchezauthor=R.+J.+DeVitaauthor=A.+F.+Stewartauthor=P.+Wang&title=Pharmacologic+and+genetic+approaches+define+human+pancreatic+%CE%B2+cell+mitogenic+targets+of+DYRK1A+inhibitors&doi=10.1172%2Fjci.insight.132594"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.132594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.132594%26sid%3Dliteratum%253Aachs%26aulast%3DAckeifi%26aufirst%3DC.%26aulast%3DSwartz%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DChalada%26aufirst%3DS.%26aulast%3DKarakose%26aufirst%3DE.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DDeVita%26aufirst%3DR.%2BJ.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DPharmacologic%2520and%2520genetic%2520approaches%2520define%2520human%2520pancreatic%2520%25CE%25B2%2520cell%2520mitogenic%2520targets%2520of%2520DYRK1A%2520inhibitors%26jtitle%3DJCI%2520Insight%26date%3D2020%26volume%3D5%26doi%3D10.1172%2Fjci.insight.132594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rachdi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kariyawasam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbones, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabar, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharfmann, R.</span></span> <span> </span><span class="NLM_article-title">Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic β-cell mass</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">960</span>– <span class="NLM_lpage">969</span>, <span class="refDoi"> DOI: 10.1007/s00125-014-3174-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1007%2Fs00125-014-3174-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=24477974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Gltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=960-969&issue=5&author=L.+Rachdiauthor=D.+Kariyawasamauthor=F.+Guezauthor=V.+Aielloauthor=M.+L.+Arbonesauthor=N.+Janelauthor=J.-M.+Delabarauthor=M.+Polakauthor=R.+Scharfmann&title=Dyrk1a+haploinsufficiency+induces+diabetes+in+mice+through+decreased+pancreatic+%CE%B2-cell+mass&doi=10.1007%2Fs00125-014-3174-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass</span></div><div class="casAuthors">Rachdi, Latif; Kariyawasam, Dulanjalee; Guez, Fanny; Aiello, Virginie; Arbones, Maria L.; Janel, Nathalie; Delabar, Jean-Maurice; Polak, Michel; Scharfmann, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">960-969</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aims/hypothesis: Growth factors and nutrients are important regulators of pancreatic beta cell mass and function.  However, the signalling pathways by which these factors modulate these processes have not yet been fully elucidated.  DYRK1A (also named minibrain/MNB) is a member of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family that has been conserved across evolution.  A significant amt. of data implicates DYRK1A in brain growth and function, as well as in neurodegenerative processes in Alzheimer's disease and Down's syndrome.  We investigated here whether DYRK1A would be an attractive candidate for beta cell growth modulation.  Methods: To study the role of DYRK1A in beta cell growth, we used Dyrk1a-deficient mice.  Results: We show that DYRK1A is expressed in pancreatic islets and provide evidence that changes in Dyrk1a gene dosage in mice strongly modulate glycemia and circulating insulin levels.  Specifically, Dyrk1a-haploinsufficient mice show severe glucose intolerance, reduced beta cell mass and decreased beta cell proliferation.  Conclusions/interpretation: Taken together, our data indicate that DYRK1A is a crit. kinase for beta cell growth as Dyrk1a-haploinsufficient mice show a diabetic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpquWxQ9-ygubVg90H21EOLACvtfcHk0lh0wYqGdxcVSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Gltr8%253D&md5=e90679f8effcee39daded5a0b15f94b7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2Fs00125-014-3174-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-014-3174-3%26sid%3Dliteratum%253Aachs%26aulast%3DRachdi%26aufirst%3DL.%26aulast%3DKariyawasam%26aufirst%3DD.%26aulast%3DGuez%26aufirst%3DF.%26aulast%3DAiello%26aufirst%3DV.%26aulast%3DArbones%26aufirst%3DM.%2BL.%26aulast%3DJanel%26aufirst%3DN.%26aulast%3DDelabar%26aufirst%3DJ.-M.%26aulast%3DPolak%26aufirst%3DM.%26aulast%3DScharfmann%26aufirst%3DR.%26atitle%3DDyrk1a%2520haploinsufficiency%2520induces%2520diabetes%2520in%2520mice%2520through%2520decreased%2520pancreatic%2520%25CE%25B2-cell%2520mass%26jtitle%3DDiabetologia%26date%3D2014%26volume%3D57%26issue%3D5%26spage%3D960%26epage%3D969%26doi%3D10.1007%2Fs00125-014-3174-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debdab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreaux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soundararajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippakopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babault, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahtouh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baratte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenreich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazureau, J.-P.</span></span> <span> </span><span class="NLM_article-title">Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge Leucettamine B: modulation of alternative pre-RNA splicing</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4172</span>– <span class="NLM_lpage">4186</span>, <span class="refDoi"> DOI: 10.1021/jm200274d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200274d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4172-4186&issue=12&author=M.+Debdabauthor=F.+Carreauxauthor=S.+Renaultauthor=M.+Soundararajanauthor=O.+Fedorovauthor=P.+Filippakopoulosauthor=O.+Lozachauthor=L.+Babaultauthor=T.+Tahtouhauthor=B.+Baratteauthor=Y.+Ogawaauthor=M.+Hagiwaraauthor=A.+Eisenreichauthor=U.+Rauchauthor=S.+Knappauthor=L.+Meijerauthor=J.-P.+Bazureau&title=Leucettines%2C+a+class+of+potent+inhibitors+of+cdc2-like+kinases+and+dual+specificity%2C+tyrosine+phosphorylation+regulated+kinases+derived+from+the+marine+sponge+Leucettamine+B%3A+modulation+of+alternative+pre-RNA+splicing&doi=10.1021%2Fjm200274d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Leucettines, a Class of Potent Inhibitors of cdc2-Like Kinases and Dual Specificity, Tyrosine Phosphorylation Regulated Kinases Derived from the Marine Sponge Leucettamine B: Modulation of Alternative Pre-RNA Splicing</span></div><div class="casAuthors">Debdab, Mansour; Carreaux, Francois; Renault, Steven; Soundararajan, Meera; Fedorov, Oleg; Filippakopoulos, Panagis; Lozach, Olivier; Babault, Lucie; Tahtouh, Tania; Baratte, Blandine; Ogawa, Yasushi; Hagiwara, Masatoshi; Eisenreich, Andreas; Rauch, Ursula; Knapp, Stefan; Meijer, Laurent; Bazureau, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4172-4186</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, optimization, and biol. characterization of leucettines, a family of kinase inhibitors derived from the marine sponge leucettamine B I (R = H, R1 = Me), was reported.  Stepwise synthesis of analogs starting from the natural structure, guided by activity testing on eight purified kinases, led to highly potent inhibitors of CLKs and DYRKs, two families of kinases involved in alternative pre-mRNA splicing and Alzheimer's disease/Down syndrome.  Leucettine L41 I (R = Ph, R1 = H) was cocrystd. with CLK3.  It interacts with key residues located within the ATP-binding pocket of the kinase.  Leucettine L41 inhibited the phosphorylation of serine/arginine-rich proteins (SRp), a family of proteins regulating pre-RNA splicing.  Indeed leucettine L41 was demonstrated to modulate alternative pre-mRNA splicing, in a cell-based reporting system.  Leucettines should be further explored as pharmacol. tools to study and modulate pre-RNA splicing.  Leucettines may also be investigated as potential therapeutic drugs in Alzheimer's disease (AD) and in diseases involving abnormal pre-mRNA splicing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTsnAcfvIJobVg90H21EOLACvtfcHk0lh0wYqGdxcVSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGls7o%253D&md5=a4abd78d51a7a36e03117a1f432e3cae</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm200274d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200274d%26sid%3Dliteratum%253Aachs%26aulast%3DDebdab%26aufirst%3DM.%26aulast%3DCarreaux%26aufirst%3DF.%26aulast%3DRenault%26aufirst%3DS.%26aulast%3DSoundararajan%26aufirst%3DM.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DFilippakopoulos%26aufirst%3DP.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DBabault%26aufirst%3DL.%26aulast%3DTahtouh%26aufirst%3DT.%26aulast%3DBaratte%26aufirst%3DB.%26aulast%3DOgawa%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DM.%26aulast%3DEisenreich%26aufirst%3DA.%26aulast%3DRauch%26aufirst%3DU.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DBazureau%26aufirst%3DJ.-P.%26atitle%3DLeucettines%252C%2520a%2520class%2520of%2520potent%2520inhibitors%2520of%2520cdc2-like%2520kinases%2520and%2520dual%2520specificity%252C%2520tyrosine%2520phosphorylation%2520regulated%2520kinases%2520derived%2520from%2520the%2520marine%2520sponge%2520Leucettamine%2520B%253A%2520modulation%2520of%2520alternative%2520pre-RNA%2520splicing%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D12%26spage%3D4172%26epage%3D4186%26doi%3D10.1021%2Fjm200274d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brierley, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, C.</span></span> <span> </span><span class="NLM_article-title">Developments in harmine pharmacology - Implications for ayahuasca use and drug-dependence treatment</span>. <i>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1016/j.pnpbp.2012.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.pnpbp.2012.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=22691716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVCjsr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2012&pages=263-272&issue=2&author=D.+I.+Brierleyauthor=C.+Davidson&title=Developments+in+harmine+pharmacology+-+Implications+for+ayahuasca+use+and+drug-dependence+treatment&doi=10.1016%2Fj.pnpbp.2012.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Developments in harmine pharmacology - Implications for ayahuasca use and drug-dependence treatment</span></div><div class="casAuthors">Brierley, Daniel I.; Davidson, Colin</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-272</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Ayahuasca is a hallucinogenic botanical mixt. originating in the Amazon area where it is used ritually, but is now being taken globally.  The 2 main constituents of ayahuasca are N,N-dimethyltryptamine (DMT), a hallucinogen, and harmine, a monoamine oxidase inhibitor (MAOI) which attenuates the breakdown of DMT, which would otherwise be broken down very quickly after oral consumption.  Recent developments in ayahuasca use include the sale of these compds. on the internet and the substitution of related botanical (anahuasca) or synthetic (pharmahuasca) compds. to achieve the same desired hallucinogenic effects.  One intriguing result of ayahuasca use appears to be improved mental health and a redn. in recidivism to alternate (alc., cocaine) drug use.  In this review we discuss the pharmacol. of ayahuasca, with a focus on harmine, and suggest pharmacol. mechanisms for the putative redn. in recidivism to alc. and cocaine misuse.  These pharmacol. mechanisms include MAOI, effects at 5-HT2A and imidazoline receptors and inhibition of dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) and the dopamine transporter.  We also speculate on the therapeutic potential of harmine in other CNS conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBCBZzc81PPLVg90H21EOLACvtfcHk0ljr-hq1GA1mJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVCjsr7P&md5=09e343f3b84458c57c6f9a00b3ba96c5</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2012.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2012.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DBrierley%26aufirst%3DD.%2BI.%26aulast%3DDavidson%26aufirst%3DC.%26atitle%3DDevelopments%2520in%2520harmine%2520pharmacology%2520-%2520Implications%2520for%2520ayahuasca%2520use%2520and%2520drug-dependence%2520treatment%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2012%26volume%3D39%26issue%3D2%26spage%3D263%26epage%3D272%26doi%3D10.1016%2Fj.pnpbp.2012.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ung, P. M.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span> <span> </span><span class="NLM_article-title">DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1021/cb500696t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500696t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOjs7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=269-278&issue=1&author=P.+M.-U.+Ungauthor=A.+Schlessinger&title=DFGmodel%3A+predicting+protein+kinase+structures+in+inactive+states+for+structure-based+discovery+of+type-II+inhibitors&doi=10.1021%2Fcb500696t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">DFGmodel: Predicting Protein Kinase Structures in Inactive States for Structure-Based Discovery of Type-II Inhibitors</span></div><div class="casAuthors">Ung, Peter Man-Un; Schlessinger, Avner</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">269-278</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein kinases exist in equil. of active and inactive states, in which the aspartate-phenylalanine-glycine motif in the catalytic domain undergoes conformational changes that are required for function.  Drugs targeting protein kinases typically bind the primary ATP-binding site of an active state (type-I inhibitors) or utilize an allosteric pocket adjacent to the ATP-binding site in the inactive state (type-II inhibitors).  Limited crystallog. data of protein kinases in the inactive state hampers the application of rational drug discovery methods for developing type-II inhibitors.  Here, we present a computational approach to generate structural models of protein kinases in the inactive conformation.  We first perform a comprehensive anal. of all protein kinase structures deposited in the Protein Data Bank.  We then develop DFGmodel, a method that takes either a known structure of a kinase in the active conformation or a sequence of a kinase without a structure, to generate kinase models in the inactive conformation.  Evaluation of DFGmodel's performance using various measures indicates that the inactive kinase models are accurate, exhibiting RMSD of 1.5 Å or lower.  The kinase models also accurately distinguish type-II kinase inhibitors from likely nonbinders (AUC > 0.70), suggesting that they are useful for virtual screening.  Finally, we demonstrate the applicability of our approach with three case studies.  For example, the models are able to capture inhibitors with unintended off-target activity.  Our computational approach provides a structural framework for chem. biologists to characterize kinases in the inactive state and to explore new chem. spaces with structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmlYsMTNeULbVg90H21EOLACvtfcHk0ljr-hq1GA1mJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOjs7rE&md5=7478a7e91251c1c8c737ab7be8f9bb75</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fcb500696t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500696t%26sid%3Dliteratum%253Aachs%26aulast%3DUng%26aufirst%3DP.%2BM.-U.%26aulast%3DSchlessinger%26aufirst%3DA.%26atitle%3DDFGmodel%253A%2520predicting%2520protein%2520kinase%2520structures%2520in%2520inactive%2520states%2520for%2520structure-based%2520discovery%2520of%2520type-II%2520inhibitors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26issue%3D1%26spage%3D269%26epage%3D278%26doi%3D10.1021%2Fcb500696t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoegdin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo-Alfredsson, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soederman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigelt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormoe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelissen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerning, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for alzheimer’s disease: design, synthesis, and characterization of pyrazines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">9107</span>– <span class="NLM_lpage">9119</span>, <span class="refDoi"> DOI: 10.1021/jm201724m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201724m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9107-9119&issue=21&author=S.+Bergauthor=M.+Berghauthor=S.+Hellbergauthor=K.+Hoegdinauthor=Y.+Lo-Alfredssonauthor=P.+Soedermanauthor=S.+von+Bergauthor=T.+Weigeltauthor=M.+Ormoeauthor=Y.+Xueauthor=J.+Tuckerauthor=J.+Neelissenauthor=E.+Jerningauthor=Y.+Nilssonauthor=R.+Bhat&title=Discovery+of+novel+potent+and+highly+selective+glycogen+synthase+kinase-3%CE%B2+%28GSK3%CE%B2%29+inhibitors+for+alzheimer%E2%80%99s+disease%3A+design%2C+synthesis%2C+and+characterization+of+pyrazines&doi=10.1021%2Fjm201724m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3β (GSK3β) Inhibitors for Alzheimer's Disease: Design, Synthesis, and Characterization of Pyrazines</span></div><div class="casAuthors">Berg, Stefan; Bergh, Margareta; Hellberg, Sven; Hoegdin, Katharina; Lo-Alfredsson, Yvonne; Soederman, Peter; von Berg, Stefan; Weigelt, Tatjana; Ormoe, Mats; Xue, Yafeng; Tucker, Julie; Neelissen, Jan; Jerning, Eva; Nilsson, Yvonne; Bhat, Ratan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9107-9119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycogen synthase kinase-3β, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metab.  Active forms of GSK3β localize to pretangle pathol. including dystrophic neuritis and neurofibrillary tangles in Alzheimer's disease (AD) brain.  By using a high throughput screening (HTS) approach to search for new chem. series and cocrystn. of key analogs to guide the optimization and synthesis of our pyrazine series, we have developed highly potent and selective inhibitors showing cellular efficacy and blood-brain barrier penetration.  The inhibitors are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDR4w7EMbaI7Vg90H21EOLACvtfcHk0ljr-hq1GA1mJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggtrc%253D&md5=f1475e38163a8e81e9ca9a24b271a0be</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm201724m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201724m%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DS.%26aulast%3DBergh%26aufirst%3DM.%26aulast%3DHellberg%26aufirst%3DS.%26aulast%3DHoegdin%26aufirst%3DK.%26aulast%3DLo-Alfredsson%26aufirst%3DY.%26aulast%3DSoederman%26aufirst%3DP.%26aulast%3Dvon%2BBerg%26aufirst%3DS.%26aulast%3DWeigelt%26aufirst%3DT.%26aulast%3DOrmoe%26aufirst%3DM.%26aulast%3DXue%26aufirst%3DY.%26aulast%3DTucker%26aufirst%3DJ.%26aulast%3DNeelissen%26aufirst%3DJ.%26aulast%3DJerning%26aufirst%3DE.%26aulast%3DNilsson%26aufirst%3DY.%26aulast%3DBhat%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520novel%2520potent%2520and%2520highly%2520selective%2520glycogen%2520synthase%2520kinase-3%25CE%25B2%2520%2528GSK3%25CE%25B2%2529%2520inhibitors%2520for%2520alzheimer%25E2%2580%2599s%2520disease%253A%2520design%252C%2520synthesis%252C%2520and%2520characterization%2520of%2520pyrazines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D21%26spage%3D9107%26epage%3D9119%26doi%3D10.1021%2Fjm201724m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mussmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kegel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andag, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burk, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onichtchouk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dohrmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austen, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of GSK3 promotes replication and survival of pancreatic β-cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">12030</span>– <span class="NLM_lpage">12037</span>, <span class="refDoi"> DOI: 10.1074/jbc.M609637200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1074%2Fjbc.M609637200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=17242403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktFeltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=12030-12037&issue=16&author=R.+Mussmannauthor=M.+Geeseauthor=F.+Harderauthor=S.+Kegelauthor=U.+Andagauthor=A.+Lomowauthor=U.+Burkauthor=D.+Onichtchoukauthor=C.+Dohrmannauthor=M.+Austen&title=Inhibition+of+GSK3+promotes+replication+and+survival+of+pancreatic+%CE%B2-cells&doi=10.1074%2Fjbc.M609637200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of GSK3 Promotes Replication and Survival of Pancreatic Beta Cells</span></div><div class="casAuthors">Mussmann, Rainer; Geese, Marcus; Harder, Friedrich; Kegel, Simone; Andag, Uwe; Lomow, Alexander; Burk, Ulrike; Onichtchouk, Daria; Dohrmann, Cord; Austen, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">12030-12037</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Recent developments indicate that the regeneration of beta cell function and mass in patients with diabetes is possible.  A regenerative approach may represent an alternative treatment option relative to current diabetes therapies that fail to provide optimal glycemic control.  Here we report that the inactivation of GSK3 by small mol. inhibitors or RNA interference stimulates replication of INS-1E rat insulinoma cells.  Specific and potent GSK3 inhibitors also alleviate the toxic effects of high concns. of glucose and the satd. fatty acid palmitate on INS-1E cells.  Furthermore, treatment of isolated rat islets with structurally diverse small mol. GSK3 inhibitors increases the rate beta cell replication by 2-3-fold relative to controls.  We propose that GSK3 is a regulator of beta cell replication and survival.  Moreover, our results suggest that specific inhibitors of GSK3 may have practical applications in beta cell regenerative therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfuejhr6RNZLVg90H21EOLACvtfcHk0lhrn4nksGe_Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktFeltro%253D&md5=3a8594690947fa652124d1477a023243</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M609637200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M609637200%26sid%3Dliteratum%253Aachs%26aulast%3DMussmann%26aufirst%3DR.%26aulast%3DGeese%26aufirst%3DM.%26aulast%3DHarder%26aufirst%3DF.%26aulast%3DKegel%26aufirst%3DS.%26aulast%3DAndag%26aufirst%3DU.%26aulast%3DLomow%26aufirst%3DA.%26aulast%3DBurk%26aufirst%3DU.%26aulast%3DOnichtchouk%26aufirst%3DD.%26aulast%3DDohrmann%26aufirst%3DC.%26aulast%3DAusten%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520GSK3%2520promotes%2520replication%2520and%2520survival%2520of%2520pancreatic%2520%25CE%25B2-cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26issue%3D16%26spage%3D12030%26epage%3D12037%26doi%3D10.1074%2Fjbc.M609637200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span> <span> </span><span class="NLM_article-title">GSK3 inhibitors: development and therapeutic potential</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1038/nrd1415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrd1415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=15173837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=479-487&issue=6&author=P.+Cohenauthor=M.+Goedert&title=GSK3+inhibitors%3A+development+and+therapeutic+potential&doi=10.1038%2Fnrd1415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 inhibitors: development and therapeutic potential</span></div><div class="casAuthors">Cohen, Philip; Goedert, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">479-487</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metab.  In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics.  Here, we describe the biol. of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL3ua5xi0_qrVg90H21EOLACvtfcHk0lhrn4nksGe_Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D&md5=165d1354bf11faa6021ac4dba797fda2</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnrd1415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1415%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DGoedert%26aufirst%3DM.%26atitle%3DGSK3%2520inhibitors%253A%2520development%2520and%2520therapeutic%2520potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D6%26spage%3D479%26epage%3D487%26doi%3D10.1038%2Fnrd1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baaten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeusen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 5-(3,4-difluorophenyl)-3-(pyrazol-4-yl)-7-azaindole (GNF3809) for β-cell survival in type 1 diabetes</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">3571</span>– <span class="NLM_lpage">3581</span>, <span class="refDoi"> DOI: 10.1021/acsomega.8b03050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.8b03050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=3571-3581&issue=2&author=Z.+Huangauthor=M.+S.+Tremblayauthor=T.+Y.+H.+Wuauthor=Q.+Dingauthor=X.+Haoauthor=J.+Baatenauthor=R.+Hillauthor=B.+Liuauthor=S.+Meeusenauthor=Y.+Zouauthor=S.+Yanauthor=Y.+Jiaauthor=V.+Nguyen-Tranauthor=W.+Shenauthor=G.+Bhatauthor=R.+Glynneauthor=B.+Laffitteauthor=J.+Liauthor=V.+Molteniauthor=Y.+A.+Liu&title=Discovery+of+5-%283%2C4-difluorophenyl%29-3-%28pyrazol-4-yl%29-7-azaindole+%28GNF3809%29+for+%CE%B2-cell+survival+in+type+1+diabetes&doi=10.1021%2Facsomega.8b03050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-(3,4-Difluorophenyl)-3-(pyrazol-4-yl)-7-azaindole (GNF3809) for β-Cell Survival in Type 1 Diabetes</span></div><div class="casAuthors">Huang, Zhihong; Tremblay, Matthew S.; Wu, Tom Y.-H.; Ding, Qiang; Hao, Xueshi; Baaten, Janine; Hill, Robert; Liu, Bo; Meeusen, Shelly; Zou, Yefen; Yan, Shanshan; Jia, Yong; Nguyen-Tran, Van; Shen, Weijun; Bhat, Ganesh; Glynne, Richard; Laffitte, Bryan; Li, Jing; Molteni, Valentina; Liu, Yahu A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">3571-3581</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pancreatic beta cell apoptosis, a hallmark of the development of type 1 diabetes (T1D), is assocd. with increased levels of pro-inflammatory cytokines.  Thus, an agent protecting beta cells from cytokine-induced stress should have an impact on maintaining functional beta cell mass in T1D.  Screening of a ∼2 million-compd. library identified a series of 7-azaindole derivs. as capable of protecting rat insulinoma (INS-1E) beta cells from death induced by pro-inflammatory cytokines.  The screening hits were optimized to result in GNF3809, a compd. which preserves insulin content and viability of beta cells in both rodent and human islets under stress induced by cytokines.  In vivo, orally bioavailable GNF3809 prevented elevated blood glucose level and improved oral glucose tolerance in a nonobese diabetic (NOD) mouse model.  This work lays the foundation for development of a new class of therapeutic interventions for T1D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6UVxw6m-JQrVg90H21EOLACvtfcHk0lhrn4nksGe_Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyms74%253D&md5=af22eae54a0159416e25c7c4cdd53992</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facsomega.8b03050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.8b03050%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DTremblay%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DT.%2BY.%2BH.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DBaaten%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DMeeusen%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DNguyen-Tran%26aufirst%3DV.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DBhat%26aufirst%3DG.%26aulast%3DGlynne%26aufirst%3DR.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DY.%2BA.%26atitle%3DDiscovery%2520of%25205-%25283%252C4-difluorophenyl%2529-3-%2528pyrazol-4-yl%2529-7-azaindole%2520%2528GNF3809%2529%2520for%2520%25CE%25B2-cell%2520survival%2520in%2520type%25201%2520diabetes%26jtitle%3DACS%2520Omega%26date%3D2019%26volume%3D4%26issue%3D2%26spage%3D3571%26epage%3D3581%26doi%3D10.1021%2Facsomega.8b03050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banasavadi-Siddegowda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nardini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobol, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornblum, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waclaw, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beullens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, I.</span></span> <span> </span><span class="NLM_article-title">MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells</span>. <i>Stem Cells (Durham, NC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1051</span>– <span class="NLM_lpage">1063</span>, <span class="refDoi"> DOI: 10.1002/stem.1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1002%2Fstem.1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=23404835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1Gjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1051-1063&issue=6&author=K.+Joshiauthor=Y.+Banasavadi-Siddegowdaauthor=X.+Moauthor=S.-H.+Kimauthor=P.+Maoauthor=C.+Kigauthor=D.+Nardiniauthor=R.+W.+Sobolauthor=L.+M.+L.+Chowauthor=H.+I.+Kornblumauthor=R.+Waclawauthor=M.+Beullensauthor=I.+Nakano&title=MELK-dependent+FOXM1+phosphorylation+is+essential+for+proliferation+of+glioma+stem+cells&doi=10.1002%2Fstem.1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells</span></div><div class="casAuthors">Joshi, Kaushal; Banasavadi-Siddegowda, Yeshavanth; Mo, Xiaokui; Kim, Sung-Hak; Mao, Ping; Kig, Cenk; Nardini, Diana; Sobol, Robert W.; Chow, Lionel M. L.; Kornblum, Harley I.; Waclaw, Ronald; Beullens, Monique; Nakano, Ichiro</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cells (Durham, NC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1051-1063</span>CODEN:
                <span class="NLM_cas:coden">STCEEJ</span>;
        ISSN:<span class="NLM_cas:issn">1066-5099</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is a life-threatening brain tumor.  Accumulating evidence suggests that eradication of glioma stem-like cells (GSCs) in GBM is essential to achieve cure.  The transcription factor FOXM1 has recently gained attention as a master regulator of mitotic progression of cancer cells in various organs.  Here, we demonstrate that FOXM1 forms a protein complex with the mitotic kinase MELK in GSCs, leading to phosphorylation and activation of FOXM1 in a MELK kinase-dependent manner.  This MELK-dependent activation of FOXM1 results in a subsequent increase in mitotic regulatory genes in GSCs.  MELK-driven FOXM1 activation is regulated by the binding and subsequent trans-phosphorylation of FOXM1 by another kinase PLK1.  Using mouse neural progenitor cells (NPCs), we found that transgenic expression of FOXM1 enhances, while siRNA-mediated gene silencing diminishes neurosphere formation, suggesting that FOXM1 is required for NPC growth.  During tumorigenesis, FOXM1 expression sequentially increases as cells progress from NPCs, to pretumorigenic progenitors and GSCs.  The antibiotic Siomycin A disrupts MELK-mediated FOXM1 signaling with a greater sensitivity in GSC compared to neural stem cell.  Treatment with the first-line chemotherapy agent for GBM, Temozolomide, paradoxically enriches for both FOXM1 (+) and MELK (+) cells in GBM cells, and addn. of Siomycin A to Temozolomide treatment in mice harboring GSC-derived intracranial tumors enhances the effects of the latter.  Collectively, our data indicate that FOXM1 signaling through its direct interaction with MELK regulates key mitotic genes in GSCs in a PLK1-dependent manner and thus, this protein complex is a potential therapeutic target for GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnuNcHO-aJSrVg90H21EOLACvtfcHk0lgTnLXN2sA79g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1Gjtbg%253D&md5=c1fff162527daa625cfdb99d814daa77</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fstem.1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fstem.1358%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%26aulast%3DBanasavadi-Siddegowda%26aufirst%3DY.%26aulast%3DMo%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DMao%26aufirst%3DP.%26aulast%3DKig%26aufirst%3DC.%26aulast%3DNardini%26aufirst%3DD.%26aulast%3DSobol%26aufirst%3DR.%2BW.%26aulast%3DChow%26aufirst%3DL.%2BM.%2BL.%26aulast%3DKornblum%26aufirst%3DH.%2BI.%26aulast%3DWaclaw%26aufirst%3DR.%26aulast%3DBeullens%26aufirst%3DM.%26aulast%3DNakano%26aufirst%3DI.%26atitle%3DMELK-dependent%2520FOXM1%2520phosphorylation%2520is%2520essential%2520for%2520proliferation%2520of%2520glioma%2520stem%2520cells%26jtitle%3DStem%2520Cells%2520%2528Durham%252C%2520NC%252C%2520U.%2520S.%2529%26date%3D2013%26volume%3D31%26issue%3D6%26spage%3D1051%26epage%3D1063%26doi%3D10.1002%2Fstem.1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Golson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maulis, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadi, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osipovich, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gannon, M.</span></span> <span> </span><span class="NLM_article-title">Activation of FoxM1 revitalizes the replicative potential of aged β-cells in male mice and enhances insulin secretion</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3829</span>– <span class="NLM_lpage">3838</span>, <span class="refDoi"> DOI: 10.2337/db15-0465</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdb15-0465" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26251404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1Klt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=3829-3838&issue=11&author=M.+L.+Golsonauthor=J.+C.+Dunnauthor=M.+F.+Maulisauthor=P.+K.+Dadiauthor=A.+B.+Osipovichauthor=M.+A.+Magnusonauthor=D.+A.+Jacobsonauthor=M.+Gannon&title=Activation+of+FoxM1+revitalizes+the+replicative+potential+of+aged+%CE%B2-cells+in+male+mice+and+enhances+insulin+secretion&doi=10.2337%2Fdb15-0465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of FoxM1 revitalizes the replicative potential of aged β-cells in male mice and enhances insulin secretion</span></div><div class="casAuthors">Golson, Maria L.; Dunn, Jennifer C.; Maulis, Matthew F.; Dadi, Prasanna K.; Osipovich, Anna B.; Magnuson, Mark A.; Jacobson, David A.; Gannon, Maureen</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3829-3838</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Type 2 diabetes incidence increases with age, while β-cell replication declines.  The transcription factor FoxM1 is required for β-cell replication in various situations, and its expression declines with age.  We hypothesized that increased FoxM1 activity in aged β-cells would rejuvenate proliferation.  Induction of an activated form of FoxM1 was sufficient to increase β-cell mass and proliferation in 12-mo-old male mice after just 2 wk.  Unexpectedly, at 2 mo of age, induction of activated FoxM1 in male mice improved glucose homeostasis with unchanged β-cell mass.  Cells expressing activated FoxM1 demonstrated enhanced glucose-stimulated Ca2+ influx, which resulted in improved glucose tolerance through enhanced β-cell function.  Conversely, our lab. has previously demonstrated that mice lacking FoxM1 in the pancreas display glucose intolerance or diabetes with only a 60% redn. in β-cell mass, suggesting that the loss of FoxM1 is detrimental to β-cell function.  Ex vivo insulin secretion was therefore examd. in size-matched islets from young mice lacking FoxM1 in β-cells.  Foxm1-deficient islets indeed displayed reduced insulin secretion.  Our studies reveal that activated FoxM1 increases β-cell replication while simultaneously enhancing insulin secretion and improving glucose homeostasis, making FoxM1 an attractive therapeutic target for diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe3qKKriOoNrVg90H21EOLACvtfcHk0lgTnLXN2sA79g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1Klt74%253D&md5=7b00512bbf1abe7b4d2546603751a242</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.2337%2Fdb15-0465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb15-0465%26sid%3Dliteratum%253Aachs%26aulast%3DGolson%26aufirst%3DM.%2BL.%26aulast%3DDunn%26aufirst%3DJ.%2BC.%26aulast%3DMaulis%26aufirst%3DM.%2BF.%26aulast%3DDadi%26aufirst%3DP.%2BK.%26aulast%3DOsipovich%26aufirst%3DA.%2BB.%26aulast%3DMagnuson%26aufirst%3DM.%2BA.%26aulast%3DJacobson%26aufirst%3DD.%2BA.%26aulast%3DGannon%26aufirst%3DM.%26atitle%3DActivation%2520of%2520FoxM1%2520revitalizes%2520the%2520replicative%2520potential%2520of%2520aged%2520%25CE%25B2-cells%2520in%2520male%2520mice%2520and%2520enhances%2520insulin%2520secretion%26jtitle%3DDiabetes%26date%3D2015%26volume%3D64%26issue%3D11%26spage%3D3829%26epage%3D3838%26doi%3D10.2337%2Fdb15-0465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alachkar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutonga, M. B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malnassy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzeler, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiddemann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlander, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, Y.</span></span> <span> </span><span class="NLM_article-title">Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">12371</span>– <span class="NLM_lpage">12382</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.18632%2Foncotarget.2642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=25365263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A280%3ADC%252BC2M3lt1ejsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=12371-12382&issue=23&author=H.+Alachkarauthor=M.+B.+G.+Mutongaauthor=N.+Fultonauthor=G.+Malnassyauthor=W.+Stockauthor=Y.+Nakamuraauthor=K.+H.+Metzelerauthor=T.+Heroldauthor=K.+Spiekermannauthor=W.+Hiddemannauthor=S.+K.+Bohlanderauthor=Y.+Matsuo&title=Preclinical+efficacy+of+maternal+embryonic+leucine-zipper+kinase+%28MELK%29+inhibition+in+acute+myeloid+leukemia&doi=10.18632%2Foncotarget.2642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia</span></div><div class="casAuthors">Alachkar Houda; Mutonga Martin B G; Fulton Noreen; Malnassy Gregory; Stock Wendy; Nakamura Yusuke; Metzeler Klaus H; Herold Tobias; Spiekermann Karsten; Hiddemann Wolfgang; Bohlander Stefan K; Matsuo Yo</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">12371-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Maternal embryonic leucine-zipper kinase (MELK), which was reported to be frequently up-regulated in various types of solid cancer, plays critical roles in formation and maintenance of cancer stem cells.  However, little is known about the relevance of this kinase in hematologic malignancies.  Here we report characterization of possible roles of MELK in acute myeloid leukemia (AML).  MELK is expressed in AML cell lines and AML blasts with higher levels in less differentiated cells.  MELK is frequently upregulated in AML with complex karyotypes and is associated with worse clinical outcome.  MELK knockdown resulted in growth inhibition and apoptosis of leukemic cells.  Hence, we investigated the potent anti-leukemia activity of OTS167, a small molecule MELK kinase inhibitor, in AML, and found that the compound induced cell differentiation and apoptosis as well as decreased migration of AML cells.  MELK expression was positively correlated with the expression of FOXM1 as well as its downstream target genes.  Furthermore, MELK inhibition resulted in downregulation of FOXM1 activity and the expression of its downstream targets.  Taken together, and given that OTS167 is undergoing a phase I clinical trial in solid cancer, our study warrants clinical evaluation of this compound as a novel targeted therapy for AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1IkpC-K_Eonp3bfzSLaX5fW6udTcc2eb27Pm9Xin7B7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3lt1ejsQ%253D%253D&md5=f7a207e2593cedd69fc2864a3e3311ca</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2642%26sid%3Dliteratum%253Aachs%26aulast%3DAlachkar%26aufirst%3DH.%26aulast%3DMutonga%26aufirst%3DM.%2BB.%2BG.%26aulast%3DFulton%26aufirst%3DN.%26aulast%3DMalnassy%26aufirst%3DG.%26aulast%3DStock%26aufirst%3DW.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DMetzeler%26aufirst%3DK.%2BH.%26aulast%3DHerold%26aufirst%3DT.%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DHiddemann%26aufirst%3DW.%26aulast%3DBohlander%26aufirst%3DS.%2BK.%26aulast%3DMatsuo%26aufirst%3DY.%26atitle%3DPreclinical%2520efficacy%2520of%2520maternal%2520embryonic%2520leucine-zipper%2520kinase%2520%2528MELK%2529%2520inhibition%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26issue%3D23%26spage%3D12371%26epage%3D12382%26doi%3D10.18632%2Foncotarget.2642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horton, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allegretti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moeller, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annes, J. P.</span></span> <span> </span><span class="NLM_article-title">Zinc-chelating small molecules preferentially accumulate and function within pancreatic β cells</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.chembiol.2018.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30527998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVChs77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=213-222&issue=2&author=T.+M.+Hortonauthor=P.+A.+Allegrettiauthor=S.+Leeauthor=H.+P.+Moellerauthor=M.+Smithauthor=J.+P.+Annes&title=Zinc-chelating+small+molecules+preferentially+accumulate+and+function+within+pancreatic+%CE%B2+cells&doi=10.1016%2Fj.chembiol.2018.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc-Chelating Small Molecules Preferentially Accumulate and Function within Pancreatic β Cells</span></div><div class="casAuthors">Horton, Timothy M.; Allegretti, Paul A.; Lee, Sooyeon; Moeller, Hannah P.; Smith, Mark; Annes, Justin P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-222.e6</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Diabetes is a hyperglycemic condition characterized by pancreatic β-cell dysfunction and depletion.  Whereas methods for monitoring β-cell function in vivo exist, methods to deliver therapeutics to β cells are lacking.  We leveraged the rare ability of β cells to conc. zinc to preferentially trap zinc-binding mols. within β cells, resulting in β-cell-targeted compd. delivery.  We detd. that zinc-rich β cells and islets preferentially accumulated TSQ (6-methoxy-8-p-toluenesulfonamido-quinoline) in a zinc-dependent manner compared with exocrine pancreas.  Next, we asked whether appending a zinc-chelating moiety onto a β-cell replication-inducing compd. was sufficient to confer preferential β-cell accumulation and activity.  Indeed, the hybrid compd. preferentially accumulated within rodent and human islets in a zinc-dependent manner and increased the selectivity of replication-promoting activity toward β cells.  These data resolve the fundamental question of whether intracellular accumulation of zinc-chelating compds. is influenced by zinc content.  Furthermore, application of this principle yielded a proof-of-concept method for β-cell-targeted drug delivery and bioactivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrUmxdaubO7Vg90H21EOLACvtfcHk0lgPQ3vDE4YiUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVChs77L&md5=284270ac8b527adcc6987f4aa60c0244</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DHorton%26aufirst%3DT.%2BM.%26aulast%3DAllegretti%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DMoeller%26aufirst%3DH.%2BP.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DAnnes%26aufirst%3DJ.%2BP.%26atitle%3DZinc-chelating%2520small%2520molecules%2520preferentially%2520accumulate%2520and%2520function%2520within%2520pancreatic%2520%25CE%25B2%2520cells%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D2%26spage%3D213%26epage%3D222%26doi%3D10.1016%2Fj.chembiol.2018.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakose, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inabnet, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libutti, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambertini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ranvier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takane, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antipin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzilov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reva, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadt, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Losic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">Insights into β-cell regeneration for diabetes via integration of molecular landscapes in human insulinomas</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fs41467-017-01662-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=28232747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsF2gtrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1-15&issue=1&author=H.+Wangauthor=A.+Benderauthor=P.+Wangauthor=E.+Karakoseauthor=W.+B.+Inabnetauthor=S.+K.+Libuttiauthor=A.+Arnoldauthor=L.+Lambertiniauthor=M.+Stangauthor=H.+Chenauthor=Y.+Kasaiauthor=M.+Mahajanauthor=Y.+Kinoshitaauthor=G.+Fernandez-Ranvierauthor=T.+C.+Beckerauthor=K.+K.+Takaneauthor=L.+A.+Walkerauthor=S.+Saulauthor=R.+Chenauthor=D.+K.+Scottauthor=J.+Ferrerauthor=Y.+Antipinauthor=M.+Donovanauthor=A.+V.+Uzilovauthor=B.+Revaauthor=E.+E.+Schadtauthor=B.+Losicauthor=C.+Argmannauthor=A.+F.+Stewart&title=Insights+into+%CE%B2-cell+regeneration+for+diabetes+via+integration+of+molecular+landscapes+in+human+insulinomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Fast kinetics of magnesium monochloride cations in interlayer-expanded titanium disulfide for magnesium rechargeable batteries</span></div><div class="casAuthors">Yoo, Hyun Deog; Liang, Yanliang; Dong, Hui; Lin, Junhao; Wang, Hua; Liu, Yisheng; Ma, Lu; Wu, Tianpin; Li, Yifei; Ru, Qiang; Jing, Yan; An, Qinyou; Zhou, Wu; Guo, Jinghua; Lu, Jun; Pantelides, Sokrates T.; Qian, Xiaofeng; Yao, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Magnesium rechargeable batteries potentially offer high-energy d., safety, and low cost due to the ability to employ divalent, dendrite-free, and earth-abundant magnesium metal anode.  Despite recent progress, further development remains stagnated mainly due to the sluggish scission of magnesium-chloride bond and slow diffusion of divalent magnesium cations in cathodes.  Here we report a battery chem. that utilizes magnesium monochloride cations in expanded titanium disulfide.  Combined theor. modeling, spectroscopic anal., and electrochem. study reveal fast diffusion kinetics of magnesium monochloride cations without scission of magnesium-chloride bond.  The battery demonstrates the reversible intercalation of 1 and 1.7 magnesium monochloride cations per titanium at 25 and 60°C, resp., corresponding to up to 400 mAh g-1 capacity based on the mass of titanium disulfide.  The large capacity accompanies with excellent rate and cycling performances even at room temp., opening up possibilities for a variety of effective intercalation hosts for multivalent-ion batteries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYULYh8ggm57Vg90H21EOLACvtfcHk0lgPQ3vDE4YiUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsF2gtrvE&md5=289dffaf7f3f59a3be62c35d7f8a03ef</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-01662-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-01662-6%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DKarakose%26aufirst%3DE.%26aulast%3DInabnet%26aufirst%3DW.%2BB.%26aulast%3DLibutti%26aufirst%3DS.%2BK.%26aulast%3DArnold%26aufirst%3DA.%26aulast%3DLambertini%26aufirst%3DL.%26aulast%3DStang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DKasai%26aufirst%3DY.%26aulast%3DMahajan%26aufirst%3DM.%26aulast%3DKinoshita%26aufirst%3DY.%26aulast%3DFernandez-Ranvier%26aufirst%3DG.%26aulast%3DBecker%26aufirst%3DT.%2BC.%26aulast%3DTakane%26aufirst%3DK.%2BK.%26aulast%3DWalker%26aufirst%3DL.%2BA.%26aulast%3DSaul%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DR.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DFerrer%26aufirst%3DJ.%26aulast%3DAntipin%26aufirst%3DY.%26aulast%3DDonovan%26aufirst%3DM.%26aulast%3DUzilov%26aufirst%3DA.%2BV.%26aulast%3DReva%26aufirst%3DB.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DLosic%26aufirst%3DB.%26aulast%3DArgmann%26aufirst%3DC.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DInsights%2520into%2520%25CE%25B2-cell%2520regeneration%2520for%2520diabetes%2520via%2520integration%2520of%2520molecular%2520landscapes%2520in%2520human%2520insulinomas%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26issue%3D1%26spage%3D1%26epage%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aemmaelae, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drury, W. J.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knerr, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlstedt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillemark-Billton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennberg-Huldt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valeur, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson-Loefmark, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundstroem, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claesson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monia, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, S.</span></span> <span> </span><span class="NLM_article-title">Targeted delivery of antisense oligonucleotides to pancreatic β-cells</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">10</span>), <span class="NLM_elocation-id">eaat3386</span> <span class="refDoi"> DOI: 10.1126/sciadv.aat3386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1126%2Fsciadv.aat3386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30345352" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&issue=10&author=C.+Aemmaelaeauthor=W.+J.+Druryauthor=L.+Knerrauthor=I.+Ahlstedtauthor=P.+Stillemark-Billtonauthor=C.+Wennberg-Huldtauthor=E.+M.+Anderssonauthor=E.+Valeurauthor=R.+Jansson-Loefmarkauthor=D.+Janzenauthor=L.+Sundstroemauthor=J.+Meullerauthor=J.+Claessonauthor=P.+Anderssonauthor=C.+Johanssonauthor=R.+G.+Leeauthor=T.+P.+Prakashauthor=P.+P.+Sethauthor=B.+P.+Moniaauthor=S.+Andersson&title=Targeted+delivery+of+antisense+oligonucleotides+to+pancreatic+%CE%B2-cells&doi=10.1126%2Fsciadv.aat3386"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.aat3386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.aat3386%26sid%3Dliteratum%253Aachs%26aulast%3DAemmaelae%26aufirst%3DC.%26aulast%3DDrury%26aufirst%3DW.%2BJ.%26aulast%3DKnerr%26aufirst%3DL.%26aulast%3DAhlstedt%26aufirst%3DI.%26aulast%3DStillemark-Billton%26aufirst%3DP.%26aulast%3DWennberg-Huldt%26aufirst%3DC.%26aulast%3DAndersson%26aufirst%3DE.%2BM.%26aulast%3DValeur%26aufirst%3DE.%26aulast%3DJansson-Loefmark%26aufirst%3DR.%26aulast%3DJanzen%26aufirst%3DD.%26aulast%3DSundstroem%26aufirst%3DL.%26aulast%3DMeuller%26aufirst%3DJ.%26aulast%3DClaesson%26aufirst%3DJ.%26aulast%3DAndersson%26aufirst%3DP.%26aulast%3DJohansson%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DR.%2BG.%26aulast%3DPrakash%26aufirst%3DT.%2BP.%26aulast%3DSeth%26aufirst%3DP.%2BP.%26aulast%3DMonia%26aufirst%3DB.%2BP.%26aulast%3DAndersson%26aufirst%3DS.%26atitle%3DTargeted%2520delivery%2520of%2520antisense%2520oligonucleotides%2520to%2520pancreatic%2520%25CE%25B2-cells%26jtitle%3DSci.%2520Adv.%26date%3D2018%26volume%3D4%26issue%3D10%26doi%3D10.1126%2Fsciadv.aat3386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrestha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aramandla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poffenberger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goff, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virostko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shostak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnahan, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevigny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, A. C.</span></span> <span> </span><span class="NLM_article-title">Ectonucleoside triphosphate diphosphohydrolase-3 antibody targets adult human pancreatic β cells for in vitro and in vivo analysis</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2018.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30449685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1WltrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=745-754&issue=3&author=D.+C.+Saundersauthor=M.+Brissovaauthor=N.+Phillipsauthor=S.+Shresthaauthor=J.+T.+Walkerauthor=R.+Aramandlaauthor=G.+Poffenbergerauthor=D.+K.+Flahertyauthor=K.+P.+Wellerauthor=J.+Pelletierauthor=T.+Cooperauthor=M.+T.+Goffauthor=J.+Virostkoauthor=A.+Shostakauthor=E.+D.+Deanauthor=D.+L.+Greinerauthor=L.+D.+Shultzauthor=N.+Prasadauthor=S.+E.+Levyauthor=R.+H.+Carnahanauthor=C.+Daiauthor=J.+Sevignyauthor=A.+C.+Powers&title=Ectonucleoside+triphosphate+diphosphohydrolase-3+antibody+targets+adult+human+pancreatic+%CE%B2+cells+for+in+vitro+and+in+vivo+analysis&doi=10.1016%2Fj.cmet.2018.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Ectonucleoside Triphosphate Diphosphohydrolase-3 Antibody Targets Adult Human Pancreatic β Cells for In Vitro and In Vivo Analysis</span></div><div class="casAuthors">Saunders, Diane C.; Brissova, Marcela; Phillips, Neil; Shrestha, Shristi; Walker, John T.; Aramandla, Radhika; Poffenberger, Greg; Flaherty, David K.; Weller, Kevin P.; Pelletier, Julie; Cooper, Tracy; Goff, Matt T.; Virostko, John; Shostak, Alena; Dean, E. Danielle; Greiner, Dale L.; Shultz, Leonard D.; Prasad, Nripesh; Levy, Shawn E.; Carnahan, Robert H.; Dai, Chunhua; Sevigny, Jean; Powers, Alvin C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">745-754.e4</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Identification of cell-surface markers specific to human pancreatic β cells would allow in vivo anal. and imaging.  Here we introduce a biomarker, ectonucleoside triphosphate diphosphohydrolase-3 (NTPDase3), that is expressed on the cell surface of essentially all adult human β cells, including those from individuals with type 1 or type 2 diabetes.  NTPDase3 is expressed dynamically during postnatal human pancreas development, appearing first in acinar cells at birth, but several months later its expression declines in acinar cells while concurrently emerging in islet β cells.  Given its specificity and membrane localization, we utilized an NTPDase3 antibody for purifn. of live human β cells as confirmed by transcriptional profiling, and, in addn., for in vivo imaging of transplanted human β cells.  Thus, NTPDase3 is a cell-surface biomarker of adult human β cells, and the antibody directed to this protein should be a useful new reagent for β cell sorting, in vivo imaging, and targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRe1GNU808ybVg90H21EOLACvtfcHk0lgwCGD5zVDxwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1WltrnP&md5=4902bddf1d3ba4fcfc62ebadb2ea117a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DSaunders%26aufirst%3DD.%2BC.%26aulast%3DBrissova%26aufirst%3DM.%26aulast%3DPhillips%26aufirst%3DN.%26aulast%3DShrestha%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DJ.%2BT.%26aulast%3DAramandla%26aufirst%3DR.%26aulast%3DPoffenberger%26aufirst%3DG.%26aulast%3DFlaherty%26aufirst%3DD.%2BK.%26aulast%3DWeller%26aufirst%3DK.%2BP.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DCooper%26aufirst%3DT.%26aulast%3DGoff%26aufirst%3DM.%2BT.%26aulast%3DVirostko%26aufirst%3DJ.%26aulast%3DShostak%26aufirst%3DA.%26aulast%3DDean%26aufirst%3DE.%2BD.%26aulast%3DGreiner%26aufirst%3DD.%2BL.%26aulast%3DShultz%26aufirst%3DL.%2BD.%26aulast%3DPrasad%26aufirst%3DN.%26aulast%3DLevy%26aufirst%3DS.%2BE.%26aulast%3DCarnahan%26aufirst%3DR.%2BH.%26aulast%3DDai%26aufirst%3DC.%26aulast%3DSevigny%26aufirst%3DJ.%26aulast%3DPowers%26aufirst%3DA.%2BC.%26atitle%3DEctonucleoside%2520triphosphate%2520diphosphohydrolase-3%2520antibody%2520targets%2520adult%2520human%2520pancreatic%2520%25CE%25B2%2520cells%2520for%2520in%2520vitro%2520and%2520in%2520vivo%2520analysis%26jtitle%3DCell%2520Metab.%26date%3D2019%26volume%3D29%26issue%3D3%26spage%3D745%26epage%3D754%26doi%3D10.1016%2Fj.cmet.2018.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ackeifi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakose, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning Fox, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrouet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorens, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ocana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. F.</span></span> <span> </span><span class="NLM_article-title">GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">530</span>), <span class="NLM_elocation-id">eaaw9996</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aaw9996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1126%2Fscitranslmed.aaw9996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=32051230" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&issue=530&author=C.+Ackeifiauthor=P.+Wangauthor=E.+Karakoseauthor=J.+E.+Manning+Foxauthor=B.+J.+Gonzalezauthor=H.+Liuauthor=J.+Wilsonauthor=E.+Swartzauthor=C.+Berrouetauthor=Y.+Liauthor=K.+Kumarauthor=P.+E.+MacDonaldauthor=R.+Sanchezauthor=B.+Thorensauthor=R.+DeVitaauthor=D.+Homannauthor=D.+Egliauthor=D.+K.+Scottauthor=A.+Garcia-Ocanaauthor=A.+F.+Stewart&title=GLP-1+receptor+agonists+synergize+with+DYRK1A+inhibitors+to+potentiate+functional+human+%CE%B2+cell+regeneration&doi=10.1126%2Fscitranslmed.aaw9996"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaw9996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaw9996%26sid%3Dliteratum%253Aachs%26aulast%3DAckeifi%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DKarakose%26aufirst%3DE.%26aulast%3DManning%2BFox%26aufirst%3DJ.%2BE.%26aulast%3DGonzalez%26aufirst%3DB.%2BJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWilson%26aufirst%3DJ.%26aulast%3DSwartz%26aufirst%3DE.%26aulast%3DBerrouet%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DKumar%26aufirst%3DK.%26aulast%3DMacDonald%26aufirst%3DP.%2BE.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DThorens%26aufirst%3DB.%26aulast%3DDeVita%26aufirst%3DR.%26aulast%3DHomann%26aufirst%3DD.%26aulast%3DEgli%26aufirst%3DD.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DGarcia-Ocana%26aufirst%3DA.%26aulast%3DStewart%26aufirst%3DA.%2BF.%26atitle%3DGLP-1%2520receptor%2520agonists%2520synergize%2520with%2520DYRK1A%2520inhibitors%2520to%2520potentiate%2520functional%2520human%2520%25CE%25B2%2520cell%2520regeneration%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26issue%3D530%26doi%3D10.1126%2Fscitranslmed.aaw9996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosado-Olivieri, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenty, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melton, D. A.</span></span> <span> </span><span class="NLM_article-title">YAP inhibition enhances the differentiation of functional stem cell-derived insulin-producing β cells</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fs41467-019-09404-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30602773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXoslGks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1-11&issue=1&author=E.+A.+Rosado-Olivieriauthor=K.+Andersonauthor=J.+H.+Kentyauthor=D.+A.+Melton&title=YAP+inhibition+enhances+the+differentiation+of+functional+stem+cell-derived+insulin-producing+%CE%B2+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">YAP inhibition enhances the differentiation of functional stem cell-derived insulin-producing β cells</span></div><div class="casAuthors">Rosado-Olivieri, Edwin A.; Anderson, Kendall; Kenty, Jennifer H.; Melton, Douglas A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Stem cell-derived insulin-producing beta cells (SC-β) offer an inexhaustible supply of functional β cells for cell replacement therapies and disease modeling for diabetes.  While successful directed differentiation protocols for this cell type have been described, the mechanisms controlling its differentiation and function are not fully understood.  Here we report that the Hippo pathway controls the proliferation and specification of pancreatic progenitors into the endocrine lineage.  Downregulation of YAP, an effector of the pathway, enhances endocrine progenitor differentiation and the generation of SC-β cells with improved insulin secretion.  A chem. inhibitor of YAP acts as an inducer of endocrine differentiation and reduces the presence of proliferative progenitor cells.  Conversely, sustained activation of YAP results in impaired differentiation, blunted glucose-stimulated insulin secretion, and increased proliferation of SC-β cells.  Together these results support a role for YAP in controlling the self-renewal and differentiation balance of pancreatic progenitors and limiting endocrine differentiation in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVP8NOk_IoyLVg90H21EOLACvtfcHk0lh8imoC7KNSbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXoslGks7w%253D&md5=bb11ed4559fd6c8236fb325d389ebba1</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-09404-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-09404-6%26sid%3Dliteratum%253Aachs%26aulast%3DRosado-Olivieri%26aufirst%3DE.%2BA.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DKenty%26aufirst%3DJ.%2BH.%26aulast%3DMelton%26aufirst%3DD.%2BA.%26atitle%3DYAP%2520inhibition%2520enhances%2520the%2520differentiation%2520of%2520functional%2520stem%2520cell-derived%2520insulin-producing%2520%25CE%25B2%2520cells%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosado-Olivieri, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aigha, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenty, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melton, D. A.</span></span> <span> </span><span class="NLM_article-title">Identification of a LIF-responsive, replication-competent subpopulation of human β cells</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2019.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2019.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=31928884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpt1Cjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=327-338&issue=2&author=E.+A.+Rosado-Olivieriauthor=I.+I.+Aighaauthor=J.+H.+Kentyauthor=D.+A.+Melton&title=Identification+of+a+LIF-responsive%2C+replication-competent+subpopulation+of+human+%CE%B2+cells&doi=10.1016%2Fj.cmet.2019.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a LIF-Responsive, Replication-Competent Subpopulation of Human β Cells</span></div><div class="casAuthors">Rosado-Olivieri, Edwin A.; Aigha, Idil I.; Kenty, Jennifer H.; Melton, Douglas A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-338.e6</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The beta (β)-cell mass formed during embryogenesis is amplified by cell replication during fetal and early postnatal development.  Thereafter, β cells become functionally mature, and their mass is maintained by a low rate of replication.  For those few β cells that replicate in adult life, it is not known how replication is initiated nor whether this occurs in a specialized subset of β cells.  We capitalized on a YAP overexpression system to induce replication of stem-cell-derived β cells and, by single-cell RNA sequencing, identified an upregulation of the leukemia inhibitory factor (LIF) pathway.  Activation of the LIF pathway induces replication of human β cells in vitro and in vivo.  The expression of the LIF receptor is restricted to a subset of transcriptionally distinct human β cells with increased proliferative capacity.  This study delineates novel genetic networks that control the replication of LIF-responsive, replication-competent human β cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh8W5YE4mVybVg90H21EOLACvtfcHk0lh8imoC7KNSbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpt1Cjsw%253D%253D&md5=8fd407c003ab85af255c990336fd540a</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2019.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2019.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DRosado-Olivieri%26aufirst%3DE.%2BA.%26aulast%3DAigha%26aufirst%3DI.%2BI.%26aulast%3DKenty%26aufirst%3DJ.%2BH.%26aulast%3DMelton%26aufirst%3DD.%2BA.%26atitle%3DIdentification%2520of%2520a%2520LIF-responsive%252C%2520replication-competent%2520subpopulation%2520of%2520human%2520%25CE%25B2%2520cells%26jtitle%3DCell%2520Metab.%26date%3D2020%26volume%3D31%26issue%3D2%26spage%3D327%26epage%3D338%26doi%3D10.1016%2Fj.cmet.2019.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicola, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babon, J. J.</span></span> <span> </span><span class="NLM_article-title">Leukemia inhibitory factor (LIF)</span>. <i>Cytokine Growth Factor Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1016/j.cytogfr.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cytogfr.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26187859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOksrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=533-544&issue=5&author=N.+A.+Nicolaauthor=J.+J.+Babon&title=Leukemia+inhibitory+factor+%28LIF%29&doi=10.1016%2Fj.cytogfr.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Leukemia inhibitory factor (LIF)</span></div><div class="casAuthors">Nicola, Nicos A.; Babon, Jeffrey J.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">533-544</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Leukemia inhibitory factor (LIF) is the most pleiotropic member of the interleukin-6 family of cytokines.  It utilizes a receptor that consists of the LIF receptor β and gp130 and this receptor complex is also used by ciliary neurotrophic growth factor (CNTF), oncostatin M, cardiotrophin 1 (CT1) and cardiotrophin-like cytokine (CLC).  Despite common signal transduction mechanisms (JAK/STAT, MAPK and PI3K) LIF can have paradoxically opposite effects in different cell types including stimulating or inhibiting each of cell proliferation, differentiation and survival.  While LIF can act on a wide range of cell types, LIF knockout mice have revealed that many of these actions are not apparent during ordinary development and that they may be the result of induced LIF expression during tissue damage or injury.  Nevertheless LIF does appear to have non-redundant actions in maternal receptivity to blastocyst implantation, placental formation and in the development of the nervous system.  LIF has also found practical use in the maintenance of self-renewal and totipotency of embryonic stem cells and induced pluripotent stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox2V6NiD3P87Vg90H21EOLACvtfcHk0lh8imoC7KNSbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOksrfL&md5=f1352a4bb21486e040194456f862fe25</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DNicola%26aufirst%3DN.%2BA.%26aulast%3DBabon%26aufirst%3DJ.%2BJ.%26atitle%3DLeukemia%2520inhibitory%2520factor%2520%2528LIF%2529%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2015%26volume%3D26%26issue%3D5%26spage%3D533%26epage%3D544%26doi%3D10.1016%2Fj.cytogfr.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetsch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corvaïa, N.</span></span> <span> </span><span class="NLM_article-title">Strategies and challenges for the next generation of antibody–drug conjugates</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrd.2016.268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=28303026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=315-337&issue=5&author=A.+Beckauthor=L.+Goetschauthor=C.+Dumontetauthor=N.+Corva%C3%AFa&title=Strategies+and+challenges+for+the+next+generation+of+antibody%E2%80%93drug+conjugates&doi=10.1038%2Fnrd.2016.268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies and challenges for the next generation of antibody-drug conjugates</span></div><div class="casAuthors">Beck, Alain; Goetsch, Liliane; Dumontet, Charles; Corvaia, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-337</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncol. therapeutics.  After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clin. trials that are evaluating more than 60 further ADC candidates.  The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody.  Furthermore, lessons learned during the past decade are now being used in the development of third-generation ADCs.  In this Review, we discuss strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues.  The selection and engineering of antibodies for site-specific drug conjugation, which will result in higher homogeneity and increased stability, as well as the quest for new conjugation chemistries and mechanisms of action, are priorities in ADC research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP7lV63Ws8rbVg90H21EOLACvtfcHk0lh8imoC7KNSbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D&md5=7358b6080dd1aed1d21e98c078cd9ef1</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.268%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DGoetsch%26aufirst%3DL.%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DCorva%25C3%25AFa%26aufirst%3DN.%26atitle%3DStrategies%2520and%2520challenges%2520for%2520the%2520next%2520generation%2520of%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D5%26spage%3D315%26epage%3D337%26doi%3D10.1038%2Fnrd.2016.268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhakta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junutula, J. R.</span></span> <span> </span><span class="NLM_article-title">Site-specific antibody drug conjugates for cancer therapy</span>. <i>mAbs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.4161/mabs.27022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.4161%2Fmabs.27022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=24423619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A280%3ADC%252BC2cvnslaltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=34-45&issue=1&author=S.+Panowskiauthor=S.+Bhaktaauthor=H.+Raabauthor=P.+Polakisauthor=J.+R.+Junutula&title=Site-specific+antibody+drug+conjugates+for+cancer+therapy&doi=10.4161%2Fmabs.27022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific antibody drug conjugates for cancer therapy</span></div><div class="casAuthors">Panowski Siler; Bhakta Sunil; Raab Helga; Polakis Paul; Junutula Jagath R</div><div class="citationInfo"><span class="NLM_cas:title">mAbs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibody therapeutics have revolutionized the treatment of cancer over the past two decades.  Antibodies that specifically bind tumor surface antigens can be effective therapeutics; however, many unmodified antibodies lack therapeutic activity.  These antibodies can instead be applied successfully as guided missiles to deliver potent cytotoxic drugs in the form of antibody drug conjugates (ADCs).  The success of ADCs is dependent on four factors--target antigen, antibody, linker, and payload.  The field has made great progress in these areas, marked by the recent approval by the US Food and Drug Administration of two ADCs, brentuximab vedotin (Adcetris) and ado-trastuzumab emtansine (Kadcyla).  However, the therapeutic window for many ADCs that are currently in pre-clinical or clinical development remains narrow and further improvements may be required to enhance the therapeutic potential of these ADCs.  Production of ADCs is an area where improvement is needed because current methods yield heterogeneous mixtures that may include 0-8 drug species per antibody molecule.  Site-specific conjugation has been recently shown to eliminate heterogeneity, improve conjugate stability, and increase the therapeutic window.  Here, we review and describe various site-specific conjugation strategies that are currently used for the production of ADCs, including use of engineered cysteine residues, unnatural amino acids, and enzymatic conjugation through glycotransferases and transglutaminases.  In addition, we also summarize differences among these methods and highlight critical considerations when building next-generation ADC therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXMRlj6bTH0hOk4JA3soTqfW6udTcc2eauMcxDA8a_7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvnslaltw%253D%253D&md5=9da883692122c03303f785e61f6c5db7</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.4161%2Fmabs.27022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fmabs.27022%26sid%3Dliteratum%253Aachs%26aulast%3DPanowski%26aufirst%3DS.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DSite-specific%2520antibody%2520drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DmAbs%26date%3D2014%26volume%3D6%26issue%3D1%26spage%3D34%26epage%3D45%26doi%3D10.4161%2Fmabs.27022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdollahpour-Alitappeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotfinia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharibi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardaneh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farhadihosseinabadi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larki, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faghfourian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepehr, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbaszadeh-Goudarzi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbaszadeh-Goudarzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johari, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zali, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagheri, N.</span></span> <span> </span><span class="NLM_article-title">Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">5628</span>– <span class="NLM_lpage">5642</span>, <span class="refDoi"> DOI: 10.1002/jcp.27419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1002%2Fjcp.27419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30478951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSgs77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=5628-5642&issue=5&author=M.+Abdollahpour-Alitappehauthor=M.+Lotfiniaauthor=T.+Gharibiauthor=J.+Mardanehauthor=B.+Farhadihosseinabadiauthor=P.+Larkiauthor=B.+Faghfourianauthor=K.+S.+Sepehrauthor=K.+Abbaszadeh-Goudarziauthor=G.+Abbaszadeh-Goudarziauthor=B.+Johariauthor=M.+R.+Zaliauthor=N.+Bagheri&title=Antibody%E2%80%93drug+conjugates+%28ADCs%29+for+cancer+therapy%3A+Strategies%2C+challenges%2C+and+successes&doi=10.1002%2Fjcp.27419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes</span></div><div class="casAuthors">Abdollahpour-Alitappeh, Meghdad; Lotfinia, Majid; Gharibi, Tohid; Mardaneh, Jalal; Farhadihosseinabadi, Behrouz; Larki, Pegah; Faghfourian, Babak; Sepehr, Koushan Sineh; Abbaszadeh-Goudarzi, Kazem; Abbaszadeh-Goudarzi, Ghasem; Johari, Behrooz; Zali, Mohammad Reza; Bagheri, Nader</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">5628-5642</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Targeted delivery of therapeutic mols. into cancer cells is considered as a promising strategy to tackle cancer.  Antibody-drug conjugates (ADCs), in which a monoclonal antibody (mAb) is conjugated to biol. active drugs through chem. linkers, have emerged as a promising class of anticancer treatment agents, being one of the fastest growing fields in cancer therapy.  The failure of early ADCs led researchers to explore strategies to develop more effective and improved ADCs with lower levels of unconjugated mAbs and more-stable linkers between the drug and the antibody, which show improved pharmacokinetic properties, therapeutic indexes, and safety profiles.  Such improvements resulted in the US Food and Drug Administration approvals of brentuximab vedotin, trastuzumab emtansine, and, more recently, inotuzumab ozogamicin.  In addn., recent clin. outcomes have sparked addnl. interest, which leads to the dramatically increased no. of ADCs in clin. development.  The present review explores ADCs, their main characteristics, and new research developments, as well as discusses strategies for the selection of the most appropriate target antigens, mAbs, cytotoxic drugs, linkers, and conjugation chemistries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYkf-vg9w2KbVg90H21EOLACvtfcHk0ljhgIXa331veQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSgs77I&md5=56789e8e2935cebae1392511c4cf497f</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fjcp.27419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.27419%26sid%3Dliteratum%253Aachs%26aulast%3DAbdollahpour-Alitappeh%26aufirst%3DM.%26aulast%3DLotfinia%26aufirst%3DM.%26aulast%3DGharibi%26aufirst%3DT.%26aulast%3DMardaneh%26aufirst%3DJ.%26aulast%3DFarhadihosseinabadi%26aufirst%3DB.%26aulast%3DLarki%26aufirst%3DP.%26aulast%3DFaghfourian%26aufirst%3DB.%26aulast%3DSepehr%26aufirst%3DK.%2BS.%26aulast%3DAbbaszadeh-Goudarzi%26aufirst%3DK.%26aulast%3DAbbaszadeh-Goudarzi%26aufirst%3DG.%26aulast%3DJohari%26aufirst%3DB.%26aulast%3DZali%26aufirst%3DM.%2BR.%26aulast%3DBagheri%26aufirst%3DN.%26atitle%3DAntibody%25E2%2580%2593drug%2520conjugates%2520%2528ADCs%2529%2520for%2520cancer%2520therapy%253A%2520Strategies%252C%2520challenges%252C%2520and%2520successes%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26issue%3D5%26spage%3D5628%26epage%3D5642%26doi%3D10.1002%2Fjcp.27419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehar, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staben, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajihara, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandlen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePalatis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazenbos, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiroshi Morisaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darwish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyet, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalfin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plise, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strandh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koefoed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wah Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariathasan, S.</span></span> <span> </span><span class="NLM_article-title">Novel antibody–antibiotic conjugate eliminates intracellular S. aureus</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>527</i></span> (<span class="NLM_issue">7578</span>),  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1038/nature16057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnature16057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26536114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOrtLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=527&publication_year=2015&pages=323-328&issue=7578&author=S.+M.+Leharauthor=T.+Pillowauthor=M.+Xuauthor=L.+Stabenauthor=K.+K.+Kajiharaauthor=R.+Vandlenauthor=L.+DePalatisauthor=H.+Raabauthor=W.+L.+Hazenbosauthor=J.+Hiroshi+Morisakiauthor=J.+Kimauthor=S.+Parkauthor=M.+Darwishauthor=B.-C.+Leeauthor=H.+Hernandezauthor=K.+M.+Loyetauthor=P.+Lupardusauthor=R.+Fongauthor=D.+Yanauthor=C.+Chalouniauthor=E.+Luisauthor=Y.+Khalfinauthor=E.+Pliseauthor=J.+Cheongauthor=J.+P.+Lyssikatosauthor=M.+Strandhauthor=K.+Koefoedauthor=P.+S.+Andersenauthor=J.+A.+Flygareauthor=M.+Wah+Tanauthor=E.+J.+Brownauthor=S.+Mariathasan&title=Novel+antibody%E2%80%93antibiotic+conjugate+eliminates+intracellular+S.+aureus&doi=10.1038%2Fnature16057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Novel antibody-antibiotic conjugate eliminates intracellular S. aureus</span></div><div class="casAuthors">Lehar, Sophie M.; Pillow, Thomas; Xu, Min; Staben, Leanna; Kajihara, Kimberly K.; Vandlen, Richard; De Palatis, Laura; Raab, Helga; Hazenbos, Wouter L.; Hiroshi Morisaki, J.; Kim, Janice; Park, Summer; Darwish, Martine; Lee, Byoung-Chul; Hernandez, Hilda; Loyet, Kelly M.; Lupardus, Patrick; Fong, Rina; Yan, Donghong; Chalouni, Cecile; Luis, Elizabeth; Khalfin, Yana; Plise, Emile; Cheong, Jonathan; Lyssikatos, Joseph P.; Strandh, Magnus; Koefoed, Klaus; Andersen, Peter S.; Flygare, John A.; Tan, Man Wah; Brown, Eric J.; Mariathasan, Sanjeev</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">527</span>
        (<span class="NLM_cas:issue">7578</span>),
    <span class="NLM_cas:pages">323-328</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Staphylococcus aureus is considered to be an extracellular pathogen.  However, survival of S. aureus within host cells may provide a reservoir relatively protected from antibiotics, thus enabling long-term colonization of the host and explaining clin. failures and relapses after antibiotic therapy.  Here we confirm that intracellular reservoirs of S. aureus in mice comprise a virulent subset of bacteria that can establish infection even in the presence of vancomycin, and we introduce a novel therapeutic that effectively kills intracellular S. aureus.  This antibody-antibiotic conjugate consists of an anti-S. aureus antibody conjugated to a highly efficacious antibiotic that is activated only after it is released in the proteolytic environment of the phagolysosome.  The antibody-antibiotic conjugate is superior to vancomycin for treatment of bacteremia and provides direct evidence that intracellular S. aureus represents an important component of invasive infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9cwgfxu2hErVg90H21EOLACvtfcHk0ljhgIXa331veQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOrtLfP&md5=09cc42906a456aaa772530d69c36aa50</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnature16057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16057%26sid%3Dliteratum%253Aachs%26aulast%3DLehar%26aufirst%3DS.%2BM.%26aulast%3DPillow%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DStaben%26aufirst%3DL.%26aulast%3DKajihara%26aufirst%3DK.%2BK.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DDePalatis%26aufirst%3DL.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DHazenbos%26aufirst%3DW.%2BL.%26aulast%3DHiroshi%2BMorisaki%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DDarwish%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DB.-C.%26aulast%3DHernandez%26aufirst%3DH.%26aulast%3DLoyet%26aufirst%3DK.%2BM.%26aulast%3DLupardus%26aufirst%3DP.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DLuis%26aufirst%3DE.%26aulast%3DKhalfin%26aufirst%3DY.%26aulast%3DPlise%26aufirst%3DE.%26aulast%3DCheong%26aufirst%3DJ.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26aulast%3DStrandh%26aufirst%3DM.%26aulast%3DKoefoed%26aufirst%3DK.%26aulast%3DAndersen%26aufirst%3DP.%2BS.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DWah%2BTan%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DE.%2BJ.%26aulast%3DMariathasan%26aufirst%3DS.%26atitle%3DNovel%2520antibody%25E2%2580%2593antibiotic%2520conjugate%2520eliminates%2520intracellular%2520S.%2520aureus%26jtitle%3DNature%26date%3D2015%26volume%3D527%26issue%3D7578%26spage%3D323%26epage%3D328%26doi%3D10.1038%2Fnature16057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weglarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampton, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollong, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambaldo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. S.</span></span> <span> </span><span class="NLM_article-title">Targeted delivery of an anti-inflammatory PDE4 inhibitor to immune cells via an antibody–drug conjugate</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2078</span>– <span class="NLM_lpage">2089</span>, <span class="refDoi"> DOI: 10.1038/mt.2016.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fmt.2016.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=27731313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKgtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=2078-2089&issue=12&author=S.+Yuauthor=A.+D.+Pearsonauthor=R.+K.+V.+Limauthor=D.+T.+Rodgersauthor=S.+Liauthor=H.+B.+Parkerauthor=M.+Weglarzauthor=E.+N.+Hamptonauthor=M.+J.+Bollongauthor=J.+Shenauthor=C.+Zambaldoauthor=D.+Wangauthor=A.+K.+Woodsauthor=T.+M.+Wrightauthor=P.+G.+Schultzauthor=S.+A.+Kazaneauthor=T.+S.+Youngauthor=M.+S.+Tremblay&title=Targeted+delivery+of+an+anti-inflammatory+PDE4+inhibitor+to+immune+cells+via+an+antibody%E2%80%93drug+conjugate&doi=10.1038%2Fmt.2016.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate</span></div><div class="casAuthors">Yu, Shan; Pearson, Aaron D.; Lim, Reyna K. V.; Rodgers, David T.; Li, Sijia; Parker, Holly B.; Weglarz, Meredith; Hampton, Eric N.; Bollong, Michael J.; Shen, Jiayin; Zambaldo, Claudio; Wang, Danling; Woods, Ashley K.; Wright, Timothy M.; Schultz, Peter G.; Kazane, Stephanie A.; Young, Travis S.; Tremblay, Matthew S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2078-2089</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4) inhibitors are approved for the treatment of some moderate to severe inflammatory conditions.  However, dose-limiting side effects in the central nervous system and gastrointestinal tract, including nausea, emesis, headache, and diarrhea, have impeded the broader therapeutic application of PDE4 inhibitors.  We sought to exploit the wealth of validation surrounding PDE4 inhibition by improving the therapeutic index through generation of an antibody-drug conjugate (ADC) that selectively targets immune cells through the CD11a antigen.  The resulting ADC consisted of a human αCD11a antibody (based on efalizumab clone hu1124) conjugated to an analog of the highly potent PDE4 inhibitor GSK256066.  Both the human αCD11a ADC and a mouse surrogate αCD11a ADC (based on the M17 clone) rapidly internalized into immune cells and suppressed lipopolysaccharide (LPS)-induced TNFα secretion in primary human monocytes and mouse peritoneal cells, resp.  In a carrageenan-induced air pouch inflammation mouse model, treatment with the ADC significantly reduced inflammatory cytokine prodn. in the air pouch exudate.  Overall, these results provide compelling evidence for the feasibility of delivering drugs with anti-inflammatory activity selectively to the immune compartment via CD11a and the development of tissue-targeted PDE4 inhibitors as a promising therapeutic modality for treating inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTURNcWDw-37Vg90H21EOLACvtfcHk0liHvwEIRhLoQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKgtL7I&md5=82964396c796f6cfda7cf938e55bcc72</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fmt.2016.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2016.175%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DS.%26aulast%3DPearson%26aufirst%3DA.%2BD.%26aulast%3DLim%26aufirst%3DR.%2BK.%2BV.%26aulast%3DRodgers%26aufirst%3DD.%2BT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DH.%2BB.%26aulast%3DWeglarz%26aufirst%3DM.%26aulast%3DHampton%26aufirst%3DE.%2BN.%26aulast%3DBollong%26aufirst%3DM.%2BJ.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZambaldo%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DA.%2BK.%26aulast%3DWright%26aufirst%3DT.%2BM.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DKazane%26aufirst%3DS.%2BA.%26aulast%3DYoung%26aufirst%3DT.%2BS.%26aulast%3DTremblay%26aufirst%3DM.%2BS.%26atitle%3DTargeted%2520delivery%2520of%2520an%2520anti-inflammatory%2520PDE4%2520inhibitor%2520to%2520immune%2520cells%2520via%2520an%2520antibody%25E2%2580%2593drug%2520conjugate%26jtitle%3DMol.%2520Ther.%26date%3D2016%26volume%3D24%26issue%3D12%26spage%3D2078%26epage%3D2089%26doi%3D10.1038%2Fmt.2016.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, R. K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazane, S. A.</span></span> <span> </span><span class="NLM_article-title">Targeted delivery of LXR agonist using a site-specific antibody–drug conjugate</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2216</span>– <span class="NLM_lpage">2222</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.5b00203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.5b00203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslGhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2216-2222&issue=11&author=R.+K.+V.+Limauthor=S.+Yuauthor=B.+Chengauthor=S.+Liauthor=N.-J.+Kimauthor=Y.+Caoauthor=V.+Chiauthor=J.+Y.+Kimauthor=A.+K.+Chatterjeeauthor=P.+G.+Schultzauthor=M.+S.+Tremblayauthor=S.+A.+Kazane&title=Targeted+delivery+of+LXR+agonist+using+a+site-specific+antibody%E2%80%93drug+conjugate&doi=10.1021%2Facs.bioconjchem.5b00203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted delivery of LXR agonist using a site-specific antibody-drug conjugate</span></div><div class="casAuthors">Lim, Reyna K. V.; Yu, Shan; Cheng, Bo; Li, Sijia; Kim, Nam-Jung; Cao, Yu; Chi, Victor; Kim, Ji Young; Chatterjee, Arnab K.; Schultz, Peter G.; Tremblay, Matthew S.; Kazane, Stephanie A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2216-2222</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Liver X receptor (LXR) agonists have been explored as potential treatments for atherosclerosis and other diseases based on their ability to induce reverse cholesterol transport and suppress inflammation.  However, this therapeutic potential has been hindered by on-target adverse effects in the liver mediated by excessive lipogenesis.  Herein, we report a novel site-specific antibody-drug conjugate (ADC) that selectively delivers a LXR agonist to monocytes/macrophages while sparing hepatocytes.  The unnatural amino acid para-acetylphenylalanine (pAcF) was site-specifically incorporated into anti-CD11a IgG, which binds the α-chain component of the lymphocyte function-assocd. antigen 1 (LFA-1) expressed on nearly all monocytes and macrophages.  An aminooxy-modified LXR agonist was conjugated to anti-CD11a IgG through a stable, cathepsin B cleavable oxime linkage to afford a chem. defined ADC.  The anti-CD11a IgG-LXR agonist ADC induced LXR activation specifically in human THP-1 monocyte/macrophage cells in vitro (EC50-27 nM), but had no significant effect in hepatocytes, indicating that payload delivery is CD11a-mediated.  Moreover, the ADC exhibited higher-fold activation compared to a conventional synthetic LXR agonist T0901317 (Tularik) (3-fold).  This novel ADC represents a fundamentally different strategy that uses tissue targeting to overcome the limitations of LXR agonists for potential use in treating atherosclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFsgPuuioq9LVg90H21EOLACvtfcHk0liHvwEIRhLoQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslGhurw%253D&md5=970224ffc9f452632dae3b8b2a2224e6</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.5b00203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.5b00203%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DR.%2BK.%2BV.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DN.-J.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DChi%26aufirst%3DV.%26aulast%3DKim%26aufirst%3DJ.%2BY.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DTremblay%26aufirst%3DM.%2BS.%26aulast%3DKazane%26aufirst%3DS.%2BA.%26atitle%3DTargeted%2520delivery%2520of%2520LXR%2520agonist%2520using%2520a%2520site-specific%2520antibody%25E2%2580%2593drug%2520conjugate%26jtitle%3DBioconjugate%2520Chem.%26date%3D2015%26volume%3D26%26issue%3D11%26spage%3D2216%26epage%3D2222%26doi%3D10.1021%2Facs.bioconjchem.5b00203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueberberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schechinger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akinturk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, S.</span></span> <span> </span><span class="NLM_article-title">In vitro phage display in a rat β-cell line: a simple approach for the generation of a single-chain antibody targeting a novel β-cell-specific epitope</span>. <i>Diabetologia</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1384</span>– <span class="NLM_lpage">1394</span>, <span class="refDoi"> DOI: 10.1007/s00125-010-1725-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1007%2Fs00125-010-1725-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=20369222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsFyrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1384-1394&issue=7&author=S.+Ueberbergauthor=D.+Zieglerauthor=W.+Schechingerauthor=J.+W.+Dietrichauthor=S.+Akinturkauthor=H.+H.+Kleinauthor=S.+Schneider&title=In+vitro+phage+display+in+a+rat+%CE%B2-cell+line%3A+a+simple+approach+for+the+generation+of+a+single-chain+antibody+targeting+a+novel+%CE%B2-cell-specific+epitope&doi=10.1007%2Fs00125-010-1725-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro phage display in a rat beta cell line: a simple approach for the generation of a single-chain antibody targeting a novel beta cell-specific epitope</span></div><div class="casAuthors">Ueberberg, S.; Ziegler, D.; Schechinger, W.; Dietrich, J. W.; Akinturk, S.; Klein, H. H.; Schneider, S.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetologia</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1384-1394</span>CODEN:
                <span class="NLM_cas:coden">DBTGAJ</span>;
        ISSN:<span class="NLM_cas:issn">0012-186X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aims/hypothesis: The aim of the present study was to evaluate in vitro phage display in a beta cell line as a novel strategy for the isolation of beta cell-specific agents/biomarkers.  Methods: A single-chain antibody (SCA) library was pre-incubated with AR42J cells in order to eliminate SCAs with exocrine binding properties.  It was then panned against INS-1 cells to select beta cell-targeted antibodies.  Results: By these means, we isolated a novel antibody, SCA B5, that binds rapidly (6.0 min) and with a 450-fold higher specificity to beta cells relative to exocrine cells.  We estd. for SCA B5 a binding affinity in the low μmol/l range and 858 binding sites per beta cell.  Confocal microscopy showed binding to the beta cell surface and confirmed subsequent internalization.  Moreover, staining of rat and human pancreatic tissue sections with SCA B5 suggests that the target epitope is presented in pancreatic beta cells of different origins.  IR imaging revealed that labeling of beta cells with tracer SCA B5 is strictly dependent on beta cell mass.  With competition assays we excluded insulin, glutamate decarboxylase, C-peptide and islet amyloid polypeptide as SCA B5 targets.  In accordance with these predictions, SCA B5 homed in vivo highly selectively to normal beta cells and dysfunctional beta cells of diabetic rats.  Moreover, accumulation of radioactively labeled SCA B5 in the pancreas was reduced by 80% after pre-injection with unlabeled SCA B5, thereby confirming the specific uptake in the pancreas.  Conclusions/interpretation: We report a simple strategy for the generation of an SCA targeting a novel beta cell-specific epitope.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxUWVKlwj24bVg90H21EOLACvtfcHk0ljhYwdOYSsbVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsFyrsrs%253D&md5=4a0a2cc022760d948184e88a5c375805</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2Fs00125-010-1725-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00125-010-1725-9%26sid%3Dliteratum%253Aachs%26aulast%3DUeberberg%26aufirst%3DS.%26aulast%3DZiegler%26aufirst%3DD.%26aulast%3DSchechinger%26aufirst%3DW.%26aulast%3DDietrich%26aufirst%3DJ.%2BW.%26aulast%3DAkinturk%26aufirst%3DS.%26aulast%3DKlein%26aufirst%3DH.%2BH.%26aulast%3DSchneider%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520phage%2520display%2520in%2520a%2520rat%2520%25CE%25B2-cell%2520line%253A%2520a%2520simple%2520approach%2520for%2520the%2520generation%2520of%2520a%2520single-chain%2520antibody%2520targeting%2520a%2520novel%2520%25CE%25B2-cell-specific%2520epitope%26jtitle%3DDiabetologia%26date%3D2010%26volume%3D53%26issue%3D7%26spage%3D1384%26epage%3D1394%26doi%3D10.1007%2Fs00125-010-1725-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khvorova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, J. K.</span></span> <span> </span><span class="NLM_article-title">The chemical evolution of oligonucleotide therapies of clinical utility</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1038/nbt.3765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnbt.3765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=28244990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlalurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=238-248&issue=3&author=A.+Khvorovaauthor=J.+K.+Watts&title=The+chemical+evolution+of+oligonucleotide+therapies+of+clinical+utility&doi=10.1038%2Fnbt.3765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The chemical evolution of oligonucleotide therapies of clinical utility</span></div><div class="casAuthors">Khvorova, Anastasia; Watts, Jonathan K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">238-248</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">After nearly 40 years of development, oligonucleotide therapeutics are nearing meaningful clin. productivity.  One of the key advantages of oligonucleotide drugs is that their delivery and potency are derived primarily from the chem. structure of the oligonucleotide whereas their target is defined by the base sequence.  Thus, as oligonucleotides with a particular chem. design show appropriate distribution and safety profiles for clin. gene silencing in a particular tissue, this will open the door to the rapid development of addnl. drugs targeting other disease-assocd. genes in the same tissue.  To achieve clin. productivity, the chem. architecture of the oligonucleotide needs to be optimized with a combination of sugar, backbone, nucleobase, and 3'- and 5'-terminal modifications.  A portfolio of chemistries can be used to confer drug-like properties onto the oligonucleotide as a whole, with minor chem. changes often translating into major improvements in clin. efficacy.  One outstanding challenge in oligonucleotide chem. development is the optimization of chem. architectures to ensure long-term safety.  There are multiple designs that enable effective targeting of the liver, but a second challenge is to develop architectures that enable robust clin. efficacy in addnl. tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhUFUW0teh-rVg90H21EOLACvtfcHk0ljhYwdOYSsbVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlalurc%253D&md5=d6c3f3ec136632eee79a63fc0be0bbfc</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fnbt.3765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.3765%26sid%3Dliteratum%253Aachs%26aulast%3DKhvorova%26aufirst%3DA.%26aulast%3DWatts%26aufirst%3DJ.%2BK.%26atitle%3DThe%2520chemical%2520evolution%2520of%2520oligonucleotide%2520therapies%2520of%2520clinical%2520utility%26jtitle%3DNat.%2520Biotechnol.%26date%3D2017%26volume%3D35%26issue%3D3%26spage%3D238%26epage%3D248%26doi%3D10.1038%2Fnbt.3765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jabs, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, P. D.</span></span> <span> </span><span class="NLM_article-title">Fomivirsen for the treatment of cytomegalovirus retinitis11Internet Advance publication at ajo.com Feb 8, 2002</span>. <i>Am. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>133</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1016/S0002-9394(02)01325-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2FS0002-9394%2802%2901325-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=11931791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD38XisV2rtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2002&pages=552-556&issue=4&author=D.+A.+Jabsauthor=P.+D.+Griffiths&title=Fomivirsen+for+the+treatment+of+cytomegalovirus+retinitis11Internet+Advance+publication+at+ajo.com+Feb+8%2C+2002&doi=10.1016%2FS0002-9394%2802%2901325-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Fomivirsen for the treatment of cytomegalovirus retinitis</span></div><div class="casAuthors">Jabs, Douglas A.; Griffiths, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Ophthalmology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">552-556</span>CODEN:
                <span class="NLM_cas:coden">AJOPAA</span>;
        ISSN:<span class="NLM_cas:issn">0002-9394</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The authors provide an editorial describing articles found in this publication on dose comparison trials for induction and maintenance fomivirsen therapy in humans with small peripheral cytomegalovirus retinitis lesions, two treatment regimens for humans with relapsed retinitis, and safety profile and adverse effects among humans treated with fomivirsen for cytomegalovirus retinitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorMucTWqlXYrVg90H21EOLACvtfcHk0ljhYwdOYSsbVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisV2rtLk%253D&md5=b4158cc7d5a9bfb041964c9599ee0e02</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0002-9394%2802%2901325-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9394%252802%252901325-9%26sid%3Dliteratum%253Aachs%26aulast%3DJabs%26aufirst%3DD.%2BA.%26aulast%3DGriffiths%26aufirst%3DP.%2BD.%26atitle%3DFomivirsen%2520for%2520the%2520treatment%2520of%2520cytomegalovirus%2520retinitis11Internet%2520Advance%2520publication%2520at%2520ajo.com%2520Feb%25208%252C%25202002%26jtitle%3DAm.%2520J.%2520Ophthalmol.%26date%3D2002%26volume%3D133%26issue%3D4%26spage%3D552%26epage%3D556%26doi%3D10.1016%2FS0002-9394%2802%2901325-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanotto, D.</span></span> <span> </span><span class="NLM_article-title">FDA-approved aligonucleotide therapies in 2017</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1075</span>, <span class="refDoi"> DOI: 10.1016/j.ymthe.2017.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.ymthe.2017.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=28366767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFeltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1069-1075&issue=5&author=C.+A.+Steinauthor=D.+Castanotto&title=FDA-approved+aligonucleotide+therapies+in+2017&doi=10.1016%2Fj.ymthe.2017.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-Approved Oligonucleotide Therapies in 2017</span></div><div class="casAuthors">Stein, Cy A.; Castanotto, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1069-1075</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0024</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oligonucleotides (oligos) have been under clin. development for approx. the past 30 years, beginning with antisense oligonucleotides (ASOs) and apatmers and followed about 15 years ago by siRNAs.  During that lengthy period of time, numerous clin. trials have been performed and thousands of trial participants accrued onto studies.  Of all the mols. evaluated as of Jan. 2017, the regulatory authorities assessed that six provided clear clin. benefit in rigorously controlled trials.  The story of these six is given in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNtVeb7iVOxrVg90H21EOLACvtfcHk0ljhYwdOYSsbVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFeltLs%253D&md5=d9f556e813d1070c6af77b34fe051fd2</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ymthe.2017.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymthe.2017.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DC.%2BA.%26aulast%3DCastanotto%26aufirst%3DD.%26atitle%3DFDA-approved%2520aligonucleotide%2520therapies%2520in%25202017%26jtitle%3DMol.%2520Ther.%26date%3D2017%26volume%3D25%26issue%3D5%26spage%3D1069%26epage%3D1075%26doi%3D10.1016%2Fj.ymthe.2017.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riches, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kernan, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochstein, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mineishi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Termuhlen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grupp, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemecek, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giralt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champlin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajwa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Agostino, R. B.,  Sr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massaro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miloslavsky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hume, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejadnik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannah, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soiffer, R. J.</span></span> <span> </span><span class="NLM_article-title">Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1656</span>– <span class="NLM_lpage">1665</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-10-676924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1182%2Fblood-2015-10-676924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26825712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ehurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=1656-1665&issue=13&author=P.+G.+Richardsonauthor=M.+L.+Richesauthor=N.+A.+Kernanauthor=J.+A.+Brochsteinauthor=S.+Mineishiauthor=A.+M.+Termuhlenauthor=S.+Araiauthor=S.+A.+Gruppauthor=E.+C.+Guinanauthor=P.+L.+Martinauthor=G.+Steinbachauthor=A.+Krishnanauthor=E.+R.+Nemecekauthor=S.+Giraltauthor=T.+Rodriguezauthor=R.+Duerstauthor=J.+Doyleauthor=J.+H.+Antinauthor=A.+Smithauthor=L.+Lehmannauthor=R.+Champlinauthor=A.+Gillioauthor=R.+Bajwaauthor=R.+B.+D%E2%80%99Agostinoauthor=J.+Massaroauthor=D.+Warrenauthor=M.+Miloslavskyauthor=R.+L.+Humeauthor=M.+Iacobelliauthor=B.+Nejadnikauthor=A.+L.+Hannahauthor=R.+J.+Soiffer&title=Phase+3+trial+of+defibrotide+for+the+treatment+of+severe+veno-occlusive+disease+and+multi-organ+failure&doi=10.1182%2Fblood-2015-10-676924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure</span></div><div class="casAuthors">Richardson, Paul G.; Riches, Marcie L.; Kernan, Nancy A.; Brochstein, Joel A.; Mineishi, Shin; Termuhlen, Amanda M.; Arai, Sally; Grupp, Stephan A.; Guinan, Eva C.; Martin, Paul L.; Steinbach, Gideon; Krishnan, Amrita; Nemecek, Eneida R.; Giralt, Sergio; Rodriguez, Tulio; Duerst, Reggie; Doyle, John; Antin, Joseph H.; Smith, Angela; Lehmann, Leslie; Champlin, Richard; Gillio, Alfred; Bajwa, Rajinder; Sr, Ralph B. D'Agostino; Massaro, Joseph; Warren, Diane; Miloslavsky, Maja; Hume, Robin L.; Iacobelli, Massimo; Nejadnik, Bijan; Hannah, Alison L.; Soiffer, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1656-1665</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Hepatic veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome (SOS), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT).  Untreated hepatic VOD/SOS with multi-organ failure (MOF) is assocd. with >80% mortality.  Defibrotide has shown promising efficacy treating hepatic VOD/SOS with MOF in phase 2 studies.  This phase 3 study investigated safety and efficacy of defibrotide in patients with established hepatic VOD/SOS and advanced MOF.  Patients (n 5 102) given defibrotide 25 mg/kg per day were compared with 32 historical controls identified out of 6867 medical charts of HSCT patients by blinded independent reviewers.  Baseline characteristics between groups were well balanced.  The primary endpoint was survival at day + 100 post-HSCT; obsd. rates equaled 38.2% in the defibrotide group and 25% in the controls (23% estd. difference; 95.1% confidence interval [CI], 5.2-40.8; P = .0109, using a propensity adjusted anal.).  Obsd. day 1100 complete response (CR) rates equaled 25.5% for defibrotide and 12.5% for controls (19% difference using similar methodol.; 95.1% CI, 3.5-34.6; P = .0160).  Defibrotide was generally well tolerated with manageable toxicity.  Related adverse events (AEs) included hemorrhage or hypotension; incidence of common hemorrhagic AEs (including pulmonary alveolar [11.8% and 15.6%] and gastrointestinal bleeding [7.8%and 9.4%])was similar between the defibrotide and control groups, resp.  Defibrotide was assocd. with significant improvement in day +100 survival and CR rate.  The historical-control methodol. offers a novel, meaningful approach for phase 3 evaluation of orphan diseases assocd. with high mortality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWcb9S-yNTwrVg90H21EOLACvtfcHk0lhXk4o6QC3asQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ehurrN&md5=59b5053e3cc6a6f48253080485aa56c7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-10-676924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-10-676924%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DRiches%26aufirst%3DM.%2BL.%26aulast%3DKernan%26aufirst%3DN.%2BA.%26aulast%3DBrochstein%26aufirst%3DJ.%2BA.%26aulast%3DMineishi%26aufirst%3DS.%26aulast%3DTermuhlen%26aufirst%3DA.%2BM.%26aulast%3DArai%26aufirst%3DS.%26aulast%3DGrupp%26aufirst%3DS.%2BA.%26aulast%3DGuinan%26aufirst%3DE.%2BC.%26aulast%3DMartin%26aufirst%3DP.%2BL.%26aulast%3DSteinbach%26aufirst%3DG.%26aulast%3DKrishnan%26aufirst%3DA.%26aulast%3DNemecek%26aufirst%3DE.%2BR.%26aulast%3DGiralt%26aufirst%3DS.%26aulast%3DRodriguez%26aufirst%3DT.%26aulast%3DDuerst%26aufirst%3DR.%26aulast%3DDoyle%26aufirst%3DJ.%26aulast%3DAntin%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DLehmann%26aufirst%3DL.%26aulast%3DChamplin%26aufirst%3DR.%26aulast%3DGillio%26aufirst%3DA.%26aulast%3DBajwa%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Agostino%26aufirst%3DR.%2BB.%26aulast%3DMassaro%26aufirst%3DJ.%26aulast%3DWarren%26aufirst%3DD.%26aulast%3DMiloslavsky%26aufirst%3DM.%26aulast%3DHume%26aufirst%3DR.%2BL.%26aulast%3DIacobelli%26aufirst%3DM.%26aulast%3DNejadnik%26aufirst%3DB.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DSoiffer%26aufirst%3DR.%2BJ.%26atitle%3DPhase%25203%2520trial%2520of%2520defibrotide%2520for%2520the%2520treatment%2520of%2520severe%2520veno-occlusive%2520disease%2520and%2520multi-organ%2520failure%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26issue%3D13%26spage%3D1656%26epage%3D1665%26doi%3D10.1182%2Fblood-2015-10-676924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, D. R.</span></span> <span> </span><span class="NLM_article-title">Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1584</span>– <span class="NLM_lpage">1600</span>, <span class="refDoi"> DOI: 10.1093/nar/gkx1239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1093%2Fnar%2Fgkx1239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=29240946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlGisb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1584-1600&issue=4&author=X.+Shenauthor=D.+R.+Corey&title=Chemistry%2C+mechanism+and+clinical+status+of+antisense+oligonucleotides+and+duplex+RNAs&doi=10.1093%2Fnar%2Fgkx1239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs</span></div><div class="casAuthors">Shen, Xiulong; Corey, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1584-1600</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  RNA plays a central role in the expression of all genes.  Because any sequence within RNA can be recognized by complementary base pairing, synthetic oligonucleotides and oligonucleotide mimics offer a general strategy for controlling processes that affect disease.  The two primary antisense approaches for regulating expression through recognition of cellular RNAs are single-stranded antisense oligonucleotides and duplex RNAs.  This review will discuss the chem. modifications and mol. mechanisms that make synthetic nucleic acid drugs possible.  Lessons learned from recent clin. trials will be summarized.  Ongoing clin. trials are likely to decisively test the adequacy of our current generation of antisense nucleic acid technologies and highlight areas where more basic research is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHfDaQwcmtD7Vg90H21EOLACvtfcHk0lhXk4o6QC3asQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlGisb7F&md5=b5bdec984635f12162386b6f8a6f6fe0</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkx1239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkx1239%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DX.%26aulast%3DCorey%26aufirst%3DD.%2BR.%26atitle%3DChemistry%252C%2520mechanism%2520and%2520clinical%2520status%2520of%2520antisense%2520oligonucleotides%2520and%2520duplex%2520RNAs%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2018%26volume%3D46%26issue%3D4%26spage%3D1584%26epage%3D1600%26doi%3D10.1093%2Fnar%2Fgkx1239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geary, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, C. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2015.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.addr.2015.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=25666165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVOqsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=46-51&author=R.+S.+Gearyauthor=D.+Norrisauthor=R.+Yuauthor=C.+F.+Bennett&title=Pharmacokinetics%2C+biodistribution+and+cell+uptake+of+antisense+oligonucleotides&doi=10.1016%2Fj.addr.2015.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides</span></div><div class="casAuthors">Geary, Richard S.; Norris, Daniel; Yu, Rosie; Bennett, C. Frank</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-51</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pharmacokinetic properties of oligonucleotides are largely driven by chem. of the backbone and thus are sequence independent within a chem. class.  Tissue bioavailability (% of administered dose) is assisted by plasma protein binding that limits glomerular filtration and ultimate urinary excretion of oligonucleotides.  The substitution of one non-bridging oxygen with the more hydrophobic sulfur atom (phosphorothioate) increases both plasma stability and plasma protein binding and thus, ultimately, tissue bioavailability.  Addnl. modifications of the sugar at the 2' position, increase RNA binding affinity and significantly increase potency, tissue half-life and prolong RNA inhibitory activity.  Oligonucleotides modified in this manner consistently exhibit the highest tissue bioavailability (> 90%).  Systemic biodistribution is broad, and organs typically with highest concns. are liver and kidney followed by bone marrow, adipocytes, and lymph nodes.  Cell uptake is predominantly mediated by endocytosis.  Both size and charge for most oligonucleotides prevents distribution across the blood brain barrier.  However, modified single-strand oligonucleotides administered by intrathecal injection into the CSF distribute broadly in the CNS.  The majority of intracellular oligonucleotide distribution following systemic or local administration occurs rapidly in just a few hours following administration and is facilitated by rapid endocytotic uptake mechanisms.  Further understanding of the intracellular trafficking of oligonucleotides may provide further enhancements in design and ultimate potency of antisense oligonucleotides in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ2gcLkd_4t7Vg90H21EOLACvtfcHk0lhXk4o6QC3asQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVOqsb4%253D&md5=20b700e0b591b2708180f651ff940173</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2015.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2015.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DGeary%26aufirst%3DR.%2BS.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DBennett%26aufirst%3DC.%2BF.%26atitle%3DPharmacokinetics%252C%2520biodistribution%2520and%2520cell%2520uptake%2520of%2520antisense%2520oligonucleotides%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2015%26volume%3D87%26spage%3D46%26epage%3D51%26doi%3D10.1016%2Fj.addr.2015.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span> <span> </span><span class="NLM_article-title">Peptide conjugates with small molecules designed to enhance efficacy and safety</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1855</span>, <span class="refDoi"> DOI: 10.3390/molecules24101855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.3390%2Fmolecules24101855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFagtb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1855&issue=10&author=R.+Heauthor=B.+Finanauthor=J.+P.+Mayerauthor=R.+D.+DiMarchi&title=Peptide+conjugates+with+small+molecules+designed+to+enhance+efficacy+and+safety&doi=10.3390%2Fmolecules24101855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide conjugates with small molecules designed to enhance efficacy and safety</span></div><div class="casAuthors">He, Rongjun; Finan, Brian; Mayer, John P.; DiMarchi, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1855</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Peptides constitute mol. diversity with unique mol. mechanisms of action that are proven indispensable in the management of many human diseases, but of only a mere fraction relative to more traditional small mol.-based medicines.  The integration of these two therapeutic modalities o ers the potential to enhance and broaden pharmacol. while minimizing dose-dependent toxicol.  This review summarizes numerous advances in drug design, synthesis and development that provide direction for next-generation research endeavors in this field.  Medicinal studies in this area have largely focused upon the application of peptides to selectively enhance small mol. cytotoxicity to more effectively treat multiple oncol. diseases.  To a lesser and steadily emerging extent peptides are being therapeutically employed to complement and diversify the pharmacol. of small mol. drugs in diseases other than just cancer.  No matter the disease, the purpose of the mol. integration remains const. and it is to achieve superior therapeutic outcomes with diminished adverse effects.  We review linker technol. and conjugation chemistries that have enabled integrated and targeted pharmacol. with controlled release.  Finally, we offer our perspective on opportunities and obstacles in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_IMrSi0d7urVg90H21EOLACvtfcHk0lhIErDlslyU_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFagtb%252FM&md5=da04d398164460a08977abcdcefdc230</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24101855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24101855%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DR.%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DMayer%26aufirst%3DJ.%2BP.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26atitle%3DPeptide%2520conjugates%2520with%2520small%2520molecules%2520designed%2520to%2520enhance%2520efficacy%2520and%2520safety%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26issue%3D10%26spage%3D1855%26doi%3D10.3390%2Fmolecules24101855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaway, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, C.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habegger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schriever, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Caceres, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabra, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hembree, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raver, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irmler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabe de Angelis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiano, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauvais-Jarvis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tilve, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfluger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelfanov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMarchi, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschoep, M. H.</span></span> <span> </span><span class="NLM_article-title">Targeted estrogen delivery reverses the metabolic syndrome</span>. <i>Nat. Med. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1847</span>– <span class="NLM_lpage">1856</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnm.3009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=23142820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1CktL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1847-1856&issue=12&author=B.+Finanauthor=B.+Yangauthor=N.+Ottawayauthor=K.+Stemmerauthor=T.+D.+Muellerauthor=C.-X.+Yiauthor=K.+Habeggerauthor=S.+C.+Schrieverauthor=C.+Garcia-Caceresauthor=D.+G.+Kabraauthor=J.+Hembreeauthor=J.+Hollandauthor=C.+Raverauthor=R.+J.+Seeleyauthor=W.+Hansauthor=M.+Irmlerauthor=J.+Beckersauthor=M.+Hrabe+de+Angelisauthor=J.+P.+Tianoauthor=F.+Mauvais-Jarvisauthor=D.+Perez-Tilveauthor=P.+Pflugerauthor=L.+Zhangauthor=V.+Gelfanovauthor=R.+D.+DiMarchiauthor=M.+H.+Tschoep&title=Targeted+estrogen+delivery+reverses+the+metabolic+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted estrogen delivery reverses the metabolic syndrome</span></div><div class="casAuthors">Finan, Brian; Yang, Bin; Ottaway, Nickki; Stemmer, Kerstin; Mueller, Timo D.; Yi, Chun-Xia; Habegger, Kirk; Schriever, Sonja C.; Garcia-Caceres, Cristina; Kabra, Dhiraj G.; Hembree, Jazzminn; Holland, Jenna; Raver, Christine; Seeley, Randy J.; Hans, Wolfgang; Irmler, Martin; Beckers, Johannes; Hrabe de Angelis, Martin; Tiano, Joseph P.; Mauvais-Jarvis, Franck; Perez-Tilve, Diego; Pfluger, Paul; Zhang, Lianshan; Gelfanov, Vasily; DiMarchi, Richard D.; Tschoep, Matthias H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1847-1856</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report the development of a new combinatorial approach that allows for peptide-mediated selective tissue targeting of nuclear hormone pharmacol. while eliminating adverse effects in other tissues.  Specifically, we report the development of a glucagon-like peptide-1 (GLP-1)-estrogen conjugate that has superior sex-independent efficacy over either of the individual hormones alone to correct obesity, hyperglycemia and dyslipidemia in mice.  The therapeutic benefits are driven by pleiotropic dual hormone action to improve energy, glucose and lipid metab., as shown by loss-of-function models and genetic action profiling.  Notably, the peptide-based targeting strategy also prevents hallmark side effects of estrogen in male and female mice, such as reproductive endocrine toxicity and oncogenicity.  Collectively, selective activation of estrogen receptors in GLP-1-targeted tissues produces unprecedented efficacy to enhance the metabolic benefits of GLP-1 agonism.  This example of targeting the metabolic syndrome represents the discovery of a new class of therapeutics that enables synergistic co-agonism through peptide-based selective delivery of small mols.  Although our observations with the GLP-1-estrogen conjugate justify translational studies for diabetes and obesity, the multitude of other possible combinations of peptides and small mols. may offer equal promise for other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQGspuH3IemrVg90H21EOLACvtfcHk0lhIErDlslyU_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1CktL7F&md5=7c080cb982964af88163a9c505d0ee83</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fnm.3009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3009%26sid%3Dliteratum%253Aachs%26aulast%3DFinan%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DOttaway%26aufirst%3DN.%26aulast%3DStemmer%26aufirst%3DK.%26aulast%3DMueller%26aufirst%3DT.%2BD.%26aulast%3DYi%26aufirst%3DC.-X.%26aulast%3DHabegger%26aufirst%3DK.%26aulast%3DSchriever%26aufirst%3DS.%2BC.%26aulast%3DGarcia-Caceres%26aufirst%3DC.%26aulast%3DKabra%26aufirst%3DD.%2BG.%26aulast%3DHembree%26aufirst%3DJ.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DRaver%26aufirst%3DC.%26aulast%3DSeeley%26aufirst%3DR.%2BJ.%26aulast%3DHans%26aufirst%3DW.%26aulast%3DIrmler%26aufirst%3DM.%26aulast%3DBeckers%26aufirst%3DJ.%26aulast%3DHrabe%2Bde%2BAngelis%26aufirst%3DM.%26aulast%3DTiano%26aufirst%3DJ.%2BP.%26aulast%3DMauvais-Jarvis%26aufirst%3DF.%26aulast%3DPerez-Tilve%26aufirst%3DD.%26aulast%3DPfluger%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGelfanov%26aufirst%3DV.%26aulast%3DDiMarchi%26aufirst%3DR.%2BD.%26aulast%3DTschoep%26aufirst%3DM.%2BH.%26atitle%3DTargeted%2520estrogen%2520delivery%2520reverses%2520the%2520metabolic%2520syndrome%26jtitle%3DNat.%2520Med.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2012%26volume%3D18%26issue%3D12%26spage%3D1847%26epage%3D1856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Va, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffitte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. Y. H.</span></span> <span> </span><span class="NLM_article-title">Pancreas-specific delivery of β-cell proliferating small molecules</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1132</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1002%2Fcmdc.201600116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=27095073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtlSit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1129-1132&issue=11&author=X.+Haoauthor=Q.+Jinauthor=P.+Vaauthor=C.+Liauthor=W.+Shenauthor=B.+Laffitteauthor=T.+Y.+H.+Wu&title=Pancreas-specific+delivery+of+%CE%B2-cell+proliferating+small+molecules&doi=10.1002%2Fcmdc.201600116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Pancreas-Specific Delivery of β-Cell Proliferating Small Molecules</span></div><div class="casAuthors">Hao, Xueshi; Jin, Qihui; Va, Porino; Li, Chun; Shen, Weijun; Laffitte, Bryan; Wu, Tom Y.-H.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1129-1132</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Our research groups recently described a series of small-mol. inducers of β-cell proliferation that could be used to increase β-cell mass.  To mitigate the risk of nonspecific proliferation of other cell types, we devised a delivery strategy built on the tissue specificity obsd. in the exptl. β-cell imaging agent (+)-dihydrotetrabenazine (DTBZ).  The β-cell proliferator agent aminopyrazine (AP) was covalently linked with (+)-DTBZ to afford conjugates that retain both the proliferation activity and binding affinity for vesicular monoamine transporter-2 (VMAT2).  In vivo mouse tissue distribution studies of a prototypical AP-DTBZ conjugate showed 15-fold pancreas exposure over plasma.  Tissue-to-plasma ratios in liver and kidneys were two- and five-fold, resp.  This work is the first demonstration of enhanced delivery of β-cell-proliferating mols. to the pancreas by leveraging the intrinsic tissue specificity of a β-cell imaging agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVn8pxJAObf7Vg90H21EOLACvtfcHk0lhIErDlslyU_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtlSit70%253D&md5=ef7f9c60a865d219a57a247a852b400a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600116%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DVa%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DLaffitte%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DT.%2BY.%2BH.%26atitle%3DPancreas-specific%2520delivery%2520of%2520%25CE%25B2-cell%2520proliferating%2520small%2520molecules%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D11%26spage%3D1129%26epage%3D1132%26doi%3D10.1002%2Fcmdc.201600116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. V.</span></span> <span> </span><span class="NLM_article-title">Zinc and insulin in pancreatic beta-cells</span>. <i>Endocrine</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1007/s12020-013-0032-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1007%2Fs12020-013-0032-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=23979673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlansrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2014&pages=178-189&issue=2&author=Y.+V.+Li&title=Zinc+and+insulin+in+pancreatic+beta-cells&doi=10.1007%2Fs12020-013-0032-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc and insulin in pancreatic beta-cells</span></div><div class="casAuthors">Li, Yang V.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">EOCRE5</span>;
        ISSN:<span class="NLM_cas:issn">1355-008X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Zinc (Zn2+) is an essential element crucial for growth and development, and also plays a role in cell signaling for cellular processes like cell division and apoptosis.  In the mammalian pancreas, Zn2+ is essential for the correct processing, storage, secretion, and action of insulin in beta (β)-cells.  Insulin is stored inside secretory vesicles or granules, where two Zn2+ ions coordinate six insulin monomers to form the hexameric-structure on which maturated insulin crystals are based.  The total Zn2+ content of the mammalian pancreas is among the highest in the body, and Zn2+ concn. reach millimolar levels in the interior of the dense-core granule.  Changes in Zn2+ levels in the pancreas have been found to be assocd. with diabetes.  Hence, the relationship between co-stored Zn2+ and insulin undoubtedly is crit. to normal β-cell function.  The advances in the field of Zn2+ biol. over the last decade have facilitated our understanding of Zn2+ trafficking, its intracellular distribution and its storage.  When exocytosis of insulin occurs, insulin granules fuse with the β-cell plasma membrane and release their contents, i.e., insulin as well as substantial amt. of free Zn2+, into the extracellular space and the local circulation.  Studies increasingly indicate that secreted Zn2+ has autocrine or paracrine signaling in β-cells or the neighboring cells.  This review discusses the Zn2+ homeostasis in β-cells with emphasis on the potential signaling role of Zn2+ to islet biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXit9l5NHEXrVg90H21EOLACvtfcHk0ljKhq1c5qLMZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlansrrJ&md5=eeef17ab5ae5a1ed01ca3e27aa5d64c6</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1007%2Fs12020-013-0032-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12020-013-0032-x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BV.%26atitle%3DZinc%2520and%2520insulin%2520in%2520pancreatic%2520beta-cells%26jtitle%3DEndocrine%26date%3D2014%26volume%3D45%26issue%3D2%26spage%3D178%26epage%3D189%26doi%3D10.1007%2Fs12020-013-0032-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A. E.</span></span> <span> </span><span class="NLM_article-title">Techniques for measuring cellular zinc</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>611</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2016.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.abb.2016.08.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=27580940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOqurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=611&publication_year=2016&pages=20-29&author=M.+C.+Carpenterauthor=M.+N.+Loauthor=A.+E.+Palmer&title=Techniques+for+measuring+cellular+zinc&doi=10.1016%2Fj.abb.2016.08.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Techniques for measuring cellular zinc</span></div><div class="casAuthors">Carpenter, Margaret C.; Lo, Maria N.; Palmer, Amy E.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">611</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-29</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The development and improvement of fluorescent Zn2+ sensors and Zn2+ imaging techniques have increased our insight into this biol. important ion.  Application of these tools has identified an intracellular labile Zn2+ pool and cultivated further interest in defining the distribution and dynamics of labile Zn2+.  The study of Zn2+ in live cells in real time using sensors is a powerful way to answer complex biol. questions.  In this review, we highlight newly engineered Zn2+ sensors, methods to test whether the sensors are accessing labile Zn2+, and recent studies that point to the challenges of using such sensors.  Elemental mapping techniques can complement and strengthen data collected with sensors.  Both mass spectrometry-based and X-ray fluorescence-based techniques yield highly specific, sensitive, and spatially resolved snapshots of metal distribution in cells.  The study of Zn2+ has already led to new insight into all phases of life from fertilization of the egg to life-threatening cancers.  In order to continue building new knowledge about Zn2+ biol. it remains important to critically assess the available toolset for this endeavor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS3pvhyccECrVg90H21EOLACvtfcHk0ljKhq1c5qLMZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOqurfJ&md5=e0c83d48f35e627a03888a23d4c11fd5</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2016.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2016.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DCarpenter%26aufirst%3DM.%2BC.%26aulast%3DLo%26aufirst%3DM.%2BN.%26aulast%3DPalmer%26aufirst%3DA.%2BE.%26atitle%3DTechniques%2520for%2520measuring%2520cellular%2520zinc%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2016%26volume%3D611%26spage%3D20%26epage%3D29%26doi%3D10.1016%2Fj.abb.2016.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNary, W. F.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Zinc-dithizone reaction of pancreatic islets</span>. <i>J. Histochem. Cytochem.</i> <span class="NLM_year" style="font-weight: bold;">1954</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1177/2.3.185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1177%2F2.3.185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=13163393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADyaG2cXnvVSrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1954&pages=185-193&author=W.+F.+McNary&title=Zinc-dithizone+reaction+of+pancreatic+islets&doi=10.1177%2F2.3.185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc-dithizone reaction of pancreatic islets</span></div><div class="casAuthors">McNary, Wm. F., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">1954</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">185-93</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    </div><div class="casAbstract">Zinc was demonstrated by means of the Okamoto diphenylthiocarbazone technique in the pancreas islet cells of the rabbit, rat, dog, mouse, monkey, and human, but not in the guinea pig.  Diffusion is a source of error owing to the soly. of the zinc-contg. cellular materials in the solvents of the Okamoto technique.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo27ZUBFXLXm7Vg90H21EOLACvtfcHk0ljKhq1c5qLMZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG2cXnvVSrtA%253D%253D&md5=54e554b2b6bc529f60a2542f9dbb5e8d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1177%2F2.3.185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2.3.185%26sid%3Dliteratum%253Aachs%26aulast%3DMcNary%26aufirst%3DW.%2BF.%26atitle%3DZinc-dithizone%2520reaction%2520of%2520pancreatic%2520islets%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D1954%26volume%3D2%26spage%3D185%26epage%3D193%26doi%3D10.1177%2F2.3.185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gee, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, R.</span></span> <span> </span><span class="NLM_article-title">Detection and imaging of zinc secretion from pancreatic β-cells using a new fluorescent zinc indicator</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>124</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">776</span>– <span class="NLM_lpage">778</span>, <span class="refDoi"> DOI: 10.1021/ja011774y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja011774y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1Sisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=776-778&issue=5&author=K.+R.+Geeauthor=Z.-L.+Zhouauthor=W.-J.+Qianauthor=R.+Kennedy&title=Detection+and+imaging+of+zinc+secretion+from+pancreatic+%CE%B2-cells+using+a+new+fluorescent+zinc+indicator&doi=10.1021%2Fja011774y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Detection and imaging of zinc secretion from pancreatic β-cells using a new fluorescent zinc indicator</span></div><div class="casAuthors">Gee, Kyle R.; Zhou, Zhang-Lin; Qian, Wei-Jun; Kennedy, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">776-778</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel Zn2+-selective visible wavelength fluoroionophore (FluoZin-3, 9) was synthesized.  The chelating portion of the mol. resembles known EGTA-based Ca2+-selective fluoroionophores, except that one of the N-acetic acid moieties has been deleted in 9. FluoZin-3 is virtually non-fluorescent in the absence of Zn2+, and exhibits a several hundred-fold fluorescence increase upon satn. with Zn2+(~100 nM), with a Kd = 15±2 nM.  A 1:1 binding stoichiometry of 9:Zn2+ was detd., and the fluorescence of the complex is pH-independent at pH > 6. FluoZin-3 was used to monitor Zn2+ that was co-secreted with insulin from pancreatic β-cells by exocytosis following stimulation with glucose.  The total Zn2+ concn. near the cells reached 600 nM, and Zn2+ was detectable at least 15 μm away from secreting cells.  Heterogeneity in secretion among cells was indicated in that some cells in a cluster did not release Zn2+.  Also, within secreting cells some regions of the cell membrane gave rise to secretion while others did not, suggesting active zones of secretion on the cell surface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5rRMroNlviLVg90H21EOLACvtfcHk0ljAEyNZDePUpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1Sisw%253D%253D&md5=3c23d26c7f3545a4dbf872d165b63ec3</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Fja011774y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja011774y%26sid%3Dliteratum%253Aachs%26aulast%3DGee%26aufirst%3DK.%2BR.%26aulast%3DZhou%26aufirst%3DZ.-L.%26aulast%3DQian%26aufirst%3DW.-J.%26aulast%3DKennedy%26aufirst%3DR.%26atitle%3DDetection%2520and%2520imaging%2520of%2520zinc%2520secretion%2520from%2520pancreatic%2520%25CE%25B2-cells%2520using%2520a%2520new%2520fluorescent%2520zinc%2520indicator%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26issue%3D5%26spage%3D776%26epage%3D778%26doi%3D10.1021%2Fja011774y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lukowiak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandewalle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riachy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr-Conte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmyr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belaich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattou, F.</span></span> <span> </span><span class="NLM_article-title">Identification and purification of functional human β-cells by a new specific zinc-fluorescent probe</span>. <i>J. Histochem. Cytochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1177/002215540104900412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1177%2F002215540104900412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=11259455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFKgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2001&pages=519-527&issue=4&author=B.+Lukowiakauthor=B.+Vandewalleauthor=R.+Riachyauthor=J.+Kerr-Conteauthor=V.+Gmyrauthor=S.+Belaichauthor=J.+Lefebvreauthor=F.+Pattou&title=Identification+and+purification+of+functional+human+%CE%B2-cells+by+a+new+specific+zinc-fluorescent+probe&doi=10.1177%2F002215540104900412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and purification of functional human β-cells by a new specific zinc-fluorescent probe</span></div><div class="casAuthors">Lukowiak, Bruno; Vandewalle, Brigitte; Riachy, Rita; Kerr-Conte, Julie; Gmyr, Valery; Belaich, Sandrine; Lefebvre, Jean; Pattou, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">519-527</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Histochemical Society, Inc.</span>)
        </div><div class="casAbstract">Pancreatic β-cells contain large amts. of zinc.  We took advantage of this to try to localize, quantify, and isolate insulin-producing cells from islet prepns.  Our study was designed to identify a non-toxic zinc-sensitive fluorescent probe able to selectively label labile zinc in viable β-cells and to exhibit excitation and emission wavelengths in the visible spectrum, making this technique exploitable by most instruments.  We tested Newport Green, a probe excitable at 485 nm with a dissocn. const. in the micromolar range corresponding to a low affinity for zinc.  The loading of the lipophilic esterified form of Newport Green was easy, rapid, specific, and non-toxic to cells.  Confocal microscopy highlighted an intense fluorescence assocd. with secretory granules.  Regression analyses showed a good relationship between zinc fluorescence and islet no. (r=0.98) and between zinc fluorescence and insulin content (r=0.81).  The detn. of Zn fluorescence per DNA enabled us to assess the quality of the different islet prepns. intended for islet allografting in terms of both purity and viability.  Cell sorting of dissocd. Newport Green-labeled cells resulted in a clear sepn. of β-cells, as judged by insulin content per DNA and immunocytochem. anal.  This zinc probe, the first able to specifically label living cells in the visible spectrum, appears very promising for β-cell experimentation, both clin. and for basic research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb9bbdhU9XerVg90H21EOLACvtfcHk0ljAEyNZDePUpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFKgtrs%253D&md5=d71bddbb05e93bb149b4a305ec3b3e90</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1177%2F002215540104900412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F002215540104900412%26sid%3Dliteratum%253Aachs%26aulast%3DLukowiak%26aufirst%3DB.%26aulast%3DVandewalle%26aufirst%3DB.%26aulast%3DRiachy%26aufirst%3DR.%26aulast%3DKerr-Conte%26aufirst%3DJ.%26aulast%3DGmyr%26aufirst%3DV.%26aulast%3DBelaich%26aufirst%3DS.%26aulast%3DLefebvre%26aufirst%3DJ.%26aulast%3DPattou%26aufirst%3DF.%26atitle%3DIdentification%2520and%2520purification%2520of%2520functional%2520human%2520%25CE%25B2-cells%2520by%2520a%2520new%2520specific%2520zinc-fluorescent%2520probe%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D2001%26volume%3D49%26issue%3D4%26spage%3D519%26epage%3D527%26doi%3D10.1177%2F002215540104900412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jindal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmeraldo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span> <span> </span><span class="NLM_article-title">A new method for quantification of islets by measurement of zinc content</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1056</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.2337/diabetes.41.9.1056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.2337%2Fdiab.41.9.1056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1499858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADyaK38XlvVOmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1992&pages=1056-1062&issue=9&author=R.+M.+Jindalauthor=R.+P.+Taylorauthor=D.+W.+R.+Grayauthor=R.+Esmeraldoauthor=P.+J.+Morris&title=A+new+method+for+quantification+of+islets+by+measurement+of+zinc+content&doi=10.2337%2Fdiabetes.41.9.1056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">A new method for quantification of islets by measurement of zinc content</span></div><div class="casAuthors">Jindal, Rahul M.; Taylor, Richard P.; Gray, Derek W. R.; Esmeraldo, Ronaldo; Morris, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1056-62</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    </div><div class="casAbstract">The ability to quantify the yield of pancreatic islet tissue after isolation is important for interlab. comparisons and for the assessment of islet yield prior to clin. transplantation.  Because pancreatic islets contain a much higher concn. of zinc than other tissues, the authors investigated the anal. of zinc as a measure of islet tissue yield.  Rat islets of std. diam. 250 μm were handpicked into samples contg. 10-80 islets.  The zinc content was measured by EAAS and showed a linear correlation with islet no.  A zinc binding fluorescent dye, TSQ, was investigated as a way of simplifying the zinc measurement for routine use.  Samples of 10-80 islets of 250 μm were sonicated in 3 mL zinc-free water, 0.18 μmol TSQ was added, and the TSQ-zinc fluorescence was measured at 480 nm.  A linear correlation was obsd.  Exocrine contamination up to 50% barely affected the results.  Islet zinc content also was shown to be correlated linearly with islet no. for freshly isolated human islets.  Measurement of zinc by TSQ fluorescence is a rapid, cheap, and objective measure of islet tissue content.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUeFEzJ9x6_LVg90H21EOLACvtfcHk0ljAEyNZDePUpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvVOmurk%253D&md5=0ec793ab59b1ba6b4e65984b05bcabbf</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.2337%2Fdiab.41.9.1056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiab.41.9.1056%26sid%3Dliteratum%253Aachs%26aulast%3DJindal%26aufirst%3DR.%2BM.%26aulast%3DTaylor%26aufirst%3DR.%2BP.%26aulast%3DGray%26aufirst%3DD.%2BW.%2BR.%26aulast%3DEsmeraldo%26aufirst%3DR.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26atitle%3DA%2520new%2520method%2520for%2520quantification%2520of%2520islets%2520by%2520measurement%2520of%2520zinc%2520content%26jtitle%3DDiabetes%26date%3D1992%26volume%3D41%26issue%3D9%26spage%3D1056%26epage%3D1062%26doi%3D10.2337%2Fdiabetes.41.9.1056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellomo, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarasov, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaut, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.-h.</span></span> <span> </span><span class="NLM_article-title">Imaging dynamic insulin release using a fluorescent zinc indicator for monitoring induced exocytotic release (ZIMIR)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">52</span>),  <span class="NLM_fpage">21063</span>– <span class="NLM_lpage">21068</span>, <span class="refDoi"> DOI: 10.1073/pnas.1109773109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1073%2Fpnas.1109773109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=22160693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVGjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=21063-21068&issue=52&author=D.+Liauthor=S.+Chenauthor=E.+A.+Bellomoauthor=A.+I.+Tarasovauthor=C.+Kautauthor=G.+A.+Rutterauthor=W.-h.+Li&title=Imaging+dynamic+insulin+release+using+a+fluorescent+zinc+indicator+for+monitoring+induced+exocytotic+release+%28ZIMIR%29&doi=10.1073%2Fpnas.1109773109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging dynamic insulin release using a fluorescent zinc indicator for monitoring induced exocytotic release (ZIMIR)</span></div><div class="casAuthors">Li, Daliang; Chen, Shiuhwei; Bellomo, Elisa A.; Tarasov, Andrei I.; Kaut, Callan; Rutter, Guy A.; Li, Wen-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">21063-21068, S21063/1-S21063/13</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Current methods of monitoring insulin secretion lack the required spatial and temporal resoln. to adequately map the dynamics of exocytosis of native insulin granules in intact cell populations in three dimensions.  Exploiting the fact that insulin granules contain a high level of Zn2+, and that Zn2+ is coreleased with insulin during secretion, we have developed a fluorescent, cell surface-targeted zinc indicator for monitoring induced exocytotic release (ZIMIR).  ZIMIR displayed a robust fluorescence enhancement on Zn2+ chelation and bound Zn2+ with high selectivity against Ca2+ and Mg2+.  When added to cultured β cells or intact pancreatic islets at low micromolar concns., ZIMIR labeled cells rapidly,. noninvasively, and stably, and it reliably reported changes in Zn2+ concn. near the sites of granule fusion with high sensitivity that correlated well with membrane capacitance measurement.  Fluorescence imaging of ZIMIR-labeled β cells followed the dynamics of exocytotic activity at subcellular resoln., even when using simple epifluorescence microscopy, and located the chief sites of insulin release to intercellular junctions.  Moreover, ZIMIR imaging of intact rat islets revealed that Zn2+/insulin release occurred largely in small groups of adjacent β cells, with each forming a "secretory unit".  Concurrent imaging of ZIMIR and Fura-2 showed that the amplitude of cytosolic Ca2+ elevation did not necessarily correlate with insulin secretion activity, suggesting that events downstream of Ca2+ signaling underlie the cell-cell heterogeneity in insulin release.  In addn. to studying stimulation-secretion coupling in cells with Zn2+-contg. granules, ZIMIR may find applications in β-cell engineering and screening for mols. regulating insulin secretion on high-throughput platforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNJA5_1YArHrVg90H21EOLACvtfcHk0ljAEyNZDePUpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVGjug%253D%253D&md5=850cf8ab3152beaf9d8715f45d0a5672</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1109773109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1109773109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBellomo%26aufirst%3DE.%2BA.%26aulast%3DTarasov%26aufirst%3DA.%2BI.%26aulast%3DKaut%26aufirst%3DC.%26aulast%3DRutter%26aufirst%3DG.%2BA.%26aulast%3DLi%26aufirst%3DW.-h.%26atitle%3DImaging%2520dynamic%2520insulin%2520release%2520using%2520a%2520fluorescent%2520zinc%2520indicator%2520for%2520monitoring%2520induced%2520exocytotic%2520release%2520%2528ZIMIR%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26issue%3D52%26spage%3D21063%26epage%3D21068%26doi%3D10.1073%2Fpnas.1109773109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maji, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elgamal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, A.</span></span> <span> </span><span class="NLM_article-title">Native zinc catalyzes selective and traceless release of small molecules in β-cells</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6477</span>– <span class="NLM_lpage">6482</span>, <span class="refDoi"> DOI: 10.1021/jacs.0c00099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.0c00099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVKksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=6477-6482&issue=14&author=M.+Leeauthor=B.+Majiauthor=D.+Mannaauthor=S.+Kahramanauthor=R.+M.+Elgamalauthor=J.+Smallauthor=P.+Kokkondaauthor=A.+Vetereauthor=J.+M.+Goldbergauthor=S.+J.+Lippardauthor=R.+N.+Kulkarniauthor=B.+K.+Wagnerauthor=A.+Choudhary&title=Native+zinc+catalyzes+selective+and+traceless+release+of+small+molecules+in+%CE%B2-cells&doi=10.1021%2Fjacs.0c00099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Native Zinc Catalyzes Selective and Traceless Release of Small Molecules in β-Cells</span></div><div class="casAuthors">Lee, Miseon; Maji, Basudeb; Manna, Debasish; Kahraman, Sevim; Elgamal, Ruth M.; Small, Jonnell; Kokkonda, Praveen; Vetere, Amedeo; Goldberg, Jacob M.; Lippard, Stephen J.; Kulkarni, Rohit N.; Wagner, Bridget K.; Choudhary, Amit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6477-6482</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The loss of insulin-producing β-cells is the central pathol. event in type 1 and 2 diabetes, which has led to efforts to identify mols. to promote β-cell proliferation, protection, and imaging.  However, the lack of β-cell specificity of these mols. jeopardizes their therapeutic potential.  A general platform for selective release of small-mol. cargoes in β-cells over other islet cells ex vivo or other cell-types in an organismal context will be immensely valuable in advancing diabetes research and therapeutic development.  Here, we leverage the unusually high Zn(II) concn. in β-cells to develop a Zn(II)-based prodrug system to selectively and tracelessly deliver bioactive small mols. and fluorophores to β-cells.  The Zn(II)-targeting mechanism enriches the inactive cargo in β-cells as compared to other pancreatic cells; importantly, Zn(II)-mediated hydrolysis triggers cargo activation.  This prodrug system, with modular components that allow for fine-tuning selectivity, should enable the safer and more effective targeting of β-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8PBBj0fuUarVg90H21EOLACvtfcHk0lihoupEtqBEYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVKksr0%253D&md5=fd7bc8705bf5eb48ef45dce4c708954a</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjacs.0c00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.0c00099%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%26aulast%3DMaji%26aufirst%3DB.%26aulast%3DManna%26aufirst%3DD.%26aulast%3DKahraman%26aufirst%3DS.%26aulast%3DElgamal%26aufirst%3DR.%2BM.%26aulast%3DSmall%26aufirst%3DJ.%26aulast%3DKokkonda%26aufirst%3DP.%26aulast%3DVetere%26aufirst%3DA.%26aulast%3DGoldberg%26aufirst%3DJ.%2BM.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DChoudhary%26aufirst%3DA.%26atitle%3DNative%2520zinc%2520catalyzes%2520selective%2520and%2520traceless%2520release%2520of%2520small%2520molecules%2520in%2520%25CE%25B2-cells%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26issue%3D14%26spage%3D6477%26epage%3D6482%26doi%3D10.1021%2Fjacs.0c00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamanaka, S.</span></span> <span> </span><span class="NLM_article-title">Induced pluripotent stem cell technology: a decade of progress</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrd.2016.245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=27980341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsl2lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=115-130&issue=2&author=Y.+Shiauthor=H.+Inoueauthor=J.+C.+Wuauthor=S.+Yamanaka&title=Induced+pluripotent+stem+cell+technology%3A+a+decade+of+progress&doi=10.1038%2Fnrd.2016.245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Induced pluripotent stem cell technology: a decade of progress</span></div><div class="casAuthors">Shi, Yanhong; Inoue, Haruhisa; Wu, Joseph C.; Yamanaka, Shinya</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">115-130</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Since the advent of induced pluripotent stem cell (iPSC) technol. a decade ago, enormous progress has been made in stem cell biol. and regenerative medicine.  Human iPSCs have been widely used for disease modeling, drug discovery and cell therapy development.  Novel pathol. mechanisms have been elucidated, new drugs originating from iPSC screens are in the pipeline and the first clin. trial using human iPSC-derived products has been initiated.  In particular, the combination of human iPSC technol. with recent developments in gene editing and 3D organoids makes iPSC-based platforms even more powerful in each area of their application, including precision medicine.  In this Review, we discuss the progress in applications of iPSC technol. that are particularly relevant to drug discovery and regenerative medicine, and consider the remaining challenges and the emerging opportunities in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosBuEbSJ5V5bVg90H21EOLACvtfcHk0lihoupEtqBEYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsl2lsg%253D%253D&md5=e6884f9743341369ab8e24e872990761</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.245%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DYamanaka%26aufirst%3DS.%26atitle%3DInduced%2520pluripotent%2520stem%2520cell%2520technology%253A%2520a%2520decade%2520of%2520progress%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D2%26spage%3D115%26epage%3D130%26doi%3D10.1038%2Fnrd.2016.245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manolagas, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, M.</span></span> <span> </span><span class="NLM_article-title">The role of estrogen and androgen receptors in bone health and disease</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2013.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrendo.2013.179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=24042328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVynu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=699-712&issue=12&author=S.+C.+Manolagasauthor=C.+A.+O%E2%80%99Brienauthor=M.+Almeida&title=The+role+of+estrogen+and+androgen+receptors+in+bone+health+and+disease&doi=10.1038%2Fnrendo.2013.179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The role of estrogen and androgen receptors in bone health and disease</span></div><div class="casAuthors">Manolagas, Stavros C.; O'Brien, Charles A.; Almeida, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">699-712</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mouse models with cell-specific deletion of the estrogen receptor (ER) α, the androgen receptor (AR) or the receptor activator of nuclear factor κB ligand (RANKL), as well as cascade-selective estrogenic compds. have provided novel insights into the function and signalling of ERα and AR.  The studies reveal that the effects of estrogens on trabecular vs. cortical bone mass are mediated by direct effects on osteoclasts and osteoblasts, resp.  The protection of cortical bone mass by estrogens is mediated via ERα, using a non-nucleus-initiated mechanism.  By contrast, the AR of mature osteoblasts is indispensable for the maintenance of trabecular bone mass in male mammals, but not required for the anabolic effects of androgens on cortical bone.  Most unexpectedly, and independently of estrogens, ERα in osteoblast progenitors stimulates Wnt signalling and periosteal bone accrual in response to mech. strain.  RANKL expression in B lymphocytes, but not T lymphocytes, contributes to the loss of trabecular bone caused by estrogen deficiency.  In this Review, we summarize this evidence and discuss its implications for understanding the regulation of trabecular and cortical bone mass; the integration of hormonal and mech. signals; the relative importance of estrogens vs. androgens in the male skeleton; and, finally, the pathogenesis and treatment of osteoporosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXOwr_v3mjKbVg90H21EOLACvtfcHk0lihoupEtqBEYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVynu77I&md5=fbda8ee8c9962a695f33c1ec3130d15d</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2013.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2013.179%26sid%3Dliteratum%253Aachs%26aulast%3DManolagas%26aufirst%3DS.%2BC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%2BA.%26aulast%3DAlmeida%26aufirst%3DM.%26atitle%3DThe%2520role%2520of%2520estrogen%2520and%2520androgen%2520receptors%2520in%2520bone%2520health%2520and%2520disease%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2013%26volume%3D9%26issue%3D12%26spage%3D699%26epage%3D712%26doi%3D10.1038%2Fnrendo.2013.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briquez, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. R.</span></span> <span> </span><span class="NLM_article-title">Engineering growth factors for regenerative medicine applications</span>. <i>Acta Biomater.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.actbio.2015.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.actbio.2015.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=26555377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWlur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=1-12&author=A.+C.+Mitchellauthor=P.+S.+Briquezauthor=J.+A.+Hubbellauthor=J.+R.+Cochran&title=Engineering+growth+factors+for+regenerative+medicine+applications&doi=10.1016%2Fj.actbio.2015.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering growth factors for regenerative medicine applications</span></div><div class="casAuthors">Mitchell, Aaron C.; Briquez, Priscilla S.; Hubbell, Jeffrey A.; Cochran, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Biomaterialia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">ABCICB</span>;
        ISSN:<span class="NLM_cas:issn">1742-7061</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Growth factors are important morphogenetic proteins that instruct cell behavior and guide tissue repair and renewal.  Although their therapeutic potential holds great promise in regenerative medicine applications, translation of growth factors into clin. treatments has been hindered by limitations including poor protein stability, low recombinant expression yield, and suboptimal efficacy.  This review highlights current tools, technologies, and approaches to design integrated and effective growth factor-based therapies for regenerative medicine applications.  The first section describes rational and combinatorial protein engineering approaches that have been utilized to improve growth factor stability, expression yield, biodistribution, and serum half-life, or alter their cell trafficking behavior or receptor binding affinity.  The second section highlights elegant biomaterial-based systems, inspired by the natural extracellular matrix milieu, that have been developed for effective spatial and temporal delivery of growth factors to cell surface receptors.  Although appearing distinct, these two approaches are highly complementary and involve principles of mol. design and engineering to be considered in parallel when developing optimal materials for clin. applications.  Growth factors are promising therapeutic proteins that have the ability to modulate morphogenetic behaviors, including cell survival, proliferation, migration and differentiation.  However, the translation of growth factors into clin. therapies has been hindered by properties such as poor protein stability, low recombinant expression yield, and non-physiol. delivery, which lead to suboptimal efficacy and adverse side effects.  To address these needs, researchers are employing clever mol. and material engineering and design strategies to both improve the intrinsic properties of growth factors and effectively control their delivery into tissue.  This review highlights examples of interdisciplinary tools and technologies used to augment the therapeutic potential of growth factors for clin. applications in regenerative medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0W98k2-jDm7Vg90H21EOLACvtfcHk0lg3U5EfM8P9eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWlur%252FK&md5=d04bfadd38b7372647cdb2fb406331bc</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.actbio.2015.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.actbio.2015.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DMitchell%26aufirst%3DA.%2BC.%26aulast%3DBriquez%26aufirst%3DP.%2BS.%26aulast%3DHubbell%26aufirst%3DJ.%2BA.%26aulast%3DCochran%26aufirst%3DJ.%2BR.%26atitle%3DEngineering%2520growth%2520factors%2520for%2520regenerative%2520medicine%2520applications%26jtitle%3DActa%2520Biomater.%26date%3D2016%26volume%3D30%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.actbio.2015.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wojda, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donahue, S. W.</span></span> <span> </span><span class="NLM_article-title">Parathyroid hormone for bone regeneration</span>. <i>J. Orthop. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2586</span>– <span class="NLM_lpage">2594</span>, <span class="refDoi"> DOI: 10.1002/jor.24075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1002%2Fjor.24075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=29926970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVKhtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=2586-2594&issue=10&author=S.+J.+Wojdaauthor=S.+W.+Donahue&title=Parathyroid+hormone+for+bone+regeneration&doi=10.1002%2Fjor.24075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Parathyroid hormone for bone regeneration</span></div><div class="casAuthors">Wojda, Samantha J.; Donahue, Seth W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Orthopaedic Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2586-2594</span>CODEN:
                <span class="NLM_cas:coden">JOREDR</span>;
        ISSN:<span class="NLM_cas:issn">0736-0266</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Delayed healing and/or non-union occur in approx. 5-10% of the fractures that occur annually in the United States.  Segmental bone loss increases the probability of non-union.  Though grafting can be an effective treatment for segmental bone loss, autografting is limited for large defects since a limited amt. of bone is available for harvest.  Parathyroid hormone (PTH) is a key regulator of calcium homeostasis in the body and plays an important role in bone metab.  Presently PTH is FDA approved for use as an anabolic treatment for osteoporosis.  The anabolic effect PTH has on bone has led to research on its use for bone regeneration applications.  Numerous studies in animal models have indicated enhanced fracture healing as a result of once daily injections of PTH.  Similarly, in a human case study, non-union persisted despite treatment attempts with internal fixation, external fixation, and autograft in combination with BMP-7, until off label use of PTH1-84 was utilized.  Use of a biomaterial scaffold to locally deliver PTH to a defect site has also been shown to improve bone formation and healing around dental implants in dogs and drill defects in sheep.  Thus, PTH may be used to promote bone regeneration and provide an alternative to autograft and BMP for the treatment of large segmental defects and non-unions.  This review briefly summarizes the unmet clin. need for improved bone regeneration techniques and how PTH may help fill that void by both systemically and locally delivered PTH for bone regeneration applications. © 2018 Orthopaedic Research Society.  Published by Wiley Periodicals, Inc.  J Orthop Res 36:2586-2594, 2018.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWvcGNijGjG7Vg90H21EOLACvtfcHk0lg3U5EfM8P9eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVKhtb%252FI&md5=8ae183f3ff0e092c2b4c17267a745d94</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1002%2Fjor.24075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjor.24075%26sid%3Dliteratum%253Aachs%26aulast%3DWojda%26aufirst%3DS.%2BJ.%26aulast%3DDonahue%26aufirst%3DS.%2BW.%26atitle%3DParathyroid%2520hormone%2520for%2520bone%2520regeneration%26jtitle%3DJ.%2520Orthop.%2520Res.%26date%3D2018%26volume%3D36%26issue%3D10%26spage%3D2586%26epage%3D2594%26doi%3D10.1002%2Fjor.24075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okajima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uemoto, S.</span></span> <span> </span><span class="NLM_article-title">Current state and future evolution of pancreatic islet transplantation</span>. <i>Ann. Gastroenterol Surg</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1002/ags3.12214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1002%2Fags3.12214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30697608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A280%3ADC%252BB3cjmvVChuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=34-42&issue=1&author=T.+Anazawaauthor=H.+Okajimaauthor=T.+Masuiauthor=S.+Uemoto&title=Current+state+and+future+evolution+of+pancreatic+islet+transplantation&doi=10.1002%2Fags3.12214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Current state and future evolution of pancreatic islet transplantation</span></div><div class="casAuthors">Anazawa Takayuki; Okajima Hideaki; Masui Toshihiko; Uemoto Shinji</div><div class="citationInfo"><span class="NLM_cas:title">Annals of gastroenterological surgery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pancreatic islet transplantation provides an effective treatment option for patients with type 1 diabetes (T1D) with intractable impaired awareness of hypoglycemia and severe hypoglycemic events.  Currently, the primary goal of islet transplantation should be excellent glycemic control without severe hypoglycemia, rather than insulin independence.  Islet transplant recipients were less likely to achieve insulin independence, whereas solid pancreas transplant recipients substantially had greater procedure-related morbidity.  Excellent therapeutic effects of islet transplantation as a result of accurate blood glucose level-reactive insulin secretion, which cannot be reproduced by current drug therapy, have been confirmed.  Recent improvement of islet transplantation outcome has been achieved by refinement of the pancreatic islet isolation technique, improvement of islet engraftment method, and introduction of effective immunosuppressive therapy.  A disadvantage of islet transplantation is that donors are essential, and donor shortage has become a hindrance to its development.  With the development of alternative transplantation sites and new cell sources, including porcine islet cells and embryonic stem/induced pluripotent stem (ES/iPS)-derived β cells, "On-demand" and "Unlimited" cell therapy for T1D can be established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSftIHOVdtXIyCEBeYuoi7AfW6udTcc2eaMevEb79ESGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjmvVChuw%253D%253D&md5=10b1cb41cb78387d67af0a4b762fcdd6</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2Fags3.12214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fags3.12214%26sid%3Dliteratum%253Aachs%26aulast%3DAnazawa%26aufirst%3DT.%26aulast%3DOkajima%26aufirst%3DH.%26aulast%3DMasui%26aufirst%3DT.%26aulast%3DUemoto%26aufirst%3DS.%26atitle%3DCurrent%2520state%2520and%2520future%2520evolution%2520of%2520pancreatic%2520islet%2520transplantation%26jtitle%3DAnn.%2520Gastroenterol%2520Surg%26date%3D2019%26volume%3D3%26issue%3D1%26spage%3D34%26epage%3D42%26doi%3D10.1002%2Fags3.12214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shahjalal, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayem, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, T.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.-G.</span></span> <span> </span><span class="NLM_article-title">Generation of pancreatic β cells for treatment of diabetes: advances and challenges</span>. <i>Stem Cell Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">355</span>, <span class="refDoi"> DOI: 10.1186/s13287-018-1099-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1186%2Fs13287-018-1099-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=30594258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFGkurvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=355&author=H.+M.+Shahjalalauthor=A.+A.+Dayemauthor=K.+M.+Limauthor=T.-i.+Jeonauthor=S.-G.+Cho&title=Generation+of+pancreatic+%CE%B2+cells+for+treatment+of+diabetes%3A+advances+and+challenges&doi=10.1186%2Fs13287-018-1099-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of pancreatic β cells for treatment of diabetes: advances and challenges</span></div><div class="casAuthors">Shahjalal, Hussain Md.; Dayem, Ahmed Abdal; Lim, Kyung Min; Jeon, Tak-il; Cho, Ssang-Goo</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Research & Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">355</span>CODEN:
                <span class="NLM_cas:coden">SCRTEK</span>;
        ISSN:<span class="NLM_cas:issn">1757-6512</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC) are considered attractive sources of pancreatic β cells and islet organoids.  Recently, several reports presented that hESC/iPSC-derived cells enriched with specific transcription factors can form glucose-responsive insulin-secreting cells in vitro and transplantation of these cells ameliorates hyperglycemia in diabetic mice.  However, the glucose-stimulated insulin-secreting capacity of these cells is lower than that of endogenous islets, suggesting the need to improve induction procedures.  One of the crit. problems facing in vivo maturation of hESC/iPSC-derived cells is their low survival rate after transplantation, although this rate increases when the implanted pancreatic cells are encapsulated to avoid the immune response.  Several groups have also reported on the generation of hESC/iPSC-derived islet-like organoids, but development of techniques for complete islet structures with the eventual generation of vascularized constructs remains a major challenge to their application in regenerative therapies.  Many issues also need to be addressed before the successful clin. application of hESC/iPSC-derived cells or islet organoids.  In this review, we summarize advances in the generation of hESC/iPSC-derived pancreatic β cells or islet organoids and discuss the limitations and challenges for their successful therapeutic application in diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1q13PgE1c07Vg90H21EOLACvtfcHk0lhVlCe6PeRvoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFGkurvN&md5=8e0a3342ea874dfd7e6c7485d46c67b2</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1186%2Fs13287-018-1099-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13287-018-1099-3%26sid%3Dliteratum%253Aachs%26aulast%3DShahjalal%26aufirst%3DH.%2BM.%26aulast%3DDayem%26aufirst%3DA.%2BA.%26aulast%3DLim%26aufirst%3DK.%2BM.%26aulast%3DJeon%26aufirst%3DT.-i.%26aulast%3DCho%26aufirst%3DS.-G.%26atitle%3DGeneration%2520of%2520pancreatic%2520%25CE%25B2%2520cells%2520for%2520treatment%2520of%2520diabetes%253A%2520advances%2520and%2520challenges%26jtitle%3DStem%2520Cell%2520Res.%2520Ther.%26date%3D2018%26volume%3D9%26spage%3D355%26doi%3D10.1186%2Fs13287-018-1099-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span> <span> </span><span class="NLM_article-title">The De-, Re-, and trans-differentiation of β-cells: Regulation and function</span>. <i>Semin. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1016/j.semcdb.2020.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.semcdb.2020.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=31948775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A280%3ADC%252BB38%252Fht1ahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2020&pages=68-75&author=J.+Zhangauthor=F.+Liu&title=The+De-%2C+Re-%2C+and+trans-differentiation+of+%CE%B2-cells%3A+Regulation+and+function&doi=10.1016%2Fj.semcdb.2020.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">The De-, Re-, and trans-differentiation of β-cells: Regulation and function</span></div><div class="casAuthors">Zhang Jingjing; Liu Feng</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in cell & developmental biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diabetes is a serious, costly, and major health problem worldwide.  Whereas diabetes could be alleviated by medication, this disease could not be fully cured at the present time due to the lack of effective therapeutic treatment for β-cell loss and/or dysfunction.  Increased β-cell mass or volume could be achieved via differentiation of embryonic stem (ES) cells or pluripotent stem cells or through β-cell renewal, including proliferation, redifferentiation, and transdifferentiation.  Data cumulated over the past several years suggest that increased β-cell dedifferentiation plays a crucial role in the progression of diabetes, shedding new light on potential targets for β-cell replacement therapy.  In this review, we summarize current views on β-cell dedifferentiation, redifferentiation, and transdifferentiation.  We also discuss potential mechanisms regulating these key processes to maintain β-cell homeostasis.  Understanding pancreatic β-cell differentiation and dedifferentiation could be provide important information on developing effective strategies to cure diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA48EmrnerrVWTCLT8lX9SfW6udTcc2eZvqgenJnTasbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252Fht1ahuw%253D%253D&md5=4bb6ba69a506317ad893de0ca7710833</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2020.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2020.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DF.%26atitle%3DThe%2520De-%252C%2520Re-%252C%2520and%2520trans-differentiation%2520of%2520%25CE%25B2-cells%253A%2520Regulation%2520and%2520function%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26date%3D2020%26volume%3D103%26spage%3D68%26epage%3D75%26doi%3D10.1016%2Fj.semcdb.2020.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simao, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barroso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristovao, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallardo, E.</span></span> <span> </span><span class="NLM_article-title">Toxicological aspects and determination of the main components of ayahuasca: a critical review</span>. <i>Medicines</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">106</span>, <span class="refDoi"> DOI: 10.3390/medicines6040106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.3390%2Fmedicines6040106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslekur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=106&issue=4&author=A.+Y.+Simaoauthor=J.+Goncalvesauthor=A.+P.+Duarteauthor=M.+Barrosoauthor=A.+C.+Cristovaoauthor=E.+Gallardo&title=Toxicological+aspects+and+determination+of+the+main+components+of+ayahuasca%3A+a+critical+review&doi=10.3390%2Fmedicines6040106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicological aspects and determination of the main components of ayahuasca: a critical review</span></div><div class="casAuthors">Simao, Ana Y.; Goncalves, Joana; Duarte, Ana Paula; Barroso, Mario; Cristovao, Ana Clara; Gallardo, Eugenia</div><div class="citationInfo"><span class="NLM_cas:title">Medicines</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">106</span>CODEN:
                <span class="NLM_cas:coden">MEDICX</span>;
        ISSN:<span class="NLM_cas:issn">2305-6320</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Ayahuasca is a psychoactive beverage prepd. traditionally from a mixt. of the leaves and stems of Psychotria viridis and Banisteriopsis caapi, resp., being originally consumed by indigenous Amazonian tribes for ritual and medicinal purposes.  Over the years, its use has spread to other populations as a means to personal growth and spiritual connection.  Also, the recreational use of its isolated compds. has become prominent.  The main compds. of this tea-like prepn. are N,N-dimethyltryptamine (DMT), β-Carbolines, and harmala alkaloids, such as harmine, tetrahydroharmine, and harmaline.  The latter are monoamine-oxidase inhibitors and are responsible for DMT psychoactive and hallucinogenic effects on the central nervous system.  Although consumers defend its use, its metabolic effects and those on the central nervous system are not fully understood yet.  The majority of studies regarding the effects of this beverage and of its individual compds. are based on in vivo expts., clin. trials, and even surveys.  This paper will not only address the toxicol. aspects of the ayahuasca compds. but also perform a comprehensive and crit. review on the anal. methods available for their detn. in biol. and non-biol. specimens, with special focus on instrumental developments and sample prepn. approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCVD50AnXcybVg90H21EOLACvtfcHk0lhVlCe6PeRvoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslekur7O&md5=7af469d0df539b2b19da8b51a380f12b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.3390%2Fmedicines6040106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmedicines6040106%26sid%3Dliteratum%253Aachs%26aulast%3DSimao%26aufirst%3DA.%2BY.%26aulast%3DGoncalves%26aufirst%3DJ.%26aulast%3DDuarte%26aufirst%3DA.%2BP.%26aulast%3DBarroso%26aufirst%3DM.%26aulast%3DCristovao%26aufirst%3DA.%2BC.%26aulast%3DGallardo%26aufirst%3DE.%26atitle%3DToxicological%2520aspects%2520and%2520determination%2520of%2520the%2520main%2520components%2520of%2520ayahuasca%253A%2520a%2520critical%2520review%26jtitle%3DMedicines%26date%3D2019%26volume%3D6%26issue%3D4%26spage%3D106%26doi%3D10.3390%2Fmedicines6040106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maji, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elgamal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkonda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, A.</span></span> <span> </span><span class="NLM_article-title">Native zinc catalyzes selective and traceless release of small molecules in β-cells</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6477</span>– <span class="NLM_lpage">6482</span>, <span class="refDoi"> DOI: 10.1021/jacs.0c00099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.0c00099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVKksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=6477-6482&issue=14&author=M.+Leeauthor=B.+Majiauthor=D.+Mannaauthor=S.+Kahramanauthor=R.+M.+Elgamalauthor=J.+Smallauthor=P.+Kokkondaauthor=A.+Vetereauthor=J.+M.+Goldbergauthor=S.+J.+Lippardauthor=R.+N.+Kulkarniauthor=B.+K.+Wagnerauthor=A.+Choudhary&title=Native+zinc+catalyzes+selective+and+traceless+release+of+small+molecules+in+%CE%B2-cells&doi=10.1021%2Fjacs.0c00099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Native Zinc Catalyzes Selective and Traceless Release of Small Molecules in β-Cells</span></div><div class="casAuthors">Lee, Miseon; Maji, Basudeb; Manna, Debasish; Kahraman, Sevim; Elgamal, Ruth M.; Small, Jonnell; Kokkonda, Praveen; Vetere, Amedeo; Goldberg, Jacob M.; Lippard, Stephen J.; Kulkarni, Rohit N.; Wagner, Bridget K.; Choudhary, Amit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6477-6482</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The loss of insulin-producing β-cells is the central pathol. event in type 1 and 2 diabetes, which has led to efforts to identify mols. to promote β-cell proliferation, protection, and imaging.  However, the lack of β-cell specificity of these mols. jeopardizes their therapeutic potential.  A general platform for selective release of small-mol. cargoes in β-cells over other islet cells ex vivo or other cell-types in an organismal context will be immensely valuable in advancing diabetes research and therapeutic development.  Here, we leverage the unusually high Zn(II) concn. in β-cells to develop a Zn(II)-based prodrug system to selectively and tracelessly deliver bioactive small mols. and fluorophores to β-cells.  The Zn(II)-targeting mechanism enriches the inactive cargo in β-cells as compared to other pancreatic cells; importantly, Zn(II)-mediated hydrolysis triggers cargo activation.  This prodrug system, with modular components that allow for fine-tuning selectivity, should enable the safer and more effective targeting of β-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8PBBj0fuUarVg90H21EOLACvtfcHk0lhVlCe6PeRvoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVKksr0%253D&md5=fd7bc8705bf5eb48ef45dce4c708954a</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjacs.0c00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.0c00099%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%26aulast%3DMaji%26aufirst%3DB.%26aulast%3DManna%26aufirst%3DD.%26aulast%3DKahraman%26aufirst%3DS.%26aulast%3DElgamal%26aufirst%3DR.%2BM.%26aulast%3DSmall%26aufirst%3DJ.%26aulast%3DKokkonda%26aufirst%3DP.%26aulast%3DVetere%26aufirst%3DA.%26aulast%3DGoldberg%26aufirst%3DJ.%2BM.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DChoudhary%26aufirst%3DA.%26atitle%3DNative%2520zinc%2520catalyzes%2520selective%2520and%2520traceless%2520release%2520of%2520small%2520molecules%2520in%2520%25CE%25B2-cells%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26issue%3D14%26spage%3D6477%26epage%3D6482%26doi%3D10.1021%2Fjacs.0c00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naparstek, Y.</span></span> <span> </span><span class="NLM_article-title">Immune modulation for prevention of type 1 diabetes mellitus</span>. <i>Trends Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.tibtech.2005.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.tibtech.2005.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=15734555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsleiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=128-134&issue=3&author=I.+Razauthor=R.+Eldorauthor=Y.+Naparstek&title=Immune+modulation+for+prevention+of+type+1+diabetes+mellitus&doi=10.1016%2Fj.tibtech.2005.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Immune modulation for prevention of type 1 diabetes mellitus</span></div><div class="casAuthors">Raz, Itamar; Eldor, Roy; Naparstek, Yaakov</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">128-134</span>CODEN:
                <span class="NLM_cas:coden">TRBIDM</span>;
        ISSN:<span class="NLM_cas:issn">0167-7799</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Prevention of type 1 diabetes mellitus requires early intervention in the autoimmune process directed against β cells of the pancreatic islets of Langerhans.  This autoimmune inflammatory process is thought to be caused by the effect of Th1 cells and their secreted cytokines (e.g. interferon) and to be suppressed by Th2-secreted anti-inflammatory cytokines (e.g. IL-4, IL-10).  Various methods aimed specifically at halting or modulating this response have been attempted.  An alternative method is the re-induction of tolerance towards the putative self antigen that causes the disease.  Proposed antigens such as insulin, glutamic acid decarboxylase (GAD) and the heat shock protein 60 (Hsp60)-derived peptide 277 have been used successfully in murine diabetes models and in initial clin. trials in early diabetes patients.  Here, we review the results of these trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5RGvDHjKu2bVg90H21EOLACvtfcHk0lhPfg-Dwc0SwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsleiur8%253D&md5=60e4fad8f948d37bfa806d4762d10356</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.tibtech.2005.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibtech.2005.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DRaz%26aufirst%3DI.%26aulast%3DEldor%26aufirst%3DR.%26aulast%3DNaparstek%26aufirst%3DY.%26atitle%3DImmune%2520modulation%2520for%2520prevention%2520of%2520type%25201%2520diabetes%2520mellitus%26jtitle%3DTrends%2520Biotechnol.%26date%3D2005%26volume%3D23%26issue%3D3%26spage%3D128%26epage%3D134%26doi%3D10.1016%2Fj.tibtech.2005.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roep, B. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tree, T. I. M.</span></span> <span> </span><span class="NLM_article-title">Immune modulation in humans: implications for type 1 diabetes mellitus</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2014.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1038%2Fnrendo.2014.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=24468651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsF2qsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=229-242&issue=4&author=B.+O.+Roepauthor=T.+I.+M.+Tree&title=Immune+modulation+in+humans%3A+implications+for+type+1+diabetes+mellitus&doi=10.1038%2Fnrendo.2014.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Immune modulation in humans: implications for type 1 diabetes mellitus</span></div><div class="casAuthors">Roep, Bart O.; Tree, Timothy I. M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">229-242</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Type 1 diabetes mellitus (T1DM) is the result of autoimmune destruction of pancreatic β cells in genetically predisposed individuals with impaired immune regulation.  The insufficiency in the modulation of immune attacks on the β cells might be partly due to genetic causes; indeed, several of the genetic variants that predispose individuals to T1DM have functional features of impaired immune regulation.  While defects in immune regulation in patients with T1DM have been identified, many patients seem to have immune regulatory capacities that are indistinguishable from those of healthy individuals.  Insight into the regulation of islet autoimmunity might enable us to restore immune imbalances with therapeutic interventions.  In this Review, we discuss the current knowledge on immune regulation and dysfunction in humans that is the basis of tissue-specific immune regulation as an alternative to generalized immune suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQCg2ICr_McrVg90H21EOLACvtfcHk0lhPfg-Dwc0SwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsF2qsL0%253D&md5=a9263cce17235d3a06e064676054dd46</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2014.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2014.2%26sid%3Dliteratum%253Aachs%26aulast%3DRoep%26aufirst%3DB.%2BO.%26aulast%3DTree%26aufirst%3DT.%2BI.%2BM.%26atitle%3DImmune%2520modulation%2520in%2520humans%253A%2520implications%2520for%2520type%25201%2520diabetes%2520mellitus%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2014%26volume%3D10%26issue%3D4%26spage%3D229%26epage%3D242%26doi%3D10.1038%2Fnrendo.2014.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herold, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluestone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Meglio, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufort, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitelman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsley, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skyler, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsalikian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wherrett, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, A.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenbaum, C. J.</span></span> <span> </span><span class="NLM_article-title">An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1902226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1056%2FNEJMoa1902226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=31180194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1GqsbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=603-613&issue=7&author=K.+C.+Heroldauthor=B.+N.+Bundyauthor=S.+A.+Longauthor=J.+A.+Bluestoneauthor=L.+A.+Di+Meglioauthor=M.+J.+Dufortauthor=S.+E.+Gitelmanauthor=P.+A.+Gottliebauthor=J.+P.+Krischerauthor=P.+S.+Linsleyauthor=J.+B.+Marksauthor=W.+Mooreauthor=A.+Moranauthor=H.+Rodriguezauthor=W.+E.+Russellauthor=D.+Schatzauthor=J.+S.+Skylerauthor=E.+Tsalikianauthor=D.+K.+Wherrettauthor=A.-G.+Zieglerauthor=C.+J.+Greenbaum&title=An+anti-CD3+antibody%2C+teplizumab%2C+in+relatives+at+risk+for+type+1+diabetes&doi=10.1056%2FNEJMoa1902226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes</span></div><div class="casAuthors">Herold, Kevan C.; Bundy, Brian N.; Long, S. Alice; Bluestone, Jeffrey A.; Di Meglio, Linda A.; Dufort, Matthew J.; Gitelman, Stephen E.; Gottlieb, Peter A.; Krischer, Jeffrey P.; Linsley, Peter S.; Marks, Jennifer B.; Moore, Wayne; Moran, Antoinette; Rodriguez, Henry; Russell, William E.; Schatz, Desmond; Skyler, Jay S.; Tsalikian, Eva; Wherrett, Diane K.; Ziegler, Anette-Gabriele; Greenbaum, Carla J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">603-613</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1 diabetes who did not have diabetes but were at high risk for development of clin. disease.  Patients were randomly assigned to a single 14-day course of teplizumab or placebo, and follow-up for progression to clin. type 1 diabetes was performed with the use of oral glucose-tolerance tests at 6-mo intervals. results A total of 76 participants (55 [72%] of whom were ≤18 years of age) underwent randomization - 44 to the teplizumab group and 32 to the placebo group.  The median time to the diagnosis of type 1 diabetes was 48.4 mo in the teplizumab group and 24.4 mo in the placebo group; the disease was diagnosed in 19 (43%) of the participants who received teplizumab and in 23 (72%) of those who received placebo.  The hazard ratio for the diagnosis of type 1 diabetes (teplizumab vs. placebo) was 0.41 (95% confidence interval, 0.22 to 0.78; P = 0.006 by adjusted Cox proportional-hazards model).  The annualized rates of diagnosis of diabetes were 14.9% per yr in the teplizumab group and 35.9% per yr in the placebo group.  There were expected adverse events of rash and transient lymphopenia.  KLRG1 + TIGIT + CD8+ T cells were more common in the teplizumab group than in the placebo group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwpYoP4iqOS7Vg90H21EOLACvtfcHk0lhPfg-Dwc0SwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1GqsbbN&md5=a91854229de7210f9bba44953cce713d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1902226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1902226%26sid%3Dliteratum%253Aachs%26aulast%3DHerold%26aufirst%3DK.%2BC.%26aulast%3DBundy%26aufirst%3DB.%2BN.%26aulast%3DLong%26aufirst%3DS.%2BA.%26aulast%3DBluestone%26aufirst%3DJ.%2BA.%26aulast%3DDi%2BMeglio%26aufirst%3DL.%2BA.%26aulast%3DDufort%26aufirst%3DM.%2BJ.%26aulast%3DGitelman%26aufirst%3DS.%2BE.%26aulast%3DGottlieb%26aufirst%3DP.%2BA.%26aulast%3DKrischer%26aufirst%3DJ.%2BP.%26aulast%3DLinsley%26aufirst%3DP.%2BS.%26aulast%3DMarks%26aufirst%3DJ.%2BB.%26aulast%3DMoore%26aufirst%3DW.%26aulast%3DMoran%26aufirst%3DA.%26aulast%3DRodriguez%26aufirst%3DH.%26aulast%3DRussell%26aufirst%3DW.%2BE.%26aulast%3DSchatz%26aufirst%3DD.%26aulast%3DSkyler%26aufirst%3DJ.%2BS.%26aulast%3DTsalikian%26aufirst%3DE.%26aulast%3DWherrett%26aufirst%3DD.%2BK.%26aulast%3DZiegler%26aufirst%3DA.-G.%26aulast%3DGreenbaum%26aufirst%3DC.%2BJ.%26atitle%3DAn%2520anti-CD3%2520antibody%252C%2520teplizumab%252C%2520in%2520relatives%2520at%2520risk%2520for%2520type%25201%2520diabetes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26issue%3D7%26spage%3D603%26epage%3D613%26doi%3D10.1056%2FNEJMoa1902226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Register, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann-Petersen, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehdizadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colon-Negron, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meza-Acevedo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backes, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluestone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papa, F. R.</span></span> <span> </span><span class="NLM_article-title">Targeting ABL-IRE1α signaling spares ER-stressed pancreatic β cells to reverse autoimmune diabetes</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">897</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2017.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2Fj.cmet.2017.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=28380378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1ylsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=883-897&issue=4&author=S.+Moritaauthor=S.+A.+Villaltaauthor=H.+C.+Feldmanauthor=A.+C.+Registerauthor=W.+Rosenthalauthor=I.+T.+Hoffmann-Petersenauthor=M.+Mehdizadehauthor=R.+Ghoshauthor=L.+Wangauthor=K.+Colon-Negronauthor=R.+Meza-Acevedoauthor=B.+J.+Backesauthor=D.+J.+Malyauthor=J.+A.+Bluestoneauthor=F.+R.+Papa&title=Targeting+ABL-IRE1%CE%B1+signaling+spares+ER-stressed+pancreatic+%CE%B2+cells+to+reverse+autoimmune+diabetes&doi=10.1016%2Fj.cmet.2017.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ABL-IRE1α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes</span></div><div class="casAuthors">Morita, Shuhei; Villalta, S. Armando; Feldman, Hannah C.; Register, Ames C.; Rosenthal, Wendy; Hoffmann-Petersen, Ingeborg T.; Mehdizadeh, Morvarid; Ghosh, Rajarshi; Wang, Likun; Colon-Negron, Kevin; Meza-Acevedo, Rosa; Backes, Bradley J.; Maly, Dustin J.; Bluestone, Jeffrey A.; Papa, Feroz R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">883-897.e8</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">In cells experiencing unrelieved endoplasmic reticulum (ER) stress, the ER transmembrane kinase/endoribonuclease (RNase)-IRE1α-endonucleolytically degrades ER-localized mRNAs to promote apoptosis.  Here we find that the ABL family of tyrosine kinases rheostatically enhances IRE1α's enzymic activities, thereby potentiating ER stress-induced apoptosis.  During ER stress, cytosolic ABL kinases localize to the ER membrane, where they bind, scaffold, and hyperactivate IRE1α's RNase.  Imatinib-an anti-cancer tyrosine kinase inhibitor-antagonizes the ABL-IRE1α interaction, blunts IRE1α RNase hyperactivity, reduces pancreatic β cell apoptosis, and reverses type 1 diabetes (T1D) in the non-obese diabetic (NOD) mouse model.  A mono-selective kinase inhibitor that allosterically attenuates IRE1α's RNase-KIRA8-also efficaciously reverses established diabetes in NOD mice by sparing β cells and preserving their physiol. function.  Our data support a model wherein ER-stressed β cells contribute to their own demise during T1D pathogenesis and implicate the ABL-IRE1α axis as a drug target for the treatment of an autoimmune disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGZtS35KHrIrVg90H21EOLACvtfcHk0liuZTMpaXd5_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1ylsbg%253D&md5=be7692b3c222ac9eb9b1d1ca68a77e47</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2017.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2017.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DVillalta%26aufirst%3DS.%2BA.%26aulast%3DFeldman%26aufirst%3DH.%2BC.%26aulast%3DRegister%26aufirst%3DA.%2BC.%26aulast%3DRosenthal%26aufirst%3DW.%26aulast%3DHoffmann-Petersen%26aufirst%3DI.%2BT.%26aulast%3DMehdizadeh%26aufirst%3DM.%26aulast%3DGhosh%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DColon-Negron%26aufirst%3DK.%26aulast%3DMeza-Acevedo%26aufirst%3DR.%26aulast%3DBackes%26aufirst%3DB.%2BJ.%26aulast%3DMaly%26aufirst%3DD.%2BJ.%26aulast%3DBluestone%26aufirst%3DJ.%2BA.%26aulast%3DPapa%26aufirst%3DF.%2BR.%26atitle%3DTargeting%2520ABL-IRE1%25CE%25B1%2520signaling%2520spares%2520ER-stressed%2520pancreatic%2520%25CE%25B2%2520cells%2520to%2520reverse%2520autoimmune%2520diabetes%26jtitle%3DCell%2520Metab.%26date%3D2017%26volume%3D25%26issue%3D4%26spage%3D883%26epage%3D897%26doi%3D10.1016%2Fj.cmet.2017.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dayan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herold, K. C.</span></span> <span> </span><span class="NLM_article-title">Changing the landscape for type 1 diabetes: the first step to prevention</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>394</i></span> (<span class="NLM_issue">10205</span>),  <span class="NLM_fpage">1286</span>– <span class="NLM_lpage">1296</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)32127-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=10.1016%2FS0140-6736%2819%2932127-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=31533907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSgtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2019&pages=1286-1296&issue=10205&author=C.+M.+Dayanauthor=M.+Korahauthor=D.+Tatovicauthor=B.+N.+Bundyauthor=K.+C.+Herold&title=Changing+the+landscape+for+type+1+diabetes%3A+the+first+step+to+prevention&doi=10.1016%2FS0140-6736%2819%2932127-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Changing the landscape for type 1 diabetes: the first step to prevention</span></div><div class="casAuthors">Dayan, Colin M.; Korah, Maria; Tatovic, Danijela; Bundy, Brian N.; Herold, Kevan C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">10205</span>),
    <span class="NLM_cas:pages">1286-1296</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Over several decades, studies have described the progression of autoimmune diabetes, from the first appearance of autoantibodies until, and after, the diagnosis of clin. disease with hyperglycemia and insulin dependence.  Despite the improved management of type 1 diabetes with exogenous insulin, most patients do not meet clin. glycemic goals, and diabetes remains an important medical problem that affects children and adults.  Clin. and preclin. studies have suggested strategies to prevent the diagnosis of type 1 diabetes in people at risk, but the outcomes of previous clin. trials have not met their primary endpoints of disease prevention or delay.  The results from the TN-10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a FcR non-binding monoclonal antibody to CD3 in people at high risk for disease.  This Series paper discusses how this clin. achievement raises new questions about for whom, and when, immunol. strategies might be developed to prevent type 1 diabetes, and how to achieve this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp85ZTak7FRELVg90H21EOLACvtfcHk0liuZTMpaXd5_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSgtrzP&md5=db7b8f06453481f7d06fd50dacf84c37</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2932127-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252932127-0%26sid%3Dliteratum%253Aachs%26aulast%3DDayan%26aufirst%3DC.%2BM.%26aulast%3DKorah%26aufirst%3DM.%26aulast%3DTatovic%26aufirst%3DD.%26aulast%3DBundy%26aufirst%3DB.%2BN.%26aulast%3DHerold%26aufirst%3DK.%2BC.%26atitle%3DChanging%2520the%2520landscape%2520for%2520type%25201%2520diabetes%253A%2520the%2520first%2520step%2520to%2520prevention%26jtitle%3DLancet%26date%3D2019%26volume%3D394%26issue%3D10205%26spage%3D1286%26epage%3D1296%26doi%3D10.1016%2FS0140-6736%2819%2932127-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ANR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ANR','PDB','3ANR'); return false;">PDB: 3ANR</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02050&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-6%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02050%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02050" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679958e89bf63bf8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
